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Abstract 
NAME: Dr Amit Chattree  
TITLE OF THESIS: Improving the Management of Large Colorectal Polyps 
HIGHER DEGREE FOR WHICH SUBMITTED: Doctor of Medicine (MD) 
YEAR OF SUBMISSION: 2015 
This thesis is focused on identifying current practices in the management of large non 
pedunculated colorectal polyps (LNPCPs) and the development of a structured management 
framework to improve outcomes. The methodology used includes a systematic review to 
ascertain current knowledge and retrospective quantitative analysis to identify current 
LNPCP management outcomes.  The English Bowel Cancer Screening Programme (BCSP) 
which has a high volume of recorded LNPCP data was used to facilitate the latter process.   
In addition, qualitative analysis using consensus methodology to create best practice 
guidelines, key performance indicators (KPIs) to audit LNPCP outcomes and a complex polyp 
multidisciplinary team process was undertaken.   
The main outcomes of this thesis were: 
   1. Confirmation of variation in LNPCP management practices leading to variable outcomes 
   2. Formulation of evidence based and expert consensus LNPCP management guidelines 
   3. Identification of KPIs to allow audit of LNPCP management and outcomes 
                 4. Identification of pertinent research questions to improve evidence LNPCP base  
   5. Development and pilot of regional complex polyp multidisciplinary team meeting  
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          Introduction  
Theme: 
Improving clinical practice towards better outcomes 
Hypothesis 
The current management of large colonic polyps is subjective and variable.  The 
development of an evidence based, coordinated framework will result in improved 
outcomes. 
Introduction: 
 
Colorectal cancer (CRC) remains one of the world’s most common forms of cancer and is the 
second most common cause of cancer death in the UK, with a significant financial burden in 
terms of hospital stay and oncological, endoscopic and surgical treatments. The importance 
of CRC is such that it is one of only three types of cancer along with breast and cervical 
cancer to have a national screening programme in the UK (1).  Its incidence has continued to 
increase, in part due to increased detection in the Bowel Cancer Screening Programme 
(BCSP) (2).  
 
Although the development of CRC is multi-factorial, approximately 90% of cases are 
understood to result from the malignant transformation of benign growths (polyps) in the 
lining of the bowel wall into adenocarcinoma over time.  These growths are known as 
adenomas or adenomatous polyps and the process is known as the ‘adenoma to carcinoma 
sequence’ (3). 
 
The most effective established modality of colorectal cancer prevention is the removal of 
adenomatous polyps in the symptomatic population and in the asymptomatic population via 
the BCSP (4). 
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Large colonic adenomas confer a significantly higher risk of malignant progression than 
smaller polyps and a significant proportion of this group may already harbour malignancy 
(5).  Their removal is vital but also more complicated than standard polyp removal in 
colonoscopy (polypectomy), in terms of being able to achieve successful clearance and in the 
prevention of complications such as heavy bleeding and a perforation of the bowel wall.  As 
such, they have traditionally been managed surgically (5, 6).  
 
However, newer advanced endoscopic techniques, such as endoscopic mucosal resection 
(EMR) that uses a submucosal fluid injection and snare resection, have increased in use.  
EMR is now widely used for the management of large colonic polyps in the UK and 
internationally, not just in high volume tertiary referral centres but increasingly in smaller 
district general hospitals and is now considered first line management (7, 8).    
In the appropriate circumstances, EMR is efficacious in the safe removal of large colonic 
adenomas, thus preventing adenocarcinoma via the adenoma-carcinoma sequence (5, 9).  In 
addition, it has significant benefits as it is associated with reduced procedural cost, length of 
hospital stay and co-morbidity than surgical methods (10, 11).  However, it should be 
considered that it is an advanced, technically difficult procedure and is associated with a 
potentially high rate of potentially life-threatening complications such as bowel perforation 
and severe bleeding.  In addition, unsuccessful EMR with residual or recurrent tissue growth 
can result in more complicated management,  often secondary surgical management, and 
the development of colorectal cancer (12).   
 
Although surgical management of large colonic polyps has reduced greatly, it is still accounts 
for up to 10% of all colonic polyps managed.  Less invasive forms of surgery such as 
laparoscopic (keyhole) surgery have largely replaced open surgery, but whilst shown to be as 
effective, have similar morbidity rates to open surgery (11, 13).  Endoscopic management 
may not be appropriate in certain circumstances. These include situations where certain 
characteristics of a polyp make complete endoscopic removal unlikely, or increase the 
likelihood of serious complications, or where there is a high risk of cancer within the lesion.  
These factors include the size, location in the colon and access to a lesion to allow a stable 
position for its removal (6), or where endoscopic features may suggest  a lesion to be 
cancerous and have deeper invasion into the bowel wall with possible nearby malignant 
spread (14-16).   In these cases endoscopic removal with EMR may be insufficient and likely 
delay definitive treatment, with surgical removal of the affected bowel required as first line 
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management.  Conversely, certain large polyps with no features suggestive of cancer may 
unnecessarily be managed surgically, which increases costs and exposes a patient to 
unnecessary hospital stay and potential increased morbidity and mortality (11). 
 
These factors highlight the great importance of the decision making process when 
considering how to manage large colorectal polyps.  Key decisions include when endoscopic 
treatment (endotherapy) or surgical management should be used in the first instance, and in 
the case of the former, who should be undertaking the procedure if high complexity is 
identified (6). 
 
There is a limited evidence base for the management of large colonic polyps and it could be 
argued that this results in management being subjective and less than optimal in many 
cases.  No prior structured guidelines or consensus framework exist for the endoscopic 
management of large non-pedunculated colorectal polyps (LNPCPs) including EMR, or the 
decision making process when deciding on an optimal management strategy, and the 
possibility exists for wide variation in practice, including decision making and the 
deployment of available equipment.  Recent figures from the BCSP demonstrated 
considerable variation in the management of LNPCPs, even by experienced endoscopists 
(17).  In addition, recent surveys not only suggest a wide variety in polypectomy practice, but 
also a wide range of experience of those tackling complex lesions endoscopically. In 
addition, over 50% of responders to these surveys who practice EMR stated that they were 
self-taught (18, 19). Incomplete excision rates vary between individual endoscopists, with 
variation wider as polyp size increases (20). In addition, the surgical and endoscopic services 
available for the management of LNPCPs appear to differ between centres and this may also 
influence management.  
 
Reported complication rates and negative outcomes vary significantly, even between 
different study groups at high volume centres. Varying endoscopist skills and a lack of 
standardised evidence-based practice may account for this (17, 21). 
 
Trials asserting good EMR outcomes have stressed the importance of using standardised 
polyp assessment and management at all stages of the endoscopy process (5, 22). It has also 
been speculated that additional modalities, such as the use of multidisciplinary meetings 
(MDMs) may better coordinate and improve outcomes as is considered to be the case in 
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other specific conditions (23, 24).  Whilst variation in certain aspects of management such as 
endoscopic technique may not be problematic if comparable outcomes are achieved, it may 
be of benefit to teach standardised practice where possible for those seeking to develop 
EMR skills.  This is already felt to be the case in conventional polypectomy where a 
standardised training and accreditation framework is now used.  In addition, in the USA, 
whilst there is no detailed programme for training in LNPCP endoscopic management, 
various principles relating to lesion assessment and equipment use have been advocated in 
a ‘core curriculum’ (25). There appears to be strong opinion within the endoscopic 
community that a more coordinated, evidence based approach is required for large colonic 
polyps and that it may improve the decision making processes and ultimately the outcomes 
achieved.  This is likely to involve ensuring that individual endoscopists are able to ensure 
minimum acceptable standards through the identification of key performance indicators 
(KPIs) and guidelines for best practice which as yet do not exist.   It does not seem likely that 
improving outcomes will involve centralising advanced endoscopic polyp removal to tertiary 
centres.  Although the bulk of EMR cases take place in high volume tertiary centres, there 
have been reports of favourable outcomes in the district hospital setting (8, 26).  
   
Programmes such as the BCSP have sought to unify and standardise endoscopic practice and 
associated outcomes.  A sizeable proportion of LNPCPs are managed within the BSCP, by 
highly experienced endoscopists.  This is perhaps due to the nature of patients involved who 
have provided abnormal stool samples containing occult blood (positive faecal occult blood 
test (FOBt)). In addition, detailed and accurate data for both units and individual 
endoscopists is recorded and scrutinised both locally and nationally within a BCSP database 
for all therapeutic procedures performed with close regional alignment and data-sharing.  
These factors suggest that the BCSP provides a suitable population for work seeking to 
improve LNPCP management and to test new measures.  Improvement in the management 
of LNPCPs is proposed via the following. 
 Appraising and collating the evidence currently available 
 Identifying areas where further evidence is required 
 Building on the evidence base for the evaluation of LNPCPs by the development and 
validation of a lesion assessment tool to improve the decision making process 
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 Using national expert consensus to develop a standardised management algorithm 
and to identify key performance indicators that allow measurement and evaluation 
of polypectomy performance 
 Providing a model for apprenticeship and training in LNPCP management 
 Assessing the efficacy of these measures through an endoscopic multidisciplinary 
network to improve the decision making process and optimise management. 
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Chapter 1: A Review of the Literature  
 
1.1)  Colorectal Polyps: An Overview 
Colorectal polyps exist in several different forms and can be subdivided as hyperplastic, 
adenomatous, metaplastic, inflammatory and serrated (27). 
Adenomas can undergo malignant transformation to become an adenocarcinoma via the 
adenoma to carcinoma pathway.  Adenomas contain abnormal glands with a varying amount 
of villous tissue and so can be subdivided as being tubular, tubulovillous and villous (27, 28). 
The ‘adenoma-carcinoma sequence’ is the most important described pathway for the 
development of colorectal cancer and is thought to account for up to 90% of CRC cases (29, 
30). The removal of adenomatous polyps using colonoscopy and endoscopic resection 
(polypectomy) has been shown to be the most effective method of reducing CRC incidence.  
The US National Polyp Study (1993) conducted a prospective cohort study (n=1418) of 
patients who underwent a colonoscopy with > 1 adenoma removed with a mean follow-up 
of 5.9 years.   In comparison with three reference groups used to calculate expected 
incidences of CRC of 48.3%, 43.4% and 20.7%, reductions in CRC  of 90% , 88% and 76%  
(p<0.001) respectively were reported (4).  These findings confirm the importance of 
polypectomy as an essential skill for endoscopists. 
Various genetic alterations have been implicated in the adenoma-carcinoma sequence.  
These include mutations of the adenomatous polyposis coli gene, mutation or over-
expression of the p53 gene with allele loss at chromosome 17p, and allele loss at the 
chromosome 18q region (encompassing the tumour suppressor genes SMAD 2 and SMAD 4) 
(31). 
Other evidence to support the adenoma to carcinoma sequence includes: 
 The presence of adenomatous tissue in CRC resection specimens (32) 
 Increased incidence of malignant cells in larger adenomas (33) 
 The similar distribution of adenomas and carcinomas seen in the colon (34)  
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1.1.1)  Polyp Morphology 
Structural features are commonly used to classify polyps with non-stalked polyps 
characterised as sessile (raised), flat and depressed lesions whereas stalked polyps are 
known as pedunculated lesions.  Polyps also exhibit surface pits and vasculature which can 
be used to further characterise a lesion.  The use of classification systems, although still not 
universal, appears important in characterising lesions.  Classification systems such as Paris 
Classification, NICE NBI and Kudo Pit pattern have been shown to be useful in the 
identification of possible malignant features in lesion assessment and assessing suitability of 
endoscopic resection and will be covered in greater detail later in this chapter.  
1.1.2) Polyps and Risk of Malignancy 
Polyp size, evidence of dysplasia and villous histology appear to be risk factors for 
subsequent malignant transformation.  A 1987 study documenting the natural history of  
unmanaged colorectal polyps >1cm found the risk of diagnosis of cancer at the polyp site at 
5, 10, and 20 years was 2.5%, 8%, and 24% respectively.  Polyps under 1cm appear to have a 
vastly lower risk of malignant transformation (3).  A retrospective analysis of 751 patients 
with polyps < 1cm found only 18 cases of CRC in over 10,000 person-years of follow-up, 
whereas 15.27 cases were expected (relative risk, 1.2) (35).   These findings were supported 
in a 1992 study (n=1618) where patients with adenomas >1cm were associated with a 
significantly higher risk of colorectal cancer on multivariate analysis (OR: 2.4, p<0.001).  The 
risk of colorectal malignancy also appeared to increase further with increased size (Rectal 
cancer standardised incidence ratio (SIR): 0.6 (95% CI: 0.2-1.5) vs. 2.1 (95% CI: 0.8-4.3) vs 2.6 
(95% CI: 0.5-7.6), p=0.02)), (Colonic Cancer SIR: 1.5 (95% CI: 0.8-2.4) vs 2.2 (95% CI: 1.1-4.6) 
vs 5.9 (95% CI: 2.8-10.6), p=0.002)(36).  The study also identified the degree of villous 
histology as a significant risk factor for malignancy on multivariate analysis (OR: 4.1, 
p<0.0001) (36).  The amount of dysplasia (high grade/low grade) was also identified as a 
significant risk factor for malignancy on univariate but not multivariate analysis (Rectal 
cancer SIR: mild dysplasia (0.6 (0.2-1.5)) vs moderate dysplasia (1.5 (0.5-3.4)) vs severe 
dysplasia (5.1 (1.6-11.9), p=0.003) (Colonic cancer SIR: mild dysplasia (1.4 (0.7-2.3)) vs 
moderate dysplasia (3.4 (2.0-5.4)) vs severe dysplasia (3.3 (1.1-8.0)), p=0.01).  Muto et al 
(1975) reported similar findings in an analysis of 2552 polyps felt to be benign.  With regards 
to the degree of atypia, malignancy was found in 5.7%, 18% and 34.5% in lesions with mild, 
moderate and severe dysplasia respectively.  Malignancy was found in 4.8 % of tubular 
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adenomas, 22.3% of tubulovillous lesions and 40.7% of lesions with villous histology.  Lesion 
size over 2cm appeared to be a strong predictor of malignancy.  Malignancy was found in 
only 1.3% of lesions under 1cm, rising to 9.5% with lesions 1-2cm in size with almost half of 
lesions >2cm (46%) malignant (32). Recent estimates suggest that 10-15% of non-
pedunculated lesions > 2cm may harbour malignancy and the increased risk of malignancy 
along with the more complicated nature of their removal (see later) suggests that these 
lesions are deserving of separate consideration (37). 
 
1.1.3)  Malignant Polyps 
A malignant polyp may refer to a macroscopically benign appearing lesion in which 
adenocarcinoma is found in the resection specimen on histological examination.  The degree 
of dysplasia has been found to have a clear association with risk of the polyp harbouring 
malignancy (38). Management of malignant lesions generally requires oncological surgical 
resection including associated lymph nodes as endoscopic removal does not remove or 
sample the lymph node drainage basin and so may be insufficient.   Endoscopic attempts at 
removal of lesions subsequently found to be malignant have increased, in part due to 
increased recognition of adenomas during the bowel cancer screening programme.  Whilst 
in many cases this may be due to incorrect assessment of a lesion, in certain cases, ‘en-bloc’ 
removal either endoscopically or surgically (removal of lesion in one whole piece) may be 
sufficient management in the case of superficial submucosal invasion (37, 38).  The depth of 
invasion of a lesion is an essential criterion in determining whether endoscopic resection is 
appropriate, as deeper invasion is associated with an increased risk of lymph node 
metastasis (16). The risk of residual or recurrent tissue is another important consideration 
when considering the possibility of en-bloc removal of a lesion containing adenocarcinoma 
(39). 
Stalked (pedunculated) lesions, although easier to remove endoscopically, may also carry a 
risk of malignant submucosal invasion (40).  Haggitt introduced a classification system for 
pedunculated tumours (see figure 2) which classified lesions based on the depth of invasion 
of adenocarcinoma (40).  Lesions with Haggitt levels 1-2 are felt to be appropriate to remove 
endoscopically with malignancy confined to the polyp head and incidence of lymph node 
metastases thought to be less than 0.3%.  Whilst there is some debate about the suitability 
of level 3 lesions for endoscopic resection, level 4 lesions are associated with submucosal 
involvement, a markedly higher risk of lymph node spread and often require surgical 
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resection (40).  As with benign lesions, the removal of malignant pedunculated lesions is 
more straightforward than with non-pedunculated lesions and can be achieved in an en-bloc 
fashion routinely.  A 2005 series (n=453) reported successful endoscopic resection in 85.4% 
of cases of malignant pedunculated lesions compared with 46.3% of non-pedunculated 
polyps (p<0.0001) (41). A model describing levels of submucosal invasion in malignant 
lesions in 3 levels after dividing the depth of the submucosa into thirds (sm1, sm2, sm3) is 
also established, known as Kikuchi levels (16, 42). The depth of invasion was found to 
correlate with the risk of lymph node metastases with moderate (sm2) and deep (sm3) 
submucosal invasion strongly associated with a higher risk of lymph node metastases than 
superficial (sm1) invasion (n=182, p<0.01) (16). Deep submucosal invasion (sm3) has been 
reported to have an incidence of lymph node metastases of up to 25% compared with  3% 
and 8% for sm1 and sm2 lesions respectively (p=0.001) (37, 39). In addition, the requirement 
of surgical resection as definitive management for sm3 lesions has been reported uniformly 
in multiple case series (39, 43). Whilst it may be possible to achieve adequate endoscopic 
removal of lesions with superficial invasion (<1000µm), where the risk of lymph node 
metastases (LNM) involvement is less likely, recording an accurate description of 
submucosal invasion may prove difficult and render successful endotherapy less feasible.  A 
2002 retrospective series (n=353) also identified lymphovascular invasion (p=0.005) and 
location in the lower third of the rectum (p=0.007) as consistent with a significantly 
increased risk of LNM (39). 
Where a concern about malignancy exists, adequate specimen retrieval is of paramount 
importance to allow optimal histological analysis staging and management.  An important 
oncological principle underpinning this is en-bloc lesion resection where possible, which 
allows the identification of resection margins and completeness of resection, the depth of 
lesion invasion and other prognostic features.  Piecemeal resection provides suboptimal 
histological specimens meaning that these features cannot be identified.  In the discovery of 
malignancy in this scenario, formal resectional surgery is often required to ensure definitive 
assessment and treatment.  A 2005 meta-analysis (n=1900) identified positive resection 
margins (OR: 22, p<0.0001), poorly differentiated carcinoma (OR: 9.2, p<0.05) and vascular 
invasion (OR: 7, p<0.05) as major risk factors for LNM whilst a 2012 series found 
indeterminate resection margin status, a frequent issue with piecemeal removal, to be 
strongly associated with residual/recurrent disease (n=143, resection margins <1mm: 16%, 
indeterminate margins: 21%, negative resection margins (>1mm): 0%, p=0.009) (41, 44).  
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Further details regarding assessment and management in the context of suspected 
malignancy are described later in this chapter. A summary of the histological features 
conferring poor prognostic features in malignant polyps and necessitating formal oncological 
resection is described below: 
 Poor differentiation 
 Lesions with submucosal invasion >1000µm  
 Resection margins < 1mm 
 Evidence of lymphovascular invasion 
 Incomplete resection or inability to detect resection margins (associated with 
piecemeal removal) 
 Location in lower third of rectum 
      Figure 1.  Poor prognostic histological features. (37, 38, 41, 44) 
 
 
Haggitt Level                           Description 
0 Malignancy confined to mucosa 
1 Invasion of submucosa but limited to the head of a polyp 
2 Invasion of malignancy extending to neck of a polyp 
3 Invasion of malignancy extending to polyp stalk 
4 Invasion of malignancy beyond stalk into submucosa but above 
muscularis propria 
Figure 2.  Anatomic landmarks of pedunculated and sessile malignant polyps  
with respect to Haggitt level. (37, 40) 
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Figure 3. Depth of submucosal invasion in sessile malignant polyps; Sm1: Invasion into upper third, 
Sm2: Invasion into middle third, Sm3: Invasion into lower third. (37) 
 
1.2) The NHS Bowel Cancer Screening Programme 
A large proportion of large colonic polyps are now identified by the NHS Bowel Cancer 
Screening Programme which has been in operation in England since 2006.  The early 
identification of malignant colonic tumours may be associated with improved patient 
prognosis, less complicated surgery and reduced treatment costs. This factor combined with 
the ability to identify and remove adenomas before malignant development suggests that 
colorectal cancer is amenable to screening and numerous studies have examined various 
approaches to colorectal cancer screening.  
Whilst colonoscopy is the ‘gold-standard’ test for the identification of adenomas and 
colorectal cancer, it is not considered economically nor logistically viable to use mass 
population screening with colonoscopy in the UK as healthcare resources do not permit this. 
The potential harms and risks of colonoscopy also need to be taken into account (17).  
Faecal occult blood testing (FOBt), first described in 1967, allows mass population screening, 
is economically viable and is both safe and acceptable for patients.  Identified high risk 
asymptomatic individuals undergo subsequent colonoscopy. Larger adenomas and colorectal 
cancers tend to bleed intermittently, meaning that the detection of blood in the faeces by 
FOBt may allow their detection (45).  
1.2.1) Predicted outcomes of Bowel Cancer Screening 
Based on data from the pilot studies around 98 in 100 people will receive a normal FOBt 
result and will be returned to routine screening. They will be invited for bowel cancer 
screening every two years if still within the eligible age range. 
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Around 2 in 100 people receive an abnormal result and will be offered a colonoscopy. 40-
50% of patients who go onto to have colonoscopy will be found to have one or more 
adenomas. Around 10% will be found to have bowel cancer (46). 
1.2.2) Colonoscopy and Polypectomy in the Bowel Cancer Screening Programme 
 Adenomatous colonic polyps are a precursor to colorectal cancer and have malignant 
potential if left untreated over time with change to adenocarcinoma (3).   
Patients with abnormal FOBt (those with 5-6 abnormal windows) are referred for 
colonoscopy at an accredited national bowel cancer screening centre.  Given the established 
relationship between adenomatous and serrated colonic polyps with malignant 
transformation, and up to a 90% reduction in CRC due to polyp removal, polypectomy is 
considered an essential skill for BCSP colonoscopists. In the context of an abnormal FOB 
result, a large number of polyps including large polyps are anticipated to be diagnosed 
within the BCSP(47).  As approximately 10% of adenomas discovered at colonoscopy are 
over 1cm in size and have greater malignant potential than smaller lesions, the importance 
of BCSP endoscopists being competent to successfully remove these larger lesions is 
apparent (3, 47). 
In the BCSP, all colonoscopies are performed at an accredited centre with strict protocols 
and auditing of individual performance data.  Screening colonoscopists are experienced 
individuals who have performed over 1000 colonoscopies, have extensive experience of 
performing polypectomy and have been through a comprehensive certification process 
involving both a written and practical assessment.  Polyp identification and assessment form 
vital components of BCSP colonoscopy.  Adenomatous polyps identified during colonoscopy 
are removed with snare polypectomy or advanced resection techniques such as endoscopic 
mucosal resection (EMR) where possible.  Subsequent follow-up is based on the endoscopic 
findings (see figure 3) with low risk patients not requiring surveillance in the BCSP.   
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Figure 4- BSG Adenoma surveillance guidelines (48). 
 
1.2.3) The Management of Large Colorectal Polyps in the Bowel Cancer Screening 
Programme 
The BCSP manages a large proportion of large colorectal polyps within the UK.  A 2013 BCSP 
case series (n=557) LNPCPs asserted the safety and effectiveness of the management of 
large colonic polyps in the BCSP (17). 78.3% were managed endoscopically in the first 
instance with 16.1% of these lesions subsequently requiring surgery meaning that of the 
endoscopically managed cases, 366 (83.9%) were managed successfully and required no 
further management.  The increased complexity associated with the endoscopic removal of 
larger LNPCPs was reflected by an increase in both endoscopic procedures and surgical 
therapy as lesion size increased, however, low rates of complications were reported 
(perforation and post polypectomy bleeding 0.5% and 3% respectively) (17).  The outcomes 
of this case series appear comparable to various international series, suggesting that LNPCP 
management within the BCSP is effective. 
 
1.2.4) New developments in the Bowel Cancer Screening Programme  
As larger adenomas and colorectal cancers bleed only intermittently, FOBt may miss up to 
50% of these lesions and improvements to the BCSP have been investigated.  Population 
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screening with flexible sigmoidoscopy was shown to be more sensitive and specific for distal 
cancers and polyps than FOBt) (49).  30-40% of cancers arise proximal to the reach of the 
sigmoidoscope and thus would be missed.  However, distal adenomas may serve as a marker 
for more proximal lesions and would prompt colonoscopy in such patients(49).  
A randomised controlled trial of one-off sigmoidoscopy between the ages of 55 and 60 
demonstrated a 23% reduction in colorectal cancer incidence and a 31% reduction in 
colorectal cancer mortality (49).  In view of these findings one off flexible sigmoidoscopy 
screening for patients aged 55 or over has been piloted from March 2013 to complement 
FOBt with national rollout anticipated in 2017 (46).   
 
 
1.3) The Removal of Colonic Polyps  
Diminutive (<5mm) and small lesions (5-9mm) can be removed in a number of ways.  In 
addition to conventional snare polypectomy, removal by cold biopsy forceps and cold 
cutting with a snare (cold snare polypectomy) is possible.   Forceps removal with the 
addition of diathermy known as ‘hot biopsy’ removal can be used to remove diminutive 
lesions, especially where the position of a lesion makes entrapment with a snare difficult. 
However, this technique is associated with greater thermal tissue injury than snare 
polypectomy and its use is now often avoided, especially in the thinner right colon (50). 
Pedunculated polyps are considered easier to remove endoscopically than sessile and flat 
lesions, although large lesions with broad stalks in a less spacious part of the colon such as 
the sigmoid colon may be more complex (51).  Although there is a reduced risk of 
perforation when compared to sessile polyps, pedunculated polyps with broader stalks (over 
1cm) are associated with increased post-polypectomy bleeding due to the presence of large 
blood vessels in the stalk and often require the use of interventions such as intra-stalk 
adrenaline injection, clip placement and endoloop either pre or post polypectomy (46). 
The removal of LNPCPs appears more complex than with smaller non-pedunculated 
colorectal polyps (NPCPs) under 2cm in size.   Key LNPCP assessment and management 
principles are described below: 
 
Endoscopic resection is recommended as first line therapy for the removal of large non-
pedunculated colorectal polyps (LNPCPs)  
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Surgical intervention has historically been used to manage LNPCPs.  However, modern 
advanced endoscopic methods such as endoscopic mucosal resection (EMR) and more 
recently, endoscopic submucosal dissection (ESD) have been developed, allowing 
endoscopic removal of even very large lesions, thus reducing the need for surgery (Moss et 
al, 2010).   EMR is an endoscopic technique where a mucosal lesion is lifted away from the 
underlying submucosa by injecting fluid around and underneath it to create a ‘submucosal 
cushion’. The polyp is then removed using an electrocautery snare in either an en bloc (one 
piece) or piecemeal fashion (where multiple smaller pieces of a lesion are sequentially 
removed to achieve complete resection) (52). 
Endoscopic submucosal dissection (ESD) is a more advanced and technically challenging 
technique that allows en-bloc retrieval of larger lesions. Its availability is still very limited in 
the Western World as opposed to EMR which is widely available, whilst technical 
considerations such as procedure time and a higher level of perforation (up to 10%) have 
also limited the feasibility of its uptake in a non-Japanese setting(53).  These factors ensure 
that EMR currently appears the most viable option for LNPCPs that are presumed benign 
until proven otherwise. Therefore, whilst ESD is discussed in more detail later in this chapter, 
endoscopic removal via EMR is covered in greater detail in this thesis. (54, 55).   
In the appropriate setting, endoscopic resection provides highly effective management of 
LNPCPs with success in approximately 90% of cases. The ACE study demonstrated treatment 
success in 91% of treatment naive lesions and 74.5% of previously attempted lesions, with 
89.2% of LNPCPS successfully removed in a single session (5).  In addition, a 2012 US study of 
315 ‘defiant’ polyps referred to an expert centre reported successful endoscopic single 
session removal in 91% of cases whilst a 2013 UK study (n=220) demonstrated successful 
endoscopic treatment in 96% of cases with 87.5% of LNPCPs felt to be the most complex 
(SMSA level 4) successfully removed (9, 56).  The economic argument for endoscopic 
management as first line treatment is strong.  In addition to a cost saving of £3301.31 
($5108.45) per patient compared to surgery demonstrated by Longcroft-Wheaton et al, an 
Australian study of 186 LNPCPs with a mean size of 30mm demonstrated similar findings.  
Cost savings of $6990 USD per patient  were estimated, with an average reduction of 
hospital stay of 6.7 days as advanced polypectomy can commonly be performed as a day-
stay procedure (10, 56).  Endoscopic removal appears safer than surgical resection which has 
reported rates of morbidity and mortality of 20% and 1% respectively (11).  Whilst there is a 
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concern about a high level of early lesions recurrence with piecemeal endoscopic resection 
(pEMR), repeated endotherapy is often successful in achieving complete resection with 
comparable efficacy to en-bloc techniques in the longer term.  Reported recurrence figures 
after 12 months vary between 2-6.9% (5, 9, 57) 
 
          Table 1.  A comparison of outcomes from trials of endoscopic management of NPCPs 
   
1.3.1) Optimising service delivery for large colorectal polyps 
 A structured LNPCP referral pathway may allow patients access to a full range of 
therapeutic services, including laparoscopic surgery and endoscopists capable of 
performing endotherapy on complex NPCPs   
 
A structured referral pathway may allow better inter-specialty communication with more 
timely and efficient management of LNPCPs (58).  A pathway enables the creation of an 
audit trail and subsequent monitoring of performance. It is desirable that patients, 
irrespective of their location, should have access to a full range of management options that 
minimises the risk of morbidity and mortality. This includes access to endoscopists capable 
of performing advanced therapy on LNPCPs. In expert hands, over 90% of lesions may be 
 Moss et al (2011) BCSP (Lee et al, 2013) Buchner et al (2012) Longcroft-Wheaton 
et al (2013) 
Number of NCPCs 479 436 308 187 
Mean size (mm) 35.6 29.5 23 41.5 
Cases with complete 
resection considered 
achieved after single 
session (%) 
89.2 NA 91 90% 
Malignancy in resection 
specimen (%) 
6.9 6 4.4 5.9 
Need for surgery (%) 16.3 16.1 10 9 
3 month recurrence (%) 20.4 16.5 27 14.5 
12 month recurrence 
(%) 
2 6 16.3 3.9 
Delayed Bleeding 2.9 3 7.2 2.7 
Perforation 1.3 0.5 0.4 0.45 
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successfully removed, and surgery avoided, including lesions previously felt to be 
endoscopically unresectable (5, 9, 59).   
 
The management of rectal lesions also requires special consideration given the availability of 
specific therapies, the complexity and morbidity associated with resectional surgery in this 
area and the possible need for a permanent stoma (60).  In this context it is important to 
differentiate between complex benign polyps (the main subject of this thesis) and early 
rectal cancer (stage I rectal cancer), where the indications for specific interventions, type of 
interventional procedures used and outcomes are often different.  The management of 
rectal LNPCPs is discussed in greater detail later in the chapter. 
 
The provision of advanced endoscopy services is also likely to be more cost effective for 
hospital trusts given the reduced costs associated with endotherapy and so a regional 
referral network may be appropriate if the necessary expertise is not available locally (56).   
In the case of lesions where surgery is required, laparoscopic surgery appears preferable as a 
minimally invasive option with an equivalent lesion resection rate and accelerated post-
operative recovery (61)  
 
Improved endoscopist experience results in improved outcomes  
 
Whilst advanced polypectomy is an effective modality in most circumstances, the increased 
technical demands mean that the potential for serious complications such as haemorrhage 
and perforation is higher than for standard snare polypectomy. Patient safety is paramount 
and the ability to accurately identify underperformance allows prompt remedial action (2, 
62).  In addition, failure to achieve complete resection complicates further management and 
means the risk of subsequent malignancy is sub-optimally managed (63). Increased 
endoscopist experience is associated with superior outcomes.  A 2002 study comparing 
endotherapy outcomes between an expert and non-expert group reported significantly 
increased successful LNPCP clearance by the expert group (76% vs 40%, p=0.01) (12).  As 
previously discussed, endoscopist inexperience conclusively appears to impact directly on 
patient safety with an increased rate of adverse events.  An almost 3 fold increase in the risk 
of heavy bleeding and perforation with the least experienced endoscopists  and significantly 
increased adverse events for therapeutic colonoscopy with less experienced endoscopists in 
large volume trials strongly highlights the importance of endoscopists managing LNPCPs 
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independently gaining sufficient experience beforehand (64-66).  Technical endotherapy skill 
appears to vary widely even amongst experienced endoscopists.  The CARE Study (n=418) 
found outcomes of incomplete resection varied widely between endoscopists of similar 
experience.  The incomplete resection rate for polyps thought to have been completely 
resected was higher than expected (IRR): 10.1% (95% CI: 6.9%–13.3%), and increased 
significantly with larger polyp size (IRR 10-20mm vs <10mm: 17.3% vs 6.8%, p=0.003) (20).  
 
These findings suggest that advanced endoscopic polypectomy is not a universal skill as 
quality between endoscopists appears to vary markedly.  The auditing of outcomes using 
identified key performance indicators (KPIs) may ensure that endoscopists managing LNPCPs 
independently are able to demonstrate competency with consistent high quality outcomes 
and result in improved outcomes and safety (59, 67). 
 
A multidisciplinary network may provide more robust LNPCP assessment and management to limit 
unnecessary surgery and ensure that all therapeutic options have been explored  
 
There is increasing support for multidisciplinary management of large complex polyps. Key 
stakeholders include those who may remove these lesions and those that can help to 
differentiate between benign and malignant LNPCPs and/or are able to establish whether 
successful management has occurred.  Relevant specialists would likely include a LNPCP 
endoscopist, a laparoscopic colorectal surgeon and a gastrointestinal histopathologist.   
Positive reports of the use of a specialised multidisciplinary team meeting (MDM) within the 
fields of gastroenterology and endoscopy have commented on increased, more rounded, 
clinician input contributing to a more robust decision-making process and closer analysis of 
the range of management options (8, 23). A 2011 analysis compared the effect of 
management of a benign hepatopancreatobiliary MDM prior to ERCP compared to control 
cases in a prospective study of 1909 patients. The use of an MDM was associated with 
improved safety, with a decreased overall complication rate of (6.9% vs. 12.0%, p<0.001) 
and severe complication rate (0.4% vs. 2.5%, p=0.035))(24). Increased interaction between 
endoscopists and colorectal surgeons may allow all possible management options to be 
evaluated.   The capabilities and quality of endoscopists is not uniform and growing evidence 
suggesting that many LNPCPs initially felt to be endoscopically unresectable and therefore 
initially referred for surgery can be removed in an expert setting (20).  Friedland et al (2013) 
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reported that 71% of lesions initially referred for surgery without biopsy proven cancer were 
managed successfully endoscopically including 26% of lesions that had previous unsuccessful 
endotherapy whilst Moss et al (2011) and Longcroft Wheaton et al (2013) were able to 
achieve complete endoscopic resection in 74.5% of previously attempted lesions and 87.5% 
of the most complex NPCPS respectively (5, 56, 67).  It can be argued that the availability of 
a multidisciplinary network with access to an expert centre may result in increased 
endoscopic options and surgery being avoided in many cases (5, 56, 59).  This appears 
preferable given the increased cost, mortality and morbidity associated with surgery (10, 
11). The discussion of benign lesions in a complex polyp MDT setting prior to surgical 
resection may allow more robust assessment of a lesion. As well as an interaction with 
colorectal surgeons, the additional involvement of endoscopists, including those with 
established competency in the removal of complex LNPCPs, may make endotherapy more 
feasible and avoid the use of surgical resection in some cases (59).  Close interaction with a 
histopathologist may also be facilitated to obtain and establish comprehensive information 
about the adequacy of histopathology specimens, the possibility of malignant features, and 
establishing whether complete resection post endotherapy can be determined. 
 
Timely management of LNPCPs is desirable due to the associated risk of malignancy 
 
It appears logical to ensure that patients diagnosed with LNPCPs do not wait for 
inappropriately long periods of time for therapy in view of the risk of malignancy in this 
patient group with up to 15% of NPCPs thought to already harbour malignancy (68). 
However, this is balanced with ensuring that patients are managed by endoscopists with the 
appropriate expertise rather than being purely target driven where a patient may be 
managed by an inappropriate endoscopist to ensure a timeframe target is met.  A timeframe 
in line with Department of Health policy that all diagnostic procedures should take place 
within six weeks may not be feasible from a service provision point of view in ensuring that 
therapy is undertaken by an endoscopist with the requisite expertise.  There is also a need to 
ensure that a lesion has been adequately assessed either at the referring or receiving centre 
prior to therapy, which may necessitate additional diagnostic endoscopy and assessment 
time to ensure optimal management.  A target more aligned with the NHS 62 day treatment 
target pathway may prove more feasible (69).  Whilst the exact time sequence for adenoma 
to carcinoma transformation with NPCPs is unclear, growth model studies have sought to 
estimate progression times.  A 2001 polyp growth model  study reported a transformation 
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rate  of 3% per year for lesions > 1cm and 20% per year for lesions with carcinoma  in situ 
(70).  A barium enema pre-colonoscopy study of polyps  > 1cm left untreated between 12 
and 229 months estimated a cumulative risk of cancer at the polyp site at 5, 10 and 20 years 
as 2.5%, 8% and 24% respectively (3).   Whilst this data is not specific for LNPCPs it appears 
unlikely that a projected time frame of several weeks will compromise patient safety as 
there is no evidence that patients will come to harm in this time period, including with 
lesions that may harbour malignancy, whilst more time is available to ensure that an 
appropriate endoscopist is available. 
 
Piecemeal endoscopic therapy appears inadequate if malignancy is suspected   
 
An important oncological principle is that malignancy is removed in an en-bloc fashion.    
Rationale for this includes strong evidence that en-bloc lesion removal is associated with a 
lower level of lesion recurrence and a higher early cure rate than piecemeal resection (71).  
In addition, en-bloc resection allows precise histological analysis such as definitive 
evaluation of lateral and vertical resection margins and depth of invasion and as such is  
essential to ascertain the presence of favourable or unfavourable histological criteria (72, 
73).  En-bloc resection is difficult to achieve with lesions >2cm with EMR, however the 
likelihood of achieving this with LNPCPs is higher with endoscopic submucosal dissection 
(ESD), with various studies demonstrating en-bloc resection with this technique at a rate of 
approximately 90% (21).  A Japanese retrospective analysis comparing lesions managed by 
ESD (n=145, 66% containing malignancy) with EMR (n=228, 69% containing malignancy) 
demonstrated only 2% recurrence with ESD compared with 14% recurrence with EMR 
(p<0.0001), reporting a markedly higher cure rate with no significant difference in 
complications between the two groups (74).  Another comparison study between en-bloc 
endoscopic removal (ESD/EMR) and piecemeal resection (pEMR) of benign lesions reported 
a similar trend for recurrence (n=269, ESD: 0%, EMR: 1.4%, pEMR 12.1%, p<0.001) with 
similar complication rates (73).  Where there is a suspicion of malignancy on lesion 
assessment, whilst piecemeal therapy is suboptimal, there is evidence that en-bloc resection 
may be effective as both a diagnostic and therapeutic tool.  A 2012 Japanese retrospective 
series (n= 589) compared ESD outcomes for lesions with suspected but not proven 
malignancy at endoscopic assessment with those of laparoscopic surgery for early 
malignancy. En-bloc and curative resection was achieved in 87% and 80% of cases 
respectively with ESD, with  lower complication rates than with laparoscopic surgery(75).  A 
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2013 multicentre Japanese study reported outcomes from a series of lesions removed by 
ESD that were retrospectively found to contain submucosal malignancy.  Lesions were 
described as ‘low risk’ if they displayed negative vertical margins, were reported as well or 
moderately differentiated adenocarcinoma, displayed no lymphovascular invasion, and had 
an invasion depth < 1000 µm.  Lesions were defined as ‘high risk’ if any of these features 
were present.  In the low risk group 5 year recurrence free survival was reported in 98% 
managed with ESD, whilst figures of 87% and 97% were reported in the high risk group for 
lesions managed with ESD and ESD + surgery respectively (76).  However, whilst the 
potential efficacy of ESD is clear, as previously discussed, there are significant challenges 
with appropriate training, access and standardisation in a non-Japanese setting.  The use of 
multidisciplinary networks appears important in ensuring increased access to ESD for UK 
patients.   
Aside from surgical resectional therapy, the use of minimally invasive surgical therapy such 
as transanal endoscopic microsurgery (TEMS) resection in the management of rectal polyps 
can be used to achieve en-bloc resection of rectal lesions where malignancy requires 
exclusion.   TEMS for the management of rectal LNPCPs has been associated with lower rates 
of early recurrence with TEMS when compared with pEMR, in addition to allowing more 
robust histological examination.  It should be noted however that late recurrence rates 
appear equivalent when allowing for repeat EMR and that TEMS has been associated with 
longer hospitalisation (77).  TEMS is discussed in greater detail later in the chapter. 
Whilst piecemeal endoscopic resection (pEMR) is already established as resulting in a higher 
level of recurrence, the risk appears larger with malignant colorectal lesions.  One study 
examining the management of malignant LNPCPs with pEMR found recurrence to be 10 
times higher when compared with benign lesions (n=50, 33.3% vs 3.1%, p<0.05) whilst a 
2009 Japanese study (n=572) also reported significantly higher recurrence with piecemeal 
resection of malignant polyps compared with benign lesions (17.1% vs 25%, p<0.01) (78, 79).  
Whilst piecemeal endoscopic resection (pEMR) is already established as resulting in a higher 
level of recurrence, the risk appears even larger with malignant colorectal lesions.  One 
study examining the management of  large malignant polyps with pEMR found recurrence to 
be 10 times higher when compared with benign lesions (n=50, 33.3% vs 3.1%, p<0.05) whilst 
a 2009 Japanese study (n=572) also reported significantly higher recurrence with piecemeal 
resection of malignant polyps compared with benign lesions (17.1% vs 25%, p<0.01)(78, 79).  
Piecemeal EMR removal of malignant colorectal polyps has also been identified as an 
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independent risk factor for incomplete resection by a 2011 Korean study (n=236, OR: 3.365, 
95% CI: 1.295-8.744, p=0.013) (80). In addition, unlike en-bloc retrieval, it results in the 
retrieval of poorer quality histological samples and it is often not possible to evaluate the 
completeness of resection, depth of invasion, lateral resection margins and other prognostic 
features.  Surgery is often required in this scenario due to inadequate staging (56).  
The ability to evaluate resection margins is vital as it helps to ascertain completeness of 
resection and can predict the likelihood of residual disease.  A meta-analysis of 31 studies 
(n=1900) identified positive resection margins (< 1mm) as a strong risk factor for residual 
disease (OR: 22, p<0.0001) (41).  A finding of indeterminate resection margin status, a 
frequent issue with piecemeal removal, may also predict an increased risk of 
residual/recurrent disease as demonstrated by Butte et al (n=143, resection margins <1mm: 
16%, indeterminate margins: 21%, negative resection margins (>1mm): 0%, p=0.009) (44).  
Evaluation of the depth of submucosal invasion is also important as the depth of submucosal 
invasion has been shown to correspond to the risk of lymph node metastases.  A large 
analysis of T1 colorectal carcinomas in 2002 (n=7543) found that lesions with deep 
submucosal invasion (sm3) were associated with a highly significant risk of lymph node 
metastases (p<0.001)(39).  This supported the findings of a 1995 study that demonstrated 
that moderate (sm2) and deep (sm3) submucosal invasion was associated with a higher risk 
of lymph node metastases than superficial (sm1) invasion (n=182, p<0.01) (16).  This 
histological information is therefore vital in establishing whether a patient has been cured, 
their risk of recurrence and planning of relevant subsequent therapy.  
Whilst piecemeal endotherapy is effective in the management of benign lesions, in the 
context of malignancy, it seems less desirable to undertake an invasive treatment that is 
associated with a higher level of recurrence and incomplete resection, and often provides 
less useful information about definitive cure.  Also, in the context of endoscopic features 
suggestive of malignancy and possible lymph node metastases (e.g. non-lifting sign in 
treatment naïve lesions, Pit Pattern V, Paris 0-IIc, LST-NG, NICE Type III, Sano capillary 
pattern type 3), endoscopic therapy may be inadequate as it cannot sample or remove the 
lymph node basin whilst piecemeal therapy is likely to result in the retrieval of suboptimal 
histological specimens (37).   
Whilst endoscopic therapy has been used with success in lesions found to have early 
malignancy, it should be specified that this only applies to lesions identified as having low 
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risk of lymph node metastases. These are early invasive adenocarcinomas with negative 
resection margins (>1mm), minimal submucosal invasion, well or moderate differentiation 
and no lymphovascular invasion (81, 82).  Deep submucosal invasion (>1000µm), 
positive/unidentified resection margin status, poorly differentiation (OR: 9.2, p< 0.05) and  
lymphovascular invasion (OR: 7, p< 0.05) are identified as high risk features indicating 
significant risk of lymph node metastases and histological exclusion of these features is 
therefore vital before deciding on en bloc endoscopic removal as primary therapy (41).  
Special consideration should also be given in the context of rectal location which is also 
identified as an additional risk factor for lymph node involvement (39).   
In addition, concerns have been expressed about the potential for tumour seeding from the 
submucosa into deeper layers as a result of endotherapy in the context of malignancy, whilst 
malignant tumours may also be more vascular than non-malignant lesions and therefore 
more likely to be subject to a large volume bleed during endotherapy (83).  Another note of 
caution is that several reports indicate high level of residual malignancy on surgical resection 
specimens where complete polypectomy had been considered to have taken place.  A study 
of 143 malignant lesions managed endoscopically reported residual malignancy in 19% of 
cases whilst another analysis of 63 lesions resected endoscopically with a retrospective 
finding of early malignancy found residual malignancy in the colon wall and/or lymph nodes 
in almost 50% of cases managed surgically (44, 84).   
 
Conservative management may be appropriate on an individualised patient basis  
 
Whilst LNPCPs are associated with a risk of malignant transformation and may sometimes 
already harbour malignancy, the risk of symptomatic malignancy and cancer-related 
mortality from these lesions may be outweighed by patient factors that may more 
imminently reduce life expectancy. In this context, subjecting a patient to the additional 
immediate risks of endoscopic or surgical resection may not be in their best interests and 
the risks and benefits of undertaking therapy require consideration.  As previously discussed, 
adenoma to carcinoma transformation to a point where a lesion becomes symptomatic may 
take several years (70).  Patient factors requiring consideration include advanced age, frailty, 
comorbidities such as chronic cardiorespiratory conditions and other established 
malignancy.  The use of mortality index models may help to stratify individual patient risk 
prior to attempting invasive therapy.  One such example is a validated model proposed by 
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Schonberg et al using a scoring system predicting 5 year mortality risk based on performance 
status and comorbidities (see tables 2 & 3)  (85) 
 
Demographic Score 
Patient Age (Years)  
65-69 0 
70-74 1 
75-79 3 
80-84 5 
85+ 7 
  
Male Sex 3 
  
Smoking Status  
Never 0 
Former 1 
Current 3 
  
Body mass index <25 kg/m2 2 
  
Comorbid conditions  
COPD† 2 
Diabetes mellitus 2 
Cancer 2 
  
Overnight hospitalizations in past year  
None 0 
One 1 
Two or more 3 
  
Perceived health  
Excellent/very good 0 
Good 1 
Fair/poor 2 
  
Functional measures  
Dependent in at least one IADL† 2 
Difficulty walking several blocks 3 
Table 2. Schonberg Scoring System (85) 
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Point Score Estimated 5 year mortality risk (%) 
((5% Confidence Interval) 
0-1 3 (1-6) 
2-3 5 (3-8) 
4-5 8 (6-10) 
6-7 12 (10-15) 
8-9 19 (16-23) 
10-11 29 (25-33) 
12-13 37 (32-42) 
14-15 49 (43-55) 
16-17 55 (48-62) 
18+ 62 (54-70) 
           Table 3. Schonberg Score with corresponding estimated 5 year mortality risk (85) 
 
Procedural issues may also pose a concern about reduced life expectancy. For patients with 
increased age or severe comorbidity, both endoscopic and surgical therapy may prove 
hazardous, with the use of sedation and general anaesthetic posing a significant 
cardiopulmonary safety concern. An Australian study reported increased risk in 30 day 
mortality in non-cardiac surgery in patients over 70 (OR: 1.09 per year over 70 years, 95% CI: 
1.04-1.13, p<0.001) (86).  Increased surgical mortality and morbidity risk is an important 
factor as is consideration about whether a patient might survive a serious endoscopic 
complication and subsequent therapy. Conservative management may therefore prove an 
appropriate strategy where life expectancy is already greatly reduced. 
 
1.3.2) Pre-Removal Assessment 
 Adequate planning (including length of time booked for procedure, endoscopist and 
nursing staff skills and endoscopic equipment) may improve endoscopist confidence 
regarding achieving single session complete resection  
 
Given the potential complexity of advanced polypectomy, adequate planning is required for 
the procedure. In addition to the exclusion of features suggesting malignancy and potential 
complications related to endotherapy, an important aim, where possible, is to attempt 
complete endoscopic resection in a single session (87).  The significance of single session 
completion is reflected by its regular reporting as an important  outcome in large volume 
trials with approximately 90% success reported whilst the ACE study demonstrated an 
increased risk of resection failure in previously attempted lesions (OR 3.75; 95% CI: 1.77–
7.94; p=0.01) (5, 9).  Key to achieving this aim is ensuring adequate time is allocated for the 
procedure and that all relevant professionals and equipment are readily available (62).  
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Another important consideration is that the complete removal of a lesion after one session 
also reduces the risk of malignant transformation at the earliest opportunity (88). 
 
 
 
1.3.3) Lesion Assessment and Identification 
 Features in non-pedunculated colorectal polyps (NPCPs) associated with  increased 
malignancy risk, increased complexity in relation to achieving successful endoscopic 
removal and avoiding adverse events have been identified 
 The identification of large non-pedunculated colorectal polyps (NPCPs) associated with 
increased malignancy risk and increased complexity may lead to improved therapeutic 
outcomes and the avoidance of adverse events 
o Lesions with Increased risk of malignancy – Lesions exhibiting; pit pattern type V, 
Paris 0-IIc or 0-IIa+IIc morphology, non-granular LST (laterally spreading type 
polyp, LST-NG), granular LSTs (LST-G) with a dominant nodule, distorted surface 
pattern, colour and vessels (NICE NBI type III), thick and irregular microvessels 
(Sano capillary pattern type III)    
o Lesions with an increased risk of incomplete excision/recurrence – Size >40mm, 
location involving ileocaecal valve, appendix, diverticulum or dentate line; within 
an inflamed segment of colitis; prior failed attempt at resection or recurrence at 
site of previous resection (excluding unifocal, diminutive and easily 
resected/ablated residual adenoma on first site check); non-lifting sign after 
submucosal injection; endoscopist concern about difficult location (e.g. behind 
flexure or fold, in stenotic diverticular disease); 
o Advanced polypectomy is associated with a vastly higher risk of serious 
complications compared to conventional snare polypectomy.  Factors associated 
with a further increased risk of adverse events include caecal location, size >40mm 
and endoscopist inexperience    
o Complex NPCP- A term to describe NPCPs with any of the following features: (a) 
increased risk of malignancy; (b) increased risk of incomplete 
resection/recurrence; (c) increased risk of adverse event; (d) SMSA level 4 
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Lesions with Increased risk of malignancy – Lesions exhibiting; pit pattern type V, Paris 0-IIc or 0-
IIa+IIc morphology, non-granular LST (laterally spreading type polyp, LST-NG), granular LSTs (LST-G) 
with a dominant nodule, distorted surface pattern, colour and vessels (NICE NBI type III), thick and 
irregular microvessels (Sano capillary pattern type III)    
NPCPs with morphological features of depression (Paris 0-IIc/IIa+c) appear to strongly 
correlate with malignancy.  A 2002 Paris workshop quoted an unpublished study of 3680 
lesions where 61% of 0-IIc lesions displayed submucosal invasion. This was markedly higher 
than the morphological group with the next highest incidence of submucosal invasion (Paris 
Is: 34%)(15).  Lesions displaying surface characteristics of pit pattern Type V have also been 
shown to be strongly associated with deep submucosal malignant invasion. Specific analysis 
of lesions with type V pit pattern found a vastly higher incidence of malignancy compared 
with other pit pattern types (56% vs 4.4% (pit pattern III) vs 5% (pit pattern IV) vs 0% (pit 
patterns I + II),  n=479, p<0.001) (5, 89).  Other lesion surface characteristics also associated 
with an increased risk of malignancy include a non-granular surface or a dominant nodule 
(>10mm) on laterally spreading type lesions and irregular microvascular network patterns 
(Sano Capillary Pattern type III) (90, 91). 
LSTs may be divided into granular (LST-G) and non-granular (LST-NG) types (54). In a study of 
511 LSTs, the frequency of submucosal invasion with LST-NG type lesions was twice that of 
LST-G type lesions (14% vs 7%, p<0.01) (90).  Closer scrutiny of LST-NG type lesions suggests 
that pseudo-depressed LST-NG lesions are associated with a substantially higher risk of 
submucosal invasion than flat elevated LST-NG lesions. A Japanese study of 1363 LSTs of at 
least 10mm in size demonstrated submucosal invasion in 42.1% of pseudo depressed LST-NG 
lesions compared with 6.1% flat elevated LST-NGs (p<0.01) (92).  LST-G lesions with a 
nodule>10mm were also demonstrated to be strongly associated with submucosal invasion 
(>10mm nodule: (29.8%) vs<10mm nodule: (2%), OR: 71.01, p<0.001) (90).  In view of these 
results it has been suggested that both LST-G type lesions with a large dominant nodule and 
LST-NGs are better suited to en-bloc removal whilst other LSTs may be suitable for 
piecemeal endoscopic therapy (92).  
 
The identification of irregular and thickened microvessels using narrow-band imaging (NBI) 
(Sano capillary pattern (CP) classification) has also been identified as an accurate method of 
determining depth of submucosal invasion of NPCPs (91).  A study of 130 lesions reported 
that the Sano CP type III pattern was associated with a 84.8% sensitivity, 88.7% specificity 
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and 87.7% diagnostic accuracy for differentiating deep submucosal invasion (sm2/3) from 
more superficial involvement (mucosal/sm1), indicating the value of this classification 
system (93). 
Another method of identifying deep submucosal invasion has recently been validated.  The 
NICE NBI classification allows examination of the surface characteristic of a polyp based on 
its surface appearance, colour and vessel pattern without the aid of magnifying colonoscopy 
(94).  NICE Type 3 lesions are differentiated from type 2 (adenoma) and type 1 (hyperplastic) 
lesions by virtue of a dark brown surface, disrupted or missing vessels and an amorphous or 
absent surface pattern (95).  A 2013 Japanese study demonstrated an overall sensitivity and 
negative predictive value for high confidence prediction of deep malignant submucosal 
invasion of 92% in a tertiary centre setting (94). 
 
Lesions with an increased risk of incomplete excision/recurrence – Size >40mm, location involving 
ileocaecal valve, appendix, diverticulum or dentate line; within an inflamed segment of colitis; prior 
failed attempt at resection or recurrence at site of previous resection (excluding unifocal, 
diminutive and easily resected/ablated residual adenoma on first site check); non-lifting sign after 
submucosal injection; endoscopist concern about difficult location (e.g. behind flexure or fold, in 
stenotic diverticular disease); 
 
Various features have been identified that may predict the difficulty of achieving complete 
endoscopic resection of LNPCPs (6, 37).  Very large lesions are more technically challenging 
and time-consuming to remove as they are associated with a higher likelihood of needing 
eventual surgical management (17, 54, 96). A US study demonstrated that very large lesions 
occupying over 75% of colonic wall circumference) were associated with an increased 
endotherapy failure rate on univariate analysis (n=315 OR: 1.11; 95% CI: 1.06-1.17; p<0.001) 
(9).  A study of LNPCPs managed within the UK Bowel Cancer Screening Programme 
identified lesions >40mm as more likely to require surgery (20mm-29mm (7.8%) vs 30mm-
39mm (23.9%) vs >40mm (27.5%), p<0.001) and requiring an increased number of 
endoscopic procedures to achieve clearance (20mm-29mm (1.84%) vs 30mm-39mm (2.31) 
vs > 40mm (2.33), p<0.001) (17).  
Polyps that cross over 2 haustral folds are felt to pose difficulty as the space between the 
folds can be difficult to access whilst there is a concern about ensnaring the full thickness of 
the colonic wall, thereby increasing the risk of perforation. Polyps behind a fold or that have 
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a ‘clamshell’ distribution around a fold can also pose an issue with obtaining adequate 
endoscopic access for visualisation and removal (96).  
 
Polyps that fail to lift in response to an accurately placed submucosal fluid injection (non-
lifting sign) without prior intervention have an increased risk of deep submucosal invasion, 
indicating a reduced likelihood of successful removal with snare polypectomy (see later)(5, 
97). NPCPs subject to a previously failed endoscopic attempt, that have occurred in the 
context of IBD or are located in a site of previous endoscopic resection are likely to be 
subject to scarring and submucosal fibrosis and may not lift adequately after submucosal 
fluid injection.  An analysis of cases of failed endotherapy highlighted non-lifting lesions as a 
major risk factor (RR 4.96, 95% CI: 3.51–7.01, p<0.001) (5). These lesions may require 
consideration for en-bloc removal with ESD or surgery (see later) (96). 
 
Peri-diverticular polyps may also pose an issue with endoscopic access as this portion of the 
colon may be narrower and less amenable to a stable endoscopic position. Moreover, polyp 
tissue may encroach into a diverticulum. Lesions involving the ileocaecal valve have also 
been associated with a higher failure rate (RR 2.61, 95% CI: 1.28–5.32, p= 0.020)(5).  These 
lesions may be difficult to access and visualise (especially in distinguishing ileal mucosa from 
adenomatous tissue) whilst ileal involvement adds further complexity (54, 96).  Rectal polyps 
involving the dentate line can be complicated due to their location in a position of high 
vascular supply and sensory nervous innervation. The endoscopic removal of these lesions is 
thus associated with a higher risk of peri-procedural pain and delayed post polypectomy 
bleeding.  In addition, their location means that they often need resection in a retroflexed 
position (54).  
A summary of features statistically identified as independent risk factors for failed 
endotherapy  include: 
 
 Previous intervention (n=479; OR: 3.75; 95% CI: 1.77–7.94; p=0.001)  
 Ileocaecal valve involvement (OR: 3.38; 95% CI: 1.20–9.52; p=0.021) 
 Difficult position (OR: 2.17; 95% CI: 1.14-4.12; p=0.019) 
 Lesion size >40mm (OR: 4.37; 95% CI: 2.43-7.88; p<0.001)  
 Previous APC use (OR: 3.51; 95% CI: 1.69-7.27; p=0.001) (5) 
 
41 
 
Advanced polypectomy is associated with a vastly higher risk of serious complications compared to 
conventional snare polypectomy. Factors associated with a further increased risk of adverse events 
include caecal location, lesion size >40mm and endoscopist inexperience    
The most serious complications related to advanced polypectomy procedure such as EMR 
and ESD are bleeding, perforation and incomplete resection.  Reported figures for EMR are 
far higher than with standard polypectomy where rates of up to  1 in 100 and 1 in 500 have 
been reported for delayed bleeding and perforation respectively (2).   The incidence of 
perforation with EMR appears to range between 0.5-1.3% whilst severe post procedure 
bleeding has been reported in approximately 3-10% of cases in large volume studies (5, 9, 
17, 57). 
LNPCPs located in the right colon, especially in the caecal pole, and lesions >40mm have 
been associated with an increased risk of adverse events following advanced polypectomy. 
Right sided lesions are associated with an increased risk of perforation due to thermal tissue 
injury with polypectomy in the thinner right sided colon (98).  Lesions involving the caecal 
pole, including those that involve the appendiceal orifice are considered to be associated 
with an increased risk of perforation as this is where the colonic wall is at its thinnest and it 
has also been suggested that the front-on angle at which polyps are accessed increases the 
potential for the entire colonic wall to be ensnared during polypectomy (54). An Australian 
study analysing risk factors for post procedure haemorrhage identified right sided location 
as an important risk factor (Adjusted OR: 4.4, 95% CI: 1.3-14.1, p=0.014) with the highest 
incidence found in the caecum (98).   These findings were similar to that of a retrospective 
analysis of 146 lesions where multivariate analysis demonstrated an almost five fold 
increased risk of delayed haemorrhage with right sided polyps (OR: 4.67, 95% CI: 1.88 – 
11.61, p=0.001) whilst univariate analysis suggested that caecal polyps conferred the highest 
risk (OR 13.82, 95% CI: 2.66–71.73).  Multivariate analysis also reported an increase in 
bleeding risk by 13% for every 1mm increase in polyp diameter (OR: 1.13, 95% CI: 1.05 – 
1.20, p < 0.001) (99).   
A polyp size of >40mm was identified as a risk factor for increased post polypectomy 
bleeding (PPB) in a study of 493 LNPCPs where PPB increased markedly post resection of 
lesions >40mm compared with resection of lesions <40 mm (OR=43.043, 95% CI: 4.306–
430.314, p=0.001) (100). 
42 
 
Further evidence of caecal location and lesion size >40mm as risk factors for adverse events 
were reported in a study of adverse events from 167208 polypectomies (130831 
colonoscopies) performed within the English Bowel Cancer Screening Programme.  Caecal 
location (OR: 2.13, 95% CI: 1.36-3.34, p<0.01) and polyp size of >40mm (OR: 3.90, 95% CI: 
3.35-4.94, p<0.001) were both identified as strong risk factors for adverse events in 
endoscopic polypectomy. The risk of adverse events increased further with combination of 
both these factors with a predicted risk of bleeding of 1 in 8 (101).  
 
Endoscopist inexperience also appears to be a clear risk factor for adverse outcomes.  A 
2008 study comparing adverse outcomes between endoscopists of varying experience  
demonstrated an almost 3 fold increase in the risk of heavy bleeding and perforation with 
inexperienced endoscopists (OR: 2.96, 95% CI: 1.57–5.61, p=0.0008) (66). A trend of 
increased adverse events post therapeutic colonoscopy by less experienced endoscopists 
has also been demonstrated in large volume studies by Singh et al ( (n=24509, RR: 5.4, 95% 
CI: 3.0-9.0, p=0.02) and Chukmaitov et al  (n=2315126, OR: 1.18, 95% CI: 1.07-1.30) (64, 65). 
 
The potential complexity of achieving successful endoscopic resection can be estimated 
Complex NPCPs may be described as lesions with a greater than average risk of malignancy, 
incomplete resection/recurrence or complications that may be best suited to management 
by clinicians with the relevant skills and experience within a multidisciplinary environment.  
An additional method of stratifying lesion complexity has also been devised.  The SMSA 
scoring system predicts the difficulty of achieving successful endoscopic polypectomy based 
on the size, morphology, site and access of a polyp (see tables 4 and 5 below).  A study 
stratifying lesions (n=220) using the SMSA scoring system reported that it was both accurate 
and simple to use and provided valuable information on the lesion complexity and success 
and complication rates of endoscopic resection.  A lower level of endoscopic clearance was 
achieved with lesions felt to be the most complex (SMSA level 4) than with less complex 
lesions (SMSA level 2 and 3) (87.5% vs 97.5%, p=0.009). This system may aid in service 
planning and stratifying lesions that require referral to an expert centre (6, 56).   
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Parameter Range Score 
Size <1cm 1 
 1-1.9cm 3 
 2-2.9cm 5 
 3-3.9cm 7 
 >4cm 9 
Morphology Pedunculated 1 
 Sessile 2 
 Flat  3 
Site Left 1 
 Right 2 
Access Easy 1 
 Difficult 3 
              Table 4. SMSA Scoring system to assess polyp difficulty (6) 
 
 
Polyp Level Range of Scores 
I 4-5 
II 6-8 
III 9-12 
IV >12 
                Table 5. SMSA scores with corresponding difficulty levels (6) 
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1.3.4) Considerations with anti-thrombotic medication 
British Society of Gastroenterology Anticoagulation Guidelines advocate the cessation of warfarin 
at least 5 days prior to endoscopic resection of NPCPs with an INR confirmed as below 1.5. General 
recommendations regarding the management of newer anticoagulants which have differing 
properties, such as rivaroxaban and dabigatran, are not currently in place due to a lack of evidence.  
 
Cessation of warfarin prior to endotherapy is advocated by both the BSG and ASGE (102, 
103).  A study of 1657 patients undergoing colonoscopic polypectomy demonstrated that 
warfarin was strongly associated with post procedure bleeding (OR: 13.37, 95% CI: 4.10-
43.65, p<0.001) (104).   The findings of a further retrospective analysis (n=1225) concurred 
with this (interrupted warfarin use vs uninterrupted warfarin use: 0.2% vs 2.6%, adjusted OR 
11.6, 95% CI: 2.3-57.3, p<0.005) (105).  A single dose of warfarin can be detectable up to 120 
hours after ingestion and therefore cessation 5 days prior to endoscopy has been 
recommended with an INR established as near normal (<1.5) (103)  
Newer anticoagulants such as dabigatran, rivaroxaban and apixaban are being used 
increasingly instead of warfarin as they do not require regular monitoring. In addition they 
have a much shorter half-life (dabigatran: 14-17 hours, rivaroxaban: 4-9 hours) meaning that 
they may be stopped closer to the time of endoscopy than warfarin. As they are renally 
excreted, caution is required with their use in the context of renal impairment especially 
prior to endoscopic polypectomy with earlier cessation likely to be needed to achieve 
normal patient clotting function (106).   In the current absence of evidence based 
recommendations, obtaining specialist input regarding the management of these 
medications pre and post endoscopy appears appropriate. 
 
British Society of Gastroenterology Antiplatelet Guidelines advocate the cessation of medications 
such as clopidogrel and prasugrel, and newer antiplatelet agents such as ticagrelor at least 7 days 
prior to advanced polypectomy  
 
Clopidogrel and prasugrel are classified as thienopyridines and have a different antiplatelet 
mechanism to aspirin.  The BSG, ESGE and ASGE advise their cessation based on an increased 
haemorrhage risk (102, 103, 107). A meta-analysis of 5 observational studies concerning 
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clopidogrel use with polypectomy compared 574 patients who continued clopidogrel 
therapy prior to polypectomy with 6169 control patients.  A significantly increased risk of 
delayed post- polypectomy bleeding RR of 4.66 (95% CI: 2.37-9.17, p<0.00001) was 
demonstrated,  concurring with another study where the incidence of delayed bleeding post 
polypectomy was over 3 times higher in the clopidogrel group (n=375, 3.5% vs 1%, p=0.02) 
but immediate bleeding incidence was similar in both groups (108, 109).  Prasugrel and 
newer antiplatelet agents such as ticagrelor appear to be more potent than clopidogrel and 
also require cessation.  An RCT comparing prasugrel with clopidogrel (n=13608) found 
prasugrel to be associated with a significantly higher rate of major bleeding (2.4% vs 1.8%, 
Hazard Ratio: 1.32,  95% CI: 1.03 to 1.68; p=0.03) (110).  Pharmacological studies have 
demonstrated that clopidogrel, prasugrel and newer, theoretically shorter acting agents 
such as ticagrelor may affect platelet aggregation for up to 7 days and so cessation at around 
7 days prior to LNPCP endotherapy appears appropriate (103, 107).  
 
The continuation of low dose aspirin prior to endotherapy appears safe but may require 
individualised patient assessment   
 
There are conflicting reports about the safety of continuing aspirin prior to advanced 
polypectomy.  Whilst it appears that many endoscopists do stop aspirin, UK and US 
guidelines advise that it can be continued (102, 103). Multiple case-control studies have 
suggested that it does not increase haemorrhage risk in colonoscopy and polypectomy (107).  
An example includes a case–control study of 20636 patients undergoing colonoscopy with 
polypectomy which showed no significant difference with aspirin use in bleeding (40%) and 
non-bleeding groups (33%) (n=20636, OR: 1.41, 95% CI: 0.68 to 3.04, p=0.32) (111).  Another 
example is a 2008 study demonstrating a similar frequency of PPB in aspirin and control 
groups (41% vs 39%; n=4592; p=0.80) (112).  Whilst specific LNPCP data is limited, a 
Japanese study examining the risk of bleeding with aspirin with ESD (n=582) demonstrated 
similar levels of PPB with both aspirin interruption (15.4%) and cessation groups (16.1%), 
suggesting aspirin continuation appears safe (113).   Given conflicting data and opinion, it 
does appear appropriate to manage aspirin use according to individualised patient risk, such 
as a scenario that an LNPCP presents a high risk of PPB. 
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1.3.5) Peri-procedural management 
Carbon dioxide improves patient comfort and safety compared to air insufflation during 
colonoscopy  
There is evidence that CO2 insufflation improves patient comfort during colonoscopy when 
compared with air insufflation, especially with longer procedures such as advanced polypectomy. 
A trial of 219 patients found that CO2 was associated with significantly reduced pain (p=0.014) 
and bloating (p<0.001) than air insufflation as well as increased patient satisfaction (p=0.04)(114). 
Another study demonstrated that CO2 use was associated with significantly reduced post 
procedure admission following endoscopic polypectomy (OR: 0.39, 95% CI: 0.16-0.95, p=0.04) 
(115). CO2 insufflation has also been associated with increased patient safety. As CO2 is non-
inflammable, the risk of combustibility with the use of diathermy and argon plasma coagulation 
(APC) (both of which are important components of advanced polypectomy) is eliminated as 
oxygen is required for an explosion (116).  The use of CO2 insufflation appears to improve patient 
experience and may allow for longer procedure times and enable the completion of endoscopic 
resection which has previously been limited by patient discomfort. 
 
1.3.6) Polyp Assessment 
Size estimation of LNPCPs, ideally by measuring against an open snare, is considered to improve 
lesion assessment   
 
Whilst pathological estimation appears to be the most accurate method of assessing lesion 
size, a size estimate of a polyp during endoscopy is important, not only for deciding upon 
surveillance intervals, but also when considering the malignant potential of a NPCP and 
technical considerations such as deciding on en-bloc or piecemeal resection or the resection 
plane (117).  There is extensive evidence that visual size estimation during endoscopy by 
clinicians continues to be inaccurate.   A 1997 study using pathological size estimation as a 
reference, examined size estimation of lesions up to 36mm in size (n=61), finding that 20% 
of lesions were inaccurately estimated (118).  A 2013 study (n=230) found that 62.6% of 
lesions were mis-sized by >33%, with 47.8% of lesions undergoing inappropriate surveillance 
because of this (119).  Specific underestimation of lesion size has been demonstrated in 
numerous cases.  A 2009 study found that endoscopist size estimates made during 
endoscopy, irrespective of experience, appeared to be inaccurate, with lesions over 2cm 
significantly underestimated in size (polyp mean deviation -5.80mm, 95% CI: 0.44-0.62) (32, 
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117, 120).  This finding was replicated in a 2014 study with lesion size underestimation in 
20% of estimates (n=2812,  range: 4-46%) (121).  The use of measurement tools has been 
shown to improve the accuracy of endoscopic size estimates.  The use of a linear probe was 
supported by a 1997 study, reporting that its use appeared to correlate closely with 
pathological measurement (0.88:Pearson correlation,95% CI: -0.16 to 0.64) (122).  A readily 
available modality is the use of an open snare and its use as a size reference may improve 
accuracy. 
The use of Paris Classification to describe polyp morphology has high accuracy in predicting 
malignancy risk 
 
Participants in a Paris workshop proposed a classification model for the description of polyps 
based on morphology in view of a previous Japanese classification model in 2002 (15). This 
was further revised in 2003 to enable the evaluation of superficial lesions with respect to the 
depth of submucosal invasion. Lesions were classified as protruding (0 – I; incorporating 
pedunculated and sessile polyps), non-protruding and non-excavated (0 – II; flat - further 
divided as elevated (IIa), flat (IIb) and depressed (IIc)), and excavated (0 - III) (123).  Lesion 
morphology appears to accurately predict the risk of malignancy.  Non protruding depressed 
lesions were highlighted as having an increased risk of malignant submucosal invasion and  
more likely to require surgical intervention (15).   The initial finding of a markedly increased 
risk of submucosal invasion with Paris 0-IIc lesions compared with sessile lesions (n=3680, 
61% vs 3%) has been repeated in a more recent study of LNPCPs (n=479) (IIc or IIa+c: 31.8% 
vs IIb: 11.1% vs Is: 7.5% (p=0.001)) (5, 15). Furthermore, these lesions also correlate with 
Kudo Pit Pattern type V, a robust and more established indicator of likely malignancy(14). 
This demonstrates the reliability of the Paris Classification in predicting malignancy and its 
use in guiding optimal management (15, 123) 
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Figure 5. Illustration showing subtype of polyps using Paris classification method (46) 
 
The use of classification systems that describe the surface characteristics of a polyp such as the NICE 
NBI classification and the Kudo Pit Pattern allow accurate lesion assessment whilst the use of image 
enhancement techniques (either digital or chromoendoscopic) can improve diagnostic accuracy 
further 
 
The characterisation of polyps by pits and vessels was first described by Kudo et al in 
1994(14). The use of pit pattern classification is well described and is not only a robust 
method of delineating between hyperplastic and adenomatous polyps, but is also accurate 
in predicting deep malignant submucosal invasion based on polyp surface characteristics 
(14, 124, 125).  As previously discussed, a finding of ‘type V’ pit pattern is strongly associated 
with a risk of deep submucosal malignancy compared with other pit pattern types (5, 89).   
Further scrutiny with sub-classification of type V pit pattern to VI (irregular arrangement) 
and VN (amorphous structure) can further stratify malignancy risk.  A study of 272 lesions 
found deep submucosal invasion in 95.7% of lesions with type VN pattern compared with 
30.7% of lesions with type VI pattern (126).  The increased association of type VN pattern 
with malignancy was confirmed by a finding of malignancy in 100% of these lesions in data 
from a 2008 Japanese analysis (127).  Further sub-classification of the type VI pattern to 
mildly irregular and severely irregular has been proposed due to a marked difference in 
malignancy incidence between the two groups (7-17% and 56-85% respectively)(126, 127).  
A potential limitation of pit pattern use is the learning curve required to interpret pit pattern 
and the potential for interobserver variation.  However, the use of training modules suggests 
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that successful pit-pattern recognition can be achieved even by inexperienced endoscopists 
(128). The diagnostic accuracy of Kudo Pit Pattern indicates that it may be used to predict 
submucosal invasion, recognise malignancy and determine the suitability of a polyp for 
endoscopic resection (14, 89, 129, 130).  
Enhanced imaging techniques may help improve diagnostic accuracy when assessing NPCPs. 
Narrow band imaging (NBI) is a form of digital image enhancement that uses narrow-band 
filters and high intensity blue light to enhance surface mucosal and vascular pattern 
visualisation (131).   A multicentre prospective RCT (n=667) found that NBI had greater 
accuracy than both standard and high definition white light endoscopy at correctly 
predicting polyp histology with a sensitivity of 90% (95% CI: 85.3-93.4, p<0.001) and 
accuracy of 82% (95% CI: 77.4-85.4%, p<0.001) (132).  The importance of NBI is also 
reflected in its role in the examination of polyp surface characteristics using the NICE 
classification system which has demonstrated accuracy in identifying deep submucosal 
malignant invasion.  In addition, it has high availability due to the lack of requirement for 
magnification endoscopy whilst it appears that it can be used by inexperienced endoscopists 
with appropriate training. A Japanese study demonstrated 90% accuracy (95% CI: 85.1-93.3) 
by a student group using the system (54, 94). 
Both NBI and magnifying chromoendoscopy appear to be accurate in delineating between 
neoplastic and non-neoplastic polyps.  A study comparing NBI and magnifying 
chromoendoscopy with white light endoscopy reported that both techniques were 
associated with a diagnostic accuracy of over 90% compared with white light endoscopy 
which was found to have only 59% diagnostic accuracy (133). The usefulness of magnifying 
chromoendoscopy has also been confirmed by a large prospective study (n=4215) which 
demonstrated the accuracy of magnifying chromoendoscopy at estimating the depth of 
invasion of early colorectal neoplasms using combined mucosal and morphological patterns.   
The sensitivity, specificity and diagnostic accuracy to differentiate mucosal cancer or 
superficial invasion (sm1) (<1000 µm) from deeper invasion (sm2–3) (≥1000 µm) was 
reported as 85.6%, 99.4%, and 98.8%, respectively (134). 
The use of virtual chromoendoscopy techniques such as flexible spectral imaging colour 
enhancement (FICE) and I-Scan may have a role in lesion assessment.  A Japanese 2010 study 
(n=235) reported comparable diagnostic accuracy between FICE and NBI magnification in 
correctly predicting histopathological diagnosis in lesions up to 130mm  (FICE: sensitivity 
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(77.7%) and speciﬁcity (100%) vs  NBI magnification: sensitivity (63.6) and specificity (99.0%)) 
whilst FICE diagnosis of benign and malignant lesions was strongly associated with the 
correct histopathological diagnosis (p<0.01) (135).  A study of 110 lesions examining the 
accuracy of I-Scan in determining polyp histology when used by endoscopists reported a 
diagnostic accuracy between 74-94% which was independent of lesion size.  However, the 
use of a training module prior to commencement of the study reflects the learning curve 
required for its use (136).    
Further endoscopic tools such as confocal electromicroscopy appears to demonstrate 
diagnostic accuracy in distinguishing neoplastic and non-neoplastic polyps but their 
availability is limited (137). 
ESGE guidelines (2014) support the use of enhanced imaging by recommending the use of 
conventional or virtual (NBI) magnified chromoendoscopy to predict the risk of invasive 
cancer and deep submucosal invasion (138).  
 
 
Figure 6. Kudo Pit Pattern Subtypes (46) 
 
 
1.4) To Resect or Refer? 
 
 Major considerations include whether a lesion is endoscopically resectable and if so 
whether the detecting endoscopist has the technical ability to achieve this.   
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 Resection of LNPCPs may not be appropriate at the time of discovery  
 
Given the potential complexity of advanced polypectomy, adequate prior planning is 
required. This includes ensuring that the correct management strategy has been selected, 
that the patient has given informed consent, that an endoscopist and assistants with the 
requisite experience are available,  and that adequate time has been allocated for the 
procedure and having relevant equipment available (62).  Important management aims 
include the exclusion of features suggesting malignancy and potential complications related 
to endotherapy and, where possible, achieving complete resection in a single session. In the 
case of many complex lesions, additional multidisciplinary support is often required to 
achieve these aims (87).  Previous incomplete endotherapy as a result of inadequate 
planning has been shown to reduce the likelihood of successful endoscopic removal 
compared with treatment naïve lesions, primarily due to submucosal fibrosis.  The ACE study 
demonstrated significantly lower treatment success with a previously attempted lesions 
(75.4%) than with treatment naïve lesions (91%) (OR 3.75, 95% CI: 1.77–7.94, p=0.01) (5).  
Outside the expert setting, successful removal rates are likely to be lower still and this 
suggests that injudicious attempts at therapy in suboptimal circumstances can complicate 
further management (9, 59, 139).   
 
As previously discussed, it is considered imperative that patients understand the specific 
risks of advanced polypectomy, in addition to all available management options (140).  
Management of an LNPCP at the time of discovery may not allow this, especially if a patient 
has been given sedation.  
 
Retrieval of lesion biopsies may complicate subsequent endoscopic resection attempts 
 
Taking biopsies of the colonic mucosa can result in fibrosis and a subsequent non-lifting sign, 
also associated with malignancy and previous endoscopic resection attempts.  This makes 
successful endoscopic removal more difficult to achieve (5). Multiple studies have reported 
that taking biopsies can complicate the removal of colorectal lesions by compromising the 
submucosal lift from a fluid injection due to submucosal fibrosis from a post-biopsy scar.  A 
2008 Korean study demonstrated a significantly reduced rate of submucosal elevation in a 
biopsy group compared to a non-biopsy group (n=42, 77% vs 45%, p=0.03) (141).   Another 
study assessing the effect of biopsies taken before an attempt at ESD reported that biopsies 
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prior to endotherapy did not provide useful information and interfered with endoscopic 
removal, finding a significant association between the use of biopsy and subsequent fibrosis 
(n=89; OR: 3.45; p=0.014) (142). A delay between taking biopsies and subsequent 
endotherapy may also increase the difficulty in achieving successful resection.  A 2008 study 
reported that a history of previous biopsy significantly increased the incidence of the non-
lifting sign, especially if lifting was attempted over 21 days post biopsy (n=76, OR: 16.208, 
95% CI: 1.024-256.442, p=0.048) (139). All lesions assessed under 21 days post biopsy did lift 
however and a conclusion was drawn that biopsies should be minimised with an advanced 
endoscopy attempt made as soon as possible after biopsy. These factors suggest that 
caution is required with biopsy use, especially when malignancy is not suspected and prompt 
repeat endoscopy cannot be guaranteed (139). 
Obtaining biopsies of a polyp may not be helpful in contributing towards an accurate 
diagnosis.  A 2005 study of 532 polyps asserted that colorectal biopsies were inadequate for 
grading of colorectal neoplasia with findings that the histopathological diagnosis was 
underestimated in up to 10% of cases whilst advanced neoplasia was underestimated in up 
to 60% of cases (143).  A 2011 Taiwanese study of 1027 polyps demonstrated a false 
negative rate of 86% for early colorectal cancer and high grade dysplasia with a randomised 
biopsy practice of adenomatous polyps whilst an earlier  UK study of 433 colorectal polyps 
reported that the biopsy of malignant polyps gave a false negative rate of 18.5%(144, 145). 
Whilst biopsies are appropriate if malignancy is a concern, careful targeting should be used 
to improve diagnostic accuracy and minimise submucosal fibrosis in the event of subsequent 
endotherapy (142).  
 
1.5) Endoscopic Resection Principles 
 Large colonic polyps can be removed either ‘en-bloc’ or ‘piecemeal’ with multiple 
pieces of a lesion taken to achieve complete resection. 
 En-bloc endoscopic snare resection of NPCPs is recommended where feasible to 
reduce the risk of recurrence and to enable more accurate histopathological 
interpretation.   
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 Caution has been advised regarding attempts at en-bloc snare resection with 
NPCPs > 20mm (LNPCPs) due to an increased risk of diathermy associated thermal 
injury and perforation  
 
En-bloc snare resection where possible is desirable due to reduced recurrence and the 
ability to obtain more accurate histological analysis.  In addition, a Korean study suggests the 
risk of incomplete resection in piecemeal resection is significantly higher with lesions > 
30mm (n= 497, OR: 2.688, 95% CI: 1.036–6.993, p= 0.042) (100).   
A 2014 meta-analysis of 33 studies examining snare removal of non-pedunculated lesions  
unequivocally demonstrated lower recurrence with en-bloc resection compared to 
piecemeal removal (3% (95% CI: 2-5%) vs 20% (95% CI: 16-25%), p<0.0001) (146).  
Whilst it is possible to remove lesions over of 2cm en-bloc with snare resection due to the 
availability of snares up to 45mm in size, it may be technically difficult to achieve due to 
reduced snare stiffness whilst uncertainty about the resection plane may lead to concerns  
about perforation due lack of control of tissue volume and from thermal injury due to an 
inability to control the cutting plane (120, 147).  A 2012 Korean study also demonstrated 
that where EMR was carried out for NPCPs > 30 mm, the chance of using piecemeal 
resection increased significantly due to technical reasons (OR: 7.246, 95% CI: 4.672– 11.235, 
p < 0.001) (100). Where en-bloc specimen retrieval is required, such as suspected 
malignancy, techniques such as ESD and surgery may be required.  However, in the case of 
benign lesions, piecemeal EMR has been shown to have comparable efficacy, especially 
when allowing for repeat treatment of recurrence with less morbidity. The high complete 
eradication rates reported by various studies such as 90% by Buchner et al and 96% quoted 
by Longcroft-Wheaton et al including 87.5% of SMSA level 4 lesions support this (9, 56).  In 
addition whilst a 2009 study reported lower rates of early recurrence with en-bloc TEMS for 
rectal lesions when compared with pEMR, it should be noted that late recurrence was 
similar in both groups when allowing for repeat endoscopic therapy (TEMS: 9.6% vs EMR: 
13.8%, p = 0.386) whilst TEMS was associated with greater morbidity and longer 
hospitalisation (3 days vs 0 days, p<0.001) (77) 
 
The creation of submucosal cushion with a fluid injection is widely recommended to 
facilitate successful endoscopic resection 
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A submucosal injection is commonly made around a lesion to create a ‘submucosal cushion’ 
prior to diathermy assisted snare polyp removal with the benefits relating to both increased 
efficacy and safety.  A 1994 Japanese study comparing efficacy of submucosal assisted 
polypectomy with non-submucosal assisted polypectomy (n=1075, 788 sessile lesions) 
reported that  submucosal injection facilitated the endoscopic removal  of lesions initially 
felt to be unresectable such as flat polyps with  improved resection rates in the submucosal 
injection group (75.7% vs 70%, p<0.05) and a reduced rate of complications (148).  The 
creation of a submucosal cushion lifts a mucosal lesion away from submucosa and deeper 
muscular layers and reduces the risk of perforation due to diathermy induced thermal tissue 
injury whilst also reducing the risk of perforation due to capturing excess tissue within a 
snare resulting in deep resection lesions (149).   
Lesions which do not lift after adequate submucosal injection are unlikely to be amenable 
to removal with conventional snare polypectomy technique.   
 
The use of a submucosal injection, although not intended as a diagnostic tool, may also be 
informative about lesion characteristics as an inability to lift a treatment naïve lesion, known 
as the ‘non-lifting sign’, is strongly associated with malignant submucosal invasion(97). 
Uno et al first described an association between non-lifting lesions in response to a 
submucosal injection and malignancy in 1994 (150).  All cases defined as non-lifting were 
found to contain malignancy. A 1999 Japanese study supported this finding by also 
demonstrating an association between the non-lifting sign and deep submucosal invasion 
(n=60). All lesions with deep submucosal invasion (sm3), lesions associated with a higher 
rate of lymph node metastases and so requiring surgery, displayed the non-lifting sign 
whereas most lesions with more superficial submucosal invasion were able to achieve lifting 
93.5% of sm1 lesions) (97). A later study repeated these findings with only 20% of sm3 
lesions lifting as opposed to 82.4% of sm1 lesions (p<0.05)(139) whilst a 2007 study reported 
that the non-lifting sign displayed an accuracy rate of 94.8% (n=271, p< 0.05) (151).  Previous 
interventions such as biopsy may cause potentially endoscopically removable lesions to also 
display the non-lifting sign but in lesions with no prior intervention, correlation between the 
non-lifting sign and deep submucosa invasion with lymph node involvement appears strong 
(67, 139).  In view of this, whilst en-bloc removal may be possible, the mucosectomy action 
of snare polypectomy is less likely to be effective in treatment naïve non-lifting lesions due 
to irregularity of the submucosal plane (37).   
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Colloidal type submucosal injection solutions are recommended in preference to normal 
saline lifting solution for 20mm and larger lesions.   
 
Whilst normal saline (0.9%) is commonly used in polypectomy and is effective in creating a 
submucosal cushion, a review of available evidence suggests that colloidal type solutions 
appear to be superior for submucosal injection in view of technical and safety factors. The 
use of colloidal type solutions in submucosal injection solutions has been recommended as it 
is felt to produce a longer lasting lifting effect and facilitate easier resection than normal 
saline(59, 152). Animal models demonstrated that colloidal type solutions such as 
hydroxypropyl methycellulose and succinated gelatin (gelofusin) enabled  a longer lasting lift 
(mean of 36 minutes) and increased en-bloc resection (153, 154).  
Sodium hyaluronate (SH) commonly used for ESD, has also demonstrated superiority over 
normal saline in porcine models (155).  A 2004 Japanese study found that SH produced a 
longer lasting lift than both normal saline and hypertonic solutions and later reported that it 
is also associated with reduced tissue injury (149, 156).  
These findings appear to have been replicated in human studies.   A 2005 study compared 
113 NPCPs removed with EMR with glycerol with 110 lesions removed by EMR with normal 
saline.  The glycerol group demonstrated a higher en-bloc resection rate (63.6% vs 48.9%, 
p<0.05) and complete resection rate (45.5% vs 24.6%, p<0.01) (157).  A double blind RCT 
found that the use of succinated gelatin, an inexpensive solution, significantly reduced 
procedure time (GS: 12.0 min (interquartile range:8.0-28.0) vs. NS: 24.5 min (15.0-36.0), 
p=0.006) and reduced the number of piecemeal resections made when compared with 
normal saline solution (GS; resections=3.0 (1.0-6.0) vs. NS; resections 5.5 (3.0-10.0), 
P=0.028) (154, 158) 
There is evidence to suggest that the use of hypertonic solutions may have a role in the 
removal of LNPCPs.  A prospective double blind RCT (n=1370) reported that 50% dextrose 
was associated with a reduced injection volume (p=0.033) and number of injections 
(p=0.028) to maintain a mucosal lift compared to normal saline.  It was also associated with 
a longer lasting submucosal lift, an effect that became more pronounced as lesion size 
increased (>20mm; p=0.039, >40mm; p=0.025).  However, the use of 50% dextrose was 
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associated with a higher incidence of post polypectomy syndrome, a finding also confirmed 
by Fujishiro et al with dextrose solutions >20% concentration, and the risk of tissue injury is a 
limiting factor in the use of hypertonic solutions (156, 159). 
 
The addition of low concentration adrenaline to the submucosal injection solution is 
considered helpful to keep the resection field clear during endoscopic resection   
 
The addition of adrenaline to submucosal injection solutions at a dilution of 1/10000 has 
been advocated to reduce the risk of immediate post-polypectomy bleeding (PPB). A 2001 
study demonstrated reduced immediate PPB with a 1:10000 adrenaline containing solution 
compared with a saline only solution (1/75 vs. 7/76, p = 0.03) whilst a 2004 study also 
reported this result (1/50 vs 8/50; p<0.05). No improvement has been demonstrated with 
delayed PPB (160, 161). A 2007 Korean study, despite reporting that adrenaline use did not 
confer an additional advantage over a saline only submucosal solution, did demonstrate 
significantly reduced immediate PPB with NPCPs. (1/75 vs 7/76; p=0.03) (107, 162). 
The use of contrast agents such as indigo carmine or methylene blue in the submucosal 
injection solution may enable lesion demarcation, its resection margins, and outline a 
clear submucosal plane    
 
There appears to be uniform acceptance of the importance of the use of contrast agents, 
which allow the demarcation of lesion extent and submucosal cushion as well as enabling 
complete resection through identification of the correct plane of resection as well as lateral 
margins in order to achieve visual complete resection (51, 55, 62, 68, 115, 163, 164).   A 
study of 445 patients described how the use of indigocarmine facilitated the recognition of 
deeper planes of resection and identification of tissue deep to submucosa.   This enabled the 
identification of all cases of post resection perforation which were subsequently managed at 
the earliest opportunity (164).   
It should be noted that an association between methylene blue and potential DNA damage 
to colonocytes has been reported in laboratory based work, a finding not associated with 
indigocarmine (165).  However, no clinical evidence has been reported that precludes its 
use. 
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1.6) Equipment 
1.6.1) Snares 
A number of different snare conformations and sizes exist.  However there is no evidence 
to support the use of a specific type 
Snare polypectomy is the method of choice for polyps larger than 1cm, however, there 
appears to be a paucity of evidence suggesting an optimal snare for use in advanced 
polypectomy. There are various sizes, shapes and textures available. Larger snares (> 2 cm) 
are preferred by some operators with the intention of en bloc resection or wide field 
resection of larger polyps though this is thought to carry a potentially increased risk of 
perforation if a large volume and depth of tissue is within the snare (166). Smaller, thinner 
(monofilament) snares are often preferred where increased precision is required and spiral 
or stiffer snares are often used by some operators where gripping of a flat elevated lesion is 
thought to be optimised (167).  A combined injection needle and stiff large snare device (‘I-
Snare’) was recently reported to be superior to another large snare (braided ‘Snare Master’ 
snare) very commonly advocated for advanced polypectomy.  The device was reported to 
both reduce polypectomy procedure time and allow piecemeal polyp retrieval in fewer, 
larger pieces  using the Sydney resection quotient (SRQ), the size of the polyp divided by the 
number of pieces resected and the amount of tissue per snare attempt (n-140, 13.8mm vs 
7.1mm, p=0.019) (168).  However, reports favouring the use of a particular snare such as 
spiral or crescentic snares appear subjective and variations in operator experience and 
expertise in these studies make a particular choice difficult to recommend (68, 169). 
 
1.6.2) Diathermy and coagulation 
Pure cutting current is associated with an increased risk of immediate post polypectomy 
bleeding whilst prolonged pure coagulation current forms are associated with increased 
risk of delayed post polypectomy bleeding and thermal tissue injury respectively  
 
International surveys of endoscopic practice have indicated variation in the choice of 
diathermy settings used for polypectomy. A US survey of endoscopic practice in 2004 
(n=198) found blended current (46%) and coagulation current (46%) to be in more common 
use with lower reported use of varied (4%) and pure cutting current (3%) (170).  A 2013 
survey of Israeli endoscopists (n=100) found that 42% used pure coagulation current with 
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38% using blended current and 20% using pure cutting current (171).  Pure cutting current is 
likely to relate to higher rates of immediate post polypectomy bleeding (PPB) due to poor 
haemostasis properties, and the avoidance of its use in endoscopic polypectomy has been 
advocated by some groups including the ESGE (107, 172).  Cutting current does have good 
incision properties, however, enabling high quality resection specimens and inducing less 
thermal tissue injury (50, 173). A 1992 study comparing the use of coagulation current with 
‘blended current’ (which appeared to be predominantly cutting current) in snare 
polypectomy (n=1485) demonstrated a significant difference in the timing of haemorrhage 
between the two groups with the former more associated with delayed haemorrhage and 
the latter associated with immediate  haemorrhage (p=0.03).  The incidence of major 
haemorrhage was low in both groups however (6/727  and 8/758 respectively) (174).   A 
subsequent multicentre study (n=5152) identified pure cutting current as one of the greatest 
risk factors for immediate post-polypectomy bleeding (OR: 6.95, 95% CI: 4.42–10.04) (107, 
175).   
 
Pure coagulation current appears to be commonly used and has good haemostasis 
properties. However, higher settings and prolonged use induce higher levels of thermal 
tissue injury. Porcine models have demonstrated a greater depth of tissue injury with 
coagulation current than both blended (p=0.0157) and pure cut current, (p=0.0461)(50). The 
increased risk of tissue injury is of particular concern in the thinner right colon which is more 
susceptible to diathermy induced perforation (62, 173, 176, 177). The use of blended current 
or automated current that regulates coagulation and cutting current (such as Endocut) have 
been advocated as safer diathermy options with the rationale that they provide adequate 
incision properties combined with effective haemostasis.  A trial comparing blended and 
microprocessor controlled automated current (n=148) found that automated current 
produced less tissue damage than blended current with a conventional electrosurgical 
generator (p<0.02) whilst also producing higher quality resection specimens (p=0.024) 
allowing for more accurate histological evaluation (p=0.046) (178).  These findings suggest 
that the rationale for use of automated current appears sound. (50, 107) 
 
Thermal coagulation techniques such as argon plasma coagulation (APC) and soft 
coagulation are available management options when snare resection of small residual 
fragments of polyp is not possible.  
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APC has been advocated as a safe  non-contact method of thermal coagulation for use in 
therapeutic endoscopy due to its provision of a  ‘limited and predictable depth of tissue 
injury’ (179). The use of APC as an adjunct to endoscopic snare resection has been 
supported by various studies.  Zlatanic et al  reported that the use of APC in lesions where 
residual adenoma had been left after initial therapy resulted in a reduction of 50% of 
residual adenoma on follow up endoscopy compared with no APC use (n=77, 100% reduced 
to 50%) (180). A 2003 Czech study also demonstrated successful endoscopic clearance with 
the additional use of APC in 90% of lesions with incomplete endoscopic snare resection 
(n=77) (181). A larger study in 2011 commented that the use of APC on visible residual 
adenoma following piecemeal polypectomy did not reduce lesion recurrence (n=105; OR: 
0.46, p = 0.29).  This finding may be due to the application of APC to larger areas of tissue 
but also highlights that APC should not be relied upon as a sole treatment of residual 
adenoma (182, 183).  
A 2002 study where the use of APC on post resection margins was examined found that the 
use of APC as an adjunctive therapy reduced the rate of adenoma recurrence following 
piecemeal EMR in lesions where complete resection was thought to have been achieved 
(1/10 APC, 7/11 no APC; p = 0.02). This effect may be due to the treatment of microscopic 
residual foci at the resection margins not visible to the endoscopist (184). In addition, whilst 
not a primary outcome, multiple large volume trials demonstrating successful clearance of 
the majority of cases of residual and recurrent tissue describe routine use of APC as an 
adjunctive therapy (5, 9).  The use of hot biopsy avulsion has also been advocated as an 
ablative technique for flat polyp tissue considered unsnarable, with a small 2014 study 
(n=20) reporting no residual tissue on surveillance in 85% of cases (185). 
Thermal coagulation may also be provided by the use of soft coagulation from diathermy 
applied to tissue via the snare tip, however no data to definitively support its use has as yet 
been demonstrated.  A prospective RCT known as the SCAR trial examining the use of soft 
coagulation in the prevention of adenoma recurrence is currently recruiting patients in 
Australia. 
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1.7) Post Resection 
Careful post-procedure inspection of the resection site may allow accurate assessment of 
completeness of resection  
 
Imaging of a resection site is important not only to document and confirm whether complete 
resection has taken place, but also to confirm inspection and exclusion of a perforation. 
Taking steps to assess for complete resection appears important as it appears incomplete 
resection appears to be far more prevalent than first thought, even amongst experienced 
endoscopists. The CARE study demonstrated increasing rates of incomplete resection with 
larger lesions. 23.3% of lesions between 10 and 20mm felt to be completely resected at 
endoscopy were found to be incompletely resected, despite the endoscopist considering 
complete resection to have taken place significantly higher than with smaller lesions (17.3% 
vs 6.8%; p=0.003) whilst almost half of serrated lesions were incompletely resected (20). A 
2014 study demonstrated histological evidence of recurrence in 7% of NPCPs where 
complete resection was felt to have occurred both on initial resection and follow-up (n=252).   
The use of a pigmented contrast agent in the submucosal injection fluid, allowing close 
inspection of the resection site and also of the underside of the resected specimen (looking 
for a ‘target sign’), may help to identify a perforation almost immediately.  This would allow 
management of the defect at the earliest opportunity (164). 
 The ASGE also recommend photo documentation in relation to the area of a tattoo post 
endoscopic resection as it may enable identification of a scar site where no residual tissue is 
present (186, 187). 
 
Tattoo application is recommended to aid endoscopic follow up or subsequent surgical 
resection.   
The use of tattoo application with an indelible marker such as India Ink has been highlighted 
as an important practice post endoscopic removal to enable identification of the resection 
site on follow up and enabling lesion identification in cases requiring surgical resection.   
Tattooing is often not required in the caecum or rectum as lesions are more easily identified 
in these areas (188). 
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Caution has been advised with regards to tattoo practice with regards to avoiding 
complicating endoscopic resection (188, 189).  Various case series have reported sub-
lesional submucosal fibrosis resulting from tattoo application compromising subsequent 
endoscopic resection by both EMR and ESD (190, 191).  A distance of at least 3cm from a 
lesion has been recommended in one Australian case series  (190).   
Retrieval of specimen 
Retrieval of the resected polyp allows histopathological analysis. Devices such as nets and 
graspers may be used to trap and retrieve resected tissue whilst smaller fragments from 
piecemeal resection may be retrieved via aspiration through the endoscope. 
 
Figure 7.  Large sessile polyp identified 
 
 
Figure 8.  Submucosal injections made to lift lesion 
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Figure 9.  Sessile adenoma with submucosal lift 
 
Figure 10.  Snare passed around adenoma 
 
 
Figure 11. Post polypectomy site with clear base 
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1.7.1) Complications  
Post-procedure bleeding (both immediate and delayed), perforation and persistent 
recurrence are recognised complications 
The most serious complications related to advanced polypectomy procedure such as EMR 
and ESD are bleeding, perforation and incomplete resection. Figures of up to 1 in 100 and 1 
in 500 have been reported for delayed bleeding and perforation respectively related to 
standard colonoscopy and polypectomy (2).  However, reported delayed bleeding and 
perforation figures for large polyps requiring EMR are markedly higher. Reported rates of 
perforation in studies using EMR appear to be between 0.5 and 1.4% whilst severe post 
procedure bleeding has been reported in approximately 3-10% of cases in large volume 
studies (5, 9, 17, 57). Information pertaining to the risk of serious complications and 
alternative treatment may be given in a written form and this practice appears to be in place 
across various centres (140).  Larger lesions carry a higher risk.  Perforation may be due to a 
full thickness bowel wall tear causing peritonitis or localised perforation with a serosal burn 
causing localised tenderness (postpolypectomy syndrome). Peritonitis is usually an 
indication for surgical intervention whereas localised perforation will usually resolve with 
conservative management (51).  Perforation seen at the time of endoscopy can sometimes 
be managed with endoclip and loop placement (9). 
Significant bleeding is reported if a patient requires hospital admission, requires a 
transfusion or repeat endoscopy for haemostasis management.  It can be classified as 
immediate (occurring within 24 hours) and delayed (up to 14 days post procedure).  The 
incidence is unclear with various studies reporting rates between 0.7 and 10% (104).  
Bleeding can often be managed with adrenaline injection, clip placement and APC.  In more 
severe cases, radiological embolisation and even surgery may be required.  Increased 
bleeding is noted with anticoagulant use, piecemeal resection, larger polyps, pedunculated 
polyps with a broad stalk (over 1cm) and patients with clotting abnormalities (51). Serositis 
is post procedural pain resembling localised peritonism with no evidence of perforation.  
Conservative management with antibiotics is usually required (51).   
Incomplete resection (failure of EMR) occurs in up to 10% of cases in expert centres, and is 
far more likely to occur in non-expert centres or if a previous unsuccessful attempt has been 
made resulting in submucosal fibrosis (5). 
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Early recurrence with the need for additional therapy is also a prominent issue with the use 
of piecemeal endotherapy.  A US study of 308 NPCPs quoted an initial recurrence rate on 
follow-up of 27% (rising to 38% for piecemeal resection) with a mean size of 23mm (OR 
11.68 (1.47-92.76), p=0.02) (9). The ACE study reported recurrence in 20.4% of cases in a 
study of 479 LSTs with a mean size of 35.6mm (piecemeal resection >6 pieces=34.2%, <6 
pieces =18.2% (OR: 2.25; 95% CI: 1.45–3.50; p=0.002) (5).  A 2014 meta-analysis examining 
piecemeal endoscopic resection suggests that early recurrence occurs in up to 20% of cases 
(146).  It would be appropriate to advise patients that early recurrence does not represent 
treatment failure as lesion clearance was achieved in the vast majority of cases with follow 
up endotherapy in almost all studies (5, 9, 146).  The potential for late recurrence after 12 
months, which may suggest treatment failure, should also be mentioned.  Recent estimates 
from studies with large follow-up numbers after 12 months suggest a figure of 
approximately 4-7% (56, 57).  Data from the English Bowel Cancer Screening Programme 
(BCSP) of 436 NPCPs with a mean size of 29.5mm reported  a recurrence rate at 12 months 
of 6% whilst Longcroft-Wheaton et al’s 2013 data reported late recurrence in 3.9% of 
cases(17, 56).  A 2010 Italian study reported 6.9% recurrence with 182 LSTs on 19 month 
follow up (mean size 24.7mm) (57) 
Complications may occur weeks after endoscopic resection  
 
There is evidence that patients with serious complications related to polypectomy, such as 
haemorrhage and perforation, may not present with symptoms until several days post-
procedure.  An analysis of post polypectomy bleeding (PPB) cases from 14,575 colonoscopies 
with polypectomy reported a mean presentation time of 5 days post procedure with a cases 
occurring up to 17 days after polypectomy, whilst there have been reports of PPB occurring 
up to 30 days post procedure (192, 193).  An analysis of post colonoscopy perforations found 
that 24% of cases presented over 48 hours post colonoscopy with 9% presenting over 15 
days after (194).  In view of this, the provision of a clear post procedure plan is important 
and may expedite appropriate management and improve patient safety. 
A copy of the endoscopy report with clear written instructions may be given to a patient 
post procedure with instructions about the course of action to take should they experience 
pain or significant bleeding following EMR.  It should be explained that severe bleeding can 
occur up to 14 days post resection and they should return to hospital for emergency 
assessment with a view to blood transfusion and endoscopic haemostasis.  
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1.7.2) Follow-Up Arrangements 
In the case of piecemeal EMR, initial follow-up is recommended within 2-6 months, with 
12 month follow-up for en-bloc resection 
 
Early follow-up endoscopy after piecemeal resection is advocated due to potentially high 
rates of incomplete resection and early lesion recurrence after primary endoscopy.  With 
piecemeal resection, histological evaluation is often unable to assess for completeness of 
resection.  In the case of successful en-bloc removal, follow-up is required due to a risk of 
new adenomas with 12 month follow-up  considered sufficient in view of low recurrence 
rates and the important ability to establish complete resection on histological analysis after 
initial resection (195).  There is evidence to suggest that recurrence levels increase the 
longer the period of time left to follow up on initial treatment, and early intervention of 
recurrent/residual tissue allows prompt treatment in an attempt to fully clear a lesion and 
prevent adenoma to carcinoma transformation (196).  A Japanese study reported recurrence 
rates of 18.4%, 23.1%, and 30.7% for follow up at 6, 12 and 24 months respectively whilst a 
US study reported a similar trend with recurrence almost 3 times higher after 24 months 
than at 12 months (79, 197).  Initial follow up at a later point such as 6 months also appears 
safe with similar levels of recurrence between 3 and 6 months and reports of recurrence 
identified at 6 months not seen at 3 months.  However, follow-up may also be appropriate 
sooner such as in the context of finding malignancy or high grade dysplasia on histology (21, 
79).  Follow-up within 6 months for piecemeal resection and at 12 month with en-bloc 
resection is in line with the position of the US Multisociety Task Force for Colorectal Cancer 
and the American Cancer Society who also recommend that lesions removed piecemeal 
should be considered for follow-up endoscopy between 2-6 month intervals until complete 
excision is completed (198).    
 
1.7.3) Residual and Recurrent Tissue 
 Residual neoplasia occurs at a level higher than previously understood 
 Image enhancement with techniques such as dye spray and digital enhancement 
may aid detection of residual neoplasia on a polypectomy scar. 
 Areas of possible residual polyp require tissue diagnosis and definitive treatment      
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There is evidence to suggest that incomplete resection occurs at a higher rate in cases of 
apparent complete resection than previously considered. The CARE study found a high 
incidence of incomplete resection (10.1%) in cases where complete resection was 
considered to have been achieved, including incomplete resection in almost half (47.6%) of 
sessile serrated adenomas, with a wide variety in rates of incomplete polyp resection 
between different endoscopists.  The results of this study appear highly noteworthy as the 
endoscopists involved were all highly experienced  and were aware of their involvement in a 
clinical trial and as such heightened scrutiny is likely to have been taken to ensure complete 
resection was considered achieved (20). Further justification for careful analysis of the scar 
site on follow-up endoscopy is provided by reports of ‘late-recurrence’ in an area where 
complete resection was believed to have occurred.  This phenomenon was first described by 
Walsh et al in 1992 where almost half of cases of recurrence occurred in cases where no 
recurrence had been identified on earlier examination (88).  A 2009 study reported late 
recurrence of residual adenoma in 4.4% of cases at 12 month follow-up (n=138).  In eight 
(7.2%) cases, evidence of residual adenoma was present in biopsy from scar sites where no 
visible adenoma was seen.  Negative biopsy results at early follow up appeared to be 
predictive of continued eradication on late follow up in 97.9% of cases when compared with 
the remaining lesions (RR; 0.15, 95% CI, 0.035-0.618, p=0.005)(199).  The practice of biopsy 
retrieval as part of follow-up resection site examination was supported by Knabe et al’s 
analysis of 252 NPCPs in which biopsy evidence of residual/recurrent adenoma in 7% of 
cases where no visible adenoma was present whilst late recurrence was seen in 10.47% of 
cases where no adenoma was identified at initial follow-up (200).  Taking biopsies from the 
polypectomy scar site when complete resection is considered to have taken place can be 
justified as it appears in some cases to have identified residual tissue for eradication 
treatment that would otherwise have been undetected. 
High rates of unknown incomplete resection and  the finding of late occurrence of residual 
tissue after no reported macroscopic recurrence may be due to the presence of recurrent 
tissue too small to visualise using standard endoscopy. This suggests that image 
enhancement  may improve diagnostic accuracy (201).  Magnification endoscopy appears 
accurate in identifying residual tissue. A study of 77 NPCPs compared prediction of 
completeness of excision with magnifying endoscopy with histological evaluation. The 
sensitivity of magnification endoscopy for predicting residual tissue at resection margins was 
98% (95% CI: 90–100).  Specificity was 90% (95% CI: 79–100), with an overall accuracy of 
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94.5% (95% CI: 87.2–98.6) (202). The use of chromoendoscopy was found to be accurate in 
predicting completeness of endoscopic resection in a 2004 study of 684 lesions (sensitivity 
80%; specificity 97%; accuracy 94% (203). A 2011 study comparing the accuracy of NBI with 
WLE (white light examination) in the detection of residual neoplasia found that NBI 
increased detection of residual neoplasia at the resection site with 63% of identified lesions 
found to be more extensive with NBI than initially thought with WLE (204).   
The use of confocal endomicroscopy (CEM) was been reported to have high diagnostic 
accuracy in predicting completeness of resection in vivo post EMR by a 2011 Chinese study 
of 24 lesions (diagnostic accuracy: 91.7%; sensitivity: 100%; specificity: 89.5%).  Similar 
findings were reported by a 2012 US study also reporting increased sensitivity in detecting 
residual neoplasia using CEM (n=129; sensitivity: 97%(p=0,045); specificity:77% positive 
predictive value (PPV): 55%; negative predictive value (NPV): 99% diagnostic accuracy: 81%) 
(137, 201). However the small sample sizes of these studies and the fact that CEM is not 
widely available indicate that these findings are not likely to be currently relevant is 
everyday wider practice.   
The management of residual/recurrent polyp tissue appears challenging with only limited 
data supporting endoscopic methods 
 
Whilst a proportion of recurrent/residual polyp tissue can be successfully treated with 
repeat snare resection, complete eradication with repeat therapy may be much more 
difficult to achieve such as with larger areas of recurrence.  Repeat therapy with EMR may 
not be achievable due to submucosal fibrosis (59).    
The use of ESD appears to be a less invasive management option in a scenario of complex 
recurrence.  There have been various reports of its efficacy in scar embedded polyps and 
subsequent avoidance of surgical resection.  A 2009 study reported successful clearance of 
lesion recurrence with ESD in 15 cases where EMR had failed to clear the original polyp (205, 
206).  A Japanese study also reported the successful use of ESD in large areas of recurrence 
(>2cm) where EMR was not possible with no subsequent recurrence (207).  However it 
should be noted that these studies are small and ESD availability in the West is still limited. 
Surgical resection remains an effective management option in this scenario whilst 
conservative management appears appropriate if patient comorbidity suggests that no 
management will not significantly affect life expectancy.  Various factors such as patient 
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wishes and comorbidity and availability of treatment modalities may affect management 
and access to a multidisciplinary network may optimise management. (8, 51, 208) 
 
Secondary surgical management is commonly required in cases of unsuccessful endoscopic 
resection, a finding of malignancy after an initial attempt at endoscopic resection and in 
the management of complications. 
Failed endoscopic attempts at removal can complicate subsequent management.  
Incomplete or inadequate attempts at EMR can result in more complicated management, 
secondary surgical management and development of colorectal cancer and so the decision 
making process in the assessment and subsequent management of large colonic polyps is of 
great importance (12).   
There is broad variation in large polypectomy practice: 
A large 2004 survey of polypectomy practice demonstrated broad variation between 
endoscopists(170).  This included advanced polypectomy, where the threshold for the use of 
submucosal injection appeared to vary widely. For large pedunculated lesions with a broad 
stalk, there was no uniform technique used for bleeding prophylaxis.  A possible reason 
given for variation in practice was the probability that many practitioners performed 
polypectomy as they were taught and the lack of available evidence from clinical trials for 
several aspects of advanced polypectomy meant that a change in practice that they were 
comfortable with was unlikely (170).  For example, many trials conducted, such as trials for 
diathermy and submucosal injection solutions, involved the use of animal models.  Variation 
in practice appears to have continued.  A more recent survey reported similar findings, with 
variation not only in the use of submucosal injection for polypectomy and bleeding 
prophylaxis for stalked polyps, but also in the choice of snares used, the constituents used in 
the submucosal injecting solution, diathermy settings used and use of imaging enhancement 
techniques such as NBI (171).  Further variation was demonstrated in a 2013 UK survey 
captured variation between UK endoscopists with aspects such as the use of biopsies and 
video recording whilst a training survey found that over 50% of respondents to a national 
survey who regularly practiced advanced polypectomy were self-taught (19).  It appears 
plausible to suggest that variation in technique may affect outcomes (209). 
Based on subjective opinion, survey results, lack of evidence in certain areas and conflicting 
trial reports, reasons for variation in practice may include: 
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 Cessation of antiplatelet agents such as aspirin 
 Use of carbon dioxide or air insufflation,  
 Routine use of classification systems 
 Use of chromoendoscopy, high definition imaging or NBI to inspect a lesion 
 Endoscopic position used to resect lesion 
 Type and constituents of lifting solution used 
 Snare sizes and type used  
 Upper limit threshold for attempting en-bloc resection 
 Threshold for attempting non-lifting lesions, whether previously attempted of not 
 The amount and type of electrocautery used 
 The use of argon plasma coagulation (APC) used at excision margins in piecemeal 
EMR 
 The use of snare tip coagulation or APC for residual tissue 
 Post polypectomy bleeding prophylaxis management such as clip application to the 
resection site  and management of bleeding 
 The management of visible perforation 
 Documentation of procedure (photos, classification systems used to describe 
systems on report).   
 Aftercare instructions given to patient 
 Timing and frequency of follow up endoscopy 
 Technical ability of the endoscopist and individual complication rates  (18) 
 
1.8)  Other therapeutic modalities 
1.8.1) Endoscopic Submucosal Dissection 
Endoscopic submucosal dissection (ESD) is a more invasive, time-consuming technique that 
allows en-bloc retrieval of larger specimens than possible with EMR, with a single ESD 
procedure potentially taking up to several hours (71, 73).  As with EMR, a submucosal 
cushion is made to lift the lesion away from the submucosa with a lifting solution.  Given the 
comparatively longer procedure time, the use of colloidal type solutions that provide a 
longer lasting cushions such as hyaluronic acid and glycerol (in combination with 1:10000 
adrenaline and a pigment dye) has been advocated (210).  Resection is performed with the 
use of an electrosurgical knife, of which various types exist much like endoscopic snares.  
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The knife is used to make an initial circumferential mucosal incision and then submucosal 
dissection is performed parallel to the muscle layer under endoscopic visualisation.  The 
knife has coagulation properties but the use of diathermy and clips may also be required to 
prevent and control bleeding, with the latter used to treat small visible perforations (211).  
The largest reported study of the use of colorectal ESD was a multicentre Japanese study of 
1111 NPCPs in 2010 with NPCPs up to 140mm in size, which reported en-bloc resection and 
curative resection rates of 88 and 89% respectively.  Procedure times varied between 1-4 
hours with a perforation rate of 4.9% and a post-procedure bleeding in 1.5% of cases (212).  
A review of studies examining the use of colorectal ESD suggests that it is highly effective 
with reported en-bloc resection rates of around 90%. Reported rates of perforation, the 
most recognised complication with ESD, in larger studies (n>200) vary between 4.9-8.2% 
which is markedly higher than reported with piecemeal EMR (0.5-1.5%)(212, 213).   
ESD has only limited availability in both the UK and the western world and there is a relative 
paucity of data with only low volume studies when compared with Asia (71).  A 2007 UK 
study of 42 NPCPs managed with ESD reported en-bloc resection in 78.6% of cases with a 
curative resection rate of 74% and perforation and post procedure bleeding at 2.6% and 
11.9% respectively (214).  A 2013 Italian study featuring lesions up to 80mm in size (n=40) 
reported figures comparable to many reported Japanese series with  en-bloc resection and 
curative resection rates of 90% and 80% respectively and comparatively low rates of 
perforation (2.5%)  and post procedure bleeding (5%)(215).  However, it should be noted 
that in addition to a small sample size, this series consisted entirely of rectal lesions which 
are felt to be easier to remove safely due to good accessibility and thicker mucosa.  
One explanation for the low availability of ESD in the West includes the steep learning curve 
associated with a highly advanced technique. Data from Saito et al’s 2010 study 
demonstrated significantly reduced perforation rates with an increased number of ESDs 
performed (< 50 ESDs: 17.6% vs 50-99: 8.2% vs >100: 5.1%, p<0.0001)(74, 212). In addition, 
there are high complication rates compared to piecemeal EMR and potential lengthy 
procedure times of several hours which may reduce the feasibility and cost effectiveness of 
providing such a service (216).  There is also evidence that the use of piecemeal EMR, which 
is widely available and less time consuming, has comparable efficacy with en-bloc resection  
techniques with benign NPCPs  when allowing for repeat endotherapy (77, 217). A hybrid 
EMR/ESD procedure where circumferential incision around a lesion is followed by en-bloc 
snare resection has been increasingly described. The use of this technique appears to allow 
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en-bloc snare resection of larger lesions due to reduced issues with judging the submucosal 
plane prior to snare resection, with snare resection having been demonstrated to reduce 
procedure times compared with ESD (Saito et al, 2010: n= 373, ESD procedure time: 108 ± 71 
min (15–360 min) vs EMR procedure time: 29 ± 25 min (3–120 min), p<0.0001) (73, 218).  A 
porcine model reported in 2010 demonstrated that a hybrid technique using circumferential 
incision allowed en-bloc resection  in 70% of lesions over 4cm in size with procedure times 
substantially shorter than for ESD as dissection beneath the lesion, the most time consuming 
part of the ESD procedure is not required (219).  A 2012 Japanese study (n=269) compared 
ESD with hybrid ESD/EMR and EMR/pEMR.  Hybrid ESD/EMR was under taken in 27 cases 
with a perforation rate of 7.1% (as a result of submucosal dissection rather than snare use), 
a delayed bleeding rate of 0% and a recurrence rate of 0% reported. Whilst treatment 
efficacy was comparable, the median procedure time was 85 min (30–360) for ESD versus 
57.5 min (9–150) for hybrid ESD/EMR (73).  A similar technique called ‘Insulated-Tip Knife 
Endoscopic Mucosal Resection’ has previously been described in Italy.  In a study of 29 
patients where 55% of lesions over 3cm were removed en-bloc with a median procedure 
time of 59 min (41–130 min) (220).  In view of the ability to achieve reasonable en-bloc 
resection rates with comparable efficacy to conventional ESD and shorter procedural times, 
in addition to the suggestion of a reduced learning curve, it has been suggested that the 
hybrid technique may be a preferable modality in the West, where reduced cost 
effectiveness due to long procedure times has limited uptake of ESD (209, 216).  
1.8.2) Cap assisted EMR 
Cap assisted EMR (EMR-C) is commonly used to remove areas of high grade dysplasia in 
Barrett’s Oesophagus as well as in upper gastrointestinal EMR.  Its use has also been 
described with large colonic lesions using a principle known as the ‘suck and cut’ method 
(221).   A single use plastic cap is attached to the tip of the endoscope with most systems 
using a band ligation device similar to that used to band oesophageal varices.  As with 
conventional colonic EMR, a submucosal injection is made below a lesion to create a 
submucosal cushion.  The raised lesion is then aspirated using suction into the affixed cap 
device with the subsequent deployment of a rubber band to trap the lesion.  A snare is then 
used to resect the lesion below the band (222, 223).  A 2010 Italian study examining the use 
of piecemeal EMR-C on NPCPs (n=255) reported 96% clearance after a median follow-up of 
approximately 12 months with no cases of perforation, intra-procedural bleeding in 7% of 
cases and no reports of post-procedural bleeding.  EMR-C was suggested as an effective 
72 
 
technique at removing large colonic polyps in a piecemeal technique (224).  A potential 
advantage over conventional snare polypectomy is that it is felt to  improve accessibility for 
lesions that are entirely or partially in a difficult position (e.g. behind a mucosal fold) whilst 
flat lesions felt difficult to grasp with a snare can be trapped with aspiration (222).  There are 
concerns about perforation associated with EMR-C due to the possibility of aspirating the 
muscularis propria into the suction cap, and use with rectal lesions where the mucosal tissue 
is thicker has been suggested for main application (224). 
 
 
 
1.8.3)  Underwater EMR 
Whilst the use of a submucosal injection is widely described to reduce the risk of 
perforation, there have been reported concerns that creating a submucosal cushion may 
alter the resection plane and complicate endoscopic resection whilst there is also a 
theoretical risk of needle tracking neoplastic cells to deeper tissue layers.  A novel 
‘underwater EMR’ (UEMR) technique without the use of a submucosal injection has been 
described (225).   The procedure commences with the evacuation of air and total immersion 
of the lumen with water during colonoscopy.  Underwater immersion is intended to ‘float’ 
the mucosa and submucosa’ away from the muscularis layer to reduce perforation risk.  The 
lesion margins are marked using APC and snare polypectomy is then used (225-227).  
In a 2012 study using UEMR with 62 NPCPs, residual tissue was found in only one case on 
follow-up after 4 months with no reports of perforation. Delayed bleeding incidence was 
comparable in series describing conventional pEMR with a rate of 4.8%.  In should be noted 
however that this was a small single centre study and larger studies are likely to be required 
before uptake of this technique increases (225).  It has also been suggested that that this 
technique may provide an important modality for the management of LNPCP recurrence.  A 
2014 retrospective analysis (n=80) compared the outcomes of UEMR vs conventional EMR 
for the management of recurrent tissue following attempted EMR resection of LNPCPs.  En 
bloc resection (47.2% vs 15.9%, p=0.002) and complete resection (88.9% vs 31.8%, p<0.001) 
rates were higher in the UEMR group.  In addition, APC ablation of visible residual tissue 
during salvage procedures was lower with UEMR (11.1% vs 65.9%, p<0.001), whilst further 
recurrence was also  significantly lower (10% vs 39.4%, p=0.02) (226). 
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1.8.4)  Surgical Therapy 
Surgical therapy provides effective management where malignancy is suspected or 
concerns about the likelihood of incomplete endoscopic resection arise  
 
Whilst expert endoscopic management is considered preferred first line management in 
benign lesions due to superior patient safety, surgical resection can be used to provide an 
effective therapy in certain circumstances with approximately 10% of large colonic 
adenomas managed surgically (10, 11).  Surgery may be preferred therapy where: 
 a lesion is felt to have features suggesting possible submucosal malignant 
invasion such as Kudo Pit Pattern type 5, depressive features or a failure to lift 
with submucosal injection in the absence of prior intervention 
 there are technical issues regarding endoscopic access or achieving a stable 
endoscope position for removal  
 the lack of availability of an endoscopist with expertise to safely remove a lesion 
endoscopically 
 other features raise a concern about potential iatrogenic perforation or bleeding 
such as lesion size or right sided location  
 
Although morbidity and mortality are likely to be higher for surgical resection than with 
endotherapy, the chances of complete resection are better and there is a markedly reduced 
need for endoscopic follow up (61).   Morbidity and mortality rates for both open and 
laparoscopy surgery has been reported at approximately 20% and 1% respectively (11).  
Complications associated with surgical management include infection, an anastomotic leak, 
wound dehiscence, ileus, electrolyte imbalance and pain (228). 
Surgical resection is also a secondary effective management option where recurrence 
cannot be managed endoscopically (5, 17, 21, 57). Even with the most advanced 
polypectomy techniques such as ESD, deeper submucosal invasion cannot be managed, with 
surgery often required when it is encountered at endoscopy.  Surgery offers the highest 
chance of oncologically complete resection for these malignant lesions.  A study of 1111 
colorectal ESD procedures featuring both benign and malignant lesions reported an en-bloc 
resection rate of 88% with a curative rate of 89% (212, 215).  Surgical resection is currently 
the only therapy where deep submucosal infiltration and lymph node infiltration may be 
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managed effectively.  Reported curative rates for surgical resection are 100% for stage 1 
disease with a rate above 91% for stage IIIa disease which indicates its efficacy (229).  There 
is a considerable rate of malignancy found post-surgically in lesions previously thought to be 
benign though this varies considerably depending on patient selection and operator 
expertise.  A study analysing histopathology post-surgical resection for 750 polyps felt to be 
benign found invasive malignancy in 17.7% of lesions (11).  This supported the findings of an 
earlier smaller study (n=63) where evidence of invasive malignancy was found in 22% of 
polyps that were considered to be both endoscopically unresectable and benign (230).  In 
view of this, where expert endoscopic resection is considered difficult or where there is 
diagnostic uncertainty, surgical resection appears to be an appropriate management option 
due to the ability to fully resect a lesion en-bloc in addition to sampling or removing adjacent 
lymph nodes providing an oncological resection (37, 38, 230). 
In addition, in cases where endoscopic access is considered difficult with a concern about 
causing complications or achieving a successful resection, surgical therapy may provide a 
safer more effective option as a primary therapy rather than as an additional invasive 
procedure to provide secondary treatment (231). This may be instead of or combined with 
endotherapy with increasing reports of the use of laparoscopically assisted endoscopic 
polypectomy (LAEP) following complex  polyp MDT discussion (232).   
 
Laparoscopic therapy is preferred to open surgery in the surgical management of 
colorectal NPCPs   
 
Laparoscopic surgery has largely replaced open surgical resection for the removal of NPCPs 
where endoscopic resection is deemed unsuitable (233). Initial concerns about laparoscopic 
surgery included the possibility of longer and more complex procedures than with open 
surgery and the retrieval of a shorter resection specimen, with suggestions that this may 
result in reduced oncological efficacy (234). A meta-analysis demonstrated comparable 
therapeutic efficacy to open surgery (OS), describing laparoscopic surgery (LS) with similar 3 
year recurrence rates, including in the management of colorectal cancer whilst also being 
minimally invasive. (Tumour recurrence at 3 years for LS: 16% vs OS: 18%; 95% CI: 0.63 to 
1.17; p=0.32). Laparoscopic surgery for malignancy is therefore considered oncologically safe 
(13, 235, 236). A retrospective UK analysis of surgical outcomes over 10 years (n=192,620, 
3709 laparoscopic procedures) reported that laparoscopic surgery was associated with a 
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reduced 30 day (OR: 0.57; 95% CI: 0.44-0.74; p < 0.001) and 365 day mortality (OR: 0.53; 95% 
CI: 0.42-0.67; p < 0.001) after correction for age, gender, diagnosis, operation type, 
comorbidity, and social deprivation (237). Other studies have commented that the rate of 
mortality and post-operative complications appears similar between open and laparoscopic 
groups but have clearly demonstrated that laparoscopic surgery is associated with 
accelerated post-operative recovery with reduced pain, the earlier return of bowel function.  
This may also be important from a financial consideration with a shorter associated hospital 
stay. (Salimath et al, n=261; OS: 4.4 days (95% CI: 4.2–4.6) vs LS: 3.7 days (95% CI: 3.9–3.5); 
p<0.001) and reduced hospital stay (Vlug et al, n=427; p<0.001), (Salimath et al; OS: 8.01 
days (95% CI: 7.1 to 8.9) vs 4.38 days (95% CI: 4.0 to 4.8); p<0.001) (238, 239).  It is also still 
associated with higher a level of co-morbidity than EMR (13, 61).   
 
Patient factors may ensure that laparoscopic surgery is not always possible, necessitating 
open resection.  Cited indications for open surgery include patient factors such as obesity 
and previous abdominal surgery with subsequent adhesions which may reduce laparoscopic 
efficacy due to reduced accessibility and manoeuvrability.  In addition, complications during 
laparoscopic surgery may necessitate conversion to open surgery to allow for more rapid 
resolution (61, 237).   
 
Laparoscopic surgery may be combined with endoscopic polypectomy to avoid bowel resection 
Laparoscopic surgery may also be used in combination with endoscopic polypectomy.  The 
use of laparoscopic assisted endoscopic polypectomy (LAEP) has been described for polyps 
where endoscopic removal was previously considered too difficult.  Reported benefits 
include the potential to manipulate polyps into a more favourable position for resection 
whilst a visible perforation may be sutured immediately.  In addition, the discovery of 
malignancy allows for laparoscopic surgical resection during the same procedure, reducing 
the need for a subsequent procedure (232, 240).  The largest reported series currently 
comes from a 2009 US study (n=209) which reported that in all cases where LAEP was 
possible, complete eradication was found in all cases in all follow-up up to 5 years post 
procedure (240).  Whilst there is a view that LAEP may reduce surgical bowel resection, its 
use internationally has only been described in small numbers (232).   
Minimally invasive surgical techniques may be considered as a suitable primary therapy for rectal 
LNPCPs where en-bloc resection is desired due to a concern of malignancy  
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The surgical management of rectal lesions requires special consideration due to the 
complexity and morbidity associated with both open and laparoscopic resectional surgery in 
this area and the availability of endotherapy and minimally invasive local resectional surgery 
such as TEMS.  A 1998 study reported (n=591) 3.2% mortality at 30 days with 30% post-
operative morbidity with open proctectomy (241) whilst a 1999 study (n=681) cited a 0.6% 
peri-operative mortality and 22% post-operative morbidity (242). A 2010 laparoscopic low 
anterior resection series (n=132) reported similar morbidity (20.5%) (243).  In addition, with 
low rectal lesions where non-sphincter saving surgery such as an abdominoperineal 
resection (APR) is often used, a permanent stoma will be required (244). 
Transanal surgical techniques, have been developed for the management of anorectal 
lesions and It is associated with significantly lower morbidity and cost than major resectional 
rectal surgery and avoids the need for a permanent stoma (77). 
TEMS (Trans-anal Endoscopic Micro-Surgery) is a surgical technique developed in the 1980s 
performed under general anaesthetic that allows removal of rectal lesions using submucosal 
dissection via a transanal approach (245).  TEMS allows en-bloc removal of large lesions by 
either submucosal dissection or full thickness rectal wall excision and is performed with the 
patient in the lithotomy position. The procedure can last for up to three hours and can be 
performed as a day-stay procedure (246).  
TEMS and variants of this technique can be used treat large rectal adenomas where en-bloc 
resection is preferred and ESD is not available, for example if there is a concern about 
malignancy. Where suspicion about malignancy exists and en-bloc resection is considered 
desirable to ensure adequate histological analysis, the use of either ESD or minimally 
invasive local resectional surgery such as TEMS is preferable to conventional resectional 
surgery, however ESD availability, as previously discussed, is still limited.  A 2014 meta-
analysis of 111 ESD and 10 TEMS series (n=2077) comparing LNPCP management outcomes 
found en bloc resection to be  higher with TEMS  (TEMS: 98.7 % (95 %CI: 97.4–99.3 %) vs 
ESD:  87.8 % (95 % CI: 84.3–90.6), (p<0.001) whilst the curative resection rate was also 
superior (TEMS: 88.5 % (95 % CI: 85.9–90.6 %) vs ESD: 74.6 % (95 %CI: 70.4–78.4 %), 
p<0.001).   (247).  A 2010 meta-analysis of TEMS also demonstrated a significantly reduced 
post-operative complication rate compared with resectional surgery (n=629, OR: 0.16 (95% 
CI: 0.06-0.38), p<0.003), whilst a 2012 study also demonstrated significantly reduced 
morbidity (n=78, 14.6 % (TEMS) vs. 37.1 % (resectional surgery), p=0.046) (60, 248).    
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The available evidence suggests that pEMR is preferable to TEMS for the management of 
rectal NPCPs where malignancy is not suspected and en-bloc resection is therefore not 
considered essential.  A retrospective comparison between TEMS and piecemeal EMR for 
the management of large rectal NPCPs (n=292)  found that whilst early recurrence rates 
were lower in TEMS (10.2% vs 31.0%, p < 0.001) when allowing for repeat endoscopic 
therapy on follow-up, late recurrence after 12 months was similar (9.6% vs 13.8%, p = 
0.386). TEMS was also associated with greater morbidity (postoperative complications: 24% 
(TEMS) vs 13% (EMR), p = 0.038) and a longer hospital stay (median hospitalization post 
procedure: 3 days (TEMS) vs 0 days (EMR), p < 0.001) (77). Another consideration is evidence 
that pEMR appears more cost effective.  International cost analysis suggests the cost of EMR 
is around $2000, with subsequent follow-up roughly half this figure.  In comparison, the cost 
of TEMS is estimated to be around $7800 (10, 56, 249).  However, TEMS may be indicated as 
first line treatment for selected benign rectal NPCPs such as mid or low rectal large flat 
‘carpet-like’ lesions (usually villous adenomas) that occupy significant rectal circumference 
and are technically difficult to remove with snare retrieval due to its soft texture and the risk 
of significant bleeding (245, 246). 
Further developments have continued to be made with regards to transanal surgery.  A 
hybrid procedure called TAMIS (Trans-Anal Minimally Invasive Surgery) combining transanal 
surgery with single port laparoscopic access under GA was first described in 2010 (250).  A 
single-incision laparoscopic surgery port is introduced into the anal canal with manual 
pressure with a patient in either a prone or lithotomy position.  Air insufflation is then 
undertaken until pneumorectum is achieved.  At this point, laparoscopic instruments such as 
graspers, thermal energy devices, and needle drives, are used to perform transanal 
excisions.  6 patients with rectal lesions (including 2 with malignancy) with a mean lesion size 
of 2.93cm underwent TAMIS with a mean procedure time of 86 minutes, shorter than with 
TEMS (average procedure time of 120-140 minutes (251).  An 100% cure rate was achieved 
with all patients discharged within 24 hours.  Overall costs were reported as being 
substantially lower than with TEMS due to shorter procedure times and lower equipment 
costs. In addition, there were no cases of anal dysfunction, a feature that has been reported 
post TEMS (250, 251). A subsequent case series of 50 patients (25 benign neoplasms, 23 
malignant lesions, and 2 neuroendocrine tumours) was described in 2013.  Almost all cases 
were undertaken as a day-stay procedure.  A mean procedure time of 74.9 minutes was 
achieved with no cases of anorectal dysfunction and no long term complications noted at 20 
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months.  Positive resection margins were seen in 3% of cases necessitating AP resection.  
Recurrence at between 6-18 months was 4% (251).  The reported benefits of TAMIS 
compared to TEMS in addition to shorter procedure times include increased rectal visibility, 
quicker equipment setup and the ability to use existing laparoscopic equipment.  In view of 
established efficacy, reduced costs, shorted procedure times, and improved visibility, TAMIS 
has been proposed as a safe and effective advanced transanal option for the removal of 
both benign large rectal adenomas and selected early stage rectal cancers (251, 252). 
1.9)  Histological and Radiological Considerations 
1.9.1)  Histopathology 
 
Whilst important, histopathological assessment appears to have a less significant role in the 
management of benign polyps than with malignancy, in which the pathological assessment, 
including depth of invasion (by Haggitt level, Kikuchi level, and quantitative measures), 
differentiation, lymphovascular invasion, tumour budding etc. are all important in 
consideration of subsequent management.  The major histopathological considerations 
regarding LNPCPs as described below: 
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 Judicious use of targeted biopsies:  Recommended only when there is suspicion of 
malignancy in a LNPCP, to help ensure endotherapy is not compromised. 
 Awareness of significant potential for under calling of malignancy in the endoscopic 
biopsy setting. 
 In polypectomy evaluation, confirmation of the adenomatous nature of the polyp 
and confirmation of benignity i.e. exclusion of adenocarcinoma arising within the 
adenoma 
 Emphasising the distinction between invasive neoplasia and so-called ‘epithelial 
misplacement’. 
 Assessment of adenoma subtype according to WHO 2010 classification as tubular, 
tubulovillous, villous or traditional serrated.  
 Assessment of grade of dysplasia/neoplasia using a two tier system. 
 Assessment of margin involvement by dysplasia, where possible, in accordance with 
the nature of the specimen received (en-bloc or piecemeal) and endoscopic 
correlation regarding completeness of excision  
   Figure 12. Major Histopathological Considerations in the Management of LNPCPs (253). 
 
 
1.9.2)  Radiological Investigations 
Radiological input may be warranted in certain cases, such as where there is difficulty in 
determining whether a lesion is benign or malignant. Whilst CT and MRI imaging may 
provide information regarding local lesion invasion for colonic and rectal lesions respectively 
where malignancy is suspected, there is an absence of evidence to suggest that radiological 
investigation commonly affects LNPCP management.  It appears that radiological input may 
therefore not be uniformly essential in LNPCP assessment but considered on a case by case 
basis.  
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Chapter 2: Consensus Methodology 
 
2.1) Consensus Methodology: An Introduction and Background 
Consensus methodology is a process where a group of individuals with relevant expertise are 
asked to record the extent to which they agree with a statement and secondly the extent to 
which participants agree with each other (254).  The use of consensus methodology in 
providing healthcare frameworks and solutions is now commonplace, with the field of 
gastroenterology an important example.  It is seen as a more robust than the previous 
approach of guidelines formulation involving by one or a few individuals as it allows for the 
learned opinion from a variety of experts involved in the management of a specific condition 
(254, 255).  A review of various consensus based approach exercises in healthcare suggests 
inter-participant agreement of at least 80% is considered to be of sufficient robustness.  
Areas considered ideal for consensus methodology use have been described as those where 
there is a lack of a structured framework, a limited evidence base and conflicting evidence 
about best practice (254).  The three main consensus approaches are described below. 
 
2.1.1) Delphi technique 
Delphi Technique is a group communication exercise designed in the USA in the 1950s by the 
RAND Corporation as a tool in program planning, needs assessment, policy determination, 
and resource utilization.  It uses participants to achieve a consensus opinion on a topic using 
a multi-stage process with a convergence of opinions (256).  Subjects used are commonly 
considered experts in relevant fields to provide learned, holistic and robust opinion. The 
process usually begins with a comprehensive literature review by a steering group with the 
results commonly used to define statements or questions used in a first voting round. Prior 
to beginning the process, a minimum figure should be set that signifies an acceptable 
consensus level for each statement used (e.g. 80%).  The voting process may have been 
undertaken using mail and email contact as well as the use of voting keypads and a summary 
of the process is shown below (256). 
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Development of statements 
Relevant statements may be formulated via a literature review, via a questionnaire of a 
participant group or input from a steering committee, some of whom maybe part of the 
subsequent consensus process.  
Round 1: 
This round can be used to revise and streamline the statements delivered for consideration 
by the Delphi group prior to further iterations.  
Round 2: 
The statements collated from the first round are evaluated by participants who are asked to 
grade their level of agreement with each statement.  Participants are often asked to provide 
supporting statements for their answers 
Round 3: 
Prior to the next round the answers are collated with variation in responses recorded. 
Participants who give answers that vary widely from the bulk of the responses may be asked 
for justification for their decisions.  The process continues with the results of the previous 
round available to the participants who are able to reconsider their initial responses. The 
results are collated with the intention of achieving a convergence of opinion.  Further rounds 
may be added where required to achieve consensus as appropriate. Following the 
completion of the process, the strength of evidence and strength of recommendation for a 
particular statement may be reported (257).  
 
Strengths and weaknesses of process 
 A strength of the Delphi consensus process is the format of anonymised voting which allows 
group members to vote without a fear of being influenced by more domineering members 
of the group, whilst they are also able to change their vote without fear of judgement (256, 
258).  In addition, it is considered to be a robust consensus technique with regards to the 
utilisation of evidence based medicine.  The dissemination of a comprehensive literature 
review and relevant references, in addition to a substantial time allowance for a participant 
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to review and potentially add to the evidence base, increases the likelihood of informed, 
evidence based decisions.  The reliability of decisions made appears to increase with a larger 
group size and participants with outlying views have less of an influence on final results 
(255).  An advantage of non face-to-face discussion between experts is that it is less costly 
and easier to organise than a group meeting.  However, this aspect of the process has been 
criticised, as this interaction can enhance complex decision-making processes by allowing 
the clarification of terminology and points made.  In view of this, a modified Delphi 
technique is often used that combines the standard voting process with face-to-face 
interactions.   
 
2.1.2)  Nominal Group Technique 
This is a structured meeting process using a panel of experts to obtain relevant information.  
Each member of the panel is asked to develop ideas and solutions for a specific problem 
prior to meeting.  At the group meeting, each member presents their ideas in turn with 
statements (such as recommendations) recorded for evaluation.  Participants are then asked 
to anonymously rate, evaluate and re-evaluate the recorded statements until consensus is 
reached.  An advantage of this process is that it allows both anonymised voting and group 
interaction.  However it may be both difficult and costly to arrange a group meeting, 
especially with a national or international process.  Another criticism of the nominal group 
technique is that it does not allow for the integration of evidence based medicine into the 
decision making process, making it a less robust process. As previously highlighted, a 
modified Delphi process (a modified Delphi technique), combining the face to face 
interaction of this technique with rigourous evidence supported voting rounds is often 
preferred (254, 259).  
 
2.1.3)  National Institutes of Health (NIH) Conference Approach 
This approach has been compared to the deliberation of a jury in a courtroom style process.  
A selected group of expert individuals present evidence and data to a separate panel with 
general methodological expertise but not considered experts in the field being discussed.  
The decisions making panel evaluate the evidence presented and may ask questions when 
appropriate.   They then deliberate over the evidence in a private setting with the leadership 
of a chairperson to reach a decision. Unlike a jury, the views presented by a minority are also 
captured and reported.  This approach has been long established and the lack of experts in 
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the decision making panel is advantageous in potentially reducing bias and conflict of 
interest.  A disadvantage with an approach of having no experts within the decision making 
panel is that there is the possibility for misinterpretation of data and the significance of 
evidence presented may be inappropriately estimated.  An additional criticism of this 
methodology is that the lack of anonymised decision making may result in some group 
members being overpowered by more dominant members of the group whilst it has also 
been felt to allow insufficient time to both deliver and deliberate over information (259). 
 
2.2)  The use of consensus methodology in endoscopic research  
The Delphi process has recently been utilised in endoscopic research with success. This 
process was by the Canadian Association of Gastroenterology in 2012 to achieve consensus 
guidelines for quality and safety indicators in endoscopy (257). More recently, Delphi 
methodology was used to formulate a system of assessing the difficulty of colonic polyps 
based on specific features. The site, morphology, size and endoscopic access (SMSA) of a 
colonic polyp were used as parameters with 4 levels of difficulty to achieve complete 
successful removal (see tables 4 & 5) (6). The SMSA system has subsequently been 
demonstrated as accurate in predicting the likelihood of complete lesion removal in a 2013 
study (56).  This is an example of qualitative research in an area with conflicting option and 
low evidence base allowing a framework to create accurate quantitative data. 
 
2.2.1)  The Use of Consensus Methodology for the Management of Large Colorectal Polyps 
The use of consensus methodology seems to be appropriate in work aimed at improving the 
management of large colonic polyps.  This topic appears to fulfil criteria described by Jones 
(1995) by being a subject where there is a lack of a structured framework, a limited evidence 
base and conflicting evidence about best practice (see table 6)(254).  It can be argued that 
the benefit of using an expert panel to achieve consensus in the management of large 
colonic polyps includes the involvement of specialists with high volume practice that are 
abreast of the evidence available and have already contributed significantly to the available 
evidence base. 
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Area with conflicting evidence Evidence for Evidence against 
Adrenaline should be added to 
injection solution to reduce risk of 
bleeding 
 
Hsieh et al (2001) 
Dobrowski et al (2004) 
Shirai et al (1994) 
Lee et al (2007) 
Clipping for prophylaxis of bleeding 
following polypectomy 
Liaquat et al (2013) Shijoi et al (2003) 
Use of APC on resection margins  Brooker et al (2002) Moss et al (2011) 
Mannath et al (2011) 
Table 6. Areas of LNPCP management with conflicting evidence base 
 
Practices in advanced endoscopic lesion removal commonly cited and recommended as 
good practice but for which a paucity of evidence exists include: 
 Gelofusin/Hyaluronic Acid should be used for lesions over 3cm 
 The snare should be marked prior to use 
 Blended current should be used for diathermy 
 Pigmented solution such as methylene blue or indigocarmine should be used in lifting 
solutions to help to demarcate lesions and its resection margins 
 The continuation of aspirin prior to advanced polypectomy 
 
2.3) Aims and Methods 
The purpose of developing guidelines and key performance indicators was to provide an 
evidence based resource and expert opinion on the optimal assessment and management of 
large non-pedunculated colorectal polyps (LNPCPs) for clinicians involved in their care.  
These include gastroenterologists, nurse practitioners, physicians, colorectal surgeons, 
radiologists and pathologists. These lesions are important as they carry an increased risk of 
colorectal cancer, yet are the most challenging lesions to resect endoscopically and carry an 
increased risk of incomplete excision and complications.  In the absence of an existing 
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framework and an unknown UK incidence of LNPCPs, key questions we sought to cover 
included: 
1. What are key definitions and terms associated with LNPCPs? 
2. What are key principles for optimal management, including both assessment and 
therapy? 
3. What are the available management options? 
4. What information should patients be given about their management? 
5. When is surgical or conservative management more appropriate than endoscopic 
therapy? 
6. Which are the most complex lesions and how should they be managed? 
7. What histopathological considerations are important in the management of LNPCPs? 
8. Can multidisciplinary input into assessment and therapy optimise management and 
what information is required to achieve this? 
9. How should anticoagulant and antiplatelet medications be managed pre and post 
procedure?  
10. How should patients be followed up following endoscopic removal of LNPCPs? 
11. What are the most appropriate key performance indicators for monitoring the quality of 
management of LNPCPs? 
12. What can be done to improve formal training in the management of LNPCPs? 
13. What aspects of LNPCP management have the weakest evidence base and what are the 
key research questions which will help address these? 
 
The British Society of Gastroenterology (BSG) Endoscopy committee was approached for 
permission to lead a BSG sanctioned process towards developing an evidence based 
framework for the management of LNPCPs with the use of a working group.  The use of a 
BSG sanctioned process was felt to be the most appropriate as the lead clinician for this 
project (Professor Rutter) had previously been approached to chair a BSG working party for 
large polyp management.   The proposal was subsequently approved by the BSG along with 
logistical support for the process.  This included use of the BSG offices and the covering of 
travel expenses for members of a BSG working group for any face to face meetings.   
BSG guidance on guideline development was used.  This included details about the use of a 
‘guideline development group’ (GDG) with multidisciplinary key stakeholders involved in 
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LNPCP management including a patient representative.  A ‘writing committee’ subgroup was 
also recommended.  A guideline development group (GDG) including gastroenterologists, 
endoscopists, colorectal surgeons, gastrointestinal pathologists and a patient representative 
was selected in accordance with BSG/NICE criteria to ensure wide ranging expertise across 
all relevant disciplines.  In addition to a patient representative, other members proposed 
included both ‘expert’ endoscopists and endoscopists who undertake advanced 
polypectomy but may refer on lesions to expert centres (referring endoscopist), colorectal 
surgeons who undertake both endoscopic and surgical polyp removal and a histopathology 
representative.  This composition was approved by the BSG endoscopy committee who 
proposed several endoscopic representatives who had both national and international 
recognition in this field.  Professor Rutter was appointed GDG chairperson whilst I served as 
the GDG coordinator and lead author for document creation in a non-voting capacity.  The 
chairs of the ACPBI and the Royal College of Pathologists were then approached to nominate 
at least 2 surgical and histopathological representatives whilst the BSG research committee 
nominated a patient representative.  Nominated persons were subsequently contacted via 
email to ascertain availability and interest to participate as a GDG member and a writing 
committee subgroup member.  Acceptance was indicated by email with their consent to 
participate confirmed with the return of a signed conflict of interest form.  A  GDG of 14 
people including Professor Rutter and myself was finalised. 
The GDG consisted of: 
 8 Expert endoscopists,  
 1 Non-expert endoscopist,  
 2 Colorectal surgeons,  
 1 Gastrointestinal Histopathologist,  
 1 Patient representative 
 1 Coordinator (myself, non-voting) 
 
2.3.1)  Consensus Methodology Use 
A modified Delphi process combining elements of both the Delphi technique and the 
nominal group technique was agreed upon as the most robust way of undertaking 
consensus methodology, combining the strengths of allowing participants the opportunity to 
vote anonymously without the potential of being intimidated by another group member 
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whilst also allowing for focussed group discussion where appropriate such as with training 
models and potential research questions, and to allow face to face clarification of points 
made where appropriate to allow for participants to be better informed prior to voting.   A 
four stage process was undertaken.   
1: Literature review and writing of draft document with recommendation statements and 
reference database: 
2: Preliminary voting round where participants were asked to vote for level of agreement 
and make comments on the appropriateness of statements, in addition to proposing 
additional or modified statements along with additional references.  This round was 
conducted to ensure as robust a voting document as possible. 
3: Voting Round 1: A finalised list of recommendation statements/parameters to vote on 
following feedback from GDG.  The GDG were also able to review their own position on 
retained statements with voting scores and comments from other members whilst they 
were also allowed to comment on deletions/modifications made to statements from the 
pilot round 
4: Voting Round 2:  Undertaken at round table meeting using electronic keypad voting for 
parameters where consensus had not been reached.  Voting also for proposed amendments 
to statement and the creation of quantitative targets and minimum standards.  The meeting 
was also used to allow focus group discussions to create recommendation documents for 
training programmes and research questions. 
A writing sub-committee, led by myself as lead author, was formed to identify key search 
terms for a comprehensive literature review about the management of NPCPs from which 
several recommendation statements relating to multidisciplinary management were made.  
Studies were classified based on their methodology including systematic reviews, meta-
analyses, randomised controlled trials (RCTs), cohort studies, diagnostic studies and 
observational studies.   
The ‘Scottish Intercollegiate Guidelines Network (SIGN) Methodology Checklist System’, a 
BSG approved critical appraisal tool for the assessment of research articles, was used to 
evaluate the rigidity and quality of studies reviewed with studies considered to be of 
suboptimal quality excluded unless they were appropriate to a specific issue (260).   
88 
 
 
A literature search for English language articles published up to the present was performed 
using PubMed. The term ‘colonic polypectomy’ was entered into the PubMed MeSH 
database. 5989 articles were returned. The terms ‘therapy’ and surgery’ were used to filter 
the results based on relevance following which, 2230 articles were returned and scrutinised 
for relevant articles. Additional PubMed searches were performed using additional search 
terms agreed by the writing sub-committee.  The search terms used were:  
‘colorectal laterally spreading type polyps’, ‘endoscopic mucosal resection’, ‘complex 
colonic polyps’, ‘difficult colonic polyps’, ‘surgical management of colorectal laterally 
spreading type polyps’, ‘endoscopic polypectomy’, ‘anticoagulation in endoscopic 
polypectomy’, ‘obtaining informed consent for endoscopic procedures’, ‘diathermy in 
polypectomy’, ‘argon plasma coagulation for polypectomy’, ‘submucosal injection for 
endoscopic mucosal resection’, ‘malignant colonic polyps’, ‘piecemeal endoscopic mucosal 
resection’, ‘colorectal endoscopic submucosal dissection’, ‘surgical management of colonic 
polyps’, ‘laparoscopic surgery of colonic polyps’, ‘training in endoscopic polypectomy’,  
‘transanal endoscopic microsurgery’, ‘key performance indicators in healthcare’ and 
‘healthcare improvement measures’ 
Returned abstracts and articles were reviewed for relevance with additional references 
obtained from cross-referencing of references and recommendations from the GDG.  
Relevant published guidelines from groups such as the British Society of Gastroenterology 
(BSG), the American Society of Gastrointestinal Endoscopy (ASGE), The NHS Bowel Cancer 
Screening Programme (NHS BCSP) and the European Society of Gastrointestinal Endoscopy 
(ESGE) were also scrutinised.   
Following a comprehensive review of relevant literature, recommendation statements and 
parameters were formed by the writing subcommittee in relation to three sections as below: 
1. Guideline development 
2. Key Performance Indicators 
3. A minimum datasheet to guide complex polyp discussion and management with the 
intention of use in a complex polyp multidisciplinary meeting. 
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Further information for each of the three sections is described in more detail in the relevant 
chapters.  A preliminary round including formulated recommendation statements was 
undertaken by the GDG to assess the suitability of the statements, to allow for modification 
in subsequent voting rounds and increase the evidence base used with recommendation of 
additional references for guideline and KPI development. The writing subcommittee 
considered the creation of a complex polyp minimum dataset to be a less complex process 
than for the other two sections with no preliminary voting round required prior to formal 
voting. For each section each statement/parameter was scored by each member of the GDG 
using a five point scale in a primary voting round.  Following the preliminary round, 
modifications, additional statements and deletion of statements were made to the 
additional list of statements/parameters based on GDG comments and suggestions.    
The modified document was then sent to the GDG and a first formal voting round was then 
undertaken.  All modifications and deletions made from the preliminary document with 
supporting comments were included for GDG review to provide a further opportunity for 
members to record comments about modifications such as if they disagreed with a 
modification or deletion.  
In voting on statements and parameters, at least 80% participant agreement was required to 
consider consensus reached.  Further discussions and a final round of voting for statements 
where consensus had not been reached took place at a round table meeting at the BSG 
offices on 26th March 2014.   Voting was anonymous throughout with the final round of 
voting made using an electronic keypad system.  Feedback from the GDG members was 
disseminated after each round to allow members to reconsider their original position.  
Proposed modifications to statements were evaluated with anonymous voting with > 80% 
agreement required for modifications to be made.  A secondary voting process was also in 
place for voting for parameters with ongoing conflict of opinion (under 80% agreement) 
where reaching consensus, either positive or negative, was considered essential by the GDG.  
For consensus to be considered reached in this scenario, over 50% agreement with less than 
20% disagreement was required. The GRADE tool was used to evaluate the strength of 
evidence and the strength of recommendations made (see table 7). 
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GRADE – Strength of evidence GRADE- Strength of recommendation 
High quality:  
Further research is very unlikely to change our 
confidence in the estimate of effect 
 
The trade-offs:   
Taking into account the estimated size of the effect 
for main outcomes, the confidence limits around 
those estimates, and the relative value placed on 
each outcome 
Moderate quality:   
Further research is likely to have an important impact 
on our confidence in the estimate of effect and may 
change the estimate 
The quality of the evidence 
 
Low quality:  
Further research is very likely to have an important 
impact on our confidence in the estimate of effect and 
is likely to change the estimate 
Translation of the evidence into practice in a 
particular setting:   
Taking into consideration important factors that could 
be expected to modify the size of expected effects 
Very low quality:   
Any estimate of effect is very uncertain 
Uncertainty about the baseline risk for the 
population of interest 
Table 7. An overview of the GRADE system (261) 
The GRADE system allows evaluation of evidence to make recommendations in two forms, 
based on the strength of evidence and the strength of a recommendation following 
consensus by an expert panel.  Whilst the strength of recommendation may often reflect the 
evidence base, the GRADE system allows for occasions where this is not the case, for 
example where there appears good sense to make a recommendation in spite of an absence 
of high quality scientific evidence such as a large randomised controlled trial. 
Following Voting Round 2, the results were collated and sent to the GDG to ensure accuracy 
and a draft document featuring guidelines, KPIs, a training template and research questions 
was then created and sent to the GDG for evaluation and further input. Following suggested 
amendments the GDG re-reviewed the document and when all members were satisfied, it 
was sent to the BSG Endoscopy Committee and the ACPBI committee for further feedback.  
Once this feedback was received, the document was modified accordingly in conjunction 
with the GDG, and formally submitted to the BSG for international review and ratification. 
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Chapter 3: British Society of Gastroenterology/Association of 
Coloproctology of Great Britain and Ireland Large Non- Pedunculated 
Colorectal Polyps Guideline Development 
 
3.1)  Introduction 
The use of consensus methodology both nationally and internationally in the formation of 
several gastroenterological guidelines is a reflection of its strength for this purpose.   A 
recent UK example of where consensus methodology has been used in guideline 
development is the 2013 BSG Guidelines for the management of Barrett’s Oesophagus 
whilst an international example is the 2013 Canadian Association of Gastroenterology 
guidelines for endoscopic practice (257, 262).  Both guidelines were formulated using a 
‘modified Delphi technique’ with methodology similar to that proposed for the creation of 
these guidelines.  As previously discussed, the development of a framework for the 
management of LNPCPs appears suitable for the consensus as it appeared to fulfil criteria as 
a field where there is a lack of agreed current practice, in part due to a lack of objective 
scientific evidence in some areas and conflicting opinion about best practice in others (see 
table in consensus chapter) (254).   
 
3.2) Methodology 
A guideline development group with a writing subcommittee was created as described in 
chapter 2.  As detailed in chapter 2, the writing subcommittee suggested various search 
terms for a comprehensive literature review as below.   The term ‘colonic polypectomy’ was 
entered into the PubMed MeSH database. 5989 articles were returned. The terms ‘therapy’ 
and surgery’ were used to filter the results based on relevance following which, 2230 articles 
were returned and scrutinised for relevant articles. Additional PubMed searches were 
performed using additional search terms agreed by the writing sub-committee.  The search 
terms used were:  
‘colorectal laterally spreading type polyps’, ‘endoscopic mucosal resection’, ‘complex 
colonic polyps’, ‘difficult colonic polyps’, ‘surgical management of colorectal laterally 
spreading type polyps’, ‘endoscopic polypectomy’, ‘anticoagulation in endoscopic 
polypectomy’, ‘obtaining informed consent for endoscopic procedures’, ‘diathermy in 
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polypectomy’, ‘argon plasma coagulation for polypectomy’, ‘submucosal injection for 
endoscopic mucosal resection’, ‘malignant colonic polyps’, ‘piecemeal endoscopic mucosal 
resection’, ‘colorectal endoscopic submucosal dissection’, ‘surgical management of colonic 
polyps’, ‘laparoscopic surgery of colonic polyps’, ‘training in endoscopic polypectomy’,  
‘transanal endoscopic microsurgery’ 
Returned abstracts and articles were reviewed for relevance with additional references 
obtained from cross-referencing of references and recommendations from the GDG.  
Relevant published guidelines from groups such as the British Society of Gastroenterology 
(BSG), the American Society of Gastrointestinal Endoscopy (ASGE), The NHS Bowel Cancer 
Screening Programme (NHS BCSP) and the European Society of Gastrointestinal Endoscopy 
(ESGE) were also scrutinised. 
 The ‘SIGN Methodology Checklist System’ was used to evaluate the rigidity and quality of 
studies reviewed with studies considered to be of suboptimal quality excluded unless they 
were appropriate to a specific issue(260).   
The Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument provided a 
methodological framework for the development of the guidelines and was used to assess 
their quality. 
Following a literature review, the writing committee selected various domains, subdomains 
and subsequent areas within these domains from which statements may be formulated.  
Domains included: governance issues, endoscopic considerations (pre, peri and post-
procedure), anticoagulation management, surgical management and histological and 
radiological considerations. 
Following the identification of potential domains and subdivisions, numerous statements 
with supporting evidence were created and subsequently discussed and finalised by the 
writing subcommittee via audioteleconference for review by the GDG (see results section).  
In the absence of evidence to support a specified training regimen for complex polyp 
management, members of the GDG were to be asked for their ideas and views on 
developing a training plan prior to a discussion forum at a later date.   
As discussed in detail in chapter 3, the statements created by the writing subcommittee 
were sent in an emailed document to the GDG who were asked to vote to record their level 
of agreement with the proposed statements, in addition to recording comments, proposed 
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amendments or additional statements and additional evidence that could be used.  All 
voting throughout the process was conducted anonymously. 
The GDG responses were then reviewed by the writing subcommittee with modifications 
proposed by the GDG incorporated where relevant to create a finalised document for voting.  
This document also contained anonymised GDG comments for consideration by members 
prior to voting.  Modifications included the removal of statements felt to be duplicated 
elsewhere or not suitable for inclusion, in addition to additional wording to statements.  The 
changes made were highlighted to allow for GDG member comments about changes made. 
A first round of anonymous voting using a scale of 1-5 as previously described was 
conducted with >80% agreement required for consensus to be considered achieved for each 
statement.  On receipt of all GDG responses, a full summary of results including anonymised 
member comments was sent to the group. 
Statements where consensus had not yet been reached were put forward for a second 
round of voting with GDG comments from the previous round intended to allow GDG 
members to reconsider their initial responses based on the comments from other members.   
A second round of voting took place using electronic keypad voting at a round table meeting 
held at the BSG headquarters. Once this process had been completed, the GDG used 
electronic keypads to vote on any proposed modifications to the wording of the statements 
whilst research questions, primarily concerning areas in which evidence regarding best 
practice was felt to be absent or limited, were also formulated. 
A structured group discussion also took place during the round table meeting to discuss a 
format for the development of a training programme for the endoscopic management of 
large colorectal polyps.  The framework for the discussion was based on GDG comments 
from the preliminary voting round with the discussion recorded to be transcribed into a 
summary document.   
Following the conclusion of the voting process, a draft guidelines document including 
recommendation statements pertaining to best practice, a framework for training and 
research questions was created and sent to the GDG for comments.  The responses were 
reviewed by the writing subcommittee and modifications were made where appropriate.  
The amended document was sent back to the GDG for final comments and was then sent to 
the BSG endoscopy committee and the ACPBI for consultation.  Alterations proposed by 
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these groups were made and the document was then sent back to the BSG and ACPGI for 
final approval.  Subsequent to this the document was submitted to ‘Gut’ journal. 
 
3.3) Results 
              A Summary of statements used/discarded at each round (Figure 13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pilot Round: 
59 recommendation 
statements 
 
Round 1: 
44 recommendation 
statements remaining 
 
15 statements 
discarded or merged 
 
Round 2: 
43 recommendation 
statements remaining 
 
1 statement 
discarded 
 
Final Document: 
42 recommendation 
statements remaining 
 
1 statement 
discarded 
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3.3.1 Summary of Key Recommendations 
 
 Definitions 
 We suggest that the term ‘Non-pedunculated colorectal polyp’ (NPCP) is the most 
appropriate term to define sessile and flat colonic lesions whilst Paris classification and 
the term ‘laterally spreading type polyp’ (LST) may be used to sub-classify lesions 
further. 
 We suggest that the term ’Large NPCP’ (LNPCP) may be used to describe NPCPs >2cm in 
size 
 We recommend that lesions displaying the following characteristics are identified as 
those with an increased risk of malignancy: Lesions exhibiting; pit pattern type V, Paris 0-
IIc or 0-IIa+IIc morphology, non-granular LST (laterally spreading type polyp, LST-NG), 
granular LSTs (LST-G) with a dominant nodule, distorted surface pattern, colour and 
vessels (NICE NBI type III), thick and irregular microvessels (Sano capillary pattern type 
III) (GRADE of evidence: Moderate; Strength of recommendation: Strong) 
 
 We recommend that the following lesions with the following characteristics are 
identified as having with an increased risk of incomplete excision/recurrence: Size 
>40mm, location involving ileocaecal valve, appendix, diverticulum or dentate line; 
within an inflamed segment of colitis; prior failed attempt at resection or recurrence at 
site of previous resection (excluding unifocal, diminutive and easily resected/ablated 
residual adenoma on first site check); non-lifting sign after submucosal injection; 
endoscopist concern about difficult location (e.g. behind flexure or fold, in stenotic 
diverticular disease); (GRADE of evidence: Low; Strength of recommendation: Strong) 
 
 We recommend that endoscopic factors associated with an increased risk of adverse 
events include: Caecal location, size >40mm and endoscopist inexperience (GRADE of 
evidence: Low; Strength of recommendation: Strong) 
 
 Complex NPCP- We suggest this term to describe NPCPs with any of the following 
features: (a) increased risk of malignancy; (b) increased risk of incomplete 
resection/recurrence; (c) increased risk of adverse event; (d) SMSA level 4 (GRADE of 
evidence: Low; Strength of recommendation: Weak) 
 
 Service provision and management principles 
 
 We recommend that hospitals that detect or manage LNPCPs should develop a referral 
pathway to facilitate their management and processes to monitor the quality of the 
service. The pathway should ensure that patients have access to and information about 
a full range of therapeutic options, including laparoscopic surgery, a provision for the 
management of complex rectal lesions and endoscopists capable of performing 
endotherapy on complex NPCPs (GRADE of evidence: Very low; Strength of 
recommendation: Strong) 
 
 We suggest that clinicians involved in the management of LNPCPs should have access to 
a multidisciplinary network such as a multidisciplinary meeting (MDM) to discuss 
complex cases (complex as defined in these guidelines). Membership should include at 
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least one complex NPCP endoscopist, at least one colorectal laparoscopic surgeon and a 
gastrointestinal histopathologist. (GRADE of evidence: Very low; Strength of 
recommendation: Weak) 
 
 We recommend that all endoscopists performing endotherapy on LNPCPs should be 
highly experienced in standard polypectomy, should have endoscopy service approval 
for this work, and should be subject to regular audit to ensure their key performance 
indicators are above minimum quality standards (GRADE of evidence:  Low; Strength of 
recommendation: Strong) 
 
 We suggest that patients with benign NPCPs should not undergo surgery without prior 
complex polyp MDM discussion (GRADE of evidence: Very low; Strength of 
recommendation: Weak) 
 
 We suggest that primary therapeutic management of LNPCPs should be undertaken 
within 8 weeks of receipt of referral (GRADE of evidence: Very low; Strength of 
recommendation: Weak) 
 
 We recommend that endoscopic resection should be first line therapy for the removal of 
LNPCPs where there is no suspicion of malignancy (suspicion of malignancy as defined in 
these guidelines) (GRADE of evidence: Moderate; Strength of recommendation: Strong)  
 
 We recommend that piecemeal resection (either endoscopic or surgical) should be 
avoided if malignancy is suspected (GRADE of evidence: Low; Strength of 
recommendation: Strong) 
 
 We suggest that in the context of significant comorbidity, conservative management 
may sometimes be appropriate following detailed patient discussion and documentation 
(GRADE of evidence: Very low; Strength of recommendation: Weak) 
 
 Lesion Assessment 
  
 We recommend that all LNPCPs should be photographed or videoed prior to removal 
(GRADE of evidence: Very low; Strength of recommendation: Strong) 
 
 We suggest that a size estimate of LNPCPs should be made, ideally by measuring against 
an open snare (GRADE of evidence: Low; Strength of recommendation: Weak) 
 
 We recommend that the Paris Classification should be used wherever possible to 
describe polyp morphology (GRADE of evidence: Low; Strength of recommendation: 
Strong) 
 
 We recommend that the surface characteristics of a polyp should be described using a 
classification system such as the NICE NBI or Kudo Pit Pattern classification. The use of 
image enhancement techniques (digital or chromoendoscopic) can improve diagnostic 
accuracy in lesion assessment (GRADE of evidence: Moderate; Strength of 
recommendation: Strong)  
 
 We suggest that if a lesion may be amenable to endoscopic removal, biopsies should be 
used with caution, as there is a risk of submucosal tethering due to scarring, rendering 
97 
 
the lesion unresectable. Where biopsies are required because of concern of cancer, they 
should be targeted to the area exhibiting features indicative of cancer, avoiding flat 
areas and the lesion periphery. Tunnelling biopsies (biopsy through biopsy) should not 
be used (GRADE of evidence: Low; Strength of recommendation: Weak) 
 
 
 Endoscopic Management: Pre-Procedure 
 
 We recommend that adequate planning should be undertaken (including length of time 
booked for procedure, endoscopist and nursing staff skills and endoscopic equipment) 
so that prior to an attempt at advanced polypectomy, the endoscopist has a high level of 
confidence that complete resection can be achieved in a single procedure (GRADE of 
evidence: Very low; Strength of recommendation: Strong) 
 
 We recommend that antiplatelet medications such as clopidogrel and prasugrel, and 
newer antiplatelet agents such as ticagrelor should be stopped at least 7 days prior to 
resection in accordance with BSG Antiplatelet Guidelines (GRADE of evidence: 
Moderate; Strength of recommendation: Strong) 
 
 We recommend that warfarin should be stopped at least 5 days prior to resection of 
LNPCPs, and INR should be confirmed as below 1.5 prior to the procedure, in accordance 
with BSG Anticoagulation Guidelines. (GRADE of evidence: Moderate; Strength of 
recommendation: Strong)  
We suggest that general recommendations regarding the management of newer 
anticoagulants which have differing properties, such as rivaroxaban and dabigatran, 
cannot currently be made due to a lack of evidence. Appropriate specialist advice should 
be sought in this scenario (GRADE of evidence: Very low; Strength of recommendation: 
Weak) 
 
 We suggest that patients should be consented for the risk of thromboembolic events 
such as stroke and venous thromboembolism when stopping anticoagulants before 
endoscopic resection (GRADE of evidence: Very low; Strength of recommendation: 
Strong).  
Advice given should be tailored to a patient’s individual risk with a ‘bridging regimen’ of 
low molecular weight heparin given to high risk individuals in accordance with BSG 
guidelines. The risk of bleeding versus risk of thromboembolic episode should also be 
explained (GRADE of evidence: Low; Strength of recommendation: Weak) 
 
 We suggest that where cessation of anticoagulants or antiplatelet medications is 
contraindicated due to comorbidity, or where there is uncertainty, appropriate specialist 
advice should be sought. If the anticoagulation/antiplatelet medication is temporary and 
the lesion has been adequately assessed as being of low risk for cancer, deferral of 
resection until after this medication can be discontinued may be appropriate (Grade of 
evidence: Very low; Strength of recommendation: Weak) 
 
 We suggest that evidence for the cessation/continuation of low dose aspirin in the 
context of LNPCPs is weak and the decision should be individualised according to patient 
risk (GRADE of evidence: Low; Strength of recommendation: Weak) 
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 We recommend that when obtaining consent for the endoscopic resection of LNPCPs, 
written information in plain English should be given. Management options including 
endoscopic therapy, surgery and conservative management should be discussed. 
Regarding endoscopic therapy, patients should be informed of the potential need for 
subsequent check procedures and surveillance endoscopy. The risks of post-procedure 
bleeding (both immediate and delayed), perforation and residual polyp/recurrence 
should be explained (GRADE of evidence: Very low; Strength of recommendation: 
Strong)  
 
 
 Endoscopic Management: Peri-Procedure 
 
 We recommend that carbon dioxide should be used in preference to air insufflation 
during colonoscopy to improve patient comfort and safety (GRADE of evidence: High; 
Strength of recommendation: Strong) 
 
 We recommend that the use of contrast agents such as indigo carmine or methylene 
blue in the submucosal injection solution may be considered to help demarcate a lesion, 
its resection margins, and to outline a clear submucosal plane (GRADE of evidence: Low; 
Strength of recommendation: Strong)  
 
 We suggest that the addition of low concentration adrenaline to the submucosal 
injection solution may be considered to keep the resection field clear during endoscopic 
resection (GRADE of evidence: Low; Strength of recommendation: Weak) 
 
 We suggest consideration of the use of colloidal type submucosal injection solutions in 
preference to normal saline lifting solution for LNPCPs (Grade of evidence: Low; Strength 
of recommendation: Weak) 
 
 We suggest that endoscopists should be familiar with the range of snares available, 
although a single optimal snare cannot currently be recommended (GRADE of evidence: 
Very low; Strength of recommendation: Weak) 
 
 We suggest that pure cutting or prolonged pure coagulation current should be avoided 
due to an increased risk of post polypectomy bleeding and thermal tissue injury 
respectively (GRADE of evidence: Low; Strength of recommendation: Weak) 
 
 We suggest that whilst en-bloc endoscopic snare resection of lesions < 20mm is 
recommended to reduce the risk of recurrence and to enable more accurate 
histopathological interpretation, this practice should be used with caution in LNPCPs due 
to an increased risk of diathermy associated thermal injury and perforation (GRADE of 
evidence: Low; Strength of recommendation: Weak) 
 
 We recommend that treatment naïve lesions that fail to lift after adequate submucosal 
injection should not be subject to attempted resection with conventional snare 
polypectomy technique (GRADE of evidence: Low; Strength of recommendation: Strong) 
 
 We recommend that during endoscopic piecemeal resection, the snare should be used 
to resect a lesion completely wherever possible. Thermal coagulation techniques such as 
argon plasma coagulation (APC) and soft coagulation may be used as adjuncts when 
99 
 
snare resection of small residual fragments of polyp is not possible (GRADE of evidence: 
Low; Strength of recommendation: Strong) 
 
 We recommend that careful post-procedure inspection of the resection site and 
photographic documentation of completeness of resection should be performed (GRADE 
of evidence: Low; Strength of recommendation: Strong) 
 
 We recommend that with the exception of the rectum or caecum, a tattoo should be 
applied in accordance with local policy to aid endoscopic follow up or subsequent 
surgical resection. As tattooing can cause submucosal fibrosis, the tattoo should be 
placed at least 3cm from the lesion (GRADE of evidence: Very low; Strength of 
recommendation: Strong) 
 
 
 Endoscopic Management: Post-procedure 
 
 We recommend that written information about the risk of post-procedure complications 
(including bleeding risk for up to 2 weeks), together with recommended actions and an 
emergency phone number should be provided to patients (Grade of evidence: Very low; 
Strength of recommendation: Strong) 
 
 We suggest that recommencement of anticoagulant and antiplatelet therapy post-
polypectomy should be considered on an individual basis, weighing up the risks of post-
procedure bleeding with the risks of a thromboembolic event. Further specialist advice 
(ideally sought prior to the procedure) may be appropriate (GRADE of evidence: Low; 
Strength of recommendation: Weak) 
 
 We recommend that in the case of piecemeal EMR, initial follow-up should take place 
within 2-6 months (GRADE of evidence: Low; Strength of recommendation: Strong)  
 
 We recommend that on follow-up, the scar site should be positively identified, 
scrutinised and photographed. Image enhancement with techniques such as dye spray 
and digital enhancement may aid detection of residual neoplasia on a polypectomy scar. 
Areas of possible residual polyp require tissue diagnosis and definitive treatment 
(GRADE of evidence: Low; Strength of recommendation: Strong)  
 
 We suggest that the management of residual/recurrent polyp tissue can be challenging 
and should be performed by an endoscopist with complex NPCP experience (GRADE: 
Low; Strength of recommendation: weak).  
We suggest that the management of ongoing recurrence should be discussed in a 
complex polyp MDM (GRADE of evidence: Low; Strength of recommendation: Weak) 
 
 
 Surgical Management of LNPCPs 
 
 We recommend that surgical therapy should be considered where malignancy is 
suspected or concerns about the likelihood of incomplete endoscopic resection arise 
following complex polyp MDM discussion (GRADE of evidence: Moderate; Strength of 
recommendation: Strong) 
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 We recommend that laparoscopic therapy should be used in preference to open surgery 
in the surgical management of LNPCPs (GRADE of evidence: High; Strength of 
recommendation: Strong) 
 
 
3.4) Agreed Statements and Voting Summary              
 3.4.1) Definitions and Terminology  
The term ‘Non-pedunculated colorectal polyp’ (NPCP) was agreed to be the clearest and 
most appropriate term to define sessile and flat colonic lesions. In accordance with other 
international series, it was agreed that Paris classification and the term ‘laterally spreading 
type polyp’ (LST) may be used to sub-classify lesions further. It was also agreed that the 
guidelines should focus primarily on polyps at least 2cm in size, given the increased 
complexity associated with their removal, and these lesions are referred to as large NPCPs 
(LNPCPs) unless specified otherwise. However, much of the guidance in this document may 
be applicable to smaller polyps. 
100% agreement reached in round 2 
No vote in round 1, participants asked to offer terminology suggestions 
Terminology changed  from ‘Laterally-spreading type polyp (LST)’ which was proposed in 
preliminary round to describe predominantly flat (Paris 0-II)  and sessile polyps (Paris Is) of at 
least 10mm in size- marked disagreement with this term, no consensus reached.  
 
1. We recommend that lesions with the following characteristics should be identified as 
those with as increased risk of malignancy: Lesions exhibiting; pit pattern type V, Paris 0-
IIc or 0-IIa+IIc morphology, non-granular LST (laterally spreading type polyp, LST-NG), 
granular LSTs (LST-G) with a dominant nodule, distorted surface pattern, colour and 
vessels (NICE NBI type III), thick and irregular microvessels (Sano capillary pattern type III)   
(GRADE of evidence: Moderate; Strength of recommendation: Strong) 
Consensus Reached at Round 1: 100% agreement 
 
Addition after preliminary round of ‘LST-G with dominant nodule’ and ‘NICE NBI type III 
lesions’  
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2. We recommend that the following lesions with the following characteristics are identified 
as having with an increased risk of incomplete excision/recurrence: Size >40mm, location 
involving ileocaecal valve, appendix, diverticulum or dentate line; within an inflamed 
segment of colitis; prior failed attempt at resection or recurrence at site of previous 
resection (excluding unifocal, diminutive and easily resected/ablated residual adenoma on 
first site check); non-lifting sign after submucosal injection; endoscopist concern about 
difficult location (e.g. behind flexure or fold, in stenotic diverticular disease); (GRADE of 
evidence: Low; Strength of recommendation: Strong) 
Consensus reached at Round 2; 92.3% agreement 
 
 Removal of ‘75% circumference’ after round 1 
 
3. We recommend that endoscopic factors associated with an increased risk of adverse 
events include: Caecal location, size >40mm and endoscopist inexperience   (GRADE of 
evidence: Low; Strength of recommendation: Strong) 
Consensus Reached at Round 1: 84.6% agreement 
Addition after preliminary round of ‘endoscopist inexperience’  
 
4. Complex NPCP: We suggest this term to describe NPCPs with any of the following features: 
(a) increased risk of malignancy; (b) increased risk of incomplete resection/recurrence; (c) 
increased risk of adverse event; (d) SMSA level 4 (GRADE of evidence:  Low; Strength of 
recommendation: Weak) 
 
Consensus reached at Round 2; 92.3% agreement 
Consensus reached at preliminary round and at round 1. However modification (addition of 
‘SMSA 4’) made at round 2. 
Deleted after preliminary round: 
 Endoscopic Mucosal Resection (EMR) – snare polypectomy with prior submucosal 
injection and lift (consensus reached at preliminary round but statement removed and 
definition described in introduction)  
102 
 
 
3.4.2)  Service Provision and Management Principles 
 
1. We recommend that hospitals that detect or manage LNPCPs should develop a referral 
pathway to facilitate their management and processes to monitor the quality of the 
service. The pathway should ensure that patients have access to and information about a 
full range of therapeutic options, including laparoscopic surgery,  a provision for the 
management of complex rectal lesions and endoscopists capable of performing 
endotherapy on complex NPCPs  (GRADE of evidence: Very low; Strength of 
recommendation: Strong) 
 
Consensus Reached at Round 1: 100% 
Consensus reached at preliminary round and round 1.  The term ‘colorectal NPCPs’ was used 
instead of ‘LST’ 
 
2. We suggest that clinicians involved in the management of LNPCPs should have access to a 
multidisciplinary network such as a multidisciplinary meeting (MDM) to discuss complex 
cases (complex as defined in these guidelines). Membership should include at least one 
complex NPCP endoscopist, at least one colorectal laparoscopic surgeon and a 
gastrointestinal histopathologist. (GRADE of evidence: Very low; Strength of 
recommendation: Weak) 
Consensus Reached at Round 2;  92% agreement  
 
Statement modified after preliminary round from ‘Clinicians involved in the management of 
colorectal LSTs should have access to a complex polyp MDT meeting, to discuss all complex 
cases. Membership should include at least one complex LST endoscopist, at least one 
colorectal laparoscopic surgeon and a gastrointestinal histopathologist’ 
 
3.        We recommend that all  endoscopists performing endotherapy on LNPCPs should   
be highly experienced in standard polypectomy, should have endoscopy service approval 
for this work  and should be subject to regular audit to ensure their key performance 
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indicators are above minimum  quality standards (GRADE of evidence:  Low; Strength of 
recommendation: Strong) 
Consensus Reached at Round 1: 100% 
Statement modified after preliminary round from ‘All endoscopists performing endotherapy 
on LSTs of at least 2cm in size should be subject to regular audit to ensure their key 
performance indicators are above minimum quality standards’. 
 
4.        We suggest that patients with benign NPCPs should not undergo surgery without prior   
       complex polyp MDM discussion (GRADE of evidence: Very low; Strength of     
       recommendation: Weak) 
 
       Consensus Reached at Round 1: 84.6% agreement        
 
5. We suggest that primary therapeutic management of LNPCPs should be undertaken within 
8 weeks of receipt of referral (GRADE of evidence: Very low; Strength of recommendation: 
Weak) 
 
        Consensus Reached at Round 2; 100% agreement 
Statement modified after preliminary round from ‘Primary therapeutic management of LSTs 
should be undertaken within 6 weeks of the detection of a colorectal LST’. 
   
6. We recommend that endoscopic resection is first line therapy for the removal of LNPCPs 
where there is no suspicion of malignancy (suspicion of malignancy as defined in these 
guidelines) (GRADE of evidence: Moderate; Strength of recommendation: Strong)  
 
Consensus Reached at Round 1;  92.3% agreement 
 
Addition of after preliminary round of ‘where there is no suspicion of malignancy’ made to 
statement following GDG feedback.  
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7. We recommend that piecemeal resection (either endoscopic or surgical) should be avoided 
if malignancy is suspected  (GRADE of evidence: Low; Strength of recommendation: 
Strong) 
Consensus Reached at Round 1; 84.6% agreement 
Statement modified after preliminary round from ‘En-bloc resection techniques (either 
endoscopic or surgical) should be used where malignancy is suspected (such as colorectal 
LSTs with Paris 0-IIc morphology, central depression, type V pit pattern, fold convergence or 
a non-lifting sign).’   
 
8. We suggest that in the context of significant comorbidity, conservative management may 
sometimes be appropriate following detailed patient discussion and documentation 
(GRADE of evidence: Very low; Strength of recommendation: Weak)    
Consensus Reached at Round 1; 85.7% agreement 
Statement modified after preliminary round from ‘Conservative management may be 
appropriate if life expectancy is less than 5 years’  
 
Deleted after preliminary round  
 Endoscopic management of complex LSTs should be performed by experienced complex 
LST endoscopists who demonstrate high quality key performance indicators from 
continuous audit- merged with another statement 
 
3.4.3) Lesion assessment 
 
1. We recommend that all LNPCPs should be photographed or videoed prior to removal 
(GRADE of evidence: Very low; Strength of recommendation: Strong) 
Consensus Reached at Round 1; 100% agreement 
 
2. We suggest that a size estimate of LNPCPs should be made, ideally by measuring against 
an open snare  (GRADE of evidence: Low; Strength of recommendation: Weak) 
Consensus Reached at Round 1; 100% agreement 
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3. We recommend that the Paris Classification should be used wherever possible to describe 
polyp morphology (GRADE of evidence: Low; Strength of recommendation: Strong) 
Consensus Reached at Round 1; 100% agreement 
  
4. We recommend that the surface characteristics of a polyp should be described using a 
classification system such as the NICE NBI or Kudo Pit Pattern classification.  The use of 
image enhancement techniques (digital or chromoendoscopic) can improve diagnostic 
accuracy in lesion assessment   (GRADE of evidence: Moderate; Strength of 
recommendation: Strong) 
 
Consensus Reached at Round 1; 91.7% agreement 
Statement modified after preliminary round from ‘Kudo Pit Pattern assessment should be 
used to describe the surface characteristics of LSTs’  
 
5. We suggest that if a lesion may be amenable to endoscopic removal, biopsies should be 
used with caution, as there is a risk of submucosal tethering due to scarring, rendering the 
lesion unresectable. Where biopsies are required because of concern of cancer, they 
should be targeted to the area exhibiting features indicative of cancer, avoiding flat areas 
and the lesion periphery. Tunnelling biopsies (biopsy through biopsy) should not be used  
(GRADE of evidence: Low; Strength of recommendation: Weak) 
Consensus Reached at Round 1; 92.3% agreement 
Deleted after preliminary round  
 The use of image enhancement techniques (either digital or chromoendoscopic) to 
examine colorectal LSTs is encouraged as they can improve diagnostic accuracy.  
 The use of cross sectional imaging such as MRI and CT scanning to assess for submucosal 
invasion and lymph node involvement may aid MDT decisions in the diagnosis, staging 
and management of malignant LSTs. 
 We suggest that the resection of LNPCPs should not be performed at the time of 
discovery, unless the patient has been specifically consented for this, and the 
endoscopist determines they have sufficient time and expertise to do so  
106 
 
 
3.4.4)  Endoscopic Management: Pre-procedure  
1. We recommend that adequate planning should be undertaken (including length of time 
booked for procedure, endoscopist and nursing staff skills and endoscopic equipment) so 
that prior to an attempt at advanced polypectomy, the endoscopist has a high level of 
confidence that complete resection can be achieved in a single procedure  (GRADE of 
evidence:  Very low; Strength of recommendation: Strong) 
 
Consensus Reached at Round 1; 100% agreement 
 
2. We recommend that antiplatelet medications such as clopidogrel and prasugrel, and 
newer antiplatelet agents such as ticagrelor should be stopped at least 7 days prior to 
resection in accordance with BSG Antiplatelet Guidelines  (GRADE of evidence: Moderate; 
Strength of recommendation: Strong)  
Consensus Reached at Round 1; 92.3% agreement 
 
3. We recommend that warfarin should be stopped at least 5 days prior to resection of 
LNPCPs and INR should be confirmed as below 1.5 prior to the procedure, in accordance 
with BSG Anticoagulation Guidelines. (GRADE of evidence: Moderate; Strength of 
recommendation: Strong) We suggest that general recommendations regarding the 
management of newer anticoagulants which have differing properties, such as rivaroxaban 
and dabigatran, cannot currently be made due to a lack of evidence. Appropriate specialist 
advice should be sought in this scenario  (GRADE of evidence: Very low; Strength of 
recommendation: Weak) 
Consensus Reached at Round 1; 92.3% agreement 
Statement modified from ‘Anticoagulants such as warfarin should be stopped at least 5 days 
in advance with an INR below 1.5 prior to advanced polypectomy, in accordance with BSG 
Anticoagulation Guidelines’ after preliminary round. 
 
4. We recommend that patients should be consented for the risk of thromboembolic events 
such as stroke and venous thromboembolism when stopping anticoagulants before 
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endoscopic resection (GRADE of evidence: Very low; Strength of recommendation: 
Strong).  We suggest that advice given should be tailored to a patient’s individual risk with 
a ‘bridging regimen’ of low molecular weight heparin given to high risk individuals in 
accordance with BSG guidelines. The risk of bleeding with this regimen should also be 
explained (GRADE of evidence: Low; Strength of recommendation: Weak) 
 
Consensus Reached at Round 1; 85.7% agreement 
Statement modified after preliminary round from ‘Patients should be consented for the risk 
of thromboembolic events such as stroke (up to nearly 3% in patients with increased 
comorbidity) when stopping antithrombotic agents before endoscopy procedures.’  
 
5. We suggest that where cessation of anticoagulants or antiplatelet medications is 
contraindicated due to comorbidity, or where there is uncertainty, appropriate specialist 
advice should be sought. If the anticoagulation/antiplatelet medication is temporary and 
the lesion has been adequately assessed as being of low risk for cancer, deferral of 
resection until after this medication can be discontinued may be appropriate  (Grade of 
evidence: Very low; Strength of recommendation: Weak) 
Consensus Reached at Round 1; 100% agreement 
 
 
6. We suggest that the evidence for the cessation/continuation of low dose aspirin in the 
context of LNPCPs is weak and the decision should be individualised according to patient 
risk (GRADE of evidence: Low; Strength of recommendation: Weak) 
Consensus Reached at Round 2; 100% agreement 
Statement modified after preliminary round from ‘Low dose Aspirin is safe to continue prior 
to advanced polypectomy ‘ 
 
7. We recommend that when obtaining consent for the endoscopic resection of LNPCPs, 
written information in plain English should be given. Management options including 
endoscopic therapy, surgery and conservative management should be discussed. 
Regarding endoscopic therapy, patients should be informed of the potential need for 
subsequent check procedures and surveillance endoscopy.  The risks of post-procedure 
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bleeding (both immediate and delayed), perforation and residual polyp/recurrence should 
be explained (GRADE of evidence: Very low; Strength of recommendation: Strong) 
 
Consensus Reached at Round 1; 92.9% agreement 
Statement modified after preliminary round from ‘When obtaining consent for advanced 
polypectomy, written information in plain English should be offered. Management options 
including endoscopic therapy, surgery and conservative management should be discussed. 
Regarding endoscopic therapy, patients should be informed of the potential need for 
repeated endoscopic procedures.’ 
 
Deleted after preliminary round 
 Regarding consent for endoscopic therapy, the risk of post-procedure bleeding (both 
immediate and delayed; up to 7% of cases), perforation (approximately 
1%),recurrence requiring additional therapy (potentially over 20%) and persistent 
recurrence (up to 7%) should be explained  
 
3.4.5) Endoscopic Management: Peri-procedure 
 
1. We recommend that carbon dioxide should be used in preference to air insufflation during 
colonoscopy to improve patient comfort and safety   (GRADE of evidence: High; Strength 
of recommendation: Strong) 
 
Consensus Reached at Round 1; 100% agreement 
   
2. We recommend that the use of contrast agents such as indigo carmine or methylene blue 
in the submucosal injection solution may be considered to help demarcate a lesion, its 
resection margins, and to outline a clear submucosal plane (GRADE of evidence: Low; 
Strength of recommendation: Strong) 
 
Consensus Reached at Round 1; 100% agreement 
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Statement modified after preliminary round to ‘The use of contrast agents such as 
methylene blue in the submucosal injection solution to help to demarcate the lesion, its 
resection margins, and to outline a clear submucosal plane is recommended’. 
  
3. We suggest that the addition of low concentration adrenaline to the submucosal injection 
solution may be considered to keep the resection field clear during endoscopic resection   
(GRADE of evidence: Low; Strength of recommendation: Weak) 
Consensus Reached at Round 1; 100% agreement 
Statement modified after preliminary round from ‘The addition of low concentration 
adrenaline to the submucosal injection solution may be considered to reduce the risk of 
peri-procedure bleeding’  
 
4. We suggest the consideration of the use of colloidal type submucosal injection solutions 
should be used in preference to normal saline lifting solution for LNPCPs  (Grade of 
evidence: Low; Strength of recommendation: Weak) 
 
Consensus Reached at Round 1; 92.3% agreement 
 
5. We suggest that endoscopists should be familiar with the range of snares available, 
although a single optimal snare cannot currently be recommended (GRADE of evidence: 
Very low; Strength of recommendation: Weak) 
 
Consensus Reached at Round 1; 100% agreement 
 
6. We suggest that pure cutting or prolonged pure coagulation current should be avoided 
due to an increased risk of post polypectomy bleeding and thermal tissue injury 
respectively (GRADE of evidence: Low; Strength of recommendation: Weak) 
 
Consensus Reached at Round 1; 92.3% agreement 
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7. We suggest that whilst en-bloc endoscopic snare resection of lesions < 20mm is 
recommended to reduce the risk of recurrence and to enable more accurate 
histopathological interpretation, this practice should be used with caution in LNPCPs due 
to an increased risk of diathermy associated thermal injury and perforation (GRADE of 
evidence: Low; Strength of recommendation: Weak) 
 
      Consensus Reached at Round 1; 84.6% agreement 
Statement modified after preliminary round from ‘En bloc endoscopic snare resection of 
LSTs up to 2cm is recommended, to reduce the risk of recurrence and to enable more 
accurate histological interpretation. En bloc endoscopic snare resection of LSTs of 2cm or 
greater in size should be used with caution due to increased risk.’ 
 
8.  We recommend that treatment naïve lesions which fail to lift after adequate submucosal 
injection should not be subject to attempted resection with conventional snare 
polypectomy technique (GRADE of evidence: Low; Strength of recommendation: Strong) 
Consensus Reached at Round 1; 92.3% agreement 
Statement modified after preliminary round from ‘Lesions which do not lift after adequate 
submucosal injection (with no prior intervention) should not be attempted with piecemeal 
endotherapy due to the risks of submucosal invasion and incomplete excision’ 
 
9. We recommend that during endoscopic piecemeal resection, the snare should be used to 
resect a lesion completely wherever possible. Thermal coagulation techniques such as 
argon plasma coagulation (APC) and soft coagulation may be used as adjuncts when snare 
resection of small residual fragments of polyp is not possible   (GRADE of evidence: Low; 
Strength of recommendation: Strong)  
 
Consensus Reached at Round 1; 100% agreement 
Statement modified after preliminary round from ‘During endoscopic piecemeal resection, 
the snare should be used to resect the lesion completely wherever possible. Thermal 
coagulation techniques such as argon plasma coagulation (APC) be used on resection 
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margins as an adjunct after piecemeal EMR to help achieve complete resection and to 
reduce recurrence, but should only be used once further snare resection is impossible.’ 
 
10. We recommend that careful post-procedure inspection of the resection site and 
photographic documentation of completeness of resection should be performed (GRADE 
of evidence: Low; Strength of recommendation: Strong) 
 
Consensus Reached at Round 1; 100% agreement 
Statement modified after preliminary round from ‘Post-procedure photographic 
documentation to document completeness of resection should be performed’ 
 
11. We recommend that with the exception of the caecum or rectum, a tattoo should be 
applied in accordance with local policy to aid endoscopic follow up or subsequent surgical 
resection.  As tattooing can cause submucosal fibrosis, the tattoo should be placed at least 
30mm from the lesion  (GRADE of evidence: Very low; Strength of recommendation: 
Strong) 
 
Consensus Reached at Round 1; 92.3% agreement 
Statement modified after preliminary round from ‘Unless previously placed, a tattoo should 
be applied in accordance with local policy to aid endoscopic follow up or subsequent surgical 
resection’ 
Deleted after preliminary round: 
 The colorectal LST should be positioned adjacent to the endoscope instrumentation 
channel to facilitate safe and effective removal  
 In circumstances such as a high risk of bleeding or prior to recommencement of 
antiplatelets/anticoagulants, post-resection mucosal defect closure with endoscopic 
clips to reduce post-resection bleeding may be considered 
Deleted after round 1: 
 Marking of the snare handle at the point where the tip of the snare just protrudes 
from the sheath is recommended. 
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3.4.6) Endoscopic Management: Post-procedure 
 
1. We recommend that written information about the risk of post-procedure complications 
(including bleeding risk for up to 2 weeks), together with recommended actions and an 
emergency phone number should be provided to patients (Grade of evidence: Very low; 
Strength of recommendation: Strong) 
 
Consensus Reached at Round 1; 100% agreement 
Statement modified after preliminary round from ‘Given the potential for complications to 
occur several days post procedure, patients should be given instructions should symptoms 
arise. This may be written in an instruction leaflet or on the endoscopy report itself which 
may not only be informative for a patient, but also an emergency doctor‘.   
 
2. We suggest that recommencement of anticoagulant and antiplatelet therapy post-
polypectomy should be considered on an individual basis, weighing up the risks of post-
procedure bleeding with the risks of a thromboembolic event. Further specialist advice 
(ideally sought prior to the procedure) may be appropriate  (GRADE of evidence: Low; 
Strength of recommendation: Weak) 
 
Consensus Reached at Round 1; 100% agreement 
3. We recommend that in the case of piecemeal EMR, initial follow-up should take place 
within 2-6 months  (GRADE of evidence: Low; Strength of recommendation: Strong)  
 
Consensus Reached at Round 1; 92.9% agreement 
 
4. We recommend that on follow-up, the scar site should be positively identified, scrutinised 
and photographed. Image enhancement with techniques such as dye spray and digital 
enhancement may aid detection of residual neoplasia on a polypectomy scar. Areas of 
possible residual polyp require tissue diagnosis and definitive treatment     (GRADE of 
evidence: Low; Strength of recommendation: Strong)   
 
Consensus Reached at Round 1; 84.6% agreement 
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Statement modified after preliminary round from ‘On endoscopic follow-up, the scar site 
should be positively identified, scrutinised and photographed to exclude recurrence. 
Consideration should be given to biopsy of the scar as additional proof.’  
 
5. We suggest that the management of residual/recurrent polyp tissue can be challenging 
and should be performed by an endoscopist with complex NPCP experience (GRADE: Low; 
Strength of recommendation: weak). We suggest that the management of ongoing 
recurrence should be discussed in a complex polyp MDM (GRADE of evidence: Low; 
Strength of recommendation: Weak) 
 
Consensus Reached at Round 1; 100% agreement 
New statement created after preliminary round 
 
Deleted after Preliminary Round 
 Image enhancement with techniques such as dye spray and digital contrast 
enhancement may aid detection of residual neoplasia on a polypectomy scar 
 Thermal coagulation techniques such as APC may be used in the management of 
residual and recurrent tissue of up to 1cm in size in cases of recurrence of 1cm or 
greater in size, the case should be discussed at a complex polyp MDT. Options such 
as ESD, surgical resection and conservative treatment may be appropriate 
 In cases of recurrence of 1cm or greater in size, the case should be discussed at a 
complex polyp MDT. Options such as ESD, surgical resection and conservative 
treatment may be appropriate. 
 Curative downsizing may be used to provide symptomatic relief 
 
3.4.7) Surgical Management 
 
1. We recommend that surgical therapy should be considered where malignancy is suspected 
or concerns about the likelihood of incomplete endoscopic resection arise following 
complex polyp MDM discussion (GRADE of evidence: Moderate; Strength of 
recommendation: Strong) 
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Consensus Reached at Round 1; 92.9% agreement 
Statement modified after preliminary round from ‘Surgical therapy should be considered in 
the multidisciplinary setting where malignancy is suspected or concerns about incomplete 
endoscopic resection arise following complex polyp MDT discussions’ 
 
2. We recommend that laparoscopic therapy should be used in preference to open surgery in 
the surgical management of LNPCPs  (GRADE of evidence: High; Strength of 
recommendation: Strong) 
 
Consensus Reached at Round 1; 92.9% agreement 
 
Deleted statements after preliminary round 
 The use of adjunctive surgery such as laparoscopic assisted endoscopic polypectomy 
(LAEP) should be considered in the multidisciplinary setting in cases where a concern 
over incomplete resection and/or perforation is associated with endotherapy 
 TEMS may be considered as an alternative primary therapeutic option for complex 
rectal LSTs 
 
3.5) Discussion 
The challenge of creating of a consensus based guideline document for the management 
of large non pedunculated colorectal polyps was considerable.  The aim of the process was 
to produce a document encompassing best practice and technical guidance in an evolving 
field, a proposed model for training in this discipline and encourage further work by the 
identification of important research questions still to be conclusively answered. 
This is an area that the BSG had sought to offer guidance for many years but had found 
difficult to coordinate.  Prior to commencing the process, the plan to create guidelines was 
shared with the Northern Region Endoscopy Research Group (NREG) with initial opinion 
pessimistic.   The main concern cited was that there was a paucity of high quality evidence 
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available to support any guidance made and that the guidelines may be based mainly on 
expert opinion only and therefore categorised as the lowest grade of evidence.   However, 
this concern was allayed upon conducting a comprehensive literature review guided by 
discussion from a BSG approved writing subcommittee with a large amount of evidence 
available covering many aspects of LNPCP assessment and management. The main 
challenge was to assess, interpret and combine evidence of a sufficient standard with 
expert opinion where evidence was unavailable.  Another important step in ensuring the 
creation of a robust document was the selection of a high quality guideline development 
group including multidisciplinary individuals of a national and/or international standing 
with experience and a background of producing important evidence in in this field.  This 
was ensured by the recommendation of GDG members by relevant bodies such as the BSG 
endoscopy committee, the ACPGBI and the Royal College of Pathologists with a group of 
clinicians aware of the best available evidence, and therefore able to add to the existing 
evidence base.  This occurred at every stage of group consultation and resulted in a sizable 
and broad range of references.  In addition, where recommendations were to be made in 
the absence of sufficient evidence, the reputation and experience of the GDG would make 
it more likely that they could be considered valid. 
The BSG have clear guidance for the formation of a guideline development group which is 
likely a reflection of the fact that consensus methodology is increasingly considered as 
essential internationally in healthcare guideline development. 
The BSG GDG criteria ensured a wide representation of disciplines involved in the 
management of LNPCPs allowing for the interests of all relevant stakeholders to be 
represented and increased applicability of the guidelines.  The GDG included both expert 
and non-expert endoscopists, managerial staff, colorectal surgeons, a gastrointestinal 
histopathologist and a patient representative.  Whilst consensus methodology raises a 
potential issue with people without specific relevant expertise being asked to vote on 
complex issues, for example in this case with patient and histopathology representatives 
voting on technical endoscopic issues.  This concern was addressed by ensuring that 
members felt suitable were recruited and felt able to vote due to the provision of 
extensive relevant information in an understandable form (such as the interpretation of 
evidence and rationale for a recommendation, in addition to the comments of other GDG 
members).  Ensuring patient representation was essential to ensure that patient’s best 
interests were represented and also a mandatory feature of any BSG approved guideline.   
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Finding patient representatives proved difficult, especially given that this would be a time 
consuming process involving reviewing complex information.   One patient representative 
withdrew from the process citing these concerns whilst also admitting that they would feel 
intimidated by working alongside clinicians considered experts in the field and unsure that 
they could make a full contribution.  The BSG were however able to identify a suitable 
patient representative who had previous experience in this role.   A vital undertaking to 
ensure that they felt engaged was the creation of an information document that could be 
interpreted by a lay person.  In view of this, the format of the provisional and subsequent 
voting documents consisted of a summary of the evidence used to make 
recommendations below all recommendation statements in addition to the evidence 
database used. In addition, whilst it was important to communicate with and be readily 
available to all members on an individual basis and deal with their queries to ensure 
continued participation, this was particularly important with the patient representative to 
help to clarify any queries they may have.  This involved regular email and phone 
exchanges and this additional interaction was important in keeping the patient 
representative engaged with the process. 
The decision to use consensus methodology, in this case a modified Delphi technique, 
appeared valid as this is a complex field with a paucity of evidence and differing opinions 
with regards to best practice in some areas.   This was apparent when reviewing 
comments and the views of GDG members (discussed later). 
The modified Delphi process, albeit requiring significant coordination due to the 
availability and differing geographical locations of the GDG participants, appeared to run 
smoothly with all participants able to return their responses.  The use of a preliminary 
round prior to subsequent formal voting appeared important in: 
 Document enhancement- This included the suggests of new statements and 
removing statements and wording felt to be inaccurate or inapplicable along 
with areas of duplication 
 Increasing robustness: Ensuring the accuracy of wording and the interpretation 
of supporting evidence  
 Building on the evidence database- Suggestions with regards to additional 
references  
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The anonymous dissemination of voting results and comments allowed for members to 
give their views without fear of prejudice from other members, whilst also helping to 
moderate strong or outlying opinions.  In addition, comments from GDG members not 
considered to be experts in the management of LNPCPs (e.g. patient representative, non-
expert endoscopists, GI Histopathologist) indicated that access to the views of other group 
members improved their understanding of the issues and content in the process.   When 
strong views were expressed it was important to be mindful of their context in relation to 
available evidence and the possibility or introducing bias.  For example, a GDG member 
suggesting the use of an experimental technique that they have had a role in developing 
over more established techniques with a larger evidence base, or refusing to advocate a 
procedure that is an alternate to a modality that they provide. 
The face to face meeting format of the final round of voting was invaluable in enabling 
consensus to be reached for recommendation statements for remaining contentious points 
positively or negatively and pertinent research questions. Logistical considerations 
included the identification of a meeting date mutually acceptable to all GDG members, 
ensuring the availability of anonymous keypad voting and directing queries regarding 
reclaiming travel expenses from the BSG.  The roundtable meeting ensured that the GDG 
were able to interact in greater depth with discussion in addition to the ability to question 
and clarify issues, whilst still able to vote anonymously. 
In addition, in the absence of any evidence supporting the creation of guidelines for a 
specific LNPCP training model, the face to face meeting allowed detailed discussion 
identifying potential training modalities that may be pioneered (see later). 
The structure and format of the guidelines was formulated based on the literature review 
undertaken into LNPCP management and a review of recent international endoscopic 
guidelines such as ESGE, BSG Barrett’s Oesophagus guidelines which favoured various 
sections and statements with voting outcomes and supporting evidence below.   Sections 
were identified to cover every aspect of LNPCP management but from the available 
evidence base, it was clear that the majority of sections would focus on endoscopic 
management and associated considerations whilst it was important to pose questions 
about known contentious issues where it was likely consensus would not be reached to 
generate discussion to ensure that a clear position on these issues could be included for 
guideline users.  
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3.5.1) Definitions 
Identifying suitable clear definitions was considered important to ensure that that there 
could be universal understanding over what is considered to be a large non pedunculated 
lesion, and that lesions associated with increased risk of malignancy, complexity for 
removal and risk of complications (‘complex’ lesions) could be easily identified prior to any 
attempt at therapy.  This would facilitate the discussion and referral of lesions between 
clinicians.  This was also felt to be important in view of evidence that lesion assessment 
appears to vary widely even amongst experienced clinicians (263). 
It was agreed that the lesions targeted by the guidelines should at least 2cm in size, given 
the increased complexity associated with their removal and the increased risk of 
malignancy in this group (17, 32).  The term ‘laterally spreading tumour’ (LST) was originally 
proposed to identify large non-pedunculated polyps however this was rejected as it did not 
encompass all relevant lesions such as sessile lesions identified as Paris Is using the Paris 
Classification  System.  It was clear that a suitable term would need to encompass 
internationally validated lesion morphology classification systems such as Paris 
classification and LST.  Other proposed terms included ‘large non-pedunculated lesion’ 
(LNL), ‘large sessile colorectal polyp’ (LSCP), ‘large non pedunculated polyp’ (LNP).  
However the term ‘Non-pedunculated colorectal polyp’ (NPCP) was unanimously 
considered the clearest and most appropriate term to define sessile and flat colonic lesions 
with lesions at least 2cm is size referred to as a large NPCP (LNPCP). In accordance with 
other international series, it was agreed that Paris classification and the term ‘laterally 
spreading type polyp’ (LST) may be used to sub-classify lesions further.  The identification 
of lesions with increased malignancy risk was straightforward due to strong evidence 
identifying subtypes with increased associated malignancy within various lesion 
classification systems such as Paris, Kudo Pit Pattern, Sano Capillary Pattern and LST.  Not 
originally included, the ‘NICE NBI’ system that characterised lesions based on vessel and 
surface pattern and colour, was not well known to most of the GDG.  However it was 
proposed by a member of the GDG who was part of the study group that had recently 
validated the system.  In view of this there was deemed sufficient evidence for its inclusion.  
On a background of good evidence showing worse outcomes with certain lesions, there 
was almost unanimous agreement with regards to the identification of lesions associated 
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with increased difficulty in achieving successful endoscopic resection based on lesion 
location and access issues and mucosal fibrosis due to inflammation and previous 
therapeutic attempts.  There was however, some initial contention in the identification of 
factors felt to be likely to increase the risk of adverse events.  Whilst size was recognised as 
a risk factor, the evidence originally included to support the inclusion of caecal location 
was not felt to be of sufficient strength.  This was remedied by the inclusion of a recent 
large BCSP study that unequivocally identified caecal location as being associated with an 
increased risk of perforation and bleeding.  The inclusion of ‘endoscopist inexperience’ was 
also suggested by the GDG with the purpose of highlighting the need for experienced 
endoscopists in the management of these large lesions and additional evidence strongly 
supporting this assertion was also provided. 
There was a query within the GDG about the need to identify ‘complex NPCPs’, however 
defining complex lesions was successfully justified as important to allow the identification 
of the most challenging lesions best suited to management by clinicians with the relevant 
skills and experience within a multidisciplinary environment and also emphasise the need 
for safety and good outcomes.  It appeared logical that lesions with an increased 
malignancy risk, risk of incomplete resection and risk of adverse events should be identified 
as complex, whilst the term also enabled inclusion of the SMSA scoring system which was 
strongly supported within the GDG and had recently been validated as an accurate method 
of assessing the likelihood of achieving successful endoscopic resection based on lesion 
characteristics. 
 
3.5.2) Service Provision and Management Principles 
This section sought to focus on promoting patient safety and a uniform standard of service 
delivery.  This included: 
 Highlighting the importance that clinicians with the requisite expertise should 
undertake management of these challenging lesions 
 Limiting exposure to unnecessary invasive procedures via careful assessment  
 The provision of a full range of assessment and management options either 
accessible within a single centre or another centre within a referral network 
service. 
 Ensuring that patients receive timely management without unnecessary delay 
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This section generated a great deal of debate throughout the consensus process as 
although the GDG agreed with these principles, there is limited scientific evidence to 
support many of the recommendations within this section.  As such, the wording of such 
statements was felt to be important to ensure that their validity was not questioned.  There 
was universal agreement with the statement ‘We recommend that hospitals that detect or 
manage LNPCPs should develop a referral pathway to facilitate their management and 
processes to monitor the quality of the service. The pathway should ensure that patients 
have access to and information about a full range of therapeutic options, including 
laparoscopic surgery,  a provision for the management of complex rectal lesions and 
endoscopists capable of performing endotherapy on complex NPCPs  (GRADE of evidence: 
Very low; Strength of recommendation: Strong)’.   
This statement was felt to encompass the importance of competent endoscopists, a referral 
pathway that can allow audit of outcomes to highlight areas for future improvement, a 
recognition of the special considerations required for rectal lesions and the ability to 
provide minimally invasive resectional surgery.   
The identification of suitable endoscopists and monitoring of outcomes was cited as a 
challenge.  
‘We recommend that all  endoscopists performing endotherapy on LNPCPs should  be 
highly experienced in standard polypectomy, should have endoscopy service approval for 
this work  and should be subject to regular audit to ensure their key performance 
indicators are above minimum  quality standards (GRADE of evidence:  Low; Strength of 
recommendation: Strong)’ 
It is likely that the application of the key performance indicators (KPIs) recently agreed by 
the GDG with existing therapeutic endoscopists may allow this over time. 
The recommendation regarding access to a multidisciplinary network such as a complex 
polyp MDM and its composition was not finalised until face to face discussion at the final 
voting round. The potential benefit of an MDM was felt to be high, especially by GDG 
members currently participating in them, but issues overs the logistics of such a meeting 
were raised.  It was anticipated that there may be resistance by clinicians with an already 
heavy schedule to another formal meeting whilst it may be perceived as increased 
interference in management, especially with limited current quantitative evidence to 
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advocate its use.   In view of this, the wording of the statement was modified to specify that 
a multidisciplinary network, which may include a complex polyp MDM (a specialised 
meeting or within an existing colorectal cancer multidisciplinary team (MDT) meeting) or 
informal discussion, should be in place to allow clinicians access to additional expertise.  
Another concern raised was ensuring that guidance was provided regarding the minimum 
dataset of information with regards to lesion and patient features and imaging (high quality 
videos or video) required for valid assessment and discussion.  This was felt to be especially 
applicable when referrals were received by less experienced endoscopists as patients may 
be then subject to extra, unnecessary diagnostic assessment via colonoscopy prior to a 
decision on therapy.   Additional work within this thesis has been undertaken to develop a 
minimum dataset for MDM discussion with prospective data analysis to validate its use (see 
chapter 6). 
Given the high availability of endotherapy such as EMR and international evidence 
supporting the efficacy, increased safety and cost-effectiveness of endotherapy compared 
with surgical resection for LNPCPs, there was no dissenting discussion within the GDG 
relating to recommending endotherapy over surgery where possible with demonstrated 
curative rates of approximately 90% (5, 9), reduced rates of morbidity and mortality (11) 
and strong economic evidence cited in cost evaluation studies (10).  
These factors, in addition to data demonstrating successful endoscopic management in 
LNPCPs initially felt to be endoscopically unresectable and originally referred for surgical 
management ensured early consensus for a statement recommending multidisciplinary 
discussion prior to undertaking surgery in LNPCPs without a suspicion of malignancy.   As 
the CARE study demonstrated, the therapeutic capabilities of different endoscopists does 
not appear uniform and multiple international series suggesting over 70% endoscopic 
success in this scenario supports a recommendation (5, 56, 67). 
Whilst the GDG were keen to emphasise the importance of endoscopic management, the 
need to recommend caution, particularly in the context of a suspicion of malignancy was 
supported. 
The statement ‘We recommend that piecemeal resection (either endoscopic or surgical) 
should be avoided if malignancy is suspected  (GRADE of evidence: Low; Strength of 
recommendation: Strong)’ was agreed on after initial discussions to discourage piecemeal 
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resection of suspected malignancy in accordance with established oncological principles 
given widespread evidence of the retrieval of suboptimal histopathological specimens 
resulting in:  
 The potential to miss malignancy and other poor prognostic features  
 An inability to comment on completeness of resection 
 A higher likelihood of recurrence if used on an intention to treat basis    
 
These factors were highlighted as important reasons to justify specifying piecemeal therapy 
an inadequate diagnostic and therapeutic tool in this scenario.  There was however 
disagreement within the GDG about the benefit of recommending en-bloc endotherapy 
such as ESD alongside surgery as anything other than a diagnostic tool, necessitating a 
change from the provisional statement of ‘En-bloc resection techniques (either endoscopic 
or surgical) should be used where malignancy is suspected’.   Whilst there was a view from 
GDG members practicing ESD that it could be used as a first line option due to the ability to 
obtain optimal histological diagnosis and the ability to comment on complete removal of 
malignancy in many cases, particularly in the rectum where there is a need to avoid 
resectional surgery, the view from the surgical representatives was that it offered 
insufficient assurance about complete lesion clearance if anything other than superficial 
malignancy was found due to an inability to sample of remove surrounding lymph tissue.  In 
addition, with regards to rectal lesions, the surgical representatives supported the surgical 
option of TEMS over en-bloc endotherapy due to greater availability and the ability to offer 
full-thickness resection.  In view of this, it was agreed that the statement should discourage 
piecemeal resection in this scenario whilst further individualised discussions over optimal 
therapy could take place within a multidisciplinary setting. 
There was support for the recommendation of conservative management as a potential 
option in the context of limited life-expectancy due to severe comorbidity as good sense in 
asymptomatic patients.  This was a practice used in certain cases by members of the GDG 
and an area not felt to be feasible to conduct further research in.  There was strong 
agreement about the need to be able to accurately identify suitable patients on an 
individualised basis and to ensure that patients or next of kin could be informed of and 
understand the rationale for this option before it could be supported (85).  Whilst LNPCPs 
are associated with a future risk of malignancy and may sometimes already harbour 
malignancy, the risk of symptomatic malignancy and cancer-related mortality is likely to be 
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outweighed by comorbidities such as advanced age, frailty, dementia, chronic 
cardiorespiratory conditions and other established malignancy. In this context, it was 
agreed that subjecting a patient to the additional immediate risks of endoscopic or surgical 
resection may not be in their best interests(86).  
 
The rationale for supporting conservative management as a potential option was 
extrapolated from the results of polyp growth studies with adenoma to carcinoma 
transformation to a point where a lesion becomes symptomatic is likely to take years(70).  
In addition, the use of mortality index models was felt to strengthen stratification of 
individual patient risk prior to attempting invasive therapy.  The Schonberg index in 
particular (described earlier) was cited as a model that could accurately predict patient 
mortality risk (85). 
The greatest source of contention in this section was agreeing on what was an acceptable 
timeframe for management of LNPCPs and indeed whether it was appropriate to propose a 
timeframe at all.  There was strong opposition by some for a timeframe as there was no 
evidence to support a specific time period and a concern that attempts to keep within the 
timeframe could result in inappropriate endoscopists undertaking therapy. A six week 
timeframe was initially proposed as being both prompt and in keeping with an NHS 
directive specifying that diagnostic tests should take place within six weeks.  Whilst there 
were some members advocating a shorter time period such as 2-4 weeks due to  an 
accepted view that over 10-15% of these lesions may harbour malignancy, specifying a 
shorter period such as two week pathway as with cancer was not felt to be necessary nor 
feasible given the likely resultant pressure on services.  Following round table discussion 
and hearing specific views from the patient representative, the need for a management 
timeframe was agreed as important to ensure timely management due to the potential for 
LNPCPs to harbour malignancy. An amended proposal of eight weeks, although not 
evidence based, was felt to be more appropriate as it allowed for more time to ensure that 
an appropriate endoscopist would undertake therapy and was aligned with the NHS 62 day 
pathway.  It was also accepted that increasing the timeframe to eight weeks was likely to be 
safe given evidence from polyp growth studies. 
 
 
124 
 
 
3.5.3) Lesion Assessment 
Recommendations regarding the use of Paris morphology classification were strongly 
supported due to established accuracy and already widespread acceptance. Image 
documentation and size assessment recommendations were supported as good sense in 
the absence of high quality scientific evidence as they were felt to be important in the 
accurate assessment of lesion characteristics such as malignant potential and technical 
issues.  Further lesion assessment based on surface characteristics was also strongly agreed 
on. However, the use of pit pattern recognition alone, whilst recognised as accurate, was 
cautioned against with GDG feedback that true Kudo pit pattern recognition relies on 
magnification and staining of pits with cresyl violet, with access to both extremely limited in 
the UK. In view of this, the recommendation was expanded to include NICE NBI 
classification which requires readily available NBI, given its recent validation including with 
inexperienced endoscopists whilst allowing for recognition of other modalities such as Sano 
classification, flexible spectral imaging colour enhancement (FICE) (FICE vs NBI accuracy; 
n=235, sensitivity: 77.7% vs 63.6,  speciﬁcity: 100% vs 99.0%, FICE association with correct 
diagnosis of malignancy p<0.01) and I-scan (diagnostic accuracy 74-94% independent of 
lesion size).  It was however important to stress the learning curves required for its use.    
Known areas of contention in lesion assessment related to biopsy practice and radiological 
investigation.  A recommendation clarifying queries about cautious biopsy practice was felt 
to be important given its association with submucosal fibrosis complicating subsequent 
endotherapy attempts, whilst recognising its diagnostic importance in the correct 
circumstances.  A recommendation regarding the potential use of radiological modalities 
for diagnostic purposes was discussed and rejected due to a lack of supporting evidence 
(see later).  
 
3.5.4) Endoscopic management: Pre-procedure 
Although having only limited supporting evidence, the statement ‘We recommend that 
adequate planning should be undertaken (including length of time booked for procedure, 
endoscopist and nursing staff skills and endoscopic equipment) so that prior to an 
attempt at advanced polypectomy, the endoscopist has a high level of confidence that 
complete resection can be achieved in a single procedure  (GRADE of evidence:  Very low; 
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Strength of recommendation: Strong)’ was strongly supported by the GDG as it was felt to 
assert that lesions should not be removed at the time of discovery unless time, facilities and 
patient consent are in place for this and also reinforce the importance of adequate planning 
to achieve single session resection where possible, given reduced patient exposure to 
invasive therapy and evidence of reduced curative resection in lesions previously 
attempted compared with treatment naïve lesions due to submucosal fibrosis (91% vs 
74%).   
 
Many of the statements in this section relate to anticoagulation management and consent 
related issues which may be complex to manage, particularly due to individual patient 
factors that would need to be accounted for.  Recommendations regarding antiplatelet 
agents such as clopidogrel, prasugrel and newer agents such as ticagrelor were 
strengthened by relatively high quality evidence demonstrating significantly increased 
bleeding risk with this class of agent and well established existing BSG recommendations in 
their antiplatelet guidelines.  Whilst less evidence was available concerning ticagrelor and 
similar newer agents however, in the context of pharmacological reports suggesting that 
modification of platelet aggregation for up to seven days, a similar period of cessation to 
clopidogrel and prasugrel was recommended. 
With regards to warfarin, still the most common anticoagulant in use, conclusive evidence 
and established BSG guidance in relation to its cessation ensured a strong recommendation 
about its cessation (five days prior to therapy) could be made. There was an issue however 
with regards to making a recommendation about newer anticoagulants such as rivaroxaban 
and dabigatran that are increasing in use.  The absence of clinical evidence related to 
endotherapy ensured that no recommendation other than consultation of relevant 
specialist advice (cardiology/haematology) prior to endotherapy was felt possible.  It was 
recognised that the cessation of antithrombotic medication poses differing risks of 
thrombotic episodes to patients and in view of this, whist evidence based 
recommendations such as the use of a bridging regimen for high risk individuals could be 
made in line with existing BSG recommendations, the potential complexity surrounding this 
issue meant that the GDG were keen to highlight the importance of relevant specialist input 
and only weak recommendations could be made. 
  
The issue of management of aspirin prior to polypectomy has proven to be controversial 
with conflicting evidence reported in international literature and differing views expressed 
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by GDG members.  Although both UK and US recommendations recommend that aspirin 
may be continued prior to polypectomy and no data reports aspirin as a statistically 
significant risk factor for bleeding, surveys of endoscopists demonstrate that a large 
proportion withhold aspirin.   As much of the available evidence pertaining to aspirin does 
not refer to LNPCPs specifically, this practice was understood and supported by various 
members of the GDG, especially as it was felt that in many cases temporary cessation of 
aspirin was unlikely to be unsafe. In light of evidence provided by a BSG reviewer 
demonstrating no increased bleeding risk with the continuation of aspirin prior to ESD, it 
was agreed that the use of aspirin was most likely safe but that its management should be 
individualised according to patient risk and a strong recommendation could not be made.  
 
It was considered vital that recommendations with regards to patient information and 
consent were comprehensive, clear and explicit to ensure the General Medical Council’s 
policy with regards to patient consent was adhered to.  This included recommending that 
information about all potential management options (including endoscopic, surgical and 
conservative and the potential benefits and risk associated with both) and the potential 
individualised thromboembolic risk with anticoagulant withdrawal prior to LNPCP removal 
were explained.  This would allow patient to participate in making a fully informed decision 
about all therapeutic options, select a preferred therapeutic option and the timing of 
therapy e.g. potentially delaying therapy until a more convenient date, such as post 
cessation in patients on temporary anticoagulants.  The statements made related to patient 
information and consent were strongly recommended as supporting patient autonomy and 
representing ‘good sense’. 
3.5.5) Endoscopic Management: Peri-procedure 
This section sought to provide recommendations about the use of equipment and 
equipment settings identified in a review of evidence as potentially beneficial in achieving  
optimal safety and results during the actual polypectomy process, strategies during the 
resection process and a position on contentious areas where the likelihood of high quality 
scientific research findings was not considered feasible to obtain.   
The use of carbon dioxide of during endoscopy is strongly supported by available evidence, 
including the findings of a randomised controlled trial, demonstrating improved patient 
comfort during endoscopy compared with air insufflation and therefore allowing for the 
longer procedure times required for advanced polypectomy.  In addition the non-
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flammable properties of CO2 indicate increased safety associated with its use.  Findings 
related to improved patient comfort and safety ensured that the use of CO2 was strongly 
recommended by the GDG. 
The use of contrast agents as part of the submucosal injection solution to lift an LNPCP 
prior to resection was considered as accepted standard practice by the GDG in line with 
international literature with strong agreement regarding improved lesion demarcation.  
Indigocarmine was considered the preferred agent described in international literature. 
However, it was noted, unlike methylene blue, that indigocarmine is not licensed for use in 
this country despite apparent widespread use.  In view of this, the initially proposed 
recommendation statement had referred specifically to methylene blue.  This was met with 
resistance from the GDG who strongly supported the recommendation of indigocarmine, 
primarily due to their longstanding use of indigocarmine and concerns within the group 
about reported association of methylene blue with potential DNA damage to colonocytes in 
laboratory based work, a finding not associated with indigocarmine. It was suggested that 
indigocarmine and not methylene blue should be included as there were no safety issues 
raised with the former, but the inclusion of both methylene blue and indigocarmine was 
accepted in the statement with a view that this recommendation may aid a change in the 
latter’s licensing conditions. 
 
A strong recommendation was agreed mainly in relation to aiding demarcation of serrated 
lesions. The CARE study demonstrated residual polyp tissue on almost half of serrated 
lesions where complete resection had been considered achieved, far higher than with other 
polyp types (20).   
 
Recommendations regarding the use of adrenaline and colloidal type solutions in 
submucosal injection solutions were supported in view of evidence suggesting reduced 
immediate bleeding (potentially allowing clearer views during resection) and easier 
resection respectively.  There was however no effect on delayed bleeding found and the 
GDG view was that a recommendation about adrenaline should specify this.  Whilst a 
concentration of 1:10000 has been reported in various trials, many members reported 
using a more dilute form, primarily due to a concern about the increased risk of 
cardiovascular compromise with higher concentrations.  In view of this, a particular solution 
strength was not specified but a warning about the potential for cardiovascular 
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compromise was included in supporting text.  It was noted that the evidence for its use was 
primarily from small retrospective studies and that further research in this area was felt to 
be feasible and so the strength of recommendation made was recorded as weak.  A 
proposed study was a prospective placebo controlled RCT assessing immediate bleeding 
rates with varying concentrations of adrenaline.  The GDG considered the evidence to 
support colloidal type solutions such as succinated gelatin strong with multiple accounts of 
a longer lasting submucosal lift, improved procedure times and en-bloc resection rates 
reported when compared with normal saline, including a small RCT by an internationally 
renowned group (158).  However, although considered beneficial, only a weak 
recommendation was made as the use of colloidal type solutions for LNPCP resection was 
not widely used by GDG members and not considered essential, especially as no 
improvement in patient safety was demonstrated. 
 
Finalising recommendations with regards to specific equipment settings and configurations 
proved difficult with opinion rather than scientific evidence prevalent and various practices 
reported both within the GDG and in international questionnaires.   The choice of specific 
snares was one such example where there are many shapes, textures and sizes available 
but no studies advocating the use of a particular shape or size.  While it was felt that clinical 
trials were possible, for example assessing the effect of various snares on procedure times, 
en-bloc resection rates, recurrence and thermal tissue injury, it was felt that these factors 
were most likely to be affected by an endoscopists familiarity and comfort with a particular 
snare, with many GDG members reporting favoured use of different snares, and therefore it 
was felt that that only advising users to become comfortable with a favoured snare was  
appropriate in this scenario. 
 
Formulating recommendations in relation to electrocautery settings proved similarly 
difficult.  In addition to various types of available current such as cutting, blended and 
coagulation current, various voltage settings exist, in addition to manufacturer variations 
meaning that equivalent voltage settings may deliver differing amounts of current.  As with 
the results of large questionnaires, the preferred configurations of electrocautery delivery 
varied within the GDG with recommendations based on experience rather than evidence.  
Observational evidence did appear to suggest that both blended and coagulation current 
were safer than pure cutting current with the latter identified as despite providing optimal 
histopathological specimens, a strong risk factor for post procedure bleeding and 
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questionnaire results suggested that this was understood with cutting current markedly less 
in use.   The potential hazards of prolonged pure coagulation current were also recognised 
with porcine evidence suggesting increased thermal tissue injury and perforation risk with 
higher voltage settings and diminished haemostasis properties with lower settings.   The 
risk of thermal tissue injury is of greater relevance in the thinner right colon and it was 
accepted that the use of lower settings would likely be safer in this setting.   Human clinical 
research in this area was not considered feasible due to the ethical issues associated with 
assessing an outcome of thermal tissue injury.  With no evidence available supporting 
specific settings, various manufacturer variables and more recent data supporting the use 
of blended current combining the properties of both cutting and coagulation current in a 
controlled manner the GDG felt the most valid recommendation possible was to caution 
against the use of prolonged cutting or coagulation current for safety reasons.   
                                 
The plan to recommend technical strategy parameters was initially met with some 
opposition within the GDG with a concern raised that technical points did not fall within the 
remit of these guidelines. The majority of feedback however indicated GDG support for 
technical recommendations with good evidence and/or rationale suggesting improved 
patient safety and reduced adverse outcomes.   One such recommendation referred to the 
risks associated with caution with the use of en-bloc snare resection for LNPCPs.  Whilst 
recommended where possible for smaller lesions, multiple expert international authors 
have reported technical difficulties with this approach with LNPCPs due to reduced snare 
stiffness and uncertainty about the resection plane leading to a concern about perforation 
due lack of control of tissue volume and thermal injury due to an inability to control the 
cutting plane.  The inclusion of this recommendation was supported with its rationale 
considered logical and likely to lead to improved patient safety. 
A recommendation advising against the use of conventional snare resection with LNPCPs 
displaying the ‘non-lifting sign’ in treatment naïve lesions in response to submucosal 
injection was supported strongly due to a strong association with deep submucosal cancer 
by large volume case series.  The wording regarding this recommendation was modified 
following GDG discussion to refer  to ‘conventional snare polypectomy resection’ such as 
pEMR as the initial proposed wording referring to ‘piecemeal endotherapy’ was felt to be 
inaccurate by multiple expert endoscopists within the GDG.  Two members asserted that 
some lesions may be amenable to a hybrid EMR & ESD type technique that may not be en-
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bloc for the whole lesion but still result in en bloc removal of the component with difficult 
lift.   
Recommendations about adjunctive thermal ablative techniques such as APC and soft snare 
coagulation in endoscopic resection were debated at length within the GDG.  Despite long 
standing evidence suggesting a reduction of residual or recurrent tissue on follow-up 
surveillance with use of APC peri-procedurally on resection margins and small residual 
areas of polyp, more recent case series have not supported this finding.  In addition, there 
were views within the GDG that APC was inferior to soft snare coagulation despite no 
current data to support the use of the latter.  There were concordant views within the GDG 
that soft coagulation use was beneficial based on personal experience and it was 
recognised that a prospective RCT examining its effect was currently recruiting patients in 
Australia based on encouraging preliminary results.  The data supporting APC use was 
considered more valid than more recent opposing data however, as they included an RCT 
and assessed the relationship between APC use and recurrence as a primary outcome, 
whilst opposing data was observational and reported APC efficacy as a secondary outcome. 
It was therefore felt that the conditions where APC was used in these case series was less 
likely to be controlled, such as use in unsuitable circumstances.  Taking these findings as a 
whole the GDG were prepared to recommend thermal coagulation use, especially APC use, 
but to specify its applicability following a full attempt at snare resection on resection 
margins where no or small fragments of residual tissues remained as opposed to an 
alternative to snare resection in larger residual areas.  The recommendation was strong 
given the likely benefit and lack of major safety concern with thermal ablative techniques 
but it was recognised that this was an area where further research was feasible.  In addition 
to the pending soft coagulation RCT, further proposed studies included a large multicentre 
APC RCT with strict criteria for its use and a head to head comparison between soft-
coagulation and APC. 
 
Other initially proposed technical recommendations relating to snare handling and 
endoscope positioning were withdrawn due to a lack of evidence, no previous prior 
consensus and ongoing disagreement about their merits.  Marking of the snare, prior to 
closure on a polyp has been advocated as ensuring an appropriate amount of tissue is 
ensnared, thus reducing the risk of perforation.  However this practice was cited by 
multiple GDG members as inaccurate and potentially dangerous with certain lesions such as 
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flat LNPCPs and a statement relating to this practice was withdrawn. A statement proposing 
standardised endoscope positioning with the LNPCP adjacent to the emergence of the 
snare from the endoscope accessory channel was withdrawn due to criticism that it was 
overly prescriptive and unnecessary with no established benefit.  In addition, a statement 
supporting the use of prophylactic clip application over the resection area to reduce the risk 
of post procedure bleeding that was created following a recent RCT advocating its use was 
rejected as there were concerns over the methodology used in the study.  The bleeding 
incidence reported in the ‘clip group’ (9%), although lower than the control group, was 
markedly higher than reported data from other international case series (<5%). 
 
The final recommendations in this section related to adequate visual documentation of the 
polyp site and allowing identification of this area on further endoscopic or surgical follow-
up.   These recommendations were strongly advocated as they were considered good 
practice and were already well established in the UK BCSP.   These recommendations were 
also considered to have specific applicability with LNPCP management.  For example, 
adequate visual documentation was not only considered good practice from a 
documentation view, it was felt that high quality imaging whether or not endoscopist 
resection had taken place may allow detailed discussion of further management, e.g. such 
as within an MDM, and optimise follow up management.  In addition, whilst tattoo marking 
is already established practice, it was felt necessary to explicitly specify tattoo application 
practice in light of multiple case reports of new and follow-up LNPCP resection 
compromised by submucosal fibrosis from tattoo application too close to the LNPCP site.  In 
view of this, it was agreed that tattoo marking at a safe distance away from the LNPCP site 
would limit the likelihood of this occurring and a distance of at least 3cm was 
recommended in accordance with international opinion (264).   
 
3.5.6) Post procedure  
The recommendations in this section sought to provide guidance for the period following 
the initial endotherapy session and subsequent follow-up.  This related to post procedure 
management, including patient instructions and medication management, and the 
detection and management of potential recurrence and residual tissue. 
Given evidence that patients may present with symptoms of serious complications such as 
bleeding and perforation over two weeks after endotherapy a recommendation regarding 
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clear patient information and instructions in the event of alarm symptoms was considered 
essential.  The inclusion of an emergency contact number was also recommended in 
accordance with JAG guidance, and considered standard practice within the GDG as this 
may allow for planning for prompt remedial management. 
Creating recommendations regarding the recommencement of antithrombotic medications 
was considered difficult, as with pre-procedure management, due to conflicting evidence 
regarding the safety of prompt recommencement balanced with the thrombotic risk of 
delayed recommencement.  An example of this was warfarin recommencement which was 
shown as safe for same day recommencement in one study but was later strongly 
associated with increased bleeding risk when restarted within seven days in a larger study.  
In addition, there was conflicting opinion within the GDG regarding optimal timing of 
recommencement and an acceptance that this may vary on an individual basis.  In view of 
this it was agreed that antithrombotic medication recommencement should be 
individualised according to patient risk with specialist input in complex cases ideally 
beforehand to ensure adequate pre and post procedural planning. 
With existing international recommendations already suggesting initial endoscopic 
surveillance follow up post piecemeal LNPCP resection within a six month period and strong 
evidence suggesting that recurrence levels rise markedly after this point, a similar 
recommendation was strongly favoured by the GDG.  There was discussion about whether 
initial follow-up should take place after either 2-3 months, as favoured by most 
endoscopists within the GDG, or at six months with available data suggesting similar 
recurrence rates and additionally, findings of recurrence seen at six months not seen at 
three months suggesting that a six month period may allow all recurrence to be caught.   It 
was felt that while surveillance endoscopy at too early a stage may not be useful due to 
likely ongoing inflammation, a finding of high grade dysplasia or concern about malignancy 
would warrant more prompt follow-up.  Recommending follow-up 2-6 months post 
endotherapy was considered acceptable with this view further strengthened by similar 
American Cancer Society guidelines. 
There was strong agreement regarding the need for recommendations regarding optimal 
assessment for and management of recurrent/residual tissue.  This need was further 
emphasised by the publication of the CARE study just prior to the commencement of the 
consensus process demonstrating levels of recurrence much higher than expected in lesions 
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where complete resection was considered to have been achieved.  The use of image 
enhancement techniques such as NBI, dyespray and magnifying high definition were all 
advocated by GDG members with evidence demonstrating superiority to conventional 
white light imaging to support all these modalities.  There was disagreement regarding the 
benefit of taking biopsies from the LNPCP resection scar site on follow-up in the absence of 
visible recurrence, in spite of evidence suggesting that significant levels of recurrence were 
detected following biopsy at sites where no visual polyp tissue was observed.  There were 
several GDG comments that the biopsy of healthy looking tissue was not justified and that 
post inflammatory tissue may be confused with true recurrence.  However, following the 
publication of a large volume case series during the consensus process that recorded 
almost identical findings, allied to the acceptance that the quality of visual assessment 
appears to vary between endoscopists as witnessed by the CARE study, and the ease of 
obtaining biopsies in this scenario, there was eventual support to recommend biopsy 
assessment. 
It was felt necessary to provide guidance about the management of recurrence tissue as 
this was considered to be a complex scenario especially with large areas of recurrence that 
may not be amenable to snare resection or APC ablation due to submucosal fibrosis and 
extensive size respectively.  As previously discussed, it was considered desirable to avoid 
surgery where possible, especially in this scenario, with evidence that endoscopic 
eradication rates may be above 70% in the appropriate expert setting and reports less 
invasive options such as ESD may also yield success.  Optimal assessment and management 
was felt to be more likely, with the involvement of an endoscopist experienced in complex 
NPCP management or preferably using a multidisciplinary network to allow assessment of 
all management options including endoscopic, surgical and conservative management.  This 
recommendation was justified as being ‘expert opinion’. 
A preliminary round proposed recommendation regarding the use of APC on 
recurrent/residual tissue was removed following strong opposition.  In the absence of 
evidence to suggest efficacy in this scenario it was felt that it should not be recommended 
as a sole therapy for treatment of recurrence of any size and should only be used in 
conjunction with resection or only after histological confirmation that there is no 
malignancy in the residual tissue.  There was also a concern that recommending the use of 
APC for recurrent/residual tissue may encourage its use in inappropriate circumstances by 
less experienced endoscopists rather than referring these cases for more learned opinion.  
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3.5.7) Surgical Management of LNPCPs 
 
Recommendations on surgical management for the management of LNPCPs were led by the 
ACPGBI colorectal surgery representatives and finalised by the ACPGB colonoscopy 
committee. This was also a section with extensive high quality evidence unlike other areas 
in the guidelines. Despite a preference for endoscopic management in the management of 
LNPCPs by all parties, it was also considered vital to highlight the importance of surgical 
management as a potential management option where endoscopic management was not 
considered technically safe or feasible or where a concern about malignancy existed.  This 
was considered especially important for centres lacking access  to more advanced and 
specialised treatment modalities and supported by extensive high quality evidence 
demonstrating the efficacy of surgery in this scenario, further strengthened  by reports that 
the level of malignancy found post-surgery in lesions previously considered benign  is vastly 
higher than first thought.  There was also strong support by both the GDG and the ACPGBI 
for recommending laparoscopic surgery over open surgery where feasible in view of 
extensive evidence demonstrating a markedly improved patient experience terms of pain, 
return of bowel function, hospital stay and earlier mobility.   
  
A statement recommending laparoscopic assisted endoscopic polypectomy (LAEP) as a 
management option for LNPCPs considered technically difficult to resect endoscopically 
was removed following opposition from multiple endoscopists within the GDG.  Although 
thought to allow colonic manipulation for improved access for endoscopic resection, allow 
for immediate management of complications and malignancy, endoscopists with 
experience with LAEP suggested that it may in fact complicate resection due to general 
anaesthetic.  In addition, supporting evidence was considered weak and with separate NICE 
guidelines regarding its use currently in development, this was initially felt to be a more 
appropriate setting.  The ACPGBI however felt that a reference to LAEP was important, on 
the basis that its consideration as a management option may result in improved 
multidisciplinary dialogue, and due to increasing case series reporting its successful use.  
These views were accepted as valid by the GDG and accommodated.  
 
The ACPGBI were also keen to emphasise the role of transanal surgery such as TEMS and 
TAMIS as primary management for rectal LNPCPs and wanted this described in greater 
detail after a proposed statement detailing transanal surgery was withdrawn following the 
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preliminary round.   This was only felt to be possible to a certain extent.  Whilst it was 
accepted that transanal surgery is an important management option, the evidence for use 
of TEMS/TAMIS in benign lesions was considered variable with very few studies showing 
comparable efficacy when compared with endoscopic studies.  Whilst initial data on TAMIS 
is encouraging, it was argued that there is not as yet enough data to routinely recommend 
its use with only a single case series of 50 patients currently published.  In contrast, EMR is 
more widely available, with evidence to suggest equal efficacy when allowing for repeat 
therapy on follow up and fewer complications (77, 217). In addition, even when allowing for 
repeat endoscopic sessions it is cheaper and is therefore may be considered more cost 
effective (56, 249).  In addition, in the context of lesions where there is no suspicion of 
malignancy, expert opinion within the GDG was that en-bloc resection is not essential.  The 
GDG felt that in view of these factors, transanal surgery could not be recommended 
routinely as first line management for benign lesions but did specify it is a viable option, 
especially where en-bloc resection is desirable or where lesion characteristics make 
successful endoscopic snare resection technically difficult, such as with extensive soft 
‘carpet-like‘ villous lesions that are difficult to adequately capture with a snare.  There was 
a concern that the exclusion of specifying transanal surgery from the guidelines would 
introduce bias.  Strong opposition to this modality was registered by GDG endoscopists who 
perform ESD, another mode of obtaining en-bloc resection.  It could be argued that ESD 
endoscopists may receive fewer referrals by the recommendation of transanal surgery 
within these guidelines. It was therefore considered important to ensure that transanal 
surgery was specified as a management option.  This was achieved with a summary of 
available opinion and evidence within the supporting text of an existing statement about 
surgical management for LNPCPs, with this approach accepted by the ACPGBI.   
The ACPGBI were strongly supportive of the guidelines overall, with strong representation 
of their membership on the GDG. They did however raise several considerations they felt 
required greater attention in addition to their views on LAEP and transanal surgery.   A main 
concern was that there was sufficient distinction between colonic and rectal lesions in view 
of differing surgical management in these areas and the availability of transanal surgery for 
rectal lesions.   
This was clearly an important consideration with resectional surgical management 
considered less of a concern for colonic than with rectal lesions where it would be avoided 
if possible with benign lesions due to:  
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 the complexity and morbidity associated with both open and laparoscopic surgery in 
the rectum   
 the potential for requirement of a permanent stoma (e.g. with non-sphincter saving 
surgery such as an abdominoperineal resection (APR) in the management of low 
rectal lesions)  
 the potential for less invasive full thickness transanal surgery for rectal lesions.   
Their final concern was the support for the use of a complex polyp MDT for lesions 
identified in the guidelines as ‘complex’.   Whilst they felt that this was an ideal scenario 
and that they supported discussion prior to management in this scenario, they were 
concerned that it may not be feasible in many centres where the infrastructure is not in 
place for a new meeting and clinicians may face time-pressures limiting their ability to 
participate in another MDM in addition to the colorectal cancer (CRC) MDT.  Their position 
was that in this scenario the existing CRC MDT was a sufficient discussion forum as a 
complex polyp MDM providing a therapeutic endoscopist was in attendance.  Whilst there 
was strong support within the GDG for a dedicated polyp meeting, primarily due to a 
concern that LNPCPs are often not be prioritised for sufficient detailed discussion in a CRC 
MDT meeting due to the absence of malignancy and the existing CRC service pressures, the 
ACPGBI’s stance was recognised as valid, particularly as it was anticipated that specifying a 
complex polyp MDM would prove controversial on dissemination of the guidelines due to 
the concerns raised above.  In view of this, a compromise was made in terms of an 
acceptable multidisciplinary forum for LNPCP discussion with the wording in the guidelines 
was amended accordingly.   
 
3.6) External consultation process  
Ensuring that these guidelines were seen as generic management guidelines as opposed to 
solely endoscopic guidelines was important given the various non endoscopic management 
options available.  In view of this, the guidelines were sent for consultation by the ACPGBI 
at multiple stages in addition to the BSG, as their endorsement would enable this. 
The initial responses from the BSG (BSG endoscopy committee and appointed reviewers) 
and ACPGBI were strongly positive.  The consensus process was considered valid, extensive, 
well referenced and likely to improve LNPCP management. 
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More specific comments from the BSG reviewers pertained to detail felt to be missing, 
limited or requiring greater clarification.  A response to the reviewers was required to 
display additional content and clarification in subsequent drafts as well as justify content in 
areas where the GDG did not agree with reviewer comments.    
An initial observation was that the GDG panel could be perceived as ‘endoscopist heavy’ 
with more endoscopists on the GDG than from other specialties.  However, BSG Guidance 
on guideline development had been followed with the recruitment of GDG members with a 
group felt to reflect the key multidisciplinary stakeholders routinely involved in the 
management of these lesions that are presumed benign until proven otherwise.   The GDG 
consisted of endoscopists (both expert and referring endoscopists), management, 
colorectal surgeons who are also advanced endoscopists, a patient representative and a GI 
histopathologist.    That there are a larger number of endoscopists as part of the GDG is 
perhaps a reflection of the fact that the majority of these lesions are managed 
endoscopically.  In addition, a respond was given that guidelines had been written in 
conjunction with the ACPGBI, who nominated the 2 surgeons on the panel and had no 
concerns over the composition of the committee.  The fact that the GI histopathologist was 
nominated by the Royal College of Pathologists was felt to further strengthen the 
multidisciplinary credentials of the guidelines. 
It was apparent from the feedback from the BSG reviewers that the GRADE tool used to 
assess the quality of a recommendation required clarification.  Multiple reviewers 
questioned why there was often a disparity between the strength of evidence and the 
strength of recommendation for a recommendation statement/parameter.   
However clarification that the GRADE system was now increasingly used to evaluate 
scientific evidence due to an ability to allow evaluation to be made based on the both 
strength of evidence and the strength of a recommendation, therefore allowing 
recommendations  to be made where there appeared to be good sense in spite of the 
absence of high quality scientific evidence, was accepted (261).   
The number of recommendations for where the strength of supporting evidence was 
recorded as ‘low’ or ‘very low’ was also seen as a potential weakness of the guidelines by 
one reviewer.  However, it was countered that the nature of LNPCP management is that it is 
an area with a large amount of evidence from observational studies and limited evidence 
resulting from RCTs whilst there are many areas within this field where conducting RCTs 
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may not be feasible.  It was argued that although many of the international series regarding 
LNPCP management were classified as observational studies and as such given a low 
strength of evidence grading, the studies were considered to be from high quality centres, 
were of high importance, made good sense and were unlikely to be disproved by further 
work and could therefore warrant a strong recommendation.  It was also stated that the 
GRADE system was applied very strictly to emphasise how robustly available evidence was 
analysed and that several GRADE recordings may in fact warrant stronger evaluation scores 
and recommendations than originally given. 
 
Another issue raised by the reviewers related to the role of histopathology in the 
management of LNPCPs which was not felt to be adequately covered in the draft guidelines.  
Specific questions felt to be unanswered included: 
 Important histopathological reporting considerations and minimal reporting 
guidance for LNPCPs 
 Why the use of existing histological grading systems such as the Kikuchi system 
were not recommended. 
 The role of the histopathologist in LNPCP management, including in the 
multidisciplinary setting such as a complex polyp MDT/MDM 
These comments were important in ensuring the detailing of important histopathological 
considerations in the management of LNPCPs in subsequent revisions of the guidelines.  It 
was important to highlight that the guidelines refer to lesions presumed benign at the time 
of assessment and lacking histopathological evidence of malignancy.  This was asserted in 
the introduction section with review of the ACPGBI position statement on malignant polyps 
and the NICE colorectal cancer guidelines advised in the event of a finding of malignancy.    
Discussion between the GDG took place in light of the reviewer comments, led by the GI 
histopathology representative, the lead author of the recent Royal College of Pathology 
Colorectal Cancer guidelines. Whilst important, histopathology was felt to have a less 
significant role in the management of benign polyps than in the management of malignant 
polyps.  Although pathological assessment, including depth of invasion (by Haggitt level, 
Kikuchi level, and quantitative measures), differentiation, lymphovascular invasion, tumour 
budding etc. are all considered important in consideration of subsequent management of 
malignant regions, these features were not considered relevant in the context of benign 
lesions.  This view was supported by the ACPGBI and the GDG considered justification for 
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this position strengthened by BSG recommendations for colonoscopy surveillance intervals 
for completely excised benign polyps, where only the number and size of adenomas 
influences follow-up management and dysplasia grade and villousness are not considered.  
This was felt to further limit the role of histopathology in the management of LNPCPs with 
the main histopathological considerations for LNPCPs felt to be:  
 Judicious use of targeted biopsies:  Recommended only when there is suspicion of 
malignancy in a LNPCP, to help ensure endotherapy is not compromised. 
 Awareness of significant potential for under calling of malignancy in the endoscopic 
biopsy setting. 
 In polypectomy evaluation, confirmation of the adenomatous nature of the polyp 
and confirmation of benignity i.e. exclusion of adenocarcinoma arising within the 
adenoma 
 Emphasising the distinction between invasive neoplasia and so-called ‘epithelial 
misplacement’. 
 Assessment of adenoma subtype according to WHO 2010 classification as tubular, 
tubulovillous, villous or traditional serrated.  
 Assessment of grade of dysplasia/neoplasia using a two tier system. 
 Assessment of margin involvement by dysplasia, where possible, in accordance with 
the nature of the specimen received (en-bloc or piecemeal) and endoscopic 
correlation regarding completeness of excision.  (253, 265) 
With regards to the multidisciplinary role of a histopathologist in LNPCP management, 
including a complex polyp MDM, it was felt that histopathological input could be delivered 
equally effectively via the existing colorectal MDT meeting or during a specialised benign 
polyp MDM, either during, pre or post meeting in person or via other secure 
communication such as encrypted email or teleconferencing.  The allowance for a 
histopathologist not to be present during a complex polyp MDM was felt to be reflective of 
the reduced input of histopathology when compared with malignant lesions.   
A concern about the lack of reference to the use of radiological modalities was also 
specified. The GDG countered that whilst it was recognised that radiological input may be 
warranted in certain cases, such as where there is difficulty in determining whether a lesion 
is benign or malignant (e.g. the use of MRI for a large rectal lesion).  It was also felt that the 
proportion of cases where radiological investigation changes management of LNPCPs was 
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low. In addition, it was argued that proposing routine radiological investigation in the 
absence of regular benefit could not be considered cost-effective and these factors 
supported a view that radiological input was therefore not considered essential in routine 
assessment but suggested for consideration on a case by case basis. It was also specified 
that a proposed recommendation statement regarding the use of radiological modalities 
was withdrawn with but it accepted that that a reference to radiological input was 
warranted with the GDG’s position specified in content regarding multidisciplinary team 
management. 
Additional comments advised the inclusion of more practical and technical advice for 
endoscopic practice in complex situations.  An example included LNPCPs crossing the 
dentate line which were cited as potentially painful to resect due to the innervation in this 
area and often more difficult to remove due to the difficulty in obtaining a stable 
endoscopic position for resection.   Instructions regarding the use of local anaesthetic 
(lignocaine) and using the retroflexed position were subsequently added. 
A final concern was that considerations for follow-up of large lesions had not been 
addressed initially.   Clearly this was an important consideration requiring inclusion and the 
GDG position that follow-up should be in line with existing BSG guidelines for polyp follow-
up following specific lesion clearance assessment follow-up was subsequently 
recommended. 
Following suitable amendments as specified above and the return of a response document 
outlining the GDG’s responses and position on the BSG reviewers’ comments, the BSG and 
ACPGBI formally approved the guidelines with a recommendation for submission to ‘Gut’ 
journal, the official journal associated with the BSG.   The guidelines were subsequently 
accepted for publication. This marked the completion of a long process complicated by the 
need to satisfy all concerned parties.  It can be concluded that these are the world’s first 
comprehensive genuinely multidisciplinary guidelines for the management of LNPCPs. It is 
anticipated and hoped that these guidelines will readily provide evidence based 
information and expert opinion on the optimal assessment and management of large non-
pedunculated colorectal polyps (LNPCPs) for all clinicians involved in their care to improve 
management. It is also hoped that the guidelines will act as a reference to guide further 
research in this field and provide a template for training in LNPCP management.  The 
141 
 
intended target audience includes gastroenterologists, nurse practitioners, physicians, 
colorectal surgeons, radiologists and pathologists.   
Whilst it must be accepted that is a paucity of evidence within this field considered to be of 
the highest scientific quality evidence such as large multicentre RCTs and meta-analyses, 
these guidelines comprehensively reference and summarise the available evidence and 
opinion in this field and appear to be a marked improvement on previous resources for 
LNPCP management.  This is confirmed by acceptance and publication in a high impact 
international journal.  
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Chapter 4: Development of Key Performance Indicators for the 
Management of Large Non-Pedunculated Colorectal Polyps 
 
4.1)  Measures of Quality in Healthcare 
In light of healthcare performance considered to be substandard both nationally and 
internationally, a means of improving healthcare performance has been sought on a 
worldwide basis.  The need to improve public safety and ensure cost effectiveness of 
healthcare services to allow continued provision is paramount, along with the objective of 
improving public confidence in the face of increasing expectations (266, 267) 
There has been a drive for improved standards internationally following cases of 
substandard care.  A US report estimated the incidence of mortality relating to medical error 
to be 44 000–98 000 cases per year whilst an Australian study found that 16.6% of hospital 
admissions were associated with an adverse event.  In the UK, the recent reports regarding 
care at the Mid Staffordshire Hospitals have also been followed with calls for improved 
standards (268-270). 
Key aims of the provision of high quality healthcare and healthcare improvement measures 
include: 
 Improving patient safety 
 Improving public confidence in healthcare  
 Improving standards of healthcare uniformly to all service users 
 Providing a more cost-effective service 
 
143 
 
A critical strategy in improving standards has been the creation of targets and standards 
across a variety of disciplines relating to both the infrastructure of services and clinical 
performance to enhance both efficiency and performance.  The aims of targets include: 
 Motivation of various centres towards a common goal 
 Achieve agreement regarding the priorities and expectations of setting targets and 
standards 
 Setting a benchmark and allowing a means to measure and monitor progress 
 Communicating to stakeholders about the priorities and expectation of services 
 The ability to make decision makers accountable (267, 271) 
Applying standards across different regions or even internationally may prove difficult.  This 
has been reported to be the case in countries such as the USA where healthcare may be 
regulated separately from state to state and provided by various private insurance 
companies between which competition for subscribers exists.  In the UK however, where a 
centralised NHS service exists, a partnership to apply key targets and standards may be 
easier to achieve.  In view of this, where widespread national and international 
implementation of standards is applied, clear definitions are required with standards 
applicable to all stakeholders (268).  
Quality healthcare has been defined as care based on assessed needs using finite resources 
efficiently to raise standards and reduce risks associated with management whilst also 
being a continuous process (see below) (272) 
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                                        Figure 14. Quality Assurance Triangle Model (273) 
 
 
Donabedian et al proposed a 3 part model of assessing healthcare quality: 
 Structures- The resources of a healthcare system to the population needs 
 Processes- What is done to improve care (e.g. indicators that measure compliance) 
 Outcomes- The results of care such as safety and change in the quality of life (274) 
 
4.2) Key Performance Indicators 
Key performance indicators (KPIs) are specific measurable elements of care provision that 
can be derived from Donabedian’s model, set either via evidence from a literature review or 
via an expert based consensus. The data used to support KPIs is standardised and the 
utilisation of KPIs as performance measurement tools have been proposed as a clear, 
defined and structured method of delivering improved health policy through the setting of 
targets and standards. In many cases, KPIs are considered essential in the setting of 
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standards, monitoring and evaluation of performance and enacting improvement in 
healthcare services with the benefits felt to markedly outweigh potential drawbacks (266).  
The potential benefits of setting targets include: 
 The collection of high quality data allowing meaningful feedback 
 Setting a benchmark to aim for and encouraging improvement 
 The identification of underperformance, allowing remedial measures 
 The increased communication and engagement of service providers regarding key 
objectives 
 Improving patient safety 
 Improving public confidence in healthcare services 
Potential drawbacks of targets include: 
 Undermining confidence in underperforming centres 
 Avoidance by centres in managing high risk cases to improve figures 
 Possibility of overlooking the needs of stakeholders in order to meet targets (275) 
The possibility of centres avoiding management of higher risk cases has been a significant 
concern however this does not appear to have occurred in previous examples where 
performance measures have been introduced (276). 
A current example of the use of KPIs in the UK is in the monitoring for endoscopy standards 
within the NHS Bowel Cancer Screening Programme for both delivery of service and clinical 
outcomes (2).  
Within this context KPIs have allowed high quality recording of performance data providing 
the public, service users and healthcare providers reliable information about current and 
desired standards by allowing meaningful comparison between different centres in relation 
to stated objectives and targets (277). 
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The establishment of compulsory standards may raise standards with a focus and aspiration 
by centres to match or better defined minimum standards or those from other centres. The 
ability for service users to choose a treatment centre may also act as an incentive to raise 
standards (278). 
When defining KPIs it is considered essential to identify aspects of healthcare delivery that 
require measurement.  These are termed ‘domains of quality’.  Lester and Roland asserted 
that these domains should incorporate the following characteristics: 
Safety:  The minimisation of risk to service users 
Effective: The best achievable outcomes are sought 
Person Centred: A focus and respect for the needs of patients  
Equitable: Fair access to care based on need and addressing health inequalities 
Efficient: Best possible use of resources to provide care (279) 
KPIs may be subdivided as either generic (relevant to the majority of the population and not 
to a specific service user group, e.g. accident and emergency waiting times) or specific 
(relevant to a specific service user population, e.g. children’s accident and emergency 
waiting times).  KPIs may also be classified according to their function (e.g. screening, 
diagnostic, intervention and follow-up).  Many factors may be used when considering the 
finalisation of a KPI (see below). 
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              Figure 15. Factors associated with KPI development (267) 
 
A number of additional factors appear important when developing robust KPIs: 
4.2.1) Definitions and Data quality 
The quality and uniformity of data collected depends on clear definitions and checks to 
ensure accurate data collection.  If this is not the case then data will not be robust enough to 
set a benchmark for performance. 
4.2.2) Service user profile 
Variations in the profiles of patients such as sex, age and co-morbidity may affect outcomes 
and the design of KPIs must reflect this to ensure that these factors do not inadvertently 
affect outcomes. 
4.2.3) Data availability 
The creation of KPIs must reflect what is felt to be likely to contribute to service 
improvement and this may help to identify gaps in data availability.  KPI should not be solely 
148 
 
dependent on what data is available as may result in measures that do not result in 
improved standards. 
4.2.4) Local application of KPIs 
Variation in healthcare funding and provisions between different regions may affect the 
performance of certain centres negating the possibility of meaningful comparison and 
setting a benchmark.  This suggests the importance of set KPIs being relevant across all 
regions and not diverting resources away from frontline healthcare services.   Ensuring equal 
awareness of KPIs across various regions may also help to more uniform uptakes of new 
measures. 
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4.3) KPI development process 
A proposed structure for the development of KPIs is described below(280-282): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consultation with key stakeholders and advisory groups 
Choosing an area to measure 
Achieving balance in measurement 
Determine Selection Criteria 
Data Collection and Handling 
Defining Targets 
Implementation 
Results reporting to Stakeholders 
Pilot Testing 
Defining the audience and purpose of the KPI 
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4.3.1) Consultation with key stakeholders and advisory groups 
Consultation with all key stakeholders and advisory groups using a multidisciplinary group 
throughout the process may help to ensure that the needs of all parties (e.g. patients and 
health providers) are met whilst improving the likelihood that the chosen KPI is of sufficient 
quality.  Consultation also enables agreement to be made about particular elements of a KPI, 
familiarises all groups with data and standards and may improve public confidence in the 
standards developed (283). 
4.3.2) Defining the audience and purpose of a KPI 
It is important to determine what the KPI is intended to achieve prior to formulation and the 
audience for whom decision making will be influenced by the indicator. Selecting the 
appropriate domains will help to structure KPI formation and may be influenced by the target 
audience (283). 
4.3.3) Choosing an area to measure 
Patient safety is regarded as the most import domain whilst other important considerations 
include the importance of a particular problem, the likelihood that improvements can be made 
and the extent to which a variable is controllable by a healthcare provider and patient (283). 
4.3.4) Achieving a balance in measurement 
Kaplan and Norton proposed a ‘balanced scorecard’ which gives 4 factors a KPI should 
incorporate to ensure that it is comprehensive.  These include the patient perspective, the key 
business factors that have been identified as necessary to provide best management, the ability 
to measure an organisation’s ability to improve and the financial perspective to ensure 
management is as cost effective as possible (284). 
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Table 8. WHO criteria used to assess rigidity of KPIs (285) 
 
Validity  
 
Does the KPI measure what it is supposed to 
measure?  
Reliability/Reproducibility 
 
Does the KPI provide a consistent measure in the 
same population and settings irrespective of who 
performs the measurement? 
Explicit evidence base  
 
Is the KPI supported by scientific evidence or the 
consensus of experts?  Has the evidence used been 
scrutinised for rigidity using a system such as the 
GRADE tool. 
Acceptability  
 
Are the KPIs acceptable to both those being assessed 
and those undertaking measurement? 
Feasibility  
 
Has feasibility analysis taken place and is it possible 
to collect the required data and is it worth the 
resources? 
Sensitivity  
 
Is the KPI capable of detecting changes in quality of 
care and reflect these in the results? 
Specificity Does the KPI actually capture changes that occur in 
the service for which the measure is intended?  
Relevance  
 
What useful decisions can be made from the KPI?  
Balance 
 
Do we have a set of KPIs that measure different 
aspects of the service, providing a comprehensive 
picture of performance?  
Tested  
 
Have previous national and international KPIs been 
considered? There should be a preference for 
indicators that have been previously tested both 
nationally and internationally over developing new 
indicators for the same purpose.  
Safety 
 
Will an undue focus on the KPI lead to potential 
adverse effects on other aspects of quality and 
safety?  
Avoidance of duplication 
 
Has consideration been given to other projects or 
initiatives to avoid duplicating work? 
Timeliness Is the information available within an acceptable 
period of time to inform decision-makers? 
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Another proposed framework is the ‘3 Es’ model citing economy (using the appropriate 
quantity and quality of resources at the lowest cost), efficiency (providing quality healthcare 
with minimum cost) and effectiveness (the degree to which an organisation attains stated 
goals) as domains (267). 
4.3.5) Determine selection criteria 
KPIs formulated either by a review of evidence or expert consensus may be tested for 
rigidity using criteria developed by the World Health Organisation (see table 8): 
4.3.6) Data Collection and Handling 
Identifying data sources is a key consideration.  It needs to be established whether newly 
created KPIs can be assessed using available data or whether additions or modifications to 
data collection need to be made.  This is part of developing a minimum dataset (the 
minimum information required to adequately measure and use a KPI).  There are also 
important issues regarding data collection and storage with the use of information 
governance required to ensure the legal and ethical handling and use of data whilst 
measures must be in place for data quality checks to verify compliance and the accuracy of 
the data (267). 
4.3.7) Defining Targets  
Defining quantitative minimum standards and targets may be determined either via a review 
of the evidence base or via expert consensus.   Other considerations include the threshold 
for undertaking remedial action when standards are not met in addition to the sanctions for 
substandard performance (267). 
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4.3.8) Results Reporting to stakeholders and pilot testing KPIs 
‘Pilot testing’ KPIs appears important before widespread implementation to ensure that 
there are no validity issues in relation to the KPI.  These include ascertaining whether there 
are any data validity and collection issues, whether the KPI contributes to improved care and 
whether modifications need to be made. 
4.3.9) Implementation 
Once the previous considerations have been satisfied, the KPI may be considered for 
widespread implementation (267). 
 
4.4) Why are LNPCPs suitable for KPIs? 
In the absence of a framework for the management of LNPCPs there have been no clear 
indicators with regards to the management of these lesions both nationally and 
internationally.  Moreover, with evidence that quality outcomes appear to vary markedly 
even between experienced endoscopists with larger polyps, a potential for serious harm to 
patients in the event of suboptimal management, and a large proportion of endoscopists 
lacking formal training in LNPCP management, it appears justified to hold the view that 
general standards are suboptimal and that this may compromise patient safety. 
4.4.1) Is the problem important? 
Yes, colorectal cancer is the second most common cause of cancer death in the UK with 90% 
of cases due to adenomatous polyps, especially LNPCPs.  There is as yet no framework for 
their management, an issue highlighted by many endoscopists as a cause for concern in a 
recent large UK survey (4). 
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4.4.2) Are there public safety concerns? 
Yes, complications related to advanced endoscopy techniques involve death, bowel 
perforation and haemorrhage, the latter two occurring in approximately 1% and >3% 
respectively and commonly requiring surgical intervention (5, 9).  There is strong evidence to 
suggest that certain lesions are associated with an increased complication rate.  Surgical 
management is associated with 20% morbidity and 1% mortality (11). 
4.4.3) Is there evidence to suggest practice is suboptimal? 
Yes, the CARE study showed marked variation in outcomes between different endoscopists 
whilst figures from the BCSP suggested incorrect management (e.g. piecemeal resection of 
malignant lesions) occurred at higher levels than previously thought (17, 20). 
4.4.4) Is there evidence to suggest practice can be improved? 
Yes, there is evidence to suggest that careful assessment and stratification of LNPCPs with 
management in the appropriate setting has led to superior outcomes with fewer 
complications and patients undergoing minimally invasive procedures (5). There is also 
evidence that the use of training modules (NBI and NICE NBI) have led to improved lesion 
recognition, a key component of LNPCP management, even by inexperienced practitioners 
(128). 
4.4.5) Can management become more cost effective? 
Yes, there is both national and international data showing large cost savings in terms of 
procedure costs and length of hospital stay in the appropriate management setting (e.g. 
there is estimated to be a cost saving of approximately $6000 with endoscopic resection 
compared to surgical removal) (10, 56). 
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Consideration of these factors suggest that the management of LNPCPs in an area where the 
development of KPIs is warranted. Access to high quality data with regards to performance 
will allow accurate benchmarking, encourage improvement and indicate where 
improvements need to be made, in a reliable consistent manner across all participating 
centres. 
 
4.5) Methodology 
 
A modified Delphi Technique was the mode of consensus methodology used.  A guideline 
development group with a writing subcommittee created, as described in chapter 2, 
suggested various search terms for a comprehensive literature review as below.   The term 
‘colonic polypectomy’ was entered into the PubMed MeSH database. 5989 articles were 
returned. The terms ‘therapy’  , ‘analysis’, ‘complications’ and ‘prevention and control’ were 
used to filter the results based on relevance following which, 2716 articles were returned 
and scrutinised for relevant articles.  Additional PubMed searches were performed using 
additional search terms agreed by the writing sub-committee.  The search terms used were:  
‘colorectal laterally spreading type polyps’, ‘endoscopic mucosal resection’, ‘complex 
colonic polyps’, ‘difficult colonic polyps’, ‘complications related to endoscopic 
polypectomy’, ‘endoscopic polypectomy’, ‘recurrence post endoscopic polypectomy’ 
,‘anticoagulation in endoscopic polypectomy’, endoscopic mucosal resection’, ‘malignant 
colonic polyps’, ‘piecemeal endoscopic mucosal resection’, ‘colorectal endoscopic 
submucosal dissection’, ‘key performance indicators in healthcare’ ‘key performance 
indicators in endoscopy’ and ‘healthcare improvement measures’ 
Returned abstracts and articles were reviewed for relevance with additional references 
obtained from cross-referencing of references and recommendations from the GDG.  
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Relevant quality assurance publications were searched for from groups such as the British 
Society of Gastroenterology (BSG), the American Society of Gastrointestinal Endoscopy 
(ASGE), The NHS Bowel Cancer Screening Programme (NHS BCSP) and the European Society 
of Gastrointestinal Endoscopy (ESGE). 
Following a review of returned international literature, including the types of outcomes 
reported, a suitable structure was devised for the development of KPIs with regards to the 
development of domains and parameters suitable within these domains.  Outcomes both 
optimal and adverse, and factors linked to improved/adverse outcomes were felt to be key 
in the identification of both potential domains and KPIs and reference points for review by 
the wider GDG were identified based on this. The agreed reference points were to focus on 
patient safety, quality of management, avoiding unnecessary delay in management, quality 
of decision-making processes and the ensuring of regular practice to maintain competency. 
A preliminary round was conducted where these reference points were sent to the GDG who 
were asked to vote anonymously to record their level of agreement with their use to guide 
the development of domains and supporting parameters.  At all points throughout this 
process, consensus was defined as GDG agreement > 80%. 
Following receipt and review of all responses, provisional domains and KPIs with supporting 
literature and rationale, both evidence based and reflecting GDG comments, were created 
and included in a formal voting document for consideration by the GDG.  A summary of 
domains, KPIS and supporting rationale is displayed below.  The full feedback was 
disseminated among group in an anonymised form prior to the formal voting round.  The 
GDG were subsequently sent the formal voting document via email and were asked to vote, 
recording their level of agreement with the proposed KPIs using the process described in 
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chapter 3. A deadline of two weeks was given to GDG members to return their voting 
documents.   
A second voting round was conducted for KPIs where consensus had not yet been reached at 
a scheduled group meeting in March 2014 where there was also an agenda to finalise the 
wording and vote on the identification and formulation of quantitative standards of agreed 
KPIs. 
Prior to the group meeting, a full anonymised summary of voting and comments from the 
first formal voting round was sent to all GDG members for consideration prior to the second 
round of voting where they would be asked to consider their initial responses. 
In addition, the GDG conducted a detailed review of outcomes relevant to the identified KPIs 
from available international large volume series reporting outcomes in the management of 
LNPCPs.  These outcomes were identified with the intention of their use as a reference for 
formulating quantitative standards for finalised KPIs. 
 
The group meeting took place at the BSG headquarters with Professor Rutter as chairperson 
and all voting taking place using anonymous keypad voting. 
On finalisation of the KPIs, voting then took place for the formulation of quantitative 
minimum and desired standards where appropriate.   
 
Discussion took place individually for each KPI, and where available, relevant identified 
outcomes from international case series (e.g. post-procedure bleeding rate of 5%) were 
reported to the GDG for consideration in identifying a quantitative figure.  Newly created 
standards were to be created reflecting the fact that reference data used was from expert 
centres.   Participants were able to set a standard of an ‘auditable outcome’ as opposed to 
an exact figure, where it was felt that there was insufficient evidence to identify a specific 
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standard.  All voting on proposed standards took place using anonymous electronic voting.  
In cases where consensus had not been reached, further discussions took place prior to  
repeat voting until consensus was reached. 
 
Following the finalisation of KPIs with minimum standards, a draft summary document was 
created outlining the domains, KPIs, standards, supporting evidence and action plans in the 
event of underperformance.  The 2011 NHS BCSP Endoscopy Quality Assurance Standards 
document was referenced when structuring the document as quality standards in BCSP 
endoscopy are well established nationally. 
 
The document was then circulated to the GDG for final comments before being sent to the 
BSG endoscopy committee and ACPBI for consultation prior to international consultation 
and submission to ‘Gut’ journal. 
 
 
 
4.6) Results 
 
               Table 9. Summary of agreed domains and KPIs for LNPCP Management        
 
 
Domain Proposed KPIs 
1. Optimal decision-
making 
 Surgery rate for LNPCPs 
2. Endoscopic skill  Recurrence/residual polyp at 12 months in endoscopically 
managed LNPCPs 
3. Safety  Perforation rate 
 Post-procedure bleeding rate 
4. Timeliness  Time from diagnosis to referral for definitive therapy 
 Time from referral to definitive therapy   
5. Volume of 
procedures 
 Number of procedure per endoscopist per year 
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4.6A) Voting Summary  
 
4.6.1) Optimal decision making 
Objective Assessment of the appropriateness of decision-making in the 
management of LNPCPs 
KPI Surgery rate for LNPCPs  
Denominator Inclusion of all patients with NPCPs, including lesions that prove to 
be cancers 
Exclusion of patients with LNPCPs undergoing primary surgery for 
cancer (where no endoscopic resection has been attempted). Do 
not exclude patients with cancers that undergo endoscopic 
therapy. 
Numerator Patients with LNPCPs undergoing surgery for that lesion 
Frequency Annual 
Level of Analysis Service level 
Minimum standard No current standard defined 
Aspirational 
standard 
No current standard defined 
Action Qualitative review of each case 
Evidence Swan et al. Gastrointest Endosc 2009, 70: 1128-1136   (10) 
Longcroft-Wheaton et al.  Dis Colon Rectum 2013, 56: 960-966   
(56) 
Bertelson et al.  Dis Colon Rectum 2012, 55: 1111-1116   (11) 
Lee et al. Br J Surg 2013. 100: 1633-1639    (17) 
Moss et al.  Gastroenterology 2011. 140: 1909-1918   (5) 
Buchner et al.  Gastrointest Endosc 2012, 76 : 255-63   (9) 
Consensus Summary Level of Agreement for KPI: 91.7%  
Level of Agreement for Standard: 92% 
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4.6.2) Endoscopic skill 
Objective Assessment of endotherapy success 
KPI Recurrence/residual polyp at 12 months in endoscopically 
managed LNPCPs 
Denominator Include all patients with recurrence/residual polyp at 12 month 
surveillance following resection of LNPCPs.  
Numerator Patients undergoing 12-15 month surveillance with endoscopic 
or histological evidence of polyp recurrence at the site of 
resected LNPCP 
Frequency Calculate annually 
Level of Analysis Individual colonoscopist  and service level  
Minimum 
standard 
<10% 
Aspirational 
standard 
<5%   
Action Qualitative review of each case 
Evidence Supporting Evidence: 
Belberbos et al. Endoscopy 2014, 46: 388-400 (146) 
Moss et al. Gastroenterology 2011, 140: 1909-1918 (5) 
Barendse et al. Colorectal Dis 2012, 11: e191-196 (77) 
Khashab et al. Gastrointest Endosc 2009, 70: 344-349 (199) 
Knabe et al. Am J Gastroenterol 2014, 109: 183-189 (200) 
 
Supporting Evidence for Quality Standard: 
Lee et al. Br J Surg 2013, 100: 1633-1639  (6%) (17) 
Longcroft Wheaton et al. Dis Colon Rectum 2013, 56: 960-6 
(3.9%)(56) 
Level of 
Consensus 
Level of Agreement for KPI: 100%  
Level of Agreement for Standard: 100% 
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4.6.3) Safety 
Objective To maximise the safety of endoscopic therapy 
KPI 1) Endotherapy perforation rate 
2) Post-polypectomy bleeding rate  
Definitions Perforation defined as: ‘air, bowel contents or instrumentation 
outside the bowel lumen’ (2, 286)  
Post Procedure Bleeding defined as: 
Rectal bleeding within 30 days of procedure resulting in any of 
the following: 
 Minor  
- Procedure aborted 
- Unplanned post procedure medical consultation 
        - Unplanned hospital admission, or prolongation of   
           hospital stay, for ≤ 3 nights 
 Intermediate 
- Haemoglobin drop of ≥ 2g 
- Transfusion 
- Unplanned admission or prolongation for 4–10  
  nights 
- ITU admission for 1 night 
- Interventional procedure (endoscopic or  
  radiological) 
 Major  
-Surgery 
- Unplanned admission or prolongation for > 10   
  nights 
-ITU admission > 1 night 
 Fatal 
-Death (2) 
Denominator Include all patients with LNPCPs undergoing endotherapy 
Numerator Patients with LNPCPs undergoing endotherapy who present with 
a perforation (definite or probable) within 30 days of 
endotherapy 
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Frequency Calculated at least annually. 
Level of Analysis Service and Individual colonoscopist level 
Minimum 
standard 
EMR:  
Perforation: <2%     PPB: <5% 
ESD:  
Perforation & PPB: No current standard defined 
Aspirational 
standard 
EMR:  
Perforation: <0.5%   PPB: No current standard defined 
ESD:  
Perforation & PPB: No current standard defined 
Action Qualitative review of each case 
Evidence Supporting Evidence- Perforation: 
Rutter et al. Endoscopy 2014, 46: 90-97 (101) 
Rabeneck et al. Gastroenterology 2008, 135: 1899–1906 (66) 
Nivatongs. Dis Colon Rectum 1986, 29: 825-830  (287) 
NHS BCSP Publication 2011 (2) 
Lee et al. Br J Surg 2013. 100: 1633-1639 (0.5%) (17) 
Moss et al. Gastroenterology 2011, 140: 1909-1918 (1.3%)  (5) 
Buchner et al. Gastrointest Endosc 2012, 76 : 255-63 (0.4%)  (9) 
Longcroft-Wheaton et al. Dis Colon Rectum 2013, 56: 960-966 
(0.45%) (56) 
 
Supporting Evidence- Post-Procedure Bleeding: 
Metz et al. Endoscopy 2009, 43: 506-511 (98) 
Sawhney et al. Endoscopy 2008, 40: 115-119 (112) 
NHS BCSP Publication 2011 (2) 
Level of Consensus Endotherapy Perforation Rate 
Level of Agreement for KPI: 100% 
Level of Agreement for standard: 92%  
Post-polypectomy bleeding rate  
Level of Agreement for KPI: 92.3% 
Level of Agreement for standard: 85% 
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4.6.4) Timeliness 
 
Objective Provide a timely service and minimise delay in cancer diagnosis and 
treatment 
KPI 1) Time from detection to referral for therapy 
2) Time from referral to definitive therapy  
Denominat
or 
Inclusions: 
Include all patients with LNPCPs 
Exclusions: 
Exclude LNPCPs removed at the time of detection 
Frequency Calculate annually 
Level of 
Analysis 
Service Level 
Minimum 
standard 
Time from diagnosis to referral: <4 weeks (28 days) - No current 
standard defined for proportion meeting this standard 
Time from referral to definitive management: <8 weeks (56 days) - No 
current standard defined for proportion meeting this standard 
Aspirational 
standard 
No current standard defined 
Action Review cases where time from diagnosis to referral is >4 weeks (28 
days) 
Review cases where time from diagnosis to referral is >8 weeks (56 
days) 
Evidence Muto et al. Cancer 1975, 36: 2251-2270(32) 
http://www.scotland.gov.uk/About/Performance/scotPerforms/partner
stories/NHSScotlandperformance/Cancerwaitingtimes(69) 
Level of 
Consensus 
Level of Agreement for KPI: 100%  
Level of Agreement for standards: 84%  
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4.6.5) Volume of Procedures 
Objective Safeguard to ensure that endoscopists undertake a sufficient 
number of procedures a year to maintain acceptable standards 
KPI Number of NPCPs of 20mm or greater in size removed per 
endoscopist per year 
Inclusions All NPCPs of 20mm or greater in size removed per endoscopist 
per year 
Frequency Annual analysis 
Level of Analysis Individual Endoscopist and service level 
Minimum 
standard 
No current standard defined 
Aspirational 
standard 
No current standard defined  
Action Review in conjunction with other KPIs. Consider focusing NPCP 
therapy on fewer clinicians to maintain and improve skills. 
Evidence Rabeneck et al. Gastroenterology 2008, 135: 1899–1906 (66) 
Singh et al. Gastrointest Endosc 2009, 69: 665-671 (64) 
Chukmaitov et al. Gastrointest Endosc 2013, 77: 436-446 (65) 
NHS BCSP Publication 2011  (2) 
Level of Consensus  Level of Agreement for KPI: 92.3%  
Level of Agreement for standard: 92%  
 
 
4.7) Discussion 
The purpose of defining KPIs and minimum standards was driven by a desire to deliver 
quality assurance (QA) and cost effective management in a field associated with complex 
therapy and potentially serious complications.  It appears logical that well defined standards 
would also help to improve public confidence in the clinicians undertaking LNPCP 
management.  During initial regional consultation, there were reservations about the 
evidence base available to identify suitable domains and KPIs in addition to potential 
minimum standards that may be specified.  However an important precedent highlighting 
the potential benefit of endoscopic KPIs are the NHS BCSP KPIs that have been credited with 
improving colonoscopy and polypectomy standards within this programme.  There was also 
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a concern that the creation of KPIs may serve to limit those managing LNPCP to clinicians in 
expert centres, and so excluding many current clinicians, and that the minimum standards 
set may be unrealistic.  It was important to be clear that this was not the intention and 
ensure that standards set were realistic based on available supporting data.  The purpose of 
developing KPIs with defined minimum and aspirational standards, was to allow a 
standardised way of monitoring and auditing clinical quality outcomes.  It was anticipated 
that KPIs may result in improved clinical outcomes by providing a benchmark and allows 
support and remedial action to be taken when underperformance is identified.   The need 
for this was emphasised by poorer than expected LNPCP management outcomes such as 
recent BCSP data.  While it was accepted that it may take time for KPIs and standards to 
become finalised, it was agreed that when established, endoscopists suitable for LNPCP 
management would be identified as those meeting minimum KPI standards irrespective of 
the setting (e.g. district general hospital or tertiary centre) with KPIs and standards refined 
over time.  With much of the supporting data for the setting of minimum standards coming 
from expert centre case series it was recognised that recommended minimum KPI standards 
should be adjusted accordingly.  For example if a figure of <3% was recorded for a specific 
parameter a more relaxed figure such as <5% may be a more realistic target for the for the 
wider endoscopic community. 
Selection of the main domains as recommended by the WHO was agreed by the GDG 
subcommittee and subsequently the entire GDG who agreed that the priorities of the KPIs 
should relate to: 
 Effective management 
 Patient Safety 
 Optimal Decision Making 
 Avoiding unnecessary delays in management 
 Demonstration of regular practice allowing maintenance of standards and ensuring 
that recorded KPI data is meaningful.  
 
The domains selected (optimal decision-making, endoscopic skill, safety, timeliness, volume 
of procedures per endoscopist) were felt to fulfil these priorities.  It was agreed that 
finalised KPIs should relate to a few parameters felt to both feasible and of the greatest 
importance rather than recommending a large number of parameters that may lack clarity 
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and be considered too prescriptive.  A filtering process was conducted with several potential 
KPI parameters within each domain offered for review in the preliminary round to: 
 generate discussion  
 identify parameters in terms of appropriateness and rank in terms of importance, 
 allow for suggested additional KPIs and modifications  
 enable selection of the most pertinent KPIs per domain prior to formal voting. 
A concern within the GDG was how data from KPIs should be interpreted and acted upon in 
areas of obvious discrepancy.  It is intended that the use of KPIs may be considered as a 
monitoring system with outliers warranting further investigation/analysis.  For example, if an 
outcome is clearly explainable, such as a skilled endoscopist tackling more complex lesions 
having a higher recurrence/residual rate than a less skilled endoscopist tackling more simple 
lesions, then this would be recognised as acceptable.  If however, endoscopists tackling 
similarly complex lesions have widely differing outcomes with an endoscopist producing 
clearly inferior outcomes, the KPI may then call into question the appropriateness for that 
individual to be managing certain lesions.  This was clearly specified in the final KPI 
document. 
 
4.7.1) Optimal Decision Making 
Initial GDG views indicated that scenarios considered undesirable regarding decision-making 
in endoscopy included piecemeal endoscopic attempts on malignant lesions and benign 
lesions referred for surgery.  Proposed parameters were created relating to both individual 
endoscopists and endoscopy centres as a whole.  However whilst there was an argument 
that the ability to manage LNPCPs and these outcomes were directly related to an 
individual’s skill and ability rather than the centre they practiced at, it was agreed that 
relevant KPIs could capture data for both these scenarios.  Preliminary KPIs such as 
‘proportion of lesions managed with primary endotherapy’ and ‘proportion of lesions 
managed with primary surgery’ were not felt to offer any information regarding the 
endoscopist decision-making process during endoscopy and were discarded.  Whilst it was 
accepted that piecemeal endotherapy on malignant lesions and surgery on benign lesions 
should be limited wherever possible, this was considered a complex area as while reported 
numbers may be absolute, rationale may be unclear.  It was also understood that these 
scenarios may be unavoidable and vary based on local available expertise, patient 
preference and technical issues.  For example, it was felt important to emphasise that 
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surgical management has an important role and that KPIs should not coerce clinicians into 
attempting endotherapy on lesions that may be felt to be too large or dangerous to remove 
endoscopically despite being benign.   
The GDG considered that an appropriate KPI related to decision making should assess the 
ability to both correctly determine whether a identified lesion is endoscopically removable 
and identify a suitable clinician for a lesion amenable to endotherapy. The use of surgery as 
a secondary management modality was considered to be the result of incorrect or 
ineffective endoscopic management, such as the use of piecemeal endotherapy with a 
malignant lesion.  Whilst it was accepted that surgical management continues to have an 
important role in LNPCP management, it was felt it was only suitable as a primary 
therapeutic modality after careful consideration of all feasible management options.   The 
KPI ‘Surgery rate for LNPCPs, excluding primary surgery for malignant lesions’ was felt to 
most succinctly assess decision making. There was agreement that this parameter would 
identify cases considered to represent incorrect management, such as cases of LNPCPs 
undergoing surgery where endoscopic management was feasible and cases of piecemeal 
endotherapy on malignant lesions.  Whilst there was available data from multiple 
international series reporting relevant outcomes (e.g. piecemeal endoscopic attempts on 
malignant lesions and surgically managed benign lesions), the figures reported varied widely, 
compromising the ability to set specific standards.  In view of this the agreed KPI within this 
domain was agreed as an auditable outcome.   
4.7.2) Endoscopic Skill 
It was felt necessary to identify a KPI to assess levels of endoscopic success.  Assessing for 
recurrent/residual polyp (RRP) was felt to be the most appropriate way of achieving this.  
KPIs recording RRP at both 2-6 (early outcome) and 12 months (late outcome) were 
proposed to assess for completeness of initial resection and curative resection respectively.  
It was felt however that whilst assessing of early outcomes was not a priority performance 
indicator nor necessarily a marker of poor performance given an established acceptance of 
high RRP rates associated with piecemeal endotherapy and widespread evidence of 
successful lesion eradication with repeat endotherapy. The GDG considered the 
measurement of 12 month outcomes to be more appropriate, relating more directly to 
health outcomes and consistent with the standardised use of 12 month recurrence rates as 
an outcome of treatment success internationally.  In addition, 12 month surveillance is 
168 
 
commonly undertaken with lesions removed both en-bloc and piecemeal and so would 
allow all LNPCPs to be assessed in an equivalent manner.  With expert centre data reporting 
12 month recurrence levels between 2-6%, a minimum target of <10% was felt to be realistic 
with an aspiration standard similar to the reported data (<5%).   
A KPI assessing compliance with a tattooing protocol was suggested but discarded as this is 
already a well established generic polypectomy standard.  
 
4.7.3) Safety 
Parameters related to the most common or serious potential complications were felt to best 
indicate patient safety.  Perforation, post procedure bleeding (PPB) and mortality were 
proposed as fulfilling this requirement.  Although desirable to record, a robust PI assessing 
mortality rates was not considered feasible as it was agreed that this data was difficult to 
collect and establish whether deaths could be directly attributed to endotherapy, 
particularly in patients with greater comorbidity.  
Assessing perforation and PPB levels was considered both essential and feasible.  However, 
it was accepted that these complications may both have differing definitions and varying 
degrees of severity.  In line with other large organisations such as the ASGE and NHS BCSP, it 
was felt that KPIs with clear definitions and allowing delineation of severity levels were 
optimal.  As such, perforation, in accordance with the BCSP and ASGE, was defined as ‘air, 
bowel contents or instrumentation outside the bowel lumen’.  In addition, it was accepted in 
relation to complex endotherapy that a perforation repaired during endoscopy, without 
patient symptoms, and not requiring hospitalisation was not problematic and did not require 
recording.  PPB was classified as minor, intermediate, major and fatal as per ASGE and BCSP 
definitions to allow recording of PPB at all severity levels, whilst it was specified that peri-
procedural bleeding successfully managed during endoscopy could be excluded.  
The specification of standards for EMR was considered straightforward with a wide range of 
data, recording perforation and PPB levels according to agreed GDG levels as below 1% and 
3% respectively.  Minimum levels were agreed as <2% and <5% respectively to acknowledge 
the consideration of expert centre data.  An aspirational target of <0.5% for perforation was 
set as felt achievable given BCSP data reporting perforation at this level.   ESD practice in the 
UK and Western World was felt to be currently too limited to set minimum standards whilst 
separate NICE guidance covers this modality.  As such, the GDG agreed that both safety KPIs 
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for ESD (perforation and post procedure bleeding) should currently be considered as 
auditable outcomes. 
 
4.7.4) Timeliness 
Whilst ensuring that management was undertaken in a timely fashion without unnecessary 
delay was considered a priority, the identification of KPIs within this domain proved difficult 
with marked initial disagreement within the GDG and consensus only reached at the final 
voting round after lengthy group discussion.  Specifying a management timeframe drew 
strong opposition from some quarters with no evidence base to support a specific 
timeframe and a concern that it could be seen as a political rather than a clinical 
performance measure.  In addition, these was a concern that a timeframe may result in 
endoscopists not suitable to undertake management performing endotherapy to meet a 
target. 
 
There was a view that LNPCPs referred to a tertiary centre are subject to longer waiting 
times due to service demand and that a management timeframe KPI should refer to the time 
of receipt of referral rather than diagnosis as a delay in referral may account for a delay in 
management beyond the control of the receiving centre.  In view of this is was felt prudent 
to assess time periods between diagnosis and referral as an additional KPI where applicable.  
A period of 4 weeks was felt sufficient for a centre to obtain supporting information such as 
histology or radiology and allow local multidisciplinary discussion prior to external referral.   
A recommendation specifying the proportion of lesions with time from receipt of referral to 
initial therapy in accompanying guidelines was repeated in the form of a proposed KPI.  As 
with the guidelines a timeframe <8 weeks as opposed to <6 weeks had greater support as it 
was considered more achievable and appropriate, with greater time to ensure that a 
suitable endoscopist undertakes therapy and no data from polyp growth studies to suggest 
this as unsafe practice.  In addition, a timeframe of eight weeks appeared to be rational as it 
was in keeping with the NHS 62 day management target pathway.  Performance indicators 
related to waiting times for follow-up procedures was felt to be less of a priority. 
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4.7.5) Volume of Procedures 
The objective of this domain was to introduce a safeguard to ensure that endoscopists 
undertake a sufficient number of procedures per year to maintain acceptable standards.  
This was considered important to assess in light of evidence associating increased procedure 
volume and experience with improved outcomes.  In addition, there was a view that 
undertaking a minimum number of procedures per year to maintain acceptable standards 
would allow a meaningful measurement of other KPIs. The BCSP was cited as an example, 
with a minimum number of 150 colonoscopies per year mandated (2, 64-66).  There was a 
strong wish to specify a minimum annual procedure number, especially to discourage 
inexperienced endoscopists from undertaking management of these lesions, but it was 
acknowledged there was no clear evidence to suggest an appropriate annual figure.  In 
addition there was an acceptance that LNPCP incidence was dependant on the volume of 
colonoscopies and population catchment size, factors that may vary greatly between centres 
and with the annual incidence of LNPCPs unknown, and it was initially felt that an evidence 
based minimum number of procedures per year per endoscopist could not be proposed or 
estimated based on population data at present.   The issue of identifying a minimum annual 
LNPCP management number was revisited following ACPGBI feedback that supported a 
provisional number to discourage inexperienced endoscopists from sporadic practice.  Some 
members proposed setting a target in spite of a lack of evidence, feeling that it may guide 
centres both nationally and internationally to develop safe high output services. They cited 
recent BSG Barrett’s Oesophagus guidelines that specified a minimum number of upper GI 
EMR per annum for lesions known to have a lower incidence than LNPCPs.  As such, 
following additional voting using the secondary voting process was undertaken with the 
question ‘should we set a minimum number of procedures per annum?’ Had consensus 
been reached by at least the secondary process a separate vote specifying potential 
minimum numbers would have taken place with the majority figure agreed as a standard.  
However, this was not the case and the KPI ‘Number of procedures per endoscopist per 
year’ was reluctantly agreed as an auditable outcome and recommended to be related to 
outcomes to ascertain if volume affects the outcome without presuming that it does. It was 
also felt that this KPI may be refined over time to delineate between management of LNPCPs 
of varying sizes (e.g. 2-3cm vs >4cm). 
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4.8) External Consultation 
 
Feedback from both the ACPGBI and BSG external reviewers was largely positive, especially 
after the opportunity to receive clarification, with the KPIs felt to be conducive to both 
allowing the audit of performance and the development of a large evidence base in addition 
to improving standards. Aside from a recommendation regarding minimum procedure 
numbers, the ACPGBI were happy with all aspects of the KPIs recognising the potential for 
them to evolve over time following the collection of data.  These views were echoed by the 
BSG reviewers although they did raise a few issues over which they required clarification 
prior to formally approving the KPIs. 
 
There was a query over the validity of KPIs and the strength of the evidence base on which 
the KPIs are based.  There was a concern that the KPIs may not meet the requirements for 
NICE quality standards.  It was countered that an internationally recognised framework had 
been followed for the identification of key performance domains and appropriate indicators 
and that this was an area considered important given factors including patient safety and 
quality outcomes which would be important to monitor.   
 
In addition, the use of KPIs, which is well established within the BCSP, was cited as an 
important precedent and was widely felt to have improved standards as well as providing a 
means to measure performance and developing an evidence base.  It was acknowledged 
that the evidence for the setting of certain KPIs was limited and expert consensus opinion 
was used where it was felt to be important (a review of outcomes reported in the 
international literature was a key factor).   As was the case with the BCSP, it was argued that 
this use of qualitative methodology to identify KPIs would provide a means to identify key 
quantitative measures that can be monitored and targeted for improvement to provide 
enhanced patient care in addition to the development of a large evidence base.  Clearly with 
a limited evidence base, it was accepted that the rigidity of the KPIs may be questioned, but 
in view of our use of available evidence and expert opinion, it was felt to be a significant step 
forward to existing measures to improve patient outcomes that could be refined and 
enhanced over time. 
 
There was also a concern about the validity of identifying certain KPIs as auditable outcomes 
in addition to the standards specified. It was also suggested that the inclusion of an optimal 
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decision making KPI may reflect a lack of evidence to support endotherapy over surgery or 
vice-versa. The response explained that while provisional quantitative figures were agreed 
where possible, in reference to relevant comparable outcomes from key international 
literature, there were domains and KPIs where it was not currently possible to give a 
quantitative figure but there was a great importance to do so.  It is well recognised that 
targets in this scenario are defined as ‘auditable outcomes’ with standards potentially 
identified following detailed audit data (288).  The ‘Optimal decision making’ domain where 
the KPI standard was an auditable outcome is an important example requiring audit.  For 
example, the audit of surgical management to identify as suitable level appears to be of 
great importance as it may be the result of ineffective lesion evaluation (especially with 
increasing evidence that the most complex LNPCPs originally referred for surgery may be 
managed effectively endoscopically in the correct circumstances) with robust international 
analysis demonstrating reduced cost-effectiveness and higher associated morbidity than 
with endotherapy (10, 56, 59).   
 
Another criticism directed at the finalised KPIs was that there should be more support for 
users of the guidelines such as audit tools (e.g. an audit form rather than a statement of 
KPIs) in line with BSG guidance and good practice in other national guidelines.  
Whilst it was agreed that an audit form may be of use, an explanation was accepted that 
audit forms may vary locally according to local trust policy and in this context it was 
appropriate not to be too prescriptive. 
 
The feedback from consultation groups indicated that the KPI development process was 
indeed worthwhile as had been hoped for and were likely to result in improved LNPCP 
management.  The development of KPIs allows a new opportunity to benchmark LNPCP 
management performance at an individual endoscopist and service level and the targeting of 
improved standards.  This view is supported by their approval by both the BSG and ACPGBI 
and acceptance for publication in ‘Gut’’ journal. 
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Chapter 5: Retrospective Analysis of BCSP 2011-12                              
Large Non-Pedunculated Colorectal Polyp Outcomes 
 
5.1) Introduction  
Evidence from national BCSP data suggests variation in the management of large non-
pedunculated colorectal polyps (LNPCPs) whilst undesirable outcomes such as piecemeal 
endoscopic resection of malignant lesions and primary surgical resection of benign lesions 
appeared to occur more frequently than previously thought. In addition international 
evidence demonstrated a wide variation in the quality of endoscopists based on outcome 
data.  The endoscopists performing endotherapy on LNPCPs within the BCSP are highly 
experienced endoscopists and it could therefore be suggested that the practice of 
endoscopists performing complex endotherapy outside the BCSP may vary further.  When 
considering the reasons for variable outcomes between both endoscopists and centres, it 
appears likely that variation in practice is a strong determining factor and analysis of 
management and outcomes over a longer time period may help to determine whether this is 
the case, especially when analysing the performance of endoscopists who have been 
through the same rigid certification process such as BCSP accreditation.  The BCSP mandates 
uniform comprehensive data recording both regionally and nationally.  A BCSP central 
database exists that has details of all aspects of a patient’s investigations, diagnosis and 
management related to their screening for bowel carcinoma.  For example, all colonoscopies 
performed are recorded in great detail, including therapies performed such as polypectomy, 
diagnoses, comfort levels, complications and sedation dosage.  It is national BCSP practice 
for these details to be uploaded onto the database around the time of procedure. There is a 
dedicated person with the sole responsibility of doing this to ensure accurate and robust 
data recording. In addition, details of any histological diagnoses, complex discussions (such 
as MDM outcomes) and other therapies such as surgical management are also uploaded.  
The database can be used to filter data entries where relevant and therefore allows access 
to a wealth of high quality information for performance analysis and outcomes. BCSP 
patients are asked to give consent prior to procedures for details to be securely stored and 
are aware that data will be used for service evaluation and development.  
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5.1.1) Null Hypothesis 
Variation in the management of LNPCPs will not result in variable outcomes  
 
5.2) Methodology 
Prior to the commencement of the study, the North East England NHS Research Ethics 
Committee were approached with regards to obtaining a waiver for ethics committee 
approval due to the lack of patient interaction involved in the data collection and analysis 
required.  This was duly granted with the work considered to be NHS service evaluation and 
development.   
LNPCPs initially diagnosed within the Bowel Cancer Screening Programme (BCSP) between 
2011-12 were the subject of the study.  This time period was considered suitable to ensure 
the collection of a sufficient sample size within the available study time period that had both 
long term outcomes (e.g. up to 15 months post management) and was recent enough to be 
considered relevant to current practice.  The collection and analysis of LNPCP data over 2 
years was intended to assess management at each screening centre over an extended 
period of time to look for trends in management as opposed to snapshot analysis.  
Permission was obtained from Professor Rutter in his capacity as Quality Assurance 
chairperson to approach the NHS BCSP Central Office for access to information concerning 
all polyps identified within the North East of England programme between 2011-12 that 
were >2cm and diagnosed as benign prior to management.  A Microsoft Excel Datasheet 
detailing this information was subsequently provided for further analysis.  In addition to 
specific patient information, the datasheet provided specific information regarding polyp 
detection dates, morphology, size and initial endoscopic and histological diagnoses  
The datasheet was then scrutinised to identify and exclude any lesions that were diagnosed 
as pedunculated or malignant prior to therapy (endoscopic and/or histologically diagnosed) 
and under 20mm in size.  Lesions identified outside of the 2011-12 time period were also 
excluded.  The updated datasheet was then filtered according to each of the four screening 
centres and a nominated Specialist Screening Practitioner (SSP) at each centre was then 
asked to analyse and provide greater detail about each of the relevant cases diagnosed at 
their centre using available facilities such as the BCSP central database and local endoscopy 
and histopathology databases. The SSPs were asked to corroborate the recorded lesion and 
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procedure details, in addition to recording short and long term management outcomes for 
each case into relevant sections on the datasheet. Information pertaining to procedure 
practice was sought, in addition to outcomes commonly reported in large international 
LNPCP case series. Information sought in addition the relevant rationale is detailed below in 
table 10. 
 
Information Sought Rationale 
Use of piecemeal endoscopic resection Commonest LNPCP management modality. 
Identify outcomes from piecemeal resection in 
relation to international case series to compare 
LNPCP management performance (e.g. curative 
resection, use of modality on malignant 
lesions)(5) 
Use of argon plasma coagulation post 
endoscopic resection 
Area of conflicting opinion, information 
regarding its use available in series as recorded 
for each individual endoscopic procedure(5, 
184) 
Early/3 month residual/recurrent polyp Assess completeness of resection(5, 9) 
Late/12 month residual/recurrent polyp Assess curative resection rate(5, 9, 17) 
Endotherapy undertaken within 8 weeks of 
referral 
Assess timeliness of management 
Discovery of malignancy Retrospectively analyse management decisions 
taken in view of finding of malignancy(17) 
Management modality used (endoscopic vs 
surgical vs conservative management) 
Correlate management approach to outcomes 
(e.g. curative resection, finding of malignancy) 
to ascertain whether appropriate management 
approach undertaken(5, 17) 
Use of secondary surgical management Assess need to correct incomplete 
management(17) 
Adverse events Assess safety of management(5, 9, 17) 
Other notable information Provide extra information relating to decision 
making process undertaken with regards to 
management 
  Table 10.  Information sought from individual LNPCP case analysis and rationale 
 
Once completed, updated datasheets were subsequently returned.  A separate repeat 
analysis of all cases was then undertaken independently. This process of regional data 
collection began with the attainment of approval and permissions to analyse LNPCPs from 
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each screening centre clinical director.  This was achieved using face to face meetings and 
confirmed in writing via email.  A BCSP endoscopist/SSP was nominated as a sponsor at each 
site to facilitate access to patient identifiable data.  
All relevant audit departments were contacted with requests to audit local BCSP and 
supporting data with sponsors included in all communications. Local audit and Caldicott 
approval forms, in addition to computer services access forms, were completed prior to 
appropriate permissions being granted. 
5.2.1) Relevant information retrieved from BCSP database and corroborated with local 
databases 
The BCSP central database was used to obtain relevant information and outcomes for each 
case.  Further information was obtained where further clarification was required by cross-
referencing cases using endoscopy reporting databases and histopathology programmes 
locally at each site.  This process was also used to provide information for cases where 
details were not available or limited on the BCSP database (e.g. subsequent follow-up 
outside the BCSP). 
Details regarding complications were provided on request by the BCSP central office in a 
separate Microsoft Word document. All 2011-12 BCSP North East complications were 
reviewed and filtered to those related to polypectomy.  Complications relating to the study 
sample were subsequently identified by matching patient details such as NHS number, date 
of birth and procedure dates. 
All information, including patient identifiable information was entered into a Microsoft Excel 
spreadsheet and transferred as required securely using NHSmail (the only approved secure 
connection for transfer of patient identifiable details).  The database was stored on a secure, 
password protected computer in a locked office in the endoscopy department at the 
University Hospital of North Tees. 
The process of double data entry was used to ensure data accuracy.  Datasheets with 
completed patient entries for each centre were sent to the relevant SSPs originally 
responsible for data entry who were asked to review the entries and compare with their 
own datasheet.  They were then asked to report any discrepancies identified (e.g. duplicated 
cases).  The datasheet was considered suitable for detailed statistical analysis following 
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amendment of identified discrepancies. Multiple variables were assessed for statistical 
association with outcomes identified in the international literature on an individual and 
combined basis (e.g. lesion size + location in relation to malignancy) where appropriate (see 
table 11 below for full list of variables and outcomes assessed) 
 
 Variable Outcome(s) assessed for 
association 
Rationale 
Lesion size 
 
-Recurrence (3 and 12 month) 
-Malignancy 
-Need for surgery (Primary +    
  Secondary) 
Previous data and international 
consensus that increased polyp 
size is associated with increased 
malignancy risk, the need for 
surgery, complications and 
difficulty in achieving curative 
resection(17, 32) 
Lesion Location 
 
-Recurrence (3 and 12 month) 
-Malignancy 
Identified risk factor for increased 
endoscopic difficulty and 
increased likelihood of need for 
surgical resection(6, 17) 
 Lesion morphology 
 (flat vs sessile) 
-Recurrence  
-Malignancy 
Association of polyp morphology 
with increased endoscopic 
difficulty and malignancy(6, 15) 
Endoscopist Procedure 
Volume (Average number 
of LNPCPs endoscopically 
managed per annum) 
-Recurrence  
-Need for surgery (Secondary) 
Evidence that increased 
therapeutic volume is associated 
with improved outcomes(64, 65) 
Screening Centre 
 
-Recurrence 
-Malignancy 
-Need for surgery (Primary +  
 Secondary) 
-Use of piecemeal  
 endotherapy with    
 malignant lesions 
-Endotherapy within 8 weeks  
  of referral 
-Adverse Events 
Compare performance between 
regional centres over a range of 
important outcomes 
Use of Argon Plasma 
Coagulation (APC) 
-Recurrence at first endoscopic 
follow-up 
Important research question, 
previous conflicting evidence in 
this area(5, 184) 
 Table 11. List of variables and outcomes 
 
Detailed statistical analysis was conducted with support from Durham University, using the 
IBM SPSS 20 statistics programme.  The Fisher’s exact test was used for univariate analysis 
with multivariable analysis undertaken using logarithmic regression to further assess for 
strength of association between variables and outcomes, and for potential interaction 
between variables due the binary nature of the outcomes (e.g. yes vs no).  A finalised, 
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completed Microsoft Excel sheet, confirmed by double data entry, was exported into the 
SPSS programme.  Recently developed key performance indicators (KPIs) (see chapter 4) 
were then retrospectively applied to the results for further comparison between centres. 
Provisional results were presented and discussed at a regional BCSP meeting in March 2015 
to ascertain potential explanations for outcomes and variation in outcomes between the 
centres. 
 
 
 
5.3) Results 
 
5.3.1) Summary of Results 
A summary of the lesions identified and results from subsequent follow-up performed is 
shown below (see figure 16) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. A summary of results and follow-up of cases 
 
3 cases/patients 
declined therapy 
and follow-up 
50 lesions 
underwent 
primary surgery 
264 lesions 
(248 patients) 
Mean size: 
31.2mm 
12 month surveillance 
in 135 lesions 
(8% recurrent/residual  
polyp) 
          
Endotherapy 
performed on 
211 lesions 
3 month surveillance in 
150 lesions 
(24% recurrent/residual 
polyp) 
2 lesions not f/up after 3 
months due to death, 9 
other lesions not f/up after 3 
month surveillance 
7 piecemeal endotherapy 
cases did not undergo 
surveillance until 12 
months 
Surgery undertaken on 39 
lesions after initial endotherapy 
(not offered in 1 case where 
cancer found) 
1 patient with 2 
lesions did not 
undergo f/up due to 
death, 8 other 
lesions lost to f/up 
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5.4) Whole Group Analysis  
 
 Malignancy was identified in 28% of all cases in the sample 
 
5.4.1)  Polyp Size 
Rationale:  
 Prevalence of data indicating that increased polyp size is associated with an 
increased risk of malignancy, the need for surgery, complications and difficulty in 
achieving curative resection(17, 32) 
 National BCSP data indicating that increased polyp size is associated with increased 
likelihood of surgery(17) 
 International consensus that increased  lesion size is associated with increased 
difficulty in achieving successful endoscopic resection(6, 56) 
 
Finding of colorectal malignancy in relation to Polyp Size  
 
 Malignancy (%) Total (n) 
n y 
Polyp size 
(mm) 
20-29 79 21 124 
30-39 72 28 75 
40+ 60 40 65 
Total 72.3% 27.7% 264 
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Polyp size was significantly associated with a higher rate of malignancy (p=0.023) 
 
Lesion Recurrence in relation to polyp size 
 
 
3 month Recurrent/Residual Polyp (RRP) 
 
 
 3 month recurrence 
(%) 
Total (n) 
n y 
Polyp Size 
(mm) 
20-29 81.1 18.9 74 
30-39 73.3 26.7 45 
40+ 67.7 32.3 31 
Total 76% 24% 150 
 
 
 
 
12 month RRP 
 
 12 month recurrence 
(%) 
Total (n) 
n y 
Polyp size 
(mm) 
20-29 93.1 6.9 72 
30-39 94.6 5.4 37 
40+ 84.6 15.4 26 
Total 91.9% 8.1% 135 
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Polyp size was not significantly associated with lesion recurrence after either 3 (p=0.316) or 
12 months (p=0.306)) 
 
Polyp Size in Relation to Need for Surgery 
 
 
 
 
Need for surgery (%) Total (n) 
n y 
Polyp Size 
(mm) 
20-29 75.8 24.2 124 
30-39 64 36 75 
40+ 50.8 49.2 65 
Total  33.7 264 
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The association between polyp size and use of surgery was strongly significant (p=0.002) 
 
5.4.2)  Polyp Morphology 
Rationale:  
 Prevalence of data suggesting that certain morphological classifications are 
associated with an increased malignancy risk(15) 
 Accepted classification of flat morphology being associated with increased difficulty 
in achieving endoscopic resection(6) 
 
 Polyp Morphology and identification of malignancy 
 
 Malignancy (%) Total (n) 
n y 
Polyp class 
Flat polyp 80 20 45 
Sessile polyp 70.8 29.2 219 
Total 72.3 27.7 264 
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Polyp class was not associated malignancy risk (p=0.140) 
 
 
 
Polyp Class in Relation to Recurrence 
 
3 month RRP 
 3 month recurrence 
(%) 
Total (n) 
n y 
Polyp class 
Flat polyp 83.3 16.7 30 
Sessile polyp 74.2 25.8 120 
Total 76 24 150 
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12 Month RRP 
 12 month recurrence 
(%) 
Total (n) 
n y 
Polyp class 
Flat polyp 96 4 25 
Sessile polyp 90.9 9.1 110 
Total 91.9 8.1 135 
 
 
 
Polyp class was not associated with RRP after either 3 (early stage) (p= 0.211) or 12 months 
(late stage) (p=0.357) 
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5.4.3) Lesion Location  
Rationale:  
 Proximal lesion location has been identified as a risk factor for increased difficulty 
with endoscopic removal and increased likelihood of need for surgical resection (6, 
17). 
Lesion Location and Recurrence 
 
 12 month recurrence 
(%) 
Total (n) 
n y 
Polyp Location 
Left 97.4 2.6 76 
Right 
(excluding 
caecum) 
90.2 9.8 41 
Caecum 72.2 27.8 18 
Total 91.9% 8.1% 135 
 
  
Lesion location was strongly associated with the likelihood of 12 month recurrence 
(p=0.003) 
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 Caecal Location and Recurrence 
 12 month recurrence (%) Total (n) 
no yes 
Caecal 
location? 
no 94.9 5.1 117 
yes 72.2 27.8 18 
Total 91.9% 8.1% 135 
 
 
  
 
Caecal location was strongly associated with lesion recurrence (p=0.007) 
 
5.4.4) Argon Plasma Coagulation Use 
Rationale:  Important research question, previous conflicting evidence in this area (5, 12, 
180) 
Argon Plasma Coagulation in Relation to Early Lesion Recurrence  
 
 Piecemeal recurrence on first f/up 
(%) 
Total (n) 
n y 
APC use 
n 68.6 31.4 86 
y 82.1 17.9 67 
Total 74.5 25.5 153 
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Statistically significant association was found between endotherapy APC use and recurrence 
found using 1-sided Fisher’s exact t-test  (0.042) but not 2 sided test (p=0.064). APC use was 
not associated with increased early lesion recurrence 
 
5.4.5) Endoscopist Procedure Volume 
 
 
Rationale:  
 Prevalence of international data demonstrating that increased endotherapy practice 
is associated with improved outcomes (64, 65) 
 
Endoscopist Procedure Volume in Relation to Curative Resection 
 
 
 
 
 
 
 
 
 
12 month recurrence 
(%) 
Total 
(n) 
n y 
Endoscopist  
procedure 
volume 
High 
>30 
 
96.8 
 
3.2 
 
62 
Low 
<30 
 
87.7 
 
12.3 
 
73 
 
Total 
 
91.9 
 
8.1 
 
135 
188 
 
 
Procedure volume was not statistically associated with lesion clearance (p= 0.050 (1-sided) 
p= 0.064 (2-sided) 
 
Endoscopist Procedure Volume In Relation to Need for Secondary Surgery 
 Secondary Surgery 
(%) 
Total (n) 
n y 
Endoscopist  
procedure 
volume 
High 
>30 
77.9 22.1 
 
86 
 
Low 
<30 
 
82.8 17.2 
 
116 
 
Total 
 
124 
 
11 
 
202 
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Procedure volume was not associated with a need for surgical management after initial 
endotherapy (p=0.243 (1-sided) p=0.471 (2-sided) 
 
 
5.5)  Intercentre Comparison 
 
5.5.1) Diagnoses of Malignancy: Assessment of decision making 
 
 
 
 
 
 
 
 Cancer confirmed (%) Total (n) 
n y 
Screening Centre 
A 80 20 40 
B 65 35 74 
C 69 31 54 
D 77 23 96 
Total 72% 28% 264 
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Malignancy found in 28% of cases of lesions initially diagnosed as benign 
 
 5.5.2) Use of Primary Endotherapy: Assessment of decision making  
 Primary endotherapy 
(%) 
Total (n) 
n y 
Screening Centre 
A 15 85 40 
B 14.9 85.1 74 
C 14.8 85.2 54 
D 28.1 71.9 96 
Total 19.7% 80.3% 264 
 
 
 
a.  
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     5.5.3) 3 month recurrence: Assessment of completeness of resection 
 
 
 
3 month recurrence 
(%) 
Total 
n y 
Screening Centre 
A 53.6 46.4 28 
B 88.2 11.8 34 
C 72.4 27.6 29 
D 81.4 18.6 59 
Total 76% 24% 150 
 
       
      Primary Endotherapy undertaken in 80.3% of cases 
    The probability of Screening Centre location affecting the likelihood of      
    primary endotherapy undertaken was not statistically significant    
     (p=0.097) 
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3 month recurrent/residual polyp (RRP) occurred in 24% of cases.  
The probability that the endoscopic centre affected the likelihood of a finding of 
residual/recurrent polyp after 3 months was statistically significant (p=0.011) 
 
5.5.4) 12 Month Recurrence: Assessment of Curative Resection 
 
 12 month recurrence 
(%) 
Total (n) 
n y 
Screening Centre 
A 91.6 8.4 24 
B 100 0 36 
C 70.8 29.2 24 
D 96.1 3.9 51 
Total 91.9% 8.1% 135 
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12 month recurrence occurred in 8.1% of cases.   
The likelihood of finding of recurrent/residual polyp after 12 months was strongly associated 
with screening centre location (p=0.001) 
 
 
5.5.5) Use of Secondary Surgery: Assessment of use of ineffective endotherapy 
 
 Use of Secondary 
Surgery (%) 
Total (n) 
n y 
Screening Centre 
A 84.8 15.2 33 
B 65.5 34.5 55 
C 82.2 17.8 45 
D 89.9 10.1 69 
Total 81% 19% 202 
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Secondary surgery was used in 19% of cases.  
The probability of screening centre location affecting the need for secondary surgery was 
statistically significant (p=0.008) 
 
5.5.6) Endotherapy within 8 weeks of diagnosis: Assessment of timeliness of management 
 
 Endotherapy within 8 
weeks (%) 
Total (n) 
n y 
Screening 
Centre 
A 5.9 94.1 34 
B 3.2 96.8 62 
C 0 100 46 
D 10.1 89.9 69 
Total 5% 95% 211 
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Endotherapy within 8 weeks of diagnosis occurred in 95% of cases.  
The probability of cases undergoing therapy within 8 weeks of referral varying between 
screening centres was not statistically significant (p=0.086) 
 
5.5.7) Endotherapy attempted on malignant lesions: Assessment of decision making 
 Endotherapy with 
cancer subsequently 
confirmed (%) 
Total (n) 
n y 
Screening Centre 
A 91.2 8.8 34 
B 75.8 24.2 62 
C 78.3 21.7 46 
D 92.8 7.2 69 
Total 84.4% 15.6% 211 
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Piecemeal endotherapy on malignant lesions took place in 15.6% of cases.   
The probability of undergoing piecemeal endotherapy on a malignant lesion being affected 
by screening centre location was statistically significant (p=0.021) 
 
 
5.5.8) Use of Primary Surgery: Assessment of decision making 
 Cancer confirmed (%) Total (n) 
n y 
Screening Centre 
A 16.7 83.3 6 
B 8.3 91.7 12 
C 0 100 5 
D 37 63 27 
Total 24% 76% 50 
197 
 
 
 
24% of lesions managed with primary surgery were benign. 
Screening centre location was not found to be significantly associated with the use of 
primary surgical management on benign lesions (p=0.145) 
 
 
5.6) Multivariable analysis: 
 
Recurrence 
Proximal location was strongly associated with an increased risk of persistent 
residual/recurrent polyp tissue (OR: 14.231, p=0.003, 95% CI: 2.491-81.283) 
Malignancy 
 
Increased lesion size was found to be strongly associated with an increased likelihood of a       
finding of malignancy (OR: 2.579, p=0.005, 95% CI: 1.333-4.990) 
 
 
 
 
 
 
198 
 
5.7) Complications 
 
The complications identified are summarised below (see table 12) 
 
Screening 
Centre 
Complication Number Severity Grade Lesion Size 
(mm) 
Lesion 
Location 
Intervention 
Required? 
A PPB 1 
 
Intermediate 25 Descending 
Colon 
Nil 
Perforation 0 - - - - 
PPS 0 
 
- - - - 
B PPB 4 
 
 
1 Major 
50 Rectum 4 unit blood 
transfusion 
and surgical 
EUA 
 
3 Minor 
23 Rectum Nil 
25 Rectum Nil 
20 Hepatic 
Flexure 
Overnight 
admission 
Perforation 0 - - - - 
PPS 
 
0 
 
 
- - - - 
C PPB 0 - - - - 
Perforation 0 - - - - 
PPS 1 -   Overnight 
admission 
D PPB 
 
2  
2 x Intermediate 
20 Rectal Overnight 
admission 
30 Ascending 
Colon 
Repeat 
endotherapy 
Perforation 0 - - - - 
PPS 0 - - - - 
Table 12.  Summary of North East BCSP LNPCP Complications 
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               5.8) Screening Centre Outcomes Applied to Key Performance Indicators 
 
Domain Optimal 
Decision 
Making 
Endoscopic 
Skill 
Timeliness Safety Number of 
endoscopic 
procedures 
KPI Surgery 
Rate (%) 
12 month 
recurrence 
(%) 
Time from 
diagnosis to 
management 
(%) 
Perforation 
(%) 
PPB 
(%) 
Annual 
Number of 
EMR     
     
procedures 
(n) 
Minimum 
Standard 
Auditable 
Outcome  
<10% <8 weeks <2% <5% Auditable 
Outcome 
A 17.1 8.4 94.1              0 2.9 17  
B 31.7 0 96.8 0 6.3 31.5 
C 16.3 29.2 100 0 0 23 
D 21.5 3.9 89.9 0 2.9 34.5 
 Table 13. KPIs applied to North East BCSP Outcomes  
 
 
5.9) Discussion 
 
BCSP facilitates collection of a robust dataset 
The method of BCSP data entry into a central database following each procedure by a 
dedicated practitioner ensures the attainment of a large, comprehensive and robust dataset 
of both endoscopic polypectomy and large colorectal polyp management.  This enabled 
access to a wealth of information regarding all colonoscopic procedures and subsequent 
therapy conducted within the BCSP, in addition to documentation of decision-making prior 
to management. In the case of LNPCPs, this includes extensive patient details, polyp details 
such as size, morphology and surface characteristics and any therapeutic options taken such 
as the use of en-bloc or piecemeal resection, the type of electrocautery used and the use of 
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argon plasma coagulation.   A similar level of detail is recorded on the database with 
information on follow up procedures, complications, multidisciplinary discussion and other 
therapies used such as surgery available.  There is also a facility to filter cases as appropriate.  
For example, information regarding patients with unplanned management or lost to follow-
up without planned surveillance was documented. As a result, cases of out of area 
management, failure to respond to appointments, cases of death and refusal of therapy 
could be identified.  These factors ensure that the BCSP generally provides an accurate and 
reliable database for analysis.  Another benefit of the use of BCSP data was the inclusion of 
only experienced endoscopists that have undergone rigid certification criteria.  This allows a 
form of standardisation of the participating endoscopists, thus reducing the likelihood of 
extraneous results due to wide variation in endoscopist quality.  The use of the BCSP central 
database ensured easier data collection, whilst the use of ‘double-data entry’ detailed in the 
methodology also further strengthened the accuracy of the data collection process and the 
validity of the data collection.  
Logistical issues  
The logistical issues with collecting and analysing data across a large geographical area such 
as the North East of England were considerable. Whilst there are four major centres (e.g. 
Tees, North of Tyne, South of Tyne and County Durham and Darlington), there are several 
different hospitals and NHS trusts attached to 3 of these centres.  This is dissimilar to many 
BCSP programmes elsewhere in the country, where BCSP centres use only one hospital site.  
The large number of hospitals involved meant that BCSP data was entered into numerous 
separate endoscopy software, pathology and radiology databases.  In view of this, 
completion of a large volume of paperwork including Caldicott Guardian approval forms and 
honorary contracts was required at each separate hospital site, in addition to a sponsor, 
before data collection could begin.  The use of the central BCSP database ensured that data 
collection was easier than originally anticipated due to the comprehensive information it 
encompassed and reduced the volume of information required onsite at each hospital site to 
enable the retrieval of a complete dataset.  
5.9.1) Whole Group Analysis 
As anticipated, gender and age did not demonstrate any impact on outcomes such as 
recurrence and malignancy.  Whilst an increased malignancy incidence is expected with 
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increased age, given the limited age range of BCSP patients (55-79) it was not unexpected 
that age was not found to be a significant factor in this series. 
A 28% incidence of malignancy in this 264 lesion North East case series  (range 20-35%) is 
significantly higher than the figure identified in a recent national BCSP case series (9.7%) of 
557 patients (p<0.0001).  This finding appears indicative of inferior lesion assessment within 
the North East Region and also strongly emphases the importance of accurate lesion 
assessment with LNPCPs given that initial biopsy results for all lesions in both series were 
benign. 
Polyp Size 
Polyp size was found to significantly affect the likelihood of a finding of malignancy.  
Malignancy was found in 21% of lesions 20-29mm in size, 28% of lesions 30-39mm in size 
and 40% in lesions >40mm (p=0.023).  This was an expected result, given similar findings in 
other large case series, whilst multivariable analysis also reaffirmed this finding as the only 
variable associated with increased malignancy risk (Odds Ratio: 2.579, 95% CI: 1.333.4.990, 
p=0.005)  
There appeared to be a noticeably higher rate of recurrence with the largest lesions 
(>40mm).  However, no statistical association was demonstrated between polyp size and 
lesion recurrence post endoscopic resection at both early (3 month: 24%, p=0.316) and late 
stages (12 month: 8.1%, p=0.306).  Recurrence rates of 18.9%, 26.7% and 32.3% a (3 
months) and 6.9%, 5.4% and 15.4% (12 months) for polyp sizes of 20-29mm, 30-39mm and 
40+mm were demonstrated respectively.  A higher rate of incomplete resection in larger 
lesions might be expected given that increased lesion size is an established indication of 
increased endoscopic difficulty (6).  However, whilst the lack of statistical association may be 
attributed to the study being underpowered, similar findings were demonstrated in a 2014 
meta-analysis(146) and national BCSP data (17).  The effect of lesion size on recurrence may 
have been reduced by the selection of certain endoscopists considered more suitable to 
manage these lesions, with only 7 or the 15 endoscopists undertaking therapy on lesions at 
least 40mm size. Increased polyp size was associated with an increased likelihood of surgery 
as with national data (20-29mm: 24.2%, 30-39mm: 36%, >40mm: 49.2%, p=0.002).  
However, increased malignancy incidence in relation to increased lesion size appears to be a 
major factor in this finding with 59/89 (66.3%) of surgical cases undergoing surgery due to 
malignancy. 
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Lesion location is related to likelihood of recurrence 
Whilst lesion location did not appear to impact on the likelihood malignancy, it did appear to 
be an important factor in recurrence with 12 month recurrence rates of 2.6%, 9.8% and 
27.8% for left colon, right colon and caecal LNPCPs respectively (p=0.003).  Further analysis 
of caecal lesions specifically identified caecal lesions specifically as being of the highest risk 
of recurrence with over a 5-fold increase in risk seen (caecal: 27.8% vs non-caecal: 5.1%, 
p=0.007 two-sided).  Multivariable analysis also demonstrated this association (Odds Ratio: 
14.231, 95%CI: 2.491-81.283, p=0.003), with proximal lesion location the only factor found 
to be associated with 12 month recurrence.  In view of this finding, it might be speculated 
that proximal location would also be associated with an increased need for surgery. 
Although this finding was reported in national data, no statistical association was 
demonstrated in this series (p=0.406), indicating that most of these lesions were eventually 
cleared endoscopically (17). Whilst, the wide 95% confidence interval highlights the need for 
further investigation into the finding of increased recurrence with more proximal LNPCPs, 
the results from this series confirms the increased technical demands associated with the 
endoscopic resection of proximal, and especially caecal LNPCPs. In view of an increased risk 
of endoscopic treatment failure, in addition to the established increased risk of adverse 
endoscopic events, it appears justified to conclude that caecal LNPCPs may benefit from 
multidisciplinary discussion and should only be managed by experienced clinicians.  
A finding of right sided lesions, particularly caecal lesions, being associated with increased 
recurrence has not previously been reported, indicating that this is a new finding.  There 
appear to be several reasons for this finding.  With large volume data identifying the 
removal of caecal lesions as being associated with an increased perforation and bleeding 
risk, it may be speculated that increased caution was used in the resection of lesions in the 
thinner right colon and caecum than in the left colon (101).  The coagulation element of 
diathermy may been used more sparingly whilst the application of measures to manage 
potential small residual pieces such as APC may have been more limited due to the concern 
of perforation.  In addition, it is possible that increased recurrence occurred due to these 
proximal lesions being removed in more numerous, smaller pieces using smaller snares than 
elsewhere in the colon to limit the potentially increased risk of perforation secondary to 
prolonged diathermy use.  The results of a 2012 Japanese study (n=222) reporting that 
lesions removed in at least five pieces had a threefold increased risk of lesion recurrence 
203 
 
compared with lesions removed in less than five pieces (p=0.005) supports this theory (289).  
In addition, the more tangential approach required for caecal therapy, as opposed to 
elsewhere may have limited the ability to undertake successful therapy such as submucosal 
lifting (101). 
Whilst the impact of this finding would likely be strengthened by corroborative data from 
larger case series, these results do support the rationale for citing right sided locations as 
more complex than those in the left colon in the SMSA scoring system (6). 
Polyp Morphology 
Assessment of polyp morphology was limited due to its varied reporting on both the BCSP 
database and on endoscopy reporting software.  In view of this polyp morphology was 
categorised as ‘flat’ or ‘sessile’.  A finding of increased recurrence with flat lesions may have 
been plausible given the potentially increased technical difficulty ensnaring a flat lesion prior 
to resection.  However, polyp morphology appeared to have no impact on the risk of 
malignancy with malignancy in flat and sessile lesions reported in 80% and 70.8% of cases 
respectively (p=0.272).  In addition, polyp morphology did not appear to affect the likelihood 
of lesion recurrence at either 3 months (flat: 16.7% vs sessile: 25.8%, p= 0.348) or 12 months 
(flat: 4% vs sessile: 9.1%, p= 0.689).  The limited nature of polyp morphology reporting in the 
BCSP may account for the lack of association seen in this series. 
Interaction analysis between all variables to ascertain possible additive risk of recurrence or 
malignancy (e.g. polyp size + lesion location) did not demonstrate any combinations 
suggesting an increased risk of either of these scenarios. 
Endoscopist procedure volume, seen as an important factor for analysis due to evidence that 
increased regular endoscopic practice leads to improved outcomes, did appear to be 
relevant in terms of LNPCP outcomes in terms of successful resection.  When procedure 
volume was split into low (n<30) and high volume (n>30) groups, an almost four-fold 
increase in 12 month RRP was seen in the low volume group (12.3% vs 3.2%, p= 0.05 (1-
sided), p=0.064 (2-sided)).  It can be argued that the p-values, although not demonstrating 
statistical significance, do approach this and are a result of the study being underpowered. 
The results may therefore indicate clinical significance and warrant further investigation with 
a larger sample size.  The use of secondary surgery, a marker to indicate both ineffective 
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endoscopic assessment and initial management did not appear to differ between the high 
and low volume groups however (22.1% vs 17.2% (p=0.243 (1-sided) p=0.471 (2-sided)). 
 
5.9.2) Argon Plasma Coagulation in relation to Residual/Recurrent tissue 
The use of argon plasma coagulation (APC) with piecemeal endotherapy has been debated 
extensively in existing literature with conflicting evidence presented with regards to it merits 
in reducing recurrent/residual polyp (RRP) on follow-up(182, 184). Whilst a 2002 UK study 
reported a marked reduction in RRP (n= 21, 10% vs 64%, p=0.02), a later Australian study 
identified APC use as an independent risk factor for RRP (n= 479, 39.5% vs 17.5%, p=0.002) 
(5, 184).  The use of APC on lesions within this series could be analysed due to the recording 
of its use being mandatory in the ‘additional therapy’ section when entering details onto the 
BCSP database.  On review of all piecemeal endoscopic cases, it was clear that its use was 
extremely mixed between the North East BCSP endoscopists with routine use by some, 
occasional use by others and lack of use by the remaining clinicians in any cases.  APC was 
used in 67 cases with the results likely to prompt further discussion.  APC use appeared to 
demonstrate reduced RRP on first follow-up (17.9% vs 31.4%, p= 0.042 1-sided, p=0.064 2-
sided).  While statistical significance was only seen on 1-sided chi-square analysis, the level 
of recurrence was over 40% lower in the APC group (31.4% vs 17.9). It can be argued that 
the study may be underpowered and that the result likely indicates clinical significance. This 
data does not support the data from other studies indicating a possible detrimental effect of 
APC. Whilst the use of APC is likely to be more standardised within the BCSP, the exact 
circumstances of its use, such as the amount of residual tissue post snare resection 
remaining prior to APC use in other studies, is unclear.  APC appears appropriate therapy for 
tiny residual polyp fragments post snare resection, as opposed to larger tissue areas. A large 
randomised controlled trial with a standardised protocol for APC application would add 
further evidence. 
 
5.9.3) Intercentre analysis 
Whilst the proportion of cases (80.3%) subject to primary endotherapy clearly identified 
endotherapy as first line management of LNPCPs, in keeping with numerous international 
case series, the level of use of primary endotherapy appeared to vary between Tees (71.9%) 
and the other centres (85%), although this difference in management was not statistically 
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significant (p=0.097).  This difference did however indicate potential for variable outcomes 
between the centres based on the decision making approach with secondary surgical rescue 
therapy considered rescue therapy for inappropriate endotherapy in the context of 
malignancy or technical issues and primary surgery for benign lesions worthy of closer 
scrutiny. 
 
Use of secondary surgery 
 
Whilst the proportion of cases requiring secondary surgery after initial endotherapy in the 
North East series was comparable to national BCSP data (19% vs 16.1%), there was 
significant variation between the centres (10-1%-34.5%) with the likelihood of screening 
centre location affecting the likelihood of secondary surgery strongly statistically significant 
(p=0.008). Similarly, the likelihood of having piecemeal endotherapy on a malignant lesion 
varied significantly based on screening centre (7.2% -24.2%, p=0.021), although the overall 
proportion of 15.6% was higher compared with national data (6.7%). Piecemeal endotherapy 
on malignant lesions took place in 15.6% of cases.  The incidence of primary surgical 
management varied widely (14.8-28.1%), a trend in accordance with national data (7-36%).  
The overall incidence of primary surgery on lesions found to be benign appeared high at 
almost 1 in 4 cases (24%) but did vary markedly between the North East centres, in spite of 
the absence of statistical significance, ranging between 0 and 37%.  These results indicate 
continued variation in decision making and management over an extended period of time, in 
keeping with the shorter term national data. 
 
Recurrence 
Analysis of recurrence rates at both early (3 month) and late stages (12 month) 
demonstrated significant variation between the centres.   Total 3 month recurrence was 
24%, compared with 16.5% in the national series however this varied markedly between the 
centres ranging between 11.8 and 46.4% (n=150, p=0.011) indicating that the choice of 
screening centre was significantly associated with the likelihood of 3 month RRP.  This 
finding may indicate inferior endoscopic technical ability in the worst performing centre but 
also may be due to superior endoscopic assessment for recurrence on follow-up.   A similar 
pattern was seen with the incidence of 12 month recurrence.  The regional level of 8.1% was 
similar to the nationally reported figure of 6% whilst individual centre outcomes ranged 
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between 0 and 29.2% (n=135, p=0.001) demonstrating screening centre choice as having a 
strongly significant association with the likelihood of 12 month recurrence .  There were five 
cases (3.7%) of recurrence identified at 12 month where none had been reported at 3 
months.  Whilst these cases may be genuine cases of new ‘late’ recurrence, it also appears 
plausible that residual tissue was not detected at earlier surveillance. 
 12 month RRP, as an internationally recognised marker for curative resection, is considered 
to be a more important outcome than at 3 months. This is not least due to the widespread 
recognition of high early recurrence rates associated with piecemeal resection that can be 
effectively treated on follow-up and these figures demonstrate a strongly significant 
difference in the likelihood of undergoing curative resection based on the screening centre.  
The implications of variation in 3 month levels are worthy of consideration however, as this 
marker is used to assess the quality and completeness of initial endoscopic resection given 
that this cannot be assessed histologically with piecemeal resection specimen.  It can 
therefore be concluded that the quality of initial endoscopic resection varies significantly 
between centres.  
Timeliness 
Ensuring a timely service is increasingly being seen as an important outcome, especially 
given the risk of malignancy within LNPCPs.  Assessment of endoscopic management time 
periods indicated that 95% of LNPCPs were managed within 8 weeks of initial diagnosis with 
individual centre figures ranging between 89.9 and 100% (p=0.086) and it can be concluded 
that the North East BCSP had continually provided a timely service.  
Endoscopist procedure volume in relation to outcomes 
Whilst it was possible to record outcomes for individual endoscopists within this period, the 
large number of BCSP endoscopists and marked variation between endoscopists in terms of 
LNPCPS managed meant that, while individual performance could be assessed, statistical 
analysis based on individual endoscopist outcomes was not feasible.  It was considered 
desirable however, to ascertain whether increased endotherapy volume was associated with 
improved outcomes in LNPCP management given previous data indicating improved 
outcomes with increased experience with standard polypectomy (65, 66).  This was 
undertaken by dividing the endoscopists into 2 groups (high volume (>30) vs low volume 
(<30) endotherapy groups). No association was demonstrated between procedure volume 
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and early residual/recurrent polyp (p=0.243 (1-sided), p=0.444 (2-sided)), or the use of 
secondary surgical management following ineffective endotherapy (p=0.276 (1-sided) p= 
0.471 (2-sided)).  In addition, no statistical association was found with persistent 
RRP/curative rate (p=0.050 (1-sided), p=0.064 (2-sided)).  However, it can be argued that the 
study was underpowered and that a clinical association was demonstrated with a p-value 
close to statistical significance and an almost 4-fold increased rate of failed curative 
resection (12.3% vs 3.2%).   
Complications 
The overall level of complications was low with no cases of mortality or perforation, one 
case of PPS and seven cases of PPB (3.3%).  Of the PPB cases, three were minor requiring no 
management, three were of intermediate severity with one requiring repeat endotherapy 
and one case was major requiring surgical intervention to achieve haemostasis.   These 
figures appear comparable with national figures (see table 13).  
Limitations 
A major limitation identified with current BCSP data collection was the paucity of 
information on the database for cases where follow up took place outside of BCSP, 
invariably due patients falling outside the BCSP age range (55-79).  Whilst information for 
these cases was obtainable onsite at the relevant hospitals, it would appear important to 
ensure that relevant surveillance information from an initial BCSP procedure is kept for all 
patients to allow accurate long term audit and quality analysis.  In addition, whilst the list of 
identified cases was accurate to the best of our knowledge, a reliance on single person data 
entry onto the central database raises the possibility of missing LNPCPs due to details not 
being captured on the BCSP database at the time of endoscopy.  This is unlikely however, 
given the fastidious nature of data entry during all BCSP procedures. 
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5.9.4) Analysis of outcomes and application of Key Performance Indicators to North East of 
England Outcomes   
There appears to be marked variation in outcomes between the individual centres with a 
statistically significant difference in many outcomes (see table 13).   The implications of 
these findings are of great importance as the quality of overall management received 
appears to vary based on screening centre location.  Furthermore these results were 
collected within a national screening programme featuring experienced accredited 
endoscopists and detailed audit in an attempt to continually maintain uniform high 
standards. 
Whilst there was a clear variation in outcomes between centres, each centre appeared to 
perform better in certain aspects.  The application of recently agreed KPIs (developed to 
assess and compare performance and previously described in this thesis) was undertaken to 
identify the best and worst performing centres, warranting further investigation, and further 
specify where improvements can be made  (see table 13). 
The application of KPIs demonstrated that the use of surgery (secondary and primary 
management for benign lesions was highest in centres B and D, the two highest volume 
centres due to service population, with the former using a high level of secondary surgery 
and the latter using primary surgery for benign lesions.  These are findings that would 
warrant further investigation.  These two centres also appeared to be the most effective 
endoscopically with the lowest rates of 12 month recurrence.  The KPIs therefore indicate 
that these centres performed worse in terms of decision making but were the best in terms 
of endoscopic efficacy.  Centre C had a 12 month recurrence rate far high than the other 
centres (29.2%), potentially indicating poorer overall endoscopic skill.  Given that endoscopic 
clearance was achieved at 15 months in six of the seven cases with recurrence at 12 months, 
whilst complications were minimal, it might be suggested that no patient harm occurred. 
However, the other case of 12 month recurrence did eventually require surgery for 
malignancy not previously identified and it cannot be discounted that malignant 
transformation occurred during endoscopic surveillance.  In view of this, the use of 12 
month outcomes as a marker of endoscopic skill does appear valid to emphasise the 
importance of achieving curative resection as soon as possible to reduce the risk of adenoma 
to carcinoma transformation.  Complication rates were acceptable in all centres whilst all 
centres appeared to provide a timely service. 
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The preliminary results were presented and discussed at a North East regional BCSP meeting 
in an attempt to identify the reasons behind the variation in outcomes.  Whilst the quality of 
decision making appeared to be an important factor, it became apparent from discussion 
that a causative factor for high rates of endoscopic resection on malignant lesions in at least 
one centre (centre B) was the reticence of local colorectal surgeons to undertake surgery on 
lesions where malignancy was suspected without biopsy proven malignancy despite high 
endoscopic suspicion.  This did not appear to be the case in other centres where it was 
reported that surgeons were happy to undertake resection based on a high suspicion of 
endoscopic malignancy.  In addition, the availability of services locally appeared to be 
important.  At centre D, where the use of primary surgery appeared higher than at other 
centres, the availability of a long- established TEMS onsite for the management of rectal 
lesions may explain why a number of rectal lesions underwent surgical management. In 
addition, it became apparent from discussion that many LNPCPs identified were not 
discussed with other endoscopists at the same site prior to a decision on management.  For 
example, multiple cases were referred for surgical management without consultation with 
another endoscopist about the feasibility of endoscopic resection.  This practice did not 
appear to occur at the other centres. Another potentially important factor was that the 
mean lesion size in centres B (37.6mm) and D (35.5mm) was larger than in centres A (32mm) 
and C (31.8mm). Increased size was found to be statistically associated with an increased 
likelihood of both requiring surgery and a finding of malignancy (with the former related to a 
finding of malignancy in many cases) and this may also explain the higher use of surgery in 
these centres.  
The higher level of 12 month recurrence at centre C was also discussed.  A potentially 
important factor was that endoscopic surveillance in certain cases (including the case where 
malignancy was eventually seen) where RRP was found at 3 months and subject to repeat 
therapy, no further surveillance took place until around 12 months.  This approach differed 
to other centres where repeat assessment/therapy frequently took place on at least a 3 
monthly basis until clearance was considered achieved.  This indicates the importance of 
frequent endoscopic assessment of residual tissue until clearance is confirmed.  In addition, 
repeat therapy appeared to be undertaken by a difference endoscopist to that undertaking 
initial therapy more frequently in centre C.  Whilst this is likely to be a result of service 
demands, it was considered an important principle that the initial endoscopist also 
undertakes surveillance and it can be speculated that a lack of endoscopic continuity may 
210 
 
have contributed to this result.  Although proximal lesion location was strongly associated 
with lesion recurrence, this does not appear to have influenced the outcomes at centre C 
with centres A and B both having a higher proportion of right sided lesions managed 
endoscopically (Centre A: 20.6% caecal lesions, 52.9% right sided lesions; Centre B:  6.8% 
caecal location, 35.1% right sided location; Centre C: 11.1% caecal location, 37.3% right sided 
location; Centre D: 14.5% caecal location, 49.3% right sided location). 
In addition, whilst all services provided a timely service, centre D had the lowest proportion 
of cases managed within 8 weeks.  It is likely that this was a result of fewer endoscopists 
undertaking LNPCP removal compared with other centres.  
Further discussions about techniques used during endotherapy indicated wide variation.  In 
addition to variable use of APC, it was apparent that various type of snares were used in 
addition to the types of lifting solutions, lifting techniques (e.g. total lesion lift vs sequential 
piecemeal lift and resect) and the choice of diathermy type  and settings.  
 
5.9A) Summary  
The outcomes from this series indicate safe, high quality overall management within the 
North East BCSP over a sustained time period, with an endoscopic curative rate of almost 
92% at 12 months and almost all cases with recurrence at 12 months reported as having 
successful subsequent eradication without the need for surgery.  In addition, there was a 
very low level of complications with no cases of perforation or mortality (see table 12).  
These figures are comparable with outcomes from various international case series (see 
table 14).  Despite this, this series demonstrates a variation in management between BCSP 
centres over a sustained period, supporting the finding from national data over a shorter 
time period.  In addition, there was a markedly higher level of piecemeal endoscopic 
resection of malignant lesions (approximately three times higher), a lower level of single 
session complete endoscopic resection and a marginally higher need for secondary surgery 
in this series.  These findings suggest inadequacies within the North East region with the 
decision making processes taken during colonoscopy and highlight the need for enhanced 
decision making modalities such as a complex polyp multidisciplinary team meeting (MDM). 
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A key benefit of analysing regional data with closely aligned centres was the enhanced 
ability to discuss findings and to identify potential causative factors for important findings.  
Whilst national analysis may be more reliant on findings from the BCSP database, regional 
analysis allowed for discussion of findings in person and closer scrutiny of details using local 
endoscopy databases.   Given the variation in decision making and endoscopic technique 
identified along with statistically significant variation on outcomes over a sustained time 
period, it can be concluded that variation in management does appear to result in variable 
outcomes in the management of LNPCPs.   In addition, this is the first case series where the 
application of KPIs has been undertaken.  The ability of KPIs to assess both performance 
areas warranting further scrutiny appears accurate and indicates their feasibility as a 
continued performance monitor of LNPCP management and performance. 
 North East 
BCSP 
Moss et al (2011) BCSP (Lee et al, 
2013) 
Buchner et al 
(2012) 
Longcroft-
Wheaton et al 
(2013) 
Number of 
NCPCs 
managed 
endoscopically 
211 479 436 308 187 
Mean size 
(mm) 
31.2 35.6 29.5 23 41.5 
Cases with 
complete 
resection 
considered 
achieved after 
single session 
(%) 
84.4 89.2 
 
Not assessed 91 90% 
Malignancy in 
resection 
specimen (%) 
15.6 6.9 6 4.4 5.9 
Need for 
surgery (%) 
18.5 16.3 16.1 10 9 
3 month 
recurrence (%) 
24 20.4 16.5 27 14.5 
12 month 
recurrence (%) 
8.1 2 6 16.3 
 
3.9 
Delayed 
Bleeding 
3.3 2.9 3 7.2 2.7 
Perforation 0 1.3 0.5 0.4 0.45 
  Table 14. Comparison of NE BCSP LNPCP Outcomes with International Series 
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Chapter 6: Establishment of a Multidisciplinary Network for the 
Management of Large Non-Pedunculated Colorectal Polyps 
 
6.1) Introduction  
The use of multidisciplinary team management and networks has long been established as 
standard practice for the management of malignancy with the intention of improving cancer 
outcomes with NICE guidelines mandating their use (290).  The use of this collaborative care 
has been credited with helping to deliver a more coordinated and standardised service for 
patients nationally and in view of this, there has been a drive to provide a multidisciplinary 
team based approach for chronic and complex conditions (280).  The combined expertise of 
various specialists is considered superior to that of single clinician or single specialty care, 
mainly due to the increased likelihood of all potential therapeutic options being considered 
(23). A central component of multidisciplinary care is the use of multidisciplinary team 
meetings (MDT) where clinicans from various relevant specialties discuss patient details such 
as comorbidity, diagnosis, histological and radiological factors, treatment options and other 
potentially important factors.   The interaction in these meetings is seen as key to delivering 
effective holistic care.  As previously discussed, there have been positive examples of MDT 
use related to complex gastroenterological conditions and complex endoscopic therapy such 
as early rectal cancer and the use of therapeutic endoscopic retrograde 
cholangiopancreatography (ERCP) for hepatobiliary disorders respectively.   For example, the 
use of an MDT approach with the management of early rectal cancer was associated with a 
reduced level of invasive surgery, thereby exposing patients to reduced morbidity (23). A 
prospective case control study demonstrated that MDT input prior to undertaking 
therapeutic ERCP was associated with a marked reduction in patient complications in 
(n=1909, MDT: 6.9% vs No MDT: 12%, p<0.001) (24). 
The use of multidisciplinary based care appears suitable for the management of large non-
pedunculated colorectal polyps (LNPCPS) and other complex polyps (see table 15).  Data 
from the Bowel Cancer Screening Programme (BCSP) has demonstrated that variation in 
practice and management exists even amongst the most highly experienced endoscopists 
(17).  In addition, suboptimal outcomes such as the piecemeal endoscopic management of 
malignant polyps and surgical resection of benign lesions are more commonplace than 
previously thought, whilst data reported in this thesis appears to confirm that variation in 
213 
 
management leads to different outcomes (20).  The consequences of incorrect management 
are significant with surgery more costly than endoscopic therapy and more hazardous with 
1% mortality and 20% morbidity reported (291).  Endoscopic therapy in certain 
circumstances may be insufficient and hazardous, exposing a patient to additional invasive 
procedures and increased morbidity.  Another compelling reason for the discussion of 
complex polyps in a multidisciplinary setting is the increase in diagnostic and therapeutic 
tools and expertise in delivering these modalities.  For example, access to centres with 
superior endoscopic equipment such as HD imaging and video recording may provide 
improved diagnostic information.  In addition, it could be argued that increased engagement 
with clinicians proficient with minimally invasive surgical techniques such as transanal 
surgery and other endoscopic options such as endoscopic submucosal dissection (ESD) not 
universally available may lead to an increased number of patients undergoing less invasive 
diagnostic and therapeutic procedures with associated reductions in patient morbidity and 
cost. 
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Issue Justification Evidence 
Evidence of uncoordinated 
suboptimal management? 
 
Yes, no current management 
framework in place. BCSP data has 
demonstrated wide variation in 
practice with a higher than expected 
rate of cases with management 
considered to be suboptimal whilst 
variation in practice appears to 
result in variable outcomes 
Lee et al, 2013 
Unpublished BCSP data in this thesis 
 
Serious consequences with 
incorrect therapy? 
 
Yes, surgical therapy is associated 
with increased procedure cost and 
associated hospital stay in addition 
to increased morbidity and should 
be avoided in the case of 
endoscopically resectable lesions. 
Inappropriate endoscopic therapy 
may result in increased 
complications and exposure to 
further invasive procedures 
Bertelson et al, 2012 
Swan et al, 2011 
Longcroft Wheaton et al, 2013 
Ahlenstein et al, 2014 
Complexity associated with 
treatment options? 
 
Yes, advanced endoscopic 
techniques such as EMR and ESD are 
associated with potentially life 
threatening complications, 
especially when conducted by 
clinicians without the requisite 
expertise.  Transanal surgery, 
although less invasive than 
resectional surgery is a complex 
procedure and may take several 
hours.  In certain circumstances, a 
combined endoscopic/laparoscopic 
surgical approach may be desirable 
Rutter et al, 2014 
Albert et al, 2013 
Barendse et al, 2012 
Franklin et al, 2009 
Availability of multiple treatment 
options? 
Yes, in addition to EMR and 
resectional surgery (open and 
laparoscopic), there is increasing 
evidence that advanced techniques 
such as ESD and transanal 
microsurgery may be used for many 
colorectal lesions with improved 
histological diagnoses and 
treatment outcomes 
Saito et al, 2011 
Albert et al, 2013 
Arezzo et al, 2014 
Limited availability of complex 
treatment options? 
 
Yes, options such as ESD and 
transanal microsurgery are 
commonly only available in tertiary 
referral centres. Establishing a 
regional network may increase 
knowledge and access of these 
treatment options 
- 
           Table 15.  Factors suggestive of MDM suitability in LNPCP management 
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The information in table 15 indicates that applying a multidisciplinary approach may better 
coordinate and improve LNPCP management.  There is an increasing appetite for this 
approach with complex polyp meetings in existence for at least 2 years at Cardiff University 
NHS Trust Hospital, Queen Alexandra Hospital NHS Trust (Portsmouth) and the Wolfson 
Endoscopy Unit, St Mark’s Hospital (London).  However, these are predominantly single 
expert centre meetings, potentially dealing with only a small selection of referred cases and 
not concerned with the coordinated decision-making and management across a 
geographical region, with little participation from a referring centre.    
There have been a number of issues reported that have made the establishment of an MDM 
more prohibitive.   An important consideration is that the ability to make robust decisions is 
strongly based on the information offered to the MDM panel, and this suggests the need for 
a standardised minimum dataset to ensure that the requisite patient and lesion information 
is obtained prior to MDM discussion.   Other reported issues are the logistics of running a 
new meeting.  In addition to finding a time and venue suitable for all key stakeholders, 
encouraging enthusiasm and cooperation by individuals already busy with other 
commitments has been cited as a potential difficulty (292).  A pilot study may determine 
whether the establishment of a regional multicentre complex polyp MDM is both beneficial 
and sustainable in spite of these factors. 
 
6.1.1) Null Hypothesis 
The implementation of a complex polyp MDM will not result in improved LNPCP 
management outcomes.  
 
6.2) Methodology 
6.2.1) Initial Planning 
The development of a complex polyp MDM was intended as a preliminary study.  Initial 
consultation took place with centres in Cardiff and Portsmouth, where polyp MDMs were 
already established, with regards to the identification of key factors required for robust case 
discussion. This information was subsequently used to identify potential key assessment 
parameters that were subsequently forwarded to an expert panel for consideration.  As 
described in chapter 2, consensus methodology using a modified Delphi technique was then 
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used to determine finalised parameters on a complex polyp MDM proforma datasheet that 
would allow a structured discussion during an MDM.   
 
6.2.2) Consensus methodology use 
A BSG sanctioned working party (GDG) of 13 individuals, with a steering group 
subcommittee, consisting of multidisciplinary key stakeholders in a potential MDM was 
created in the process described in chapter 3. The panel, featuring nominations by the BSG 
endoscopy committee, the Association of Coloproctology of Great Britain and Ireland 
(ACPBI) and the Royal College of Pathology,  consisted of key stakeholders in a 
multidisciplinary process including, endoscopists (expert and referring), colorectal surgeons, 
a gastrointestinal pathologist and a patient representative.  Identified individuals were then 
approached via email to enquire about their interest and availability in participating in the 
consensus process.  A literature review was conducted as described in chapter 2 and, 
combined with the input obtained from the Cardiff and Portsmouth centres, a minimum 
dataset proforma was created containing features felt vital with regards the comprehensive 
complex polyp discussion.  The GDG were then asked to vote via email their level of 
agreement with included parameters on a 5 point scale from 1-5 (1=strongly agree, 5 = 
strongly disagree) in addition to their comments including suggestions for other potential 
parameters.  A minimum of 80% agreement was required for consensus to be considered 
achieved.  A second round of voting was conducted via email for remaining parameters 
where consensus was not yet reached with participants allowed to see anonymised 
comments and scores from the group for the previous round.  Plans for a third round of 
voting during a scheduled group meeting were in place if required.  Following the consensus 
process, the final agreed proforma was reviewed by the GDG for final comments prior to 
use. 
Following finalisation of the proforma, a proposed framework for MDM meetings was 
formulated. The MDM was implemented within the BCSP due to the large volume of lesions 
encountered within the programme, the high quality of endoscopists who have passed strict 
certification criteria and the infrastructure already in place that ensured comprehensive 
documentation of procedures and clinician collaboration.  However, it was agreed that the 
meeting should provide a forum for discussion of both BCSP and non-BCSP cases to increase 
both the intended benefit and sample size.  A framework discussion document was sent for 
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consultation to all members of NHS BCSP North East (Clinical Directors, endoscopists and 
specialist screening practitioner nurses (SSPs)) and all were invited to participate. Each 
screening centre was asked to nominate at least 2 colorectal surgeons to regularly 
participate in MDM process with the intention of increasing the potential management 
options (e.g. laparoscopic surgery and transanal surgery) to the MDM.  National expert 
centre endoscopists were approached from the GDG to provide a ‘national expert pool’ for 
cases where an MDM recommendation could not be made, such as areas with ongoing 
disagreement or where local expertise was not considered to be available. 
 
6.3) Organisation and Implementation of Regional Complex Polyp Multidisciplinary  
        Meeting 
6.3.1) Logistical Issues and Solutions  
Discussions took place at a BCSP regional meeting in May 2014 to discuss the logistics 
regarding the provision of a regular complex polyp MDM.   There was a stated desire to 
reduce both the use of surgery for benign lesions and piecemeal endoscopic management of 
malignant lesions whilst reducing the variation in management seen between different 
centres.  
Potential difficulties cited included potential limitations of participant availability.  It was felt 
that the extra time demands on participants with an already busy schedule may limit 
enthusiasm for full participation and there was an initial unwillingness by some BCSP 
endoscopists to become involved in the process.  Professor Rutter was able to mandate 
participation by the North East BCSP unilaterally in his capacity as Quality Assurance (QA) 
chair.  This included the mandatory referral of all LNPCPs fulfilling specific criteria.  In 
addition, ensuring both a feasible and robust method of allowing participant communication 
was an issue.  It was not possible to hold a physical meeting in a single centre given the large 
number of screening centres and geographical area covered by the North East BCSP.  In 
addition, the technology available to different centres in the area varied widely, an example 
included access to videoconference facilities. The lack of a single centre meeting also raised 
difficulties about ensuring that participants had access to relevant information such as 
patient and lesion factors, and imaging (such as high quality photos and videos) that allowed 
for valid input and robust decision making.  More specifically, a method of sharing large file 
videos was required, whilst it was vital to ensure that the transfer of patient identifiable 
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information between participants was conducted in a secure manner approved by all 
involved NHS trusts.  Other crucial considerations were the identification of key 
multidisciplinary stakeholders required for the meetings and obtaining agreement about 
which lesions required MDM discussion, with a need to ensure that the MDM did not delay 
the management of routine lesions and that there was sufficient time to discuss cases 
thoroughly. In addition, meetings needed to be held regularly enough to ensure that 
management was not delayed unnecessarily due to waiting for MDM discussion.  
An MDM terms of reference document detailing meeting proposals such as meeting format, 
information transfer and indications for mandatory referral was then sent to all relevant 
persons including BCSP endoscopists and SSPs.  This was routinely re-sent on a monthly basis 
along with separate reminders about meeting times and mandatory referral criteria to 
increase awareness about the MDM process. 
Polyps defined as ‘complex polyps’ during the formulation of large polyp management 
guidelines in chapter 3 (see figure 17) were identified as suitable for discussion in the MDM. 
There was also agreement that all benign lesions being considered for surgery warranted 
referral whilst endoscopists were encouraged to refer any lesions that they felt warranted 
discussion from both within and outside of the BCSP (see below). 
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Inclusion criteria 
 Any benign lesions planned for surgical management 
 Any lesions >40mm  
 Lesions classified as complex in accordance with BSG Guidelines: 
o increased risk of malignancy - Pit pattern type V, Paris 0-IIc or 0-IIa+c morphology, 
non-granular LST (laterally spreading type polyp, LST-NG), granular LSTs (LST-G) with a 
dominant nodule, distorted surface pattern, colour and vessels (NICE NBI type III), 
thick and irregular microvessels (Sano capillary pattern type III)   
o increased risk of incomplete resection/recurrence - Size of at least 40mm; involving 
ileocaecal valve, appendix, diverticulum or dentate line; within an inflamed segment 
of colitis; prior failed attempt at resection or recurrence at site of previous resection 
(excluding unifocal, diminutive and easily resected/ablated residual adenoma on first 
site check); non-lifting sign after submucosal injection; endoscopist concern about 
difficult location (e.g. behind flexure or fold, in stenotic diverticular disease); 
o increased risk of adverse event - Caecal location of 20+mm; elsewhere a size of at 
least 40mm 
o SMSA level 4  
 Any lesion felt to warrant inclusion by endoscopist 
Figure 17. Mandatory referral criteria for LNPCPs identified within BCSP 
 
 
An email survey was conducted to identify participant availability with clinicians asked to 
indicate their availability during the week to participate in addition to obtaining their views 
on the frequency of meetings.  Fortnightly one hour meetings (case permitting) on alternate 
Thursdays at 5pm were agreed based on voting indicative that this time and frequency 
would ensure maximum participation.  It was agreed that the fortnightly format may be 
reviewed depending on the demand for the service whilst the meeting day was flexible 
depending on potential changes in participant availability. Key multidisciplinary stakeholders 
required for the meeting and for as required input were identified according to the 
disciplines identified in the development of BSG guidelines.  These included BCSP 
endoscopists, laparoscopic colorectal surgeons, advanced endoscopists, gastrointestinal 
histopathology (input as required) and gastrointestinal radiology (input as required). 
Audio teleconferencing was proposed as the communication modality of choice for the 
MDM. This allowed participants to dial in at any location, facilitating easier participation, as 
opposed to attempting to physically convene clinicians in one room.  In addition, the need 
for videoconferencing facilities, not available to all centres, was negated. A case document 
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detailing cases for discussion along with relevant media (still images/videos) was circulated 
to an MDM mailing list approximately 48 hours before meetings.   This would allow those 
unable to attend but wishing to participate to give input, thereby maximising the potential 
for participation.  All participants were required to obtain an NHSmail account as this is the 
only approved method by NHS trusts for transferring NHS patient identifiable information 
between different NHS sites at the time of MDM establishment.  MDM outcomes were sent 
to the mailing list 24-48 hours post MDM discussion to allow comments on management 
plans reached from those unable to attend to ensure that decisions made were as robust as 
possible, as well as providing an educational resource to participants. 
The MDM proforma, agreed using consensus methodology as described earlier was designed 
with the intention of ensuring that all relevant information pertaining to both patient and 
lesion factors would be shared.  Video files of referred lesions were identified as the 
preferred media as this allowed for more robust image assessment by MDM participants. 
However, high quality images were also encouraged in view of a variation in the availability 
of video recording facilities across the region.  The ability to obtain and disseminate high 
quality imaging was considered as not only important in guiding case discussion, but also to 
reduce the need for repeat endoscopy for diagnostic purposes which had been an issue 
previously. Videos could not be sent routinely using NHSmail due to a size limit of 20 
megabytes per email as this limit would only allow for videos of a few seconds.  Videos were 
thus sent via the NHSmail secure file transfer application which allowed for transfer of files 
up to one gigabyte in size and password access to both send and receive files.  Instructions 
were also sent to participants on the mailing list on how to set up and use the NHSmail 
secure file transfer application  
Editing of videos was undertaken using ‘RealPlayer’ computer software with the attainment 
of high quality still images from the videos also possible using the provided image capture 
software. This ensured best possible imaging in scenarios where video transfer/playback was 
not possible.  Following discussions with the North Tees and Hartlepool NHS Foundation 
Trust information technology department about suitable media playback platforms on NHS 
computers, the ‘VLC video player’ and ‘JPEG’ imaging modalities were used for viewing 
images across the region. 
The meetings discussed new cases in addition to re-discussion of cases that had undergone 
management and or follow-up management.  Professor Rutter chaired meetings in his 
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capacity as the BCSP QA chairperson and an expert endoscopist whist I undertook the role of 
MDM scribe and coordinator.  A nominated deputy chairperson (Dr Jamie Barbour) was also 
available for both chairing and scribing duties if needed.  Essential participants at the 
meetings included core participants (chair and deputy chairpersons and coordinator), 
referring endoscopists and at least one laparoscopic colorectal surgeon.  Participants were 
encouraged to make parallel referrals to existing colorectal cancer MDTs in cases with a 
strong suspicion of malignancy to ensure no delay in potential cancer management due to a 
wait for complex polyp MDM discussion, whilst also enabling continued detailed radiological 
and histological input for these cases.  With regards to the complex polyp MDM, 
gastrointestinal radiological and histological input was obtained by nominated specialists at 
each centre on an as required basis in advance of case discussions at meetings.  A pool of 
external endoscopists considered national experts were secured to provide expertise in 
cases with ongoing regional conflict or where potential suitable therapies were not available 
within the North East region. 
A Microsoft Excel Database of all cases discussed was kept securely on a password protected 
trust computer in a locked room with the intention of building a prospective polyp MDM 
database and serving as a reminder to chase follow-up case outcomes. Data transfer was 
only conducted via secure NHS email accounts. The database was also used as a means of a 
reminder for re-discussion of cases with outcomes. 
Compliance with the MDM process was assessed on a 3 monthly basis.  A datasheet with all 
identified complex lesions in this period was obtained from BCSP central database.  This 
datasheet was readily available to Professor Rutter in his capacity as QA chairperson and 
was compared with our database to assess compliance.  Details about non-referred cases 
and reminders about the MDM referral criteria were sent to non-complying endoscopists 
and centres.   
After seven months, data was analysed to assess for any benefit from the meeting, such as 
an improvement in regional performance and reduced variation in practice.  
Feedback was also sought via an email questionnaire and in person at a regional BCSP 
meeting scheduled around the pilot endpoint to ascertain whether participants considered 
the MDM to have resulted in improved LNPCP management. 
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6.4) Results 
 
       6.4.1) Identification of Parameters for Inclusion in MDT Minimum Dataset Proforma 
 
A. Patient details 
 
1. Significant drug history (e.g. warfarin) 
                 Consensus reached at round 1: 100% Agreement 
 
2. Other pathology in the colon, e.g. IBD 
       Consensus reached at round 1:  100% Agreement 
 
3. Patient wishes/preference? 
       Consensus reached at round 1: 100% Agreement 
 
4. Significant comorbidities (including ASA status) 
Consensus reached at round 1: 100% Agreement 
 
5. Patient Symptoms 
Consensus reached at round 1: 100% Agreement 
 
B. Polyp details 
 
1. Site 
                 Consensus reached at round 1: 100% Agreement 
2. Size 
               Consensus reached at round 1: 100% Agreement 
 
3. Paris morphology/description 
 Consensus reached at Round 1: 100% Agreement 
 
4. Polyp Surface Characteristics (e.g. Pit Pattern(s), Sano Capillary Patterns, NICE 
NBI Classification)’ 
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Parameter modified from ‘Pit Pattern(s) after round 1.  Consensus reached at round 2: 
92.3% agreement 
 
5. Features indicating high risk of cancer (pit pattern v, depressed or ulcerated 
features, LST-non-granular, non-lifting sign) 
       Consensus reached at round 1: 92.3% Agreement 
 
6. Issues regarding endoscopic access (proximal aspect of fold, previous 
difficult/poorly tolerated colonoscopy) 
        Consensus reached at round 1: 100% Agreement 
 
7. Features suggesting high risk of recurrence/incomplete excision (40+mm, >75% 
lumen, dentate line, ICV, appendix, diverticulum, anastomotic suture line, 
previous failed attempts) 
 
             Consensus reached at round 1: 100% Agreement 
 
8. Available photos or video 
 
                    Consensus reached at round 1: 100% Agreement 
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   6.4.2) Final Complex Polyp Minimum Dataset Sheet (Figure 18) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient details:        NAME :                                                                  NHS NUMBER:   
DoB/Age     
Gender  
Endoscopist+ Centre  
Any significant comorbidity/ASA score  
Any significant drug history (e.g. warfarin)  
Patient Symptoms  
Any other pathology in the colon? e.g. IBD  
Does patient have any particular 
wishes/preference? 
 
Polyp details 
Site  
Size  
Paris morphology/description 0-IIc or 0-
IIa+c? 
 
Polyp Surface Characteristics (e.g. Pit 
pattern(s), Sano Capillary Pattern, NICE NBI 
Classification) 
Pit Pattern V/Sano CP III/NICE NBI Type 3 
 
Any other polyp features indicating high risk 
of cancer (depressed or ulcerated features, 
LST-NG, LST-G with dominant nodule non-
lifting sign)? 
 
Any access issues (proximal aspect of fold, 
previous difficult/poorly tolerated 
colonoscopy etc.) 
 
Any high risk of recurrence/incomplete 
excision (40+mm, >75% lumen, dentate line, 
ICV, appendix, diverticulum, anastomotic 
suture line, previous failed attempts) 
 
Known Histopathology/Radiology  
Please provide photos or video (if providing 
photos please include full lesion margins and 
chromoendoscopic imaging) 
 
Previous management?   
Question for MDM : 
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6.4.3) Cases Discussed 
 
1) 62 year old male with 60mm hepatic flexure LNPCP   
 
This LNPCP had been removed during a BCSP colonoscopy prior to MDM referral with 
piecemeal endoscopic mucosal resection (pEMR) and application of argon plasma 
coagulation (APC) to the resection margins.  Complete resection was considered to have 
taken place but a referral was made to discuss whether endotherapy was considered by 
others to be the correct treatment and agree on further follow up.  Histology was benign 
with the LNPCP reported as a tubular adenoma with low grade dysplasia.  Video assessment 
of the lesion was available and there was unanimous agreement that endotherapy was the 
correct decision.  3 month surveillance was suggested which confirmed lesion eradication 
and 12 month repeat surveillance was agreed at repeat MDM discussion.  In this case the 
MDM was felt to have helped to reassure the endoscopist regarding their assessment and 
decision making approaches used, in addition to ensuring an educational element with 
discussion between participants to discuss their decision making approaches during 
colonoscopy. In addition, as the first case discussed it was the first opportunity to test the 
rigidity of the BSG agreed MDM minimum dataset proforma and the use of photo and video 
imaging modalities in guiding discussion and recommendations. 
 
2) 70 year old male with 40mm ileocaecal valve LNPCP.   
 
The lesion concerned was a 40mm laterally spreading type polyp (LST) identified during a 
BCSP colonoscopy involving the ileocaecal valve and described as having a ‘non-granular’ 
surface (LST-NG).  It’s classification as an LST-NG indicated an increased malignancy risk 
whilst the detecting endoscopist was unable to ascertain lesion margins with a concern that 
it invaded the ileocaecal valve and involved the terminal ileum.  The detecting endoscopist 
did not consider themselves suitable to attempt endotherapy as assessment of the lesion 
using the SMSA system defined it as a level 4 lesion and therefore being of the greatest 
complexity in terms of achieving successful endoscopic resection.  The concerns about 
potential malignancy, unknown margins, ileal involvement and endoscopic complexity 
prompted the referrer to question whether endoscopic resection was preferable to surgical 
resection where en-bloc resection would be guaranteed.  The patient concerned had no 
comorbidities but preferred endoscopic resection.  The MDM opinion was that the images 
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provided made a definitive decision difficult and that expert endoscopic assessment was 
needed.  It was agreed that both endoscopic and surgical options should be explained to the 
patient.  In addition, it was suggested that if the patient was agreeable and the full lesion 
margins could be ascertained, an attempt at lifting the lesion with a submucosal injection 
could be attempted with subsequent resection.  Repeat endoscopic assessment was 
successful with successful endoscopic resection taking place and subsequent histology 
benign.  3 month endoscopic assessment confirmed complete eradication and 12 month 
surveillance was suggested.  The referral to MDM in this case was considered beneficial as it 
ensured robust endoscopic assessment, identified a suitable endoscopist to conduct 
successful endotherapy, and resulted in the avoidance of surgery for a benign lesion. 
 
3) 84 year old male with 60mm rectal polyp 
 
This gentleman was found to have a large lumen filling sessile lesion in the upper rectal 
region following a colonoscopy for fresh rectal bleeding.  The endoscopist, considered an 
expert endoscopist, commented on poor views stating that he was unable to ascertain 
whether there were 2 small lesions or one large one, in addition to being unable to 
accurately comment on polyp morphology.  The poor views were considered to significantly 
impact on the ability to achieve successful endoscopic resection.  In addition, review of the 
images during the MDM led to the opinion that the likelihood of malignancy was high 
despite initial histology reporting a tubulovillous adenoma with low grade dysplasia.  In 
addition, an MRI scan reported T2 invasion suggesting malignancy but as the lesion was in 
the upper rectum the scan was considered suboptimal.  In this context, en-bloc excision was 
considered desirable but the inability to fully assess the extent of the lesion was a reason as 
to why transanal surgery had not yet been considered for this purpose.  There was concern 
that the lesion could extend into the sigmoid colon and in this scenario, transanal surgery 
would not be able to reach the more proximal area of the lesion. In addition, in the context 
of multiple comorbidities, the patient was not considered fit for resectional surgery.   This 
was considered to be an extremely complex case.  The referring endoscopist had considered 
an attempt at endoscopic management and the possibility of conservative management was 
also raised although this was established to be unacceptable to the patient.  The MDM 
opinion was that endoscopic resection was not appropriate in this case due to likely 
malignancy and limited lesion access and that en-bloc resection was needed if possible.  It 
was agreed that assessment for transanal surgery should take place with excision to be 
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undertaken if the lesion margins could be ascertained and the proximal aspect reached with 
transanal surgery apparatus.  This gentleman subsequently underwent successful transanal 
surgery with histological confirmation of malignancy (T2) and establishment of complete 
lesion removal.  The patient was subsequently discharged to primary care.  This was 
considered an excellent outcome with safe successful management in a complicated 
scenario and the avoidance of inadequate endoscopic resection due to a perceived lack of 
alternatives. 
 
4) 62 year female with 100mm rectal LNPCP 
The case was referred through the BCSP with what was felt to initially be a 50mm rectal 
laterally spreading tumour with a granular surface pattern (LST-G).  Initial histology was 
benign with the LNPCP reported as a tubular adenoma with low grade dysplasia.  In addition 
CT and MRI scanning did not suggest malignancy whilst the referring endoscopist felt there 
were no endoscopic features suggestive of malignancy such as depression, surface 
characteristics or a dominant nodule and favoured endoscopic resection.  The images 
submitted were considered to be inadequate but based on the information given, both 
endoscopic resection and transanal surgery with TEMS were considered appropriate.  The 
endoscopic representatives favoured the former whilst surgical counterparts favoured the 
latter and it was recommended that both options should be discussed with the patient prior 
to a decision on therapy.  The patient favoured endoscopic resection and subsequently 
underwent this modality.  During resection the lesion was found to be approximately 10cm 
in size, substantially larger than on first assessment but complete pEMR was considered 
achieved with subsequent histology benign.  A small area of recurrence (3-4mm) seen on 3 
month assessment was treated with APC with lesion eradication confirmed 3 months later.  
This case was notable with the patient able to choose a preferred treatment modality with 
more than one suitable modality.  
 
5) 62 year old male with 15mm ileocaecal valve LNPCP  
This gentleman was diagnosed with ileocaecal valve LST-NG over 18 months prior to the 
commencement of the complex polyp MDM.  He had previously been deemed unsuitable for 
the colorectal cancer MDT due to the absence of established malignancy and had 4 
colonoscopic assessments prior to MDM discussion. He had refused any therapeutic 
intervention citing concerns about the morbidity associated with surgery due to his chronic 
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obstructive pulmonary disease (COPD) (ASA 3) and the possibility of needing a stoma 
subsequently.  He was also reticent to consider endotherapy stating that only 50% chance of 
endotherapy success had previously been quoted to him.  As such, he would only agree to 
colonoscopic surveillance to assess for malignant change.  No change in lesion 
characteristics were described whilst histopathology reporting described the lesion as 
benign (TVA with LGD) from biopsies on 3 occasions.  He was referred from a general 
gastroenterology clinic to identify a definitive management strategy in view of the risk of 
eventual malignancy and was reported as being willing to consider management options 
recommended from expert opinion within the MDM.  The images provided were of high 
quality whilst 2 of the MDM participants had undertaken colonoscopy on the patient 
meaning that the lesion and case could be described in detail.  It was agreed that given the 
lack of malignant change up until this point and the small size of the lesion that an attempt 
at endoscopic therapy would be preferable to surgical resection however there was concern 
that the margins of the lesion were difficult to identify during colonoscopy whilst multiple 
biopsies over a long time period would render endoscopic lift and resection of the lesion 
difficult due to submucosal fibrosis.  It was felt that an attempt at endotherapy should be 
undertaken by an expert endoscopist and that surgical resection should ideally only be 
offered if this was unsuccessful but would be offered as primary therapy if the patient still 
considered endotherapy unacceptable.  It was agreed that both options were considered 
low risk in terms of morbidity and mortality in his case and that the likelihood of requiring a 
stoma was negligible.  The patient was seen in clinic and subsequently agreed to 
endotherapy which was successful with no recurrence seen on follow-up. In this case it was 
felt that the MDM provided an expert forum and robust management plan for a complicated 
case where there had been almost 2 years of a stasis in management and a risk of 
preventable malignancy.    
 
6) 62 year old male with 90mm rectal LNPCP 
This gentleman was diagnosed with a rectal LST-G estimated to be between 50-60mm.  High 
definition video recording of the LNPCP was available and the opinion of the MDM was that 
the lesion appeared benign.  Endoscopic resection was felt achievable by all the participants 
however the colorectal surgical opinion was that the use of TEMS to achieve en-bloc 
resection would also be appropriate, especially as the histology demonstrated high grade 
dysplasia, a precursor for cancer, increasing concern about this lesion being malignant.  
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Endoscopic resection was attempted but the lesion much larger (90mm) than originally 
estimated and complete resection not possible with a posterior component considered to be 
fibrous and probably malignant.  Histology confirmed malignancy and the patient 
subsequently underwent surgical resection.  The video was retrospectively analysed by an 
external clinician, without prior knowledge case details, who correctly diagnosed 
malignancy. This case was an example of an incorrect MDM decision despite detailed 
discussion between several clinicians considered polyp experts.  The consequence of this 
was that the patient underwent unnecessary invasive therapy and had a delay in receiving 
definitive surgical treatment.  MDM reflection from this case was that in spite of the use of 
high quality media allowing robust assessment in this case, there was insufficient expertise 
within the existing MDM group with regards to rectal lesions and this was corrected by the 
inclusion of a surgeon specialising in transanal surgery for all referred rectal lesions. 
 
7) 87 year old woman with advanced dementia with 30mm sigmoid colon LNPCP 
A 30mm sigmoid colon LST-G was detected during a colonoscopy following rectal bleeding.  
Histology results suggested that the lesion was benign (TVA with LGD).  The question posed 
to the MDM was whether any therapy was appropriate as opposed to conservative 
management.  The use of a validated life expectancy scoring system (Schonberg Index) 
suggested that the patient’s risk of mortality within 5 years was over 50%, irrespective of the 
LNPCP diagnosis.  This was felt to be far more significant than the likelihood of mortality or 
morbidity from this lesion whilst there was unanimous opinion that attempting therapy 
would expose the patient to the unnecessary risk of a complex invasive procedure.   This 
opinion was shared with the patient’s next of kin who was in full agreement and 
conservative management was undertaken.  The MDM was felt to have been invaluable in a 
complex and sensitive scenario, providing a robust consensus based decision which single 
clinician decision making would not have permitted. 
 
8) 68 year old female with 60mm sigmoid colon LNCPCP  
This LST-G was identified during a BCSP colonoscopy.  Initial histology results reported the 
lesion as benign (TVA with LGD) whilst high definition video imaging was available. 
Endoscopic resection was recommended and considered successful however the histology 
results, although benign, suggested that the lesion was precancerous with high grade 
dysplasia (HGD).  In view of this, prompt follow-up within 2-3 months was recommended to 
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reduce the risk of malignant transformation.  Surveillance endoscopy confirmed successful 
eradication.  The availability of video imaging was considered to have allowed more detailed 
lesion discussion than was previously possible prior to the establishment of the MDM with 
high confidence in the recommendation made.  This case was also notable as regional 
agreement on endoscopic surveillance for lesions with HGD was agreed following its 
discussion. 
 
9) 70 year old male with 40mm mid transverse colon LNCPC 
The lesion, classified as an LST-G, was identified during a BCSP colonoscopy.  There was 
strong endoscopist suspicion that the lesion contained a malignant focus.  Histopathology 
reporting did not confirm malignancy as expected but did report HGD.  The MDM reached 
the same conclusion following video assessment that the lesion was likely to be malignant 
and that colorectal cancer MDT referral and surgical resection was the best management 
option.  Surgical resection demonstrated malignancy, confirming the correct decision had 
been made.  This case was noticeable as the MDM was considered to have provided a 
robust, multidisciplinary recommendation to ensure an inappropriate endotherapy attempt 
was not enforced as in the absence of proven malignancy, a scenario considered common 
prior to the complex polyp MDM.  
  
10) 62 year old male with 50mm LNPCP in distal transverse colon detected on BCSP 
colonoscopy.   
This lesion was referred following an attempt at endotherapy.  It was initially thought to be a 
20mm polyp. However, after lifting and an attempt at resection, the lesion was found to be 
substantially larger (50mm) and traversing a fold. The latter factor ensured reduced lesion 
visibility and increased complexity associated with removal.  The lesion was considered to 
have been completely removed but the endoscopist accepted that residual tissue was 
possible due to poor visibility and that resection of such a large lesion at that time was 
unplanned and would not have occurred if the full lesion margins had been identified 
initially.  Histology identified HGD, necessitating prompt follow up in 2-3 months.  A large 
area of recurrence was seen on follow up (15mm) with further snare resection and APC 
advised to achieve eradication.  Eradication was confirmed at endoscopic surveillance 3 
months later. This case was considered notable the first where MDM input was sought for 
guidance about the clearance of complex recurrent/residual tissue.  In addition the case was 
231 
 
considered to have important educational value as it was felt to emphasise the importance 
of undertaking LNPCP assessment and resection in a meticulous, planned and controlled 
manner. 
 
11) 78 year old female with 120mm rectosigmoid lesion. 
This lesion was referred following a colonoscopy arranged following a change in bowel habit.  
This lesion was described as a diffuse circumferential lesion LST-G with a dominant nodule 
occupying almost all of the rectosigmoid junction.  Histology did not detect malignancy (TVA 
with LGD).  The sheer size of the lesion meant that endoscopic resection was not considered 
feasible whilst the lesion was also thought to be too proximal to be suitable for transanal 
surgery.  The presence of a dominant nodule also indicated increased risk necessitating the 
need for en-bloc resection.  The patient refused surgery having been told the risk of 
requiring a stoma was significant and wanted endoscopic resection despite being advised 
that it would probably be unsuccessful and the referring endoscopist hoped for advice on 
how to proceed.  Video imaging was available and there was agreement that both 
endoscopic resection with EMR and transanal surgery were not suitable in this case, that 
surgery may be required and that assessment regarding further non-surgical modalities was 
not available within the region. The lesion was therefore referred out of region to an 
endoscopist considered an international expert in advanced endotherapy such as 
endoscopic submucosal dissection (ESD).  This assessment was conducted with a colorectal 
surgeon present and concurred that whilst the lesion was considered benign, endotherapy 
was not feasible.  However, rectal sparing surgery was considered possible.  This case was 
notable for the use of a national network to ensure a robust management recommendation 
that improved patient confidence following initial disagreement with local opinion.   
 
12) 78 year old female with 60mm anorectal lesion 
This patient underwent a colonoscopy following a complaint of loose stools and was found 
to have a 60mm LST-G in the anorectum with a dominant nodule.  The dominant nodule 
raised a concern about potential malignancy whilst the position of the LNPCP meant that 
endoscopic resection would need to be undertaken in a retroflexed and unstable position.  It 
was felt that successful endotherapy would be technically difficult whilst transanal 
endoscopic microsurgery (TEMS) was available at the same centre and considered 
achievable with the benefit of enabling en-bloc resection (which was desirable in the context 
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of the dominant nodule).  En-bloc resection was achieved using TEMS with complete 
resection achieved and malignancy excluded. This was the first large rectal lesion discussed 
since a previously incorrectly managed rectal LNPCP and the first with a transanal surgical 
specialist present. This case was highlighted as an example where endotherapy may have 
been recommended prior to the MDM despite low endoscopic confidence regarding 
successful resection.  In addition it was considered an example of improvement in the 
evolving MDM process, whilst there was confidence by all participants that the MDM was 
now of sufficient quality to discuss complex rectal lesions.  
 
13) 68 year old woman with 120mm rectal lesion 
This LST-G was identified during a BCSP colonoscopy with histology benign (TVA with LGD).  
Video assessment was available.  The lesion was estimated to be approximately 55mm in 
size on endoscopic assessment. Two MDM members were worried that a small area looked 
irregular and that malignancy could not be excluded.  In view of this, an attempt at en-bloc 
resection with transanal surgery was preferred over pEMR as the treatment of choice to 
ensure optimal histological assessment. The lesion was considerably larger than previously 
considered at 120-130mm in size and although 1 large piece, approximately 120mm in size 
was retrieved, separate pieces of tissue at the margins were also taken for macroscopic 
complete resection to have taken place, signifying piecemeal resection.  Post resection 
histology identified the lesion as a traditional serrated adenoma with no malignancy.  In 
addition, no residual tissue was seen at 3 month surveillance. Although en-bloc resection 
was not possible and pEMR was feasible in this case, it was felt that the principle to attempt 
en-bloc specimen retrieval in the context of a concern about malignancy was sound.  This 
case was also noted as being reflective of the increased acceptance by endoscopists to 
consider non-endoscopic management where available. 
 
14) 62 year old male with 60mm  rectosigmoid lesion 
This lesion, described as a 35mm LST-G with benign histology (TVA with LGD) by the 
referring team, was referred with only limited images.  The lesion was considered benign 
and amenable to endoscopic resection by the referring centre, but the photos suggested 
that the lesion appeared larger and more complex than described.  An MRI scan was 
reported as a suboptimal scan offering no information about possible malignant invasion.  
The referring endoscopist did not participate in the MDM and it was felt that the lesion 
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required reassessment prior to a definitive management decision.  The referring centre 
opted for endotherapy locally with unsuccessful endotherapy due to the finding of 
malignancy and a subsequent need for surgery.  This case was notable as the MDM 
recommendation was not followed, likely resulting in an undesirable outcome.  The case also 
highlighted the importance of adequate visual imaging in the assessment of LNPCPs and the 
potential to suggest incorrect management in the absence of sufficient information.   
 
15)   75 year old male with 55mm rectal LNCPCP  
This gentleman was found to have an LST-G with a large dominant nodule near the anorectal 
margin during a colonoscopy following a history of rectal bleeding.  Histology reported the 
lesion as a TVA with mixed LGD/HGD.  Whilst there was an opinion within the MDM that 
endotherapy was feasible, there was sufficient concern from examination of surface 
characteristics that the lesion may harbour malignancy and transanal surgery with TEMS was 
recommended to ensure en-bloc resection for optimal histopathological assessment.  En-
bloc resection from TEMS confirmed early malignancy (T1) with complete resection removal 
confirmed as a result of optimal histopathological specimen retrieval.  In this case the 
patient successfully underwent successful minimally invasive removal of malignancy and this 
case was considered to highlight the improvement in the MDM process, especially with 
regards to the management of rectal lesions that had previously been highlighted as a 
weakness. 
 
16) 68 year old male with 40mm mid transverse colon LNPCP 
This sessile lesion identified within the BCSP was felt to be benign at the time of discovery 
with biopsy results also suggestive of this (tubular adenoma with low grade dysplasia).  This 
view was supported at the MDM following a review of video imaging and endoscopic 
resection was subsequently undertaken successfully, confirming no malignancy and no 
recurrence on follow-up endoscopy.  With surgery avoided, the subsequent MDM 
recommendation was for endoscopic surveillance at 12 months.   
 
17) 79 year old female with 50mm rectosigmoid colon LNPCP 
This patient was referred to the MDM following the discovery of a LNPCP thought to be 
approximately 30mm in size.  It was also considered benign with biopsy results defining the 
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lesion as a tubular adenoma with LGD.  No video imaging was available for the MDM 
discussion but the images provided suggested that the lesion was indeed benign but larger 
than first considered.  The recommendation made was for repeat expert endoscopist 
assessment with endotherapy at that time if no there were no technical or malignancy 
concerns.  The lesion was found to be approximately 50mm in size but with no other 
concerns, pEMR with APC application was subsequently undertaken with complete resection 
considered achieved and the lesion to be confirmed as benign.  Video imaging of the 
endotherapy process was available during follow-up MDM discussion with agreement that 
endotherapy appeared successful.  With surgical resection avoided due to the selection of 
an appropriate endoscopist, lesion eradication was confirmed at 3 month surveillance and 
further surveillance at 12 months was agreed. 
 
18) 73 year old male with 120mm rectosigmoid LNPCP 
This gentleman with a history of rectal bleeding had subsequently undergone transanal 
surgery for this lesion prior to referral to MDM.  The lesion was felt to occupy over 75% of 
the bowel wall circumference and considered too extensive for endoscopic therapy using 
EMR.  In addition the sheer size of the lesion was considered a risk factor for malignancy in 
addition to a histological finding of high grade dysplasia.  The patient was reluctant to agree 
to resectional surgery and transanal minimally invasive surgery (TAMIS) was undertaken 
with the intention of achieving en-bloc resection.  The TAMIS procedure was unsuccessful 
with only piecemeal resection possible and the proximal extent of the lesion not reached by 
the TAMIS apparatus, leaving a large portion of residual tissue (40mm) and subsequent 
fibrous bowel narrowing (stenosis) in this region.  The case was referred to the MDM for 
advice on how to manage this case in the context of complex recurrence/residual tissue 
complicated by previous therapy.  Following review of the case details and videos it was 
agreed that the decision to undertake transanal surgery has been incorrect as the lesion was 
too proximal to allow successful eradication and it had not been established that the 
proximal portion was accessible prior to commencement of therapy.  In addition, it was also 
agreed to feed this back to the referring centre.  In this case, an attempt at resection 
complicated further management but the patient still did not wish for resectional surgery 
due to the risk of requiring a stoma.   Whilst surgical resection was considered to be a likely 
outcome, it was agreed that an attempt at EMR on the residual polyp should be made with 
surgery recommended to the patient if successful EMR was not possible.  It was felt that had 
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the lesion been referred prior to an attempt at management, the patient would have not 
been exposed to incorrect invasive therapy. An attempt at EMR was considered largely 
effective given the circumstances with the vast majority of the residual polyp removed, 
however it was felt that there be remaining fragments of tissue within the stenosis less 
accessible but potentially suitable for APC ablation in the future. 
This case was notable as first referral seeking advice for salvage therapy following complex 
recurrence and inappropriate therapy.  The importance of MDM discussion was also felt to 
have been emphasised as a similar case to this that had been referred prior to therapy had 
been referred externally for a second opinion with a robust management plan delivered.  
There was also felt to be an important educational component to this case with regards to 
the applicability of transanal surgery and the management of complex recurrent tissue.  
 
19) 68 year old male with 40mm sigmoid LNCPC 
This gentleman was found to have a 40mm sigmoid lesion during a BCSP colonoscopy that 
the endoscopist felt was a likely malignancy requiring surgery.  However the histopathology 
results were unexpected with a report stating that the biopsies taken could not be 
distinguished between bowel wall prolapse and malignancy although the former was 
favoured.  A second histopathology opinion was sought which supported the initial finding.  
In addition, detailed CT imaging did not demonstrate evidence of malignancy. Whilst there 
was a wish to avoid surgery in a lesion without confirmed malignancy there was sufficient 
agreement that malignancy could not be excluded based on endoscopic features.  It was felt 
that only surgical resection could guarantee total lesion clearance and optimal histological 
analysis and negate the possibility of leaving residual undetected malignancy.  In view of this 
the patient underwent surgery and was found have malignancy. 
This scenario was cited as a previous source of conflict prior to the establishment of the 
MDM with surgeons unhappy to operate in some cases in the absence of biopsy proven 
malignancy despite endoscopist concern with inappropriate endotherapy reluctantly 
undertaken.   In this case the strength of recommendation from interdisciplinary discussion 
the MDM was considered sufficient to make a decisive management decision.  This was also 
the first case where additional detailed histological input was required prior to the 
agreement of a management strategy.  Although there is no regular histopathology 
representative during MDMs and it was agreed that histopathology input obtained on an as 
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required basis fed back to the MDM was sufficient and did not compromise the strength of 
discussion.   In addition, this case was also felt to demonstrate the validity of the detailed 
endoscopic lesion assessment encouraged by the MDM, even in the absence of supporting 
histological and radiological findings. 
 
20)  66 year old gentleman with 10mm NPCP encircling appendiceal orifice  
This gentleman was referred for an opinion regarding optimal management following the 
discovery of a lesion encircling the appendiceal orifice during a BCSP colonoscopy.  Although 
the lesion was small and there was no concern of malignancy (TVA with LGD), there was 
concern from the referring centre that endotherapy may not be sufficient due to the 
probability of a portion of the lesion involving the appendix and therefore being 
endoscopically inaccessible. They reluctantly queried whether surgical resection was 
appropriate to provide definitive management.  Opinion within the MDM membership was 
divided over the choice or endoscopic or surgical therapy and in view of this the case was 
referred for consultation by the national expert pool.  Their opinion was that a high risk of 
appendiceal involvement rendered endotherapy inappropriate and that a laparoscopic 
surgical option (laparoscopic extended appendicectomy) would be both minimally invasive 
and provide definitive therapy.  This option was accepted by the MDM membership and the 
patient underwent successful surgery.  This case was noticeable for the use of the national 
expert pool to reach a robust management decision where opinion had been divided, whilst 
a precedent was set for similar lesions subsequently recommended.  
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Case Patient 
Details 
Lesion 
Details 
Initial 
Management 
prior to MDM 
referral? 
Specific 
Concerns 
Outcome Correct 
decision 
considered 
reached? 
Outstanding 
Issues 
1   62 year 
old male 
60 mm 
transverse colon 
hepatic flexure 
sessile LNPCP 
Initial pEMR with 
additional APC use 
Was initial 
decision 
correct? 
Did resection 
look complete?  
Initial decision 
considered 
correct with 
complete 
resection 
considered 
achieved 
No recurrence 
seen at 3 
month follow-
up 
Yes Confirm 
eradication at 
12 months 
2  70 year  
old male 
40mm ileocaecal 
valve flat LNPCP 
None Unable to 
assess full 
lesion margins, 
felt to be 
technically 
difficult to 
remove, 
concern over 
potential 
malignancy risk 
due to LST-NG 
morphology 
Successful 
endoscopic 
resection 
undertaken 
with no 
evidence of 
malignancy and 
no recurrence 
seen on follow-
up  
Yes, surgical 
resection 
avoided 
Confirm 
eradication at 
12 months 
3  84 year 
old male 
60mm sessile 
rectal polyp 
None Unable to 
assess full 
lesion margins. 
Lesion 
considered 
technically 
difficult to 
remove and 
concern over 
potential 
malignancy.  
Frail  patient 
not suitable for 
rectal surgery 
En-bloc 
resection using 
transanal 
surgery. 
Malignancy 
identified with 
successful 
removal 
confirmed 
Yes, definitive 
removal of 
malignant 
lesion with  
avoidance of 
complex 
rectal surgery 
None 
4  62 year 
old 
female 
100mm rectal 
laterally 
spreading polyp 
None Large lesion- 
MDM advice 
sought with 
regards to 
lesion 
assessment to 
exclude 
malignancy and 
an opinion on 
whether lesion 
was 
endoscopically 
resectable 
Patient offered 
choice between 
pEMR at 
referring site 
and transanal 
surgery at 
neighbouring 
centre.  Patient 
opted for EMR- 
lesion felt to be 
substantially 
larger than first 
thought).  Small 
area of 
recurrence 
seen on initial 
follow-up 
treated with 
APC with 
clearance seen 
on further 
follow-up 
Yes , lesion 
eradicated 6 
months after 
initial 
resection 
whilst patient 
given 
preferred 
treatment 
Confirm 
eradication at 
12 months 
5 62 year 
old male 
15mm ileocaecal 
valve flat LNPCP 
None Lesion 
diagnosed over 
2 year prior to 
MDM 
discussion.  
Patient 
concerned 
about 
likelihood of 
endotherapy 
failure and risk 
of stoma 
Discussion in 
clinic regarding 
endotherapy 
attempt by 
expert 
endoscopist, for 
surgery if 
failure of 
endotherapy 
preferred to 
primary 
surgery.  
Yes, 
avoidance of 
surgery  
Confirm 
eradication at 
12 months 
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associated with 
surgery 
Successful 
endotherapy 
undertaken 
with no 
recurrence 
seen on follow-
up 
 
 
 
 
 
6 62 year 
old 
female 
90mm rectal flat 
polyp 
None Assessment 
about 
suitability for 
endotherapy 
and exclusion 
of malignancy 
Endotherapy 
abandoned due 
to discovery of 
malignancy.  
Patient 
underwent 
resectional 
surgery.   
No- piecemeal 
endotherapy 
attempt on 
malignant 
lesion with 
surgery 
required as 
definitive 
management 
None 
7 87 year 
old 
female 
30mm sessile 
rectal LNPCP 
None Patient with 
advanced 
dementia, 
unable to 
consent for 
treatment. 
Assessment 
about whether 
therapy 
suitable 
5 year mortality 
rate estimated 
>50% using 
Schonberg 
Index with 
therapy 
considered not 
likely to 
improve 
prognosis. 
Conservative 
management 
opted for with 
agreement of 
next of kin 
Yes- 
avoidance of 
risks of 
invasive 
procedures 
None 
8 68 year 
old 
female 
60mm sigmoid 
colon sessile 
LNPCP 
None Assessment for 
suitability for 
endotherapy, 
exclusion of 
malignancy and 
selection of 
appropriate 
endoscopist 
Successful 
endoscopic 
resection 
undertaken 
with lesion 
eradication 
confirmed at 3 
month 
endoscopic 
surveillance 
Yes, 
avoidance of 
surgery 
Confirm 
eradication at 
12 months 
9 70 year 
old male 
40mm mid-
transverse colon 
sessile polyp 
None Strong 
endoscopist 
concern that 
lesion was 
malignant- felt 
not suitable for 
endotherapy 
despite lack of 
biopsy proven 
malignancy 
Patient 
underwent 
surgical 
resection- 
malignancy 
found 
Yes, high 
quality visual 
assessment 
resulted in  
avoidance of 
piecemeal 
endotherapy 
on malignancy 
despite 
equivocal 
histology  
None 
10 62 year 
old male  
50mm distal 
transverse colon 
sessile LNPCP 
Unplanned 
piecemeal 
endoscopic 
resection 
undertaken after 
inaccurate lesion 
margin estimation 
To ascertain 
whether 
complete 
resection had 
taken place and 
advice 
regarding 
appropriate 
follow-up 
Early (2-3) 
month 
surveillance 
advised in view 
of likely 
recurrence.  
Large area 
(15mm) of 
recurrence 
seen requiring 
repeat EMR and 
APC with 
eradication 
confirmed at 
next 
surveillance  
Yes, advice 
given 
regarding 
management 
of complex 
recurrence 
with 
successful 
lesion 
eradication 
Confirm 
eradication at 
12 months 
11 78 year 
old 
female 
120mm 
rectosigmoid flat 
lesion 
None Preference for 
en-bloc 
resection due 
to dominant 
nodule 
increasing risk 
of malignancy, 
size of lesion 
precluded 
suitable 
endotherapy 
Patient referred 
out of region 
for 
consideration 
for ESD, by 
international 
expert- lesion 
considered not 
endoscopically 
resectable but 
suitable for 
Yes, detailed 
lesion 
assessment 
with full 
consideration 
of all potential 
management 
options 
undertaken 
and improved 
patient 
Await result of 
surgical 
management 
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within North 
East region.   
Patient refused 
resectional 
surgery and 
lesion not 
suitable for 
transanal 
surgery due to 
proximal 
location 
rectal sparing 
surgery- not yet 
undertaken 
confidence in 
advice given 
locally 
12 78 year 
old 
female 
120mm 
anorectal LNPCP 
None Preference for 
en-bloc 
resection as 
lesion LST with 
dominant 
nodule.  In 
addition 
anorectal lesion 
meant that 
piecemeal 
resection was 
technically 
difficult due to 
unstable 
position  
TEMS elected  Yes, successful 
resection with 
optimal 
histology 
specimen 
Confirm 
eradication at 
12 months 
13 68 year 
old 
female 
120mm rectal 
LNPCP 
None Lesion 
identified as 
granular LST 
(LST-G)- 
concern about 
small focus 
within lesion 
Concern about 
small focus in 
lesion shared 
by MDT, unable 
to confidently 
exclude 
malignancy 
with en-bloc 
resection 
preferred to 
obtain optimal 
histological 
specimen- 
TEMS 
undertaken.  
Lesion 
estimated at 
12-130mm 
rather than 
55mm as 
initially 
estimated at 
endoscopy and 
only piecemeal 
resection 
achieved.  No 
residual tissue 
at 3 month 
check 
Principle 
underpinning 
decision 
considered 
correct. En-
bloc specimen 
retrieval 
permitted 
confident 
exclusion of 
malignancy 
whilst 
resectional 
surgery 
avoided 
Confirm 
eradication at 
12 months 
14 62 year 
old male 
60mm sigmoid 
sessile LNPCP 
None Lesion 
considered 
benign and 
suitable for 
endoscopic 
resection MDM 
opinion sought 
to corroborate 
this prior to 
management 
decision 
Image quality 
considered 
suboptimal 
with lesion 
appearing more 
extensive than 
described 
(35mm). 
Recommendati
on for 
reassessment 
by more 
experienced 
endoscopist 
advised. 
Endotherapy 
attempt 
favoured by 
local centre 
with 
unsuccessful 
attempt due to 
finding of 
malignancy. 
Yes, 
undesirable 
outcome likely 
due to MDM 
advice not 
being 
followed 
None 
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            Table 16.  Summary of Complex Polyp MDM Cases Discussed 
Surgery 
required 
15 75 year 
old male 
55mm rectal 
polyp 
None Laterally 
spreading 
polyp with 
dominant 
nodule and 
initial histology 
showing high 
grade dysplasia 
-suspicion 
regarding 
malignancy 
En-bloc 
resection 
favoured due to 
malignancy 
risk- TEMS 
undertaken 
with early T1 
malignancy 
found and 
complete 
resection 
confirmed 
Yes due to 
retrieval of 
en-bloc 
specimen and 
certain 
successful 
removal of 
malignancy in 
minimally 
invasive 
fashion. 
Confirm 
eradication at 
12 months 
16 68 year 
old male 
40mm mid 
transverse colon 
sessile LNPCP 
None Lesion 
considered 
benign and 
suitable for 
piecemeal 
endotherapy- 
MDM opinion 
sought to 
corroborate 
pEMR 
undertaken 
with no residual 
or recurrent 
tissue seen on 
follow-up 
Yes, 
avoidance of 
surgery 
Confirm 
eradication at 
12 months 
17 79 year 
old 
female 
50mm 
rectosigmoid 
sessile LNPCP 
None Lesion 
considered 
benign and 
suitable for 
piecemeal 
endotherapy-  
MDM opinion 
sought to 
corroborate 
pEMR 
undertaken 
with no residual 
or recurrent 
tissue seen on 
follow-up 
Yes, 
avoidance of 
surgery 
Confirm 
eradication at 
12 months 
18 73 year 
old male 
120mm 
rectosigmoid 
LNPCP 
Previous attempt 
at transanal 
surgery  
Unsuccessful 
transanal 
surgery- 
incomplete 
piecemeal 
resection with 
proximal 40mm 
of lesion not 
reachable with 
apparatus.  In 
addition, bowel 
wall narrowing 
(stenosis) from 
further 
complicating 
situation 
Resectional 
surgery felt to 
be most likely 
to be successful 
but had been 
refused by 
patient.  
Agreement 
regarding 
salvage attempt 
at EMR. EMR  
considered 
successful 
Yes, removal 
of residual 
polyp 
Confirm 
eradication on 3 
monthly basis 
until clear 
19 68 year 
old male 
40mm sigmoid 
sessile polyp 
None Endoscopist 
concern about 
malignancy but 
equivocal 
histology 
unable to 
delineate 
between bowel 
wall prolapse 
changes and 
malignancy  
Given 
malignancy 
concern en-bloc 
therapy 
considered 
preferable with 
resectional 
surgery 
undertaken- 
malignancy 
identified at 
surgery 
Yes, accurate 
endoscopic 
assessment 
resulted in 
correct 
therapy and 
minimal 
patient risk 
despite 
conflicting 
information 
None 
20 66 year 
old male 
10mm flat 
appendiceal 
orifice lesion 
None Lesion 
encircling 
appendiceal 
orifice with 
concern that 
there was 
appendix 
involvement 
limiting 
feasibility of 
endotherapy 
Following split 
opinion within 
region between 
endotherapy 
and surgical 
resection, 
national panel 
consulted for 
opinion- 
minimally 
invasive 
surgical option 
favoured as 
definitive 
therapy 
Yes, although 
malignancy 
not 
suspected, 
avoidance of 
endotherapy 
where there 
was   low 
confidence of 
successful 
resection and 
identification 
of minimally 
invasive 
surgical 
option 
None 
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6.4.4) A Summary of Participation by North-East England BCSP Centres 
A summary of cases referred to the MDM and details of non-referred cases mandatory for 
referral are described in figure 19 and table 17 respectively 
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                              Figure 19. A summary of cases referred by centre 
 
 
Centre Case Details Outcome  Reason case not referred 
A 71 year old male with 40mm 
sessile caecal LNPCP 
Removed piecemeal at time of 
detection, no recurrence 
described on follow-up  but 
documentation of 40mm 
ascending colon lesion not 
previously reported 
Case not deemed necessary for 
referral by endoscopist 
A 67 year old male with 30mm flat 
caecal LNPCP 
Removed piecemeal at time of 
detection, 3mm recurrence 
detected at 3 months, with 
eradication confirmed at 6 
months 
Case not deemed necessary for 
referral by endoscopist 
B 71 year old male with 40mm 
rectal sessile  LNPCP 
Removed piecemeal at time of 
detection, eradication confirmed 
at 3 month surveillance 
Case not deemed necessary for 
referral by endoscopist 
C 68 year old female with 20mm 
sessile caecal LNPCP 
Removed en-bloc at time of 
detection, complete resection 
confirmed histologically 
Endoscopist unfamiliarity with 
referral criteria 
C 75 year old male with 40mm 
sessile rectal LNPCP 
Removed piecemeal at time of 
detection.  Eradication confirmed 
at 3 month surveillance 
Endoscopist unfamiliarity with 
referral criteria 
D 71 year old male with 25mm 
sessile caecal LNPCP 
Cancer detected elsewhere in 
colon, patient underwent surgery 
Referral to benign lesion meeting 
not deemed appropriate by 
endoscopist in view of malignancy 
elsewhere 
Table 17.  Summary of cases not referred during first 3 months of MDM pilot  
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6.5) Discussion 
 
The modified Delphi consensus process used to identify and finalise a minimum dataset 
proforma ensuring consideration of all information relevant to ensuring robust LNPCP 
assessment and management was straightforward, with a second voting round required for 
only one parameter and 100% agreement for almost all parameters.  The identification of all 
relevant patient and lesion factors was essential to ensure that management decisions were 
safe, feasible and did not ignore important considerations such as patient wishes, 
comorbidity and medication issues which could impact on management outcomes.  In 
addition, the minimum dataset ensured discussion and/or exclusion of features that could 
compromise successful endoscopic resection such as size, morphology, location and features 
suggesting increased complexity (increased malignancy risk, failure to achieve resection and 
likelihood of adverse events).  The only parameter requiring a second round of voting 
related to the assessment of polyp surface characteristics.  The initial parameter specifying 
only the mandatory documentation of pit pattern with regards to polyp surface 
characteristics was considered dated, insufficient and potentially inaccurate given the 
availability of other validated polyp surface assessment systems and the limited availability 
of cresyl violet staining and magnifying endoscopy essential for true pit pattern assessment 
in the UK.  In view of this, the amended parameter allowed for the inclusion of any validated 
polyp surface assessment system such as the NICE NBI and Sano Capillary Pattern 
classification systems and was unanimously approved.   The inclusion of various classification 
systems was also considered important to update and educate clinicians about the latest 
systems available. 
It had been anticipated that potential new parameters or considerations may be identified 
when the minimum dataset was piloted during the complex polyp MDM.  The need to 
discuss patient symptoms was subsequently identified as an important factor in determining 
management recommendations in certain scenarios such as the discovery of an LNPCP in 
elderly, frail patients where a lack of symptoms may justify conservative management as 
appropriate over therapy.   The proposal to include patient symptoms as a parameter was 
unanimously agreed.  In addition, the need to specify the extent of imaging required by 
photographic imaging where video recording was unavailable was identified following cases 
where insufficient imaging limited the ability to assess and issue strong recommendations on 
243 
 
lesions.  Instructions related to minimum imaging information and standards were also 
subsequently added with full approval following which the minimum dataset proforma was 
considered both comprehensive and complete of all factors related to LNPCP management.  
Although the MDM was not aimed solely as BCSP cases, the existing infrastructure of the 
BCSP with regionally audited data and close clinician collaboration (with regular formal 
meetings) ensured access to a multidisciplinary network and the ability to monitor and 
discuss regional outcomes.  In addition, the ability of Professor Rutter to mandate the 
establishment of the MDM and referral of relevant lesions for quality assurance purposes in 
his position as QA chair ensured the viability of the meeting.   
 
6.5.1) Initial Concerns   
An initial concern was the reliance on clinicians to comply with MDM protocol and ensuring 
that BCSP nurses were also fully aware of the mandatory lesion referral criteria to maximise 
participation. There was initial opposition to the establishment of an MDM with a 
mandatory referral system with criticism that the measure was unproven, unnecessary and 
too prescriptive.  There was also a concern that and the meeting would lead to an increased 
workload for clinicians who already had a busy work schedule.   The measure was justified 
however by the presentation of regional BCSP data suggesting evidence of disconcordant 
management, a higher level of suboptimal management than previously thought (see 
chapter 5) and an accepted need to improve standards and develop a more coordinated 
management approach within the region.  In addition, there was support from a number of 
colorectal surgeons within the region who felt that LNPCPs were often not prioritised or 
discussed in sufficient detail within existing colorectal MDT meetings given the burden of 
colorectal cancer cases, the absence of biopsy proven malignancy in these lesions and the 
common lack of an advanced endoscopist.  Whilst the MDM had been mandated, it was 
appreciated that cooperation from all parties was needed to increase the likelihood of a 
successful process.  As a result, a pilot study over 6-7 months was agreed to ascertain the 
feasibility and impact of a complex polyp MDM with a view to permanent establishment if 
considered successful.  In addition, only lesions identified as complex based on fulfilling the 
evidence based criteria in recent BSG approved guidelines (see chapter 3) were mandatory 
for referral whilst fears over a concern about potential delays in management of malignancy 
were allayed by the encouragement of parallel referral of lesions with strongly suspected 
malignancy to the existing colorectal cancer MDT as before, which also ensured detailed 
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radiological and histological input.   It was also agreed that MDM outcomes were not binding 
and were recommendations only, in line with established NHS MDM policy. 
    
6.5.2) Overcoming Logistical Issues 
The initial logistical issues associated with the creation of a regional complex polyp MDM 
whilst numerous, were mostly anticipated in advance and factored into the methodology 
process.  For example, it was clear that teleconferencing would be required as a single venue 
was not feasible for a multicentre meeting covering a large geographical area. Audio-
teleconferencing, preferred to video teleconferencing due to widespread availability, 
appeared to facilitate participant involvement as participation was possible from anywhere.  
Patient and lesion information using the BSG approved minimum dataset proforma could be 
disseminated securely via the NHSmail email system along with high quality images and 
video recordings.  These factors ensured a meeting format allowing structured and 
comprehensive discussion that was reproducible nationwide.  As expected, it was not 
possible to choose a regular meeting time and pattern suitable for all clinicians.  With a core 
pool of BCSP endoscopists available on a regular basis, the meeting time was chosen around 
the availability of surgical and rectal expertise to ensure a multidisciplinary component at all 
meetings.  The decision to disseminate case information to a BCSP mailing list including all 
BCSP endoscopists and nominated surgeons 48 hours prior to meetings was successful in 
encouraging participation from clinicians unable to attend.  This format was vital in ensuring 
multidisciplinary input for all cases, especially where teleconference attendance was limited.  
For example, on the few occasions where a surgical presence was not possible, detailed pre-
meeting input was obtained and considered to have strengthened discussions during the 
teleconference. Email and text message reminders about meetings also appeared to ensure 
regular participation was maintained.  The proposed fortnightly one hour meeting schedule 
agreed by the BCSP endoscopists via questionnaire was frequent enough to ensure that no 
cases suffered a delay in management awaiting an MDM outcome whilst it was not 
considered too onerous by participants with other significant clinical commitments.   
Engagement with the MDM process varied across the region.  Figure 19 demonstrates that 
the bulk of referrals came from centres C and D. Whilst an increased number of referrals 
compared with centres A and B may simply be reflective of the number of suitable LNPCPs, 
increased engagement is suggested by the both centres referring multiple non-mandatory 
cases (e.g. cases not meeting referral criteria or discovered outside of BCSP).  Access to the 
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BCSP database enabled assessment of each centre’s compliance with the mandatory referral 
criteria for BCSP cases.  Six mandatory referral BCSP cases were not referred in the first 3 
months of the meeting (2 from centre A, 2 from centre C, 1 from  centre B and 1 from centre 
D) (see figure 17).  The reasons given for non–referral of cases at centres A and B was a 
belief that referrals were not necessary. With regards to centre C, it was asserted that non-
referral was a result of endoscopist unfamiliarity with the referral criteria whilst in the case 
of centre D, referral was not deemed appropriate due to the discovery of a malignancy 
elsewhere in the colon. The benefit of using the regional BCSP to pilot the MDM was the 
closely aligned service meaning that the issue of non-referred cases could be addressed at 
frequent regional BCSP meetings and by liasing with relevant SSPs.  Participation improved 
as the meeting became more established, with no mandatory cases not referred in the final 
3 months of the MDM pilot.  
 
6.5.3) Comprehensive Follow-up of Cases 
 
Ensuring that all referred cases remained subject to follow-up within the MDM process was 
achieved by the use of a regularly updated Microsoft Excel spreadsheet with all discussed 
cases.  This was made available to all MDM participants to capture and record updated 
details such as therapy and surveillance outcomes to assess longer term outcomes of all 
discussed cases. This spreadsheet recorded all management decisions (e.g. endoscopic, 
conservative and surgical management), specific procedure information (e.g. use of 
piecemeal or en-bloc removal, use of argon plasma coagulation with piecemeal endotherapy 
etc.) and outcomes (e.g. complications and findings of incomplete resection at early and late 
stages). A major intention of the use of the spreadsheet was to provide a growing 
prospective database to allow subsequent quantitative and statistical analysis of MDM 
cases.  
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6.5.4) Feedback 
Positive Feedback 
Feedback was obtained via group discussion at regional BCSP meeting coinciding with the 
end of the pilot study and via an emailed survey.  All parties regularly involved with the 
MDM process had largely positive opinions, with the MDM considered to have aided 
management across a wide variety of cases.  The meetings were seen as a valuable resource 
in improving assessment and decision making processes taken in LNPCP management, with 
comments that there was greater cooperation and co-ordination within the region. In 
addition, it was noted that there was greater agreement within the region about how to 
manage certain lesion types (e.g. high grade dysplasia or appendiceal location).  It was 
considered that LCPCPs were subject to more comprehensive and structured discussion than 
previously, providing clinicians with support and guidance with complex cases in a format 
that was reproducible using existing NHS resources.  A cited example was case 5, where 
almost two years of a stasis in management posed a subsequent risk of malignancy that was 
considered entirely avoidable.  The ability to deliver a robust collective recommendation 
that resulted in a positive outcome was seen as a particular example of where the role of the 
MDM was important. 
There was also increased confidence in the management recommendations made due to 
improved interdisciplinary cooperation as a result of the establishment of the MDM.  This 
was seen in cases 9 and 15 where surgical therapy was recommended and subsequently 
undertaken as first line management based on endoscopic suspicion of malignancy due to 
lesion surface characteristics in spite of initial benign histological findings from biopsies.  This 
appears to be an improvement on previously reported scenarios within the region where 
piecemeal endotherapy was undertaken with malignant lesions despite a strong endoscopic 
suspicion of malignancy because surgical therapy had been refused based on a lack of biopsy 
proven malignancy.  Whilst piecemeal resection of malignant lesions did occur in 2 cases 
(cases 6 and 14),  one case (case 6) was early in the MDM process and led to more extensive 
MDM membership (e.g. a TEMS performing surgeon), whilst in the other case (case 14), the 
MDM recommendation of repeat assessment prior to management was not followed.  It was 
also considered that the increased dialogue generated from the meetings led to a more 
coordinated management approach for most complex lesions within the region.  This 
included the selection of conservative management in an elderly and frail patient where on 
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balance the risks of therapy were felt to outweigh the potential benefit (case 7).  Discussion 
of the cases managed also prompted agreement that increased regional collaboration 
enhanced patient choice and experience.  For example, there were cases where patients 
were offered treatment modalities such as transanal surgery that were not available within 
their immediate area and as a result may not have previously been considered.  In addition, 
with varying levels of expertise with LNPCP management within the region, MDM discussion 
enabled the selection of endoscopists considered suitable to undertake therapy in cases 
where endotherapy was preferred thus avoiding unnecessary surgery.     Collaboration also 
allowed clinicians to utilise contacts of other participants and expand their network of 
contacts out of the region to the benefit of patients.  Evidence supporting this view was seen 
in case 11 where the patient was unhappy with the local recommendation for resectional 
surgery and there was lack of expertise within the region to provide an assessment for 
advanced alternative therapies.  Referral to a recommended external contact resulted in the 
patient receiving assessment for ESD that is only available in limited UK centres.  Whilst an 
alternative to surgery was ultimately not considered possible, the patient was happy that all 
treatment options had been explored prior to agreeing to surgery and that adequate 
assurances had been given regarding the low likelihood of requiring a stoma. 
Negative Feedback 
It was accepted that there were enough cases to support the importance of the MDM as a 
modality and the MDM process was extended to at least 12 months.  The main criticism 
cited regarding the MDM format was that it scheduling meant that it was not possible for all 
clinicians to participate in the meeting during the teleconference and as such it was felt that 
not all clinicians were able to benefit from the educational aspect of the meeting. This 
comment was made by one of the MDM’s biggest original sceptics, suggesting that they did 
feel that the meeting had value but that an inability to participate in the 
audioteleconference was their main issue.  It was also suggested that a face to face meeting 
format with discussion of cases at the regional BCSP endoscopist meetings would be 
preferable.  It was countered that the scheduling of the meeting was based on the 
preferences of the majority of clinicians in response to a questionnaire regarding their 
availability, including surgical representatives whose presence was essential to ensure a 
truly multidisciplinary process.  In addition, the dissemination of meeting information pre 
and post MDM was accepted as a solution, albeit a limited one. Whilst a face to face single 
location meeting was desirable, in addition to clinician availability and geographical issues 
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being limiting factors, the regional BCSP meetings took place every few months only and 
were therefore too infrequent.  This approach would have resulted in a delay in 
management in many cases whilst awaiting MDM recommendations.   There were also 
concerns amongst a few clinicians that the purpose of the MDM was to centralise advanced 
polypectomy to only certain individuals within the region rather than providing management 
support.  A reason given for this opinion was interpretation of some of the wording of MDM 
feedback given to referring centres.  For example, recommending endotherapy at the local 
centre only if suitable expertise was available and identifying other regional endoscopists 
willing to take on the case was seen as patronising and casting aspersions on the ability of 
the referring centre’s endoscopists.  Whilst neither this nor the centralisation of services was 
intended, this criticism was acknowledged as a disadvantage of referring individuals not 
being part of the teleconference and it was agreed that the wording of MDM 
recommendations would be more considered in future. The perceived advantages and 
disadvantages of the complex polyp MDM are summarised in table 18 (see below). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
249 
 
Central Meeting 
Components  
Perceived Advantages Perceived Disadvantages Mitigation of Perceived 
Disadvantages 
Establishment of 
virtual meeting using 
teleconferencing and 
email  
Able to remotely connect 
clinicians across region with 
face to face single centre 
meeting not feasible  
 
 
Greater coordination 
between specialties and 
more robust lesion 
assessment and decision 
making 
Lack of face to face 
interaction 
 
 
 
 
 
Concern about potential 
for delay in management 
whilst awaiting MDM 
outcome 
Use of BSG approved 
minimum dataset to 
ensure standardised and 
comprehensive discussion 
of patient and polyps 
factors 
 
Fortnightly meeting 
format to ensure prompt 
MDM discussion 
Use of NHSmail for 
transfer of all patient 
media 
Secure, approved method 
of transfer of patient 
identifiable information 
nationally 
1 gigabyte file limit for 
media/video transfer 
Use of video editing and 
compression to facilitate 
large file transfer 
Regional format with 
national expert group 
Enhanced management 
options for patients- access 
to modalities not available 
locally 
 
Expert advice available for 
cases where MDM 
consensus not reached 
Concern that LNPCP 
management may 
become more centralised 
as a result of MDM- 
potential for reduced 
participation as a result 
Commitment in terms of 
reference that MDM 
outcomes are 
recommendations only 
and non-binding- in line 
with established NHS 
MDM protocol  
Educational role Improves knowledge base 
of participants 
Reduced educational role 
for clinicians unable to 
attend teleconference 
Outcomes, feedback and 
other educational points 
disseminated to group 
post meeting 
 
Discussion of cases and 
important issues at 
regional BCSP group 
meetings 
Use of digital imaging 
for multi-clinician 
lesion assessment 
(video and still images) 
High quality imaging 
allowed detailed multi-
clinician visual assessment 
and management 
recommendation without 
need for repeat diagnostic 
endoscopy 
Visual appearances 
central to decision 
making. Variation in 
availability of high quality 
media recording within 
region (e.g. video 
recording, high definition 
imaging).  Potential for 
poor quality images to 
limit decision making 
Guidance detailing  
recording of quality and 
comprehensive  images 
Standardised meeting 
day and time 
Allows familiarity with and 
establishment of  meeting 
format 
Meeting time not suitable 
for all participants 
 
Dissemination of cases 48 
hours before and MDM 
outcomes 48 hours post 
MDM to maximise input 
           Table 18. Perceived Advantages and Disadvantages of MDM 
 
6.5.5) Imaging 
The quality of LNPCP images captured was considered as essential in facilitating adequate 
LNPCP assessment and of greater significance than with other specialist MDM meetings, 
given the strong established relationship between visual polyp characteristics and malignant 
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potential and feasibility of endoscopic resection.  Strong recommendations could not be 
made in many cases where image quality was considered poor, resulting in either equivocal 
recommendations or a need for repeat diagnostic assessment by an additional clinician in 
some cases.   The use of video imaging with referrals, although not uniformly available 
within the region, was considered to greatly enhance MDM discussion and increase the 
likelihood of robust recommendations when compared with photographic imaging.  Video 
assessment was reported to allow detailed examination of lesion characteristics such as 
surface patterns, full margins and precise location and was therefore considered comparable 
to being present at the relevant colonoscopy itself in terms of enabling image assessment.   
This reduced the need for repeat diagnostic assessment in many cases with a decision on 
whether a specific therapy was possible from review of the video.  For example, it was 
agreed that decisions on whether transanal surgery was likely to be successful in the 
management of rectal lesions based on full lesion accessibility and the exclusion of sigmoid 
colon involvement could confidently be made from video imaging.  This was particularly 
relevant when considering case 18 where a decision on therapy had been made outside of 
the MDM setting without repeat diagnostic assessment with endoscopy or video recording 
resulting in a lesion undergoing unsuccessful transanal surgery despite being in an 
unsuitable location and further complicating the likelihood of successful management. 
Radiological imaging modalities such as CT and MRI scanning whilst recommended on a case 
by case basis were not found to change management outcomes in any of the cases 
discussed. 
 
6.5.6) Refinement of Meeting Format 
It was recognised that given the preliminary nature of the MDM process, issues and 
limitations of the meeting format would be identified with the strength of the MDM process 
evolving and improved over time. For example, given the importance of visual assessment in 
LNPCP management, in many cases it was considered that the quality of photographic 
images provided with referral was suboptimal and provided limited information in cases 
where video imaging was not available.  This subsequently impacted on the strength of 
recommendation considered possible. The response to this was the addition of guidance on 
the MDM referral proforma relating to the minimum level of imaging required.  This 
included recommendations regarding image clarity and ensuring that full lesion margins 
could be ascertained and this measure was credited with improved image quality with 
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subsequent referrals.  In addition, whilst consultation of histopathology and radiology 
services was available on an as required basis, including through the colorectal cancer MDT 
where malignancy was strongly suspected, suspicions that the initial member composition of 
the MDM lacked the requisite expertise with regards to complex rectal lesion cases were 
confirmed by the outcome in case 6 where despite detailed lesion assessment featuring high 
quality video by a number of experienced clinicians, a finding of malignancy was missed 
resulting in an inappropriate endotherapy attempt and subsequent resectional surgery 
where less invasive transanal surgery would have been appropriate as first line therapy.    
The use of a pool of national experts for areas with continued conflicting opinion was 
considered to strengthen the process whilst addition of a rectal surgical specialist was 
considered essential.  The outcome of case 15 in which there was successful assessment and 
management of a complex rectal lesion using TEMS following a concern over increased 
malignancy risk and conflicting opinion on management was seen to demonstrate a marked 
improvement in the MDM’s ability to assess and manage complex rectal cases. 
 
6.5.7) Educational Role 
The complex polyp MDM was also widely seen to have been beneficial in providing an 
important educational role in LNPCP management to its membership.  Participants were 
able to test their assessment skills by reviewing cases prior to therapy and subsequently 
receiving feedback with the dissemination of outcomes.  The opportunity to share expertise 
and knowledge was considered invaluable with improved confidence in lesion assessment 
ability reported due to an increased awareness of image classification systems.  In addition, 
exposure to complex scenarios encouraged exposure to potentially new and valuable 
resources.  An example was the application of the Schonberg index, a validated but not 
widely known classification system in case 7 to predict mortality risk in an elderly patient in 
whom an LNPCP had been found, resulting in conservative management.  This case was 
credited with improving awareness of individual patient morbidity and mortality risk. 
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6.6) MDM Role in Decision Making- Application of Optimal Decision Making Key  
        Performance Indicator 
 
The ability to apply key performance indicators (KPIs) to the pilot MDM data is limited by 
both the small sample size and the lack of long term outcomes (e.g. 12-15 month outcomes).  
However, an assessment of optimal decision making using the ‘use of surgery’ KPI (use of 
surgery as secondary management (e.g. following endoscopic management of malignancy) 
and as management of benign lesions) was possible.  Applying the KPI criteria, the surgical 
rate for this sample was 30%.  Whilst this figure is higher than the average surgical rate 
recorded within the region in the retrospective data described in chapter 5 (21.7%), an 
important consideration is that the lesions included in the MDM cohort are considered 
amongst the most complex as identified in the guidelines in chapter 4.  As opposed to the 
retrospective BCSP sample that includes any non-pedunculated lesion at least 20mm in size, 
this complex sample includes lesions that are: 
o Very large (some up to 120mm in size)  
o Identified with an increased suspicion of malignancy, 
o Subject to previous management 
o Assessed as having other technical considerations (e.g. difficult location) potentially 
compromising endoscopic removal  
The use of surgical management, which took place in four of the six ‘surgical KPI’ cases, 
appears appropriate despite an absence of malignancy, given the higher likelihood of failed 
endoscopic therapy compared with the retrospective series. For example, surgical 
management was recommended for a benign lesion in one case by a clinician considered a 
world expert in advanced endotherapy. In addition, of the two cases where piecemeal 
endotherapy was used on malignant lesions (11 cases of primary endoscopic management), 
the MDM recommendation was ignored in one case suggesting that an inappropriate 
recommendation was made in only one of the MDM cases (e.g. use of piecemeal 
endotherapy on malignancy: 10% (MDM sample) vs 15.6% (retrospective BCSP sample).  
Despite the limited sample size of this series, it appears that the decision-making KPI 
requires enhancement, at least in regards to the use of surgery in complex LNPCPs, to 
capture suboptimal decision making in this population. 
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6.7) Conclusions 
The findings from this pilot study appear to confirm the validity of the minimum dataset 
proforma in ensuring structured and comprehensive LNPCP discussion. 
In addition, whilst single centre complex polyp MDMs are already in place, this is the first 
reported example of a multicentre approach.  The development and establishment of a 
complex polyp MDM appears feasible, with its use indicating improved decision making in 
LNPCP management and a more coordinated approach with improved patient outcomes and 
potentially more cost effective management.  However at this stage outcomes are 
qualitative only with longer term outcome data needed.  The complex polyp MDM may also 
be seen as an educational tool and has a reproducible format using the BSG approved 
proforma and existing NHS technology that may be best implemented within an existing 
regional infrastructure such as a regional BCSP.  The complex polyp MDM may also 
complement existing colorectal services and be used to provide guidance and robust 
recommendations with regards to: 
 Optimal primary therapy and more robust decision making  
 Obtaining feedback about management strategy undertaken 
 Consideration of full range of therapeutic options 
 Widening of clinicians’ regional and national network resulting in increased 
treatment options for patients 
 Improved inter-specialty relationships 
 Complex scenarios such as extensive lesion recurrence and the consideration of 
conservative therapy 
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Chapter 7: Discussion and Overall Conclusions 
 
The findings of this thesis confirm the hypothesis that current management of large non-
pedunculated colorectal polyp (LNPCPs) varies widely and is uncoordinated, leading to 
suboptimal outcomes.  This is reflected by the long term regional data from the Bowel 
Cancer Screening Programme (BCSP) detailed within this thesis, a programme shown to 
manage a large volume of LNPCPs by multiple large volume series (17, 101).  The work 
undertaken, including the development of a structured framework encompassing 
assessment and management guidelines, key performance indicators (KPIs) and a decision 
aid model offers solutions with regards to improving management in this field. 
 
7.1) Findings and achievements 
Work undertaken as part of this thesis has resulted in the following. 
 A retrospective analysis of large non-pedunculated colorectal polyp (LNPCP) 
management confirming that variation in assessment and management of LNPCPs 
results in significantly different outcomes 
 The development of comprehensive evidence based and expert opinion LNPCP 
assessment and management guidelines earning both BSG and ACPGBI approval and 
publication in ‘Gut’ journal 
 The development of BSG and ACPGBI approved ‘Key Performance Indicators’ (KPIs) 
to allow auditing, monitoring and comparison of LNPCP outcomes with subsequent 
publication in ‘Gut’ journal 
 The application of KPIs to retrospective data to ascertain the validity of KPIs 
 The development of a regional complex polyp multidisciplinary team meeting 
resulting in more robust and coordinated LNPCP management  
 The development and  validation of a minimum dataset proforma detailing  features 
relevant to LNPCP assessment and management, allowing comprehensive and 
structured discussion 
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 The identification of pertinent research questions to improve the evidence base 
relating to LNPCP management 
 
7.2) Implications of this research 
Prior to undertaking this thesis, the development of a LNPCP management framework 
including guidelines and performance, had not previously been achieved.  This was in spite 
of a strong desire within the international endoscopic community to do so, with opinion 
prevalent that there were insurmountable challenges precluding it.   Professor Rutter (BSG 
large polyp working group chairperson) was approached by the BSG in 2006 to undertake 
work in this field.   Indeed, there was a great deal of scepticism within the Northern Region 
Endoscopy Group (NREG) when the plan to develop an LNPCP management framework was 
discussed, with a widely held view that there was an absence of evidence to suggest that 
variation in management contributed to variable and suboptimal outcomes.   There was also 
a belief that there was a paucity of evidence to help create both guidelines and KPIs.    
Despite this, the use of extensive available evidence and multidisciplinary consensus opinion 
has resulted in the production of the world’s first internationally peer reviewed guidelines 
and standardised performance measures (KPIs). These were warmly received by both the 
BSG and ACPGBI who indicated that they greatly improved the support available to clinicians 
involved in LNPCP management and were likely to contribute to more coordinated and 
improved outcomes.  As a result both groups were happy to endorse them.  This work also 
satisfies the demand for structured guidance in LNPCP management reported in recent 
national surveys. 
  
 British Society of Gastroenterology (BSG)/ Association of Coloproctology of Great 
Britain and Ireland (ACPGBI) Guidelines 
The BSG/ACPGBI guidelines, devised as part of this thesis provide evidence based 
information and expert opinion on the optimal assessment and management of large non-
pedunculated colorectal polyps (LNPCPs) for clinicians. It is also anticipated that the 
guidelines will act as a stimulus for further research in this field and provide a template for 
training in LNPCP management.  The intended target audience includes gastroenterologists, 
nurse practitioners, physicians, colorectal surgeons, radiologists and pathologists.   
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 Key Performance Indicators 
The development of KPIs provides a new and standardised opportunity for both clinicians 
and centres to audit, monitor and compare outcomes in LNPCP management and set a 
benchmark for minimum standards of practice internationally. This will allow the 
identification of underperformance and remedial action to improve standards.  Whilst the 
scientific basis for their development may be argued, there is a clear precedent within the 
field of endoscopy for the improvement of standards using KPIs for example, for 
colonoscopy services in the BCSP.  The use of qualitative methodology to identify KPIs 
provides a means to identify key quantitative measures that can be monitored and targeted 
for improvement to provide enhanced patient care. 
 
 Regional complex polyp multidisciplinary team meeting (MDM)  
Whilst single centre complex polyp MDMs are already in place, this is the first reported 
example of a regional, multicentre MDM.  Its use was considered to improve LNPCP 
management by its participants whilst the model used to develop and establish the meeting 
is reproducible using existing NHS resources in other regions.  This intervention allowed 
greater coordination and robustness of decision making, with improved patient satisfaction 
and outcomes and potentially more cost effective management.  The complex polyp MDM 
may also be seen as an educational tool with the opportunity to learn from experience and 
other participants’ expertise.  The complex polyp MDM may also complement existing 
colorectal services and be used to provide guidance and robust recommendations with 
regards to the following: 
 Optimal primary therapy and more robust decision making  
 Obtaining feedback about management strategy undertaken 
 Consideration of full range of therapeutic options 
 Widening of clinicians’ regional and national network resulting in increased 
treatment options for patients 
 Improved inter-specialty relationships 
 Complex scenarios such as extensive lesion recurrence and the consideration of 
conservative therapy 
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The development of an evidence based and validated minimum dataset for LNPCPs  may 
enable improved management in situations where a complex polyp MDM is not feasible, for 
example where the absence of a network of colleagues results in a clinician working in 
isolation.  The structured format of the proforma can serve as a checklist to ensure that 
features suggesting or precluding particular management options are not missed whilst 
enabling structured and comprehensive discussion, for example when referring lesions to 
tertiary referral centres. 
 
 
7.3) Limitations  
Retrospective analysis 
The analysis of established practice within this thesis has identified wide variation in 
endoscopic practice and decision making as having a significant impact on outcomes.  The 
relatively small sample size of the regional series compared with other similar international 
series appears to be a limiting factor in the impact of these findings. For example, whilst 
findings related to argon plasma coagulation use and endoscopist procedure volume 
indicated clinical significance, it cannot be discounted that statistical association was not 
accurately proven or excluded due to an underpowered study. Limitations were also 
apparent in certain aspects of BCSP polyp data collection.  In addition to the lack of 
information regarding surveillance therapy on BCSP patients discharged from the 
programme (mainly due to being out of the age range), there was a paucity of information in 
relation to detailed polyp morphology such as Paris and LST classification, with sufficient 
information only to classify lesions as ‘flat’ or ‘sessile’.  Given the established accuracy of 
detailed polyp morphology in identifying LNPCPs with higher malignancy risk, the insufficient 
relevant information appears to have affected the validity of findings related to polyp 
morphology in this study.  In addition, a main reliance on the central BCSP database for the 
retrieval of outcomes does not preclude inaccuracy based on potential data entry errors.  
However, the likelihood of this is reduced by both the fastidious nature of BCSP data input 
and the use of double data entry where all cases were also checked on the relevant sites to 
ensure accuracy. 
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Guideline development 
There is a paucity of evidence in this field of the highest scientific quality such as large 
multicentre randomised controlled trials and meta-analyses to formulate guidelines.  Many 
of the recommendations and findings pertaining to LNPCP management are drawn from the 
findings of observational studies, the quality of which would be classed as ‘low’ rather than 
‘high’ when using systems designed to assess the strength of scientific evidence.  It can be 
argued that the nature of LNPCP management renders the ability to conduct large human 
trials as not feasible in certain areas such as the determination of the level of tissue damage 
in response to varying degrees of diathermy, an area where porcine models have previously 
been used.  This issue is similar to many other healthcare fields in this respect and may have 
led to increased uptake of the GRADE assessment tool that includes a separate ‘strength of 
recommendation’ process, allowing for recommendations after detailed consideration of 
variable factors as opposed to the study design solely.   In addition, it appears that in many 
areas of the evidence base for LNPCP management, the recommendations and findings 
derive from multiple large volume papers from high impact journals and are unlikely to be 
changed by further research.  The work undertaken for this thesis comprehensively 
references and summarises the available evidence and expert opinion in this field and 
appears to be a marked improvement on previous resources for LNPCP management.  It can 
also be argued that the identification of several potential research areas (see later) increases 
the likelihood of improving on the current evidence base and strengthening the robustness 
of recommendations made from this research. 
 
Key Performance Indicators 
 
A lack of evidence deemed to be ‘high quality’ may also call into question the validity of 
certain KPIs identified as auditable outcomes, in addition to the standards specified.  
However, the use of established KPI healthcare strategy, with the identification of domains 
and subsequent KPIs related mainly to patient experience and safety, as well as 
consideration of outcomes widely considered by international literature as measures of 
quality, appears sound. In addition, whilst an attempt has been made to set realistic 
minimum standards based on findings from international literature, there are many KPIs for 
which a standard has not been set and are therefore identified as ‘auditable outcomes’.  It 
can be argued that the KPIs are currently incomplete because of this. This factor, allied to a 
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limited evidence base in some areas, may provoke resistance to their uptake.  It will also 
likely take time to obtain enough data to validate and enhance the KPIs and finalise 
standards such as those currently defined as auditable outcomes.  However, it was felt 
important not to set unwarranted standards without any appropriate justification as this 
would damage the credibility of the finalised KPIs.  This scenario is well recognised in KPI 
development in that such parameters are defined as ‘auditable outcomes’ with standards 
likely identifiable following detailed data audit (288).  In addition, whilst the decision making 
KPI does appear to accurately identify centres with a higher use of surgery, it appears 
apparent that optimisation is required for use with complex LNPCPs.  An increased use of 
primary surgery may be anticipated in this sample and likely considered more acceptable 
due to limitations of endotherapy in providing curative resection. However, the 
development of KPIs is a dynamic process and will likely be enhanced when applied to a 
growing sample size.  Despite the limitations of KPI development, as discussed previously, 
the use of qualitative methodology to develop KPIs provides an opportunity to provide a 
large quantitative evidence database.  
 
Regional complex polyp multidisciplinary team meeting 
 
Whilst the regional MDM development process was considered a success, limitations were 
identified.  The associated logistical issues confirmed that commitment from an established 
network of clinicians, such as those within regional BCSP services, is required to ensure the 
ongoing viability of the meeting, in addition to facilitating access to relevant data sources 
such as ongoing case information.  In addition, the ability to mandate case referrals from 
within the BCSP where endoscopists are subject to individual data audit was essential in 
ensuring the ongoing viability of the process in its early stages, prior to more widespread 
acceptance,  a modality that is not likely to be as readily available outside of the BCSP. 
The need to use NHSmail emailing for security purposes appeared to limit initial uptake of 
MDM compliance as it was apparent that many clinicians did not use this email account 
regularly and would thus miss meeting details.  The use of reminders sent to clinicians’ main 
trust email accounts, in addition to text message reminders did increase participation.  An 
upgrade in NHSmail security during the MDM process allowing patient identifiable data 
transfer from NHSmail to NHS trust accounts enabled larger participation and engagement 
but this crucially did not allow for video imaging transfer.  Given the importance of imaging 
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with regards to lesion assessment, the disparity in imaging technology available to difference 
centres within the region did appear to impact on the strength of MDM recommendations 
made.  For example, video recording, considered vastly superior to still photographic images, 
was only available in limited centres meaning that the strength of the MDM 
recommendations offered seemed to vary based on the location of the referring centre.  
Another issue was the ability to transfer a maximum file size of one gigabyte via secure file 
transfer.  This resulted in the need for video editing in many cases.  Whilst this was not 
considered to impact on decision making ability in the cases described, the increased 
availability of higher definition recording requiring larger file sizes may pose an issue with 
the file size limit.  Whilst there may be an initial financial cost associated with the 
procurement of video recording equipment, it may be argued that this cost can be recouped 
over time from a reduction in diagnostic procedures required to reassess LNPCPs where 
initial imaging was inadequate.  In addition, video recording, despite being a relatively new 
standard is increasing in availability in the UK meaning that image quality will likely become 
a less prominent limiting factor. 
It may also be argued that the small MDM case volume limits the significance of its findings.  
The limited time period available reduced the ability to increase the case series size, 
however, the decision to extend the MDM process will allow collection of a larger sample 
size. In addition, at present there is a lack of longer term outcomes, such as 12 month 
surveillance outcomes, due to the limited timeframe.  It may be argued that this impacts on 
the significance of the findings of this pilot study, especially in view of other case series 
reporting a finding of ‘new recurrence’ at 12 months where complete eradication had 
previously been considered.  However, it appears that the findings from 12 month 
surveillance are highly unlikely to result in new findings in many of the cases detailed, such 
as endoscopic cases with complete clearance already established, with this phenomenon 
only having been described in very limited cases and likely in part to be the result of 
inadequate lesion assessment at earlier surveillance.  In addition, 12 month findings are just 
one outcome, with this pilot primarily focused on more acute parameters (such as decision 
making outcomes and subjective opinion).  Whilst analysis of this case series is ongoing 
meaning that longer term outcomes will soon be available for analysis, the major limitation 
of this pilot study is that the main findings are mainly qualitative (e.g. perceptual 
improvement) with a lack of quantitative outcomes.   
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7.4) Inability to create guidelines for advanced polypectomy training and 
accreditation                                                                                                                                            
Whilst the GDG discussed ways to improve training in the management of LNPCPs and were 
keen to create guidelines in this area, this was not felt possible due to an absence of 
evidence.  In view of this, a reference model was devised with key points as described 
below: 
 Entry requirements for training 
 
There was agreement that reaching a minimum number of diagnostic colonoscopy 
procedures was required to allow development of essential basic colonoscopy and 
therapeutic skills before entering advanced polypectomy training.  There was broad opinion 
that handling and decision making skills develop after around 250-350 colonoscopies with 
further development following an extensive period of independent practice.  Evidence that 
increased endoscopic experience is associated with improved performance and a reduced 
rate of adverse events reinforced this view.  A minimum number of 500 independent (post 
certification) colonoscopies was felt to be a suitable number to ensure that adequate 
experience has been achieved in both observed and independent practice. There was 
unanimous opinion that snare polypectomy experience and skill were the key identifiers of 
endoscopists suitable for advanced training and that competency in snare polypectomy of 
smaller lesions (up to 20mm) needed to be established.  This may be assessed with a formal 
assessment tool such as the DOPyS assessment tool (293).  In addition to formal assessment, 
evidence of regular snare polypectomy experience with lesions greater than 1cm in the 
preceding year was considered desirable, in addition to performance data for all 
colonoscopy practice in that period.   
 
 Training Programme 
 
An apprenticeship programme such as a dedicated fellowship in a recognised advanced 
endoscopy centre was considered to be the preferred model for delivering advanced 
polypectomy training to trainees whereas non-trainees such as consultants wishing to 
develop advanced polypectomy skills would require a period of mentorship.  The availability 
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of fellowships in specific regions may be linked to population demands.  An agreed 
appropriate learning curve commences with a trainee continuing to develop individual 
colonoscopy skills whilst watching and assisting their mentor resect large lesions.  During 
this period, trainees may gain significant experience and develop their technique on colonic 
lesions between 10-19 mm in size before progressing to larger lesions and piecemeal 
resection. At this point trainees would be encouraged to bring cases to dedicated training 
lists.  LNPCP location and accessibility also confers increased lesion complexity in addition to 
size and rectal lesions where the bowel wall is thicker and access is easier may be an ideal 
starting point for obtaining hands-on experience.  Trainers and mentors would be required 
to ensure that their performance data (KPIs) met minimum standards before supervising 
fellows. 
 
 Certification 
 
Dividing certification into provisional and full certification was strongly supported.   
Achieving provisional certification would be based on outcomes data and mentor opinion 
and would be the start of independent practice (i.e. trainer not in the room).  Full 
certification would be obtained based on achieving satisfactory KPIs whilst provisionally 
certified in addition to mentor opinion and maintenance of full certification status would be 
dependent on achieving satisfactory KPIs. 
 
 Other potential training modalities 
  
Training workshops were suggested as a modality for reinforcing technical and decision 
making skills obtained during a fellowship programme whilst simulator and tissue simulator 
models allow hands-on exposure in a safe setting. There is also growing support for the use 
of live animal training models.  In the UK, the British Society of Gastroenterology have 
indicated their support for this modality. 
 
7.5) Reflections from undertaking thesis 
 Logistical Issues 
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The development of an LNPCP management framework was a major undertaking requiring 
the coordination and cooperation of clinicians, both regionally and nationally, and large 
bodies such as the BSG and ACPGBI.  The logistics required, in addition to the limited 
evidence base in certain areas, may explain why no previous attempts at the creation of a 
framework have been made. 
 Variation in Practice  
Whilst international surveys demonstrated clear variation in LNPCP practice such as 
assessment and management, and this may not be unexpected for clinicians practicing in 
relative isolation, it was surprising to see such a marked variation in practice within a region 
between a group of closely aligned BCSP endoscopists who meet and discuss cases regularly. 
This not only included the decision making process but endoscopic technique and 
equipment use such as snare choice, diathermy settings, submucosal lifting practice and the 
use of APC.  Whilst greater coordination is sought, especially in light of a resultant variation 
in outcomes, this has allowed for analysis of important research questions such as the 
efficacy of APC use in pEMR that might not otherwise have been possible. 
 BCSP Database  
The use of the central BCSP database proved invaluable as a comprehensive information 
source for both retrospective and prospective data collection and reduced the logistical 
demands of data collection over a large regional area. However, the database appeared to 
lack information about follow-up procedures and findings for patients undergoing LNPCP 
therapy within the BCSP and subsequently discharged from the programme due to age 
(>75).  Whilst this information was available via individual case review on relevant hospital 
sites, the inclusion of all follow-up information for LNPCPs managed within the BCSP on the 
central BCSP database may make further audit of practice easier.  
 Resistance to change in practice 
Although the result of work undertaken as part of this thesis was undertaken successfully 
with valuable contributions from many people, the level of resistance to service 
development proposals from some quarters was surprising.  This appeared to be the case 
with regards to the implementation of the complex polyp MDM, especially the mandatory 
referral criteria.  There were concerns voiced that the MDM was unnecessary, would make 
practice too prescriptive and serve as a means to centralise LNPCP management and 
264 
 
marginalise some clinicians.  In addition, there was a concern that MDM recommendations 
could be mandated as management despite assurances to the contrary.   These concerns 
may be a result of defensiveness, due to a perceived potential for increased personal 
scrutiny of practice and concerns about possible sanctions such as limiting autonomy of 
practice.   It may also be the case that many experienced clinicians are simply uncomfortable 
with being told how to undertake a procedure they feel they have been performing well long 
beforehand. 
 Decision making 
The process of reaching consensus and collective decision-making were major components 
of the work undertaken. They formed the basis of the methodology used for the 
development of guidelines, KPIs and the complex polyp MDM. Although evidence-based 
decisions were sought wherever possible, opinion-based decision making was required in 
numerous cases, a situation commonplace in healthcare.  The processes of collective 
decision-making in healthcare may be seen as inferior to other industries such as business 
which have used technology for a long time to optimise decision making.   An example of 
this is the widespread use of organisation decision support systems (ODSS), databases 
consisting of various sources of information to predict the possibilities of outcomes using 
statistical decision theory (SDT) (294).  ODSS supported decision making has been discussed 
as suitable in certain healthcare areas for some time due to the many factors and decision-
makers often required in deciding management therapy, but this has not yet become 
commonplace (295, 296).  Until recently, healthcare decision making regarding healthcare 
policy such as guidelines and management appears to have been based on individuals, with 
collective decision making a relatively new phenomenon(295).  An example of this is 
management guideline development, in which the use of consensus methodology only 
recently appears to have been adopted internationally.  However, the method commonly 
used, a derivative of the Delphi technique, was initially developed for use in the business 
setting by the RAND corporation in the 1950s (258).  The decision making processes in 
LNPCP management may be an area amenable to enhancement with the development of an 
ODSS (see later).  
 High malignancy incidence in North East dataset 
Another observation was the high incidence of malignancy in the North East region 
compared with nationally within the BCSP for polyps initially diagnosed as benign (28% vs 
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9.7%, p<0.0001).  Whilst this finding may be multifactorial it raises a query about whether 
lesion assessment skills in the North East are inferior to those nationally or whether 
management skills are inferior with endoscopists incorrectly believing that they can 
endoscopically manage malignant lesions. 
 
 
7.6) Further Work 
 Management Guidelines 
Further potential work following on from these guidelines includes undertaking prospective 
studies in relation to the important research questions identified.  In addition, in view of 
national and international questionnaires specifying the lack of guidelines and limited 
training as a major limiting factor in delivering optimal LNPCP management, an international 
questionnaire following widespread dissemination of guidelines may confirm if these 
guidelines have been effective in improving management and training.   
 KPIs 
The most important next step with regards to KPI development appears to be optimisation 
of the decision making domain/KPI, especially with regards to auditing the most complex 
lesions.  With clear definitions of complex LNPCPS now available from internationally peer 
reviewed guidelines, the decision making ‘surgery’ KPI may be expanded further.  For 
example the KPI may be expanded to sub-classify LNPCPS managed with primary surgery 
according to visual characteristics that suggest a ‘high’ or ‘low’ risk of malignancy or a ‘high’ 
or low’ risk of failed endoscopic resection.  This may help to better identify surgically 
managed LNPCPs that would have been be better suited to endotherapy such as those with 
a low risk of malignancy and a high chance of successful endoscopic resection. Further work 
with regards to KPIs has commenced with the retrospective application of KPIs to existing 
regional BCSP data to determine applicability and feasibility.  In addition, continuous annual 
prospective analysis and audit of LNPCP outcomes using KPIs in a programme with 
established high quality data collection such as the BCSP would help to establish whether 
the KPIs have led to improved standards and a large database to identify robust standards.   
 Retrospective analysis 
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Further work arising from the BCSP case series includes ongoing audit of outcomes with the 
application of KPIs and recently agreed guidelines to assess for improvement in 
management.  Furthermore, certain findings, such as the higher level of polyp recurrence 
following endotherapy in the caecum, improved outcomes in higher volume endoscopists 
and the potential benefit of argon plasma coagulation (APC) use as an adjunct to 
endotherapy indicate the need for larger studies.  For example, in the case of APC use, a 
large randomised controlled trail (RCT) with a standardised proforma for APC application 
may unequivocally establish whether its use is associated with reduced lesion recurrence.   
 Pertinent future research questions  
 
The following research questions and potential studies were suggested by the GDG as the 
most feasible to expand the LNPCP management evidence base: 
o How common are LNPCPs and what is the optimal number of LNPCP endoscopists 
per 100,000 population? 
o What is an appropriate timeframe for the management of LNPCPs? 
o What is the pre-resection accuracy of prediction of malignancy within an LNPCP and 
how can the endoscopic identification of malignant features be improved? 
o What it the length of time to malignant transformation for LNPCPs and when is 
conservative management the most appropriate management strategy? 
o Does continuation of aspirin prior to the endoscopic resection of LNPCPs result in 
increased post-polypectomy bleeding? 
o What is the optimal type of submucosal injection solution for use in advanced 
polypectomy? 
o Does the use of dye in submucosal injection fluid improve completeness of 
endoscopic resection? 
o Does the use of adrenaline in submucosal injection fluid improve peri-procedural 
visibility and reduce immediate and delayed bleeding and post endoscopic 
resection? 
o What are optimal diathermy settings for advanced polypectomy? 
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o Does the use of argon plasma coagulation on post resection margins reduce the risk 
of lesion recurrence 
o When is the optimal time to restart anticoagulation/antiplatelet medication post-
polypectomy? 
o What are the appropriate KPI standards, where none currently exist? 
o Does the implementation of a complex polyp MDT improve outcomes? 
o What is the minimum number of procedures per year that is required to 
reach/maintain competency in the endoscopic management of LNPCPs? 
o What is the role of laparoscopic-assisted endoscopic polypectomy? 
 
 Complex Polyp MDM 
Further work arising from the development of the complex polyp MDM includes the 
collection of longer term outcomes from the existing MDM case series, in addition to the 
ongoing collection of prospective cases.  Long term outcomes from a larger case series over 
a sustained time period may strengthen the evidence supporting the use of a complex polyp 
MDM.  In addition, an RCT comparing the outcomes from cases discussed in the MDM 
compared with outcomes from cases not discussed the MDM may also demonstrate a 
significant association with improved outcomes.  
 
7.6.1) Alternative options in the development of LNPCP decision-making processes 
Whilst logistical issues may limit the ability to implement an MDM, the development of the 
minimum dataset proforma and guidance regarding adequate imaging may still provide a 
means to improve decision making for those working in greater isolation, allowing for 
structured and comprehensive LNPCP discussion.  This may be achieved by the use of an 
online centralised secure NHS or BSG national database where clinicians may post lesion 
information and imaging onto a shared website using the secure NHSmail email system for 
review by other relevant multidisciplinary clinicians and experts.  This may enable clinicians 
to establish a national network, rather than working in isolation, potentially resulting in 
more robust management decisions and resulting in improved treatment options for 
patients.  Furthermore, the popularity of current online endoscopy forums indicates the 
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potential for a scheme such as this, with an online forum used to directly improve patient 
care in addition to being an educational tool.    
Another possibility is the harnessing of technology applied in the business world, through 
collaboration with a software technology company to create an ODSS software package to 
guide the decision making process.  The piloting of the evidence based minimum dataset 
proforma during the MDM process suggests that all relevant patient and lesion information 
required can be obtained and entered into a database.  In addition, a growing collection of 
images (photographic and video) and outcomes from the MDM could be used for 
comparison with referred lesion details and imaging to provide suggested management 
options and probability of their success.  Although undoubtedly more difficult to achieve, 
this measure may provide an example of more scientifically sound decision making in the 
healthcare field than before and comparable with those used in business models.  
 
 
7.7) Conclusions 
It is hoped that the work undertaken as part of this thesis will lead to greater clinician 
support and more coordinated and improved LNPCP management both nationally and 
internationally, as well as enabling audit, monitoring and comparison of standards to 
benchmark LNPCP practice.  Additionally, the identification of pertinent future research 
questions provides guidance on how to best improve the LNPCP evidence database. 
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